<!DOCTYPE html>
 <!--[if lt IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8 lt-ie7"> <![endif]--> <!--[if IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8"> <![endif]--> <!--[if IE 8]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9"> <![endif]--> <!--[if gt IE 8]><!--> <html class="aui ltr" dir="ltr" lang="en-US" prefix="og: http://ogp.me/ns#"> <!--<![endif]--> <head> <title>Synbiotics, prebiotics and probiotics for people with chronic kidney disease - Cooper, TE - 2023 | Cochrane Library</title> <meta content="Synbiotics, prebiotics and probiotics for people with chronic kidney disease - Cooper, TE - 2023 | Cochrane Library" property="og:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD013631.pub2/full" property="og:url"/> <meta content="article" property="og:type"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" property="og:image"/> <meta content="summary_large_image" name="twitter:card"/> <meta content="Synbiotics, prebiotics and probiotics for people with chronic kidney disease - Cooper, TE - 2023 | Cochrane Library" name="twitter:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD013631.pub2/full" name="twitter:url"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" name="twitter:image"/> <meta content="initial-scale=1.0, width=device-width" name="viewport"/> <meta content="10.1002/14651858.CD013631.pub2" name="dc.identifier" scheme="DOI"/> <meta content="Synbiotics, prebiotics and probiotics for people with chronic kidney disease" name="citation_title"/> <meta content="Tess E Cooper" name="citation_author"/> <meta content="The University of Sydney" name="citation_author_institution"/> <meta content="tess.cooper@sydney.edu.au" name="citation_author_email"/> <meta content="Rabia Khalid" name="citation_author"/> <meta content="Samuel Chan" name="citation_author"/> <meta content="Princess Alexandra Hospital" name="citation_author_institution"/> <meta content="Jonathan C Craig" name="citation_author"/> <meta content="Carmel M Hawley" name="citation_author"/> <meta content="Princess Alexandra Hospital" name="citation_author_institution"/> <meta content="Martin Howell" name="citation_author"/> <meta content="David W Johnson" name="citation_author"/> <meta content="Princess Alexandra Hospital" name="citation_author_institution"/> <meta content="Allison Jaure" name="citation_author"/> <meta content="Armando Teixeira-Pinto" name="citation_author"/> <meta content="Germaine Wong" name="citation_author"/> <meta content="Cochrane Database of Systematic Reviews" name="citation_journal_title"/> <meta content="John Wiley &amp; Sons, Ltd" name="citation_publisher"/> <meta content="10" name="citation_issue"/> <meta content="10.1002/14651858.CD013631.pub2" name="citation_doi"/> <meta content="2023" name="citation_date"/> <meta content="2023/10/23" name="citation_online_date"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD013631.pub2/abstract" name="citation_abstract_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD013631.pub2/full" name="citation_fulltext_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD013631.pub2/pdf/full" name="citation_pdf_url"/> <meta content="1465-1858" name="citation_issn"/> <meta content="en" name="citation_language"/> <meta content="Dysbiosis [complications, therapy]; Indican; Prebiotics; *Probiotics [therapeutic use]; *Renal Insufficiency, Chronic [complications, therapy]; *Synbiotics; Uremic Toxins" name="citation_keywords"/> <link href="https://fonts.googleapis.com/css?family=Source+Sans+Pro:400,700,600,900" rel="stylesheet"/> <script src="https://cmp.osano.com/AzZdRbSORDOOzF9W/d594efc1-9663-477d-9528-6576640e64fd/osano.js"></script> <style> .osano-cm-widget{display: none;} </style> <script src="https://static.addtoany.com/menu/page.js"></script> <script async="" charset="utf-8" src="https://platform.twitter.com/widgets.js"></script> <script async="async" src="//script.crazyegg.com/pages/scripts/0056/6375.js" type="text/javascript"></script> <script type="text/javascript">window.dataLayer={};var xtend=function(){var a={};var b=false;var c=0;var d=arguments.length;if(Object.prototype.toString.call(arguments[0])==="[object Boolean]"){b=arguments[0];c++}var f=function(g){for(var h in g){if(Object.prototype.hasOwnProperty.call(g,h)){if(b&&Object.prototype.toString.call(g[h])==="[object Object]"){a[h]=xtend(true,a[h],g[h])}else{a[h]=g[h]}}}};for(;c<d;c++){var e=arguments[c];f(e)}return a};</script> <!-- Global site tag (gtag.js) - Google Analytics --> <script src="https://www.googletagmanager.com/gtag/js?id=UA-189672-63&amp;l=gDataLayer"></script> <script>window.gDataLayer=window.gDataLayer||[];function gtag(){gDataLayer.push(arguments)}gtag("js",new Date());gtag("config","UA-189672-63");</script> <script type="text/javascript">var o={auth:{customerIds:[],individualId:null,brandedCustomer:null,roles:["Guest"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <script type="text/javascript">var o={page:{siteSection:"Content",languageCode:"en",cms:{pageTitle:"Content"}}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <meta content="text/html; charset=utf-8" http-equiv="content-type"/> <link href="https://www.cochranelibrary.com/cochrane-theme/images/favicon.ico" rel="Shortcut Icon"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013631.pub2&amp;doi=10.1002/14651858.CD013631.pub2&amp;type=cdsr&amp;contentLanguage=" rel="canonical"/> <link href="https://www.cochranelibrary.com/zh/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013631.pub2&amp;doi=10.1002/14651858.CD013631.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANS" rel="alternate"/> <link href="https://www.cochranelibrary.com/zh_HANT/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013631.pub2&amp;doi=10.1002/14651858.CD013631.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANT" rel="alternate"/> <link href="https://www.cochranelibrary.com/hr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013631.pub2&amp;doi=10.1002/14651858.CD013631.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hr-HR" rel="alternate"/> <link href="https://www.cochranelibrary.com/nl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013631.pub2&amp;doi=10.1002/14651858.CD013631.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="nl-NL" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013631.pub2&amp;doi=10.1002/14651858.CD013631.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="x-default" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013631.pub2&amp;doi=10.1002/14651858.CD013631.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="en-US" rel="alternate"/> <link href="https://www.cochranelibrary.com/fr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013631.pub2&amp;doi=10.1002/14651858.CD013631.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="fr-FR" rel="alternate"/> <link href="https://www.cochranelibrary.com/de/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013631.pub2&amp;doi=10.1002/14651858.CD013631.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="de-DE" rel="alternate"/> <link href="https://www.cochranelibrary.com/hi/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013631.pub2&amp;doi=10.1002/14651858.CD013631.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hi-HI" rel="alternate"/> <link href="https://www.cochranelibrary.com/hu/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013631.pub2&amp;doi=10.1002/14651858.CD013631.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hu-HU" rel="alternate"/> <link href="https://www.cochranelibrary.com/in/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013631.pub2&amp;doi=10.1002/14651858.CD013631.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="in-ID" rel="alternate"/> <link href="https://www.cochranelibrary.com/ja/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013631.pub2&amp;doi=10.1002/14651858.CD013631.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ja-JP" rel="alternate"/> <link href="https://www.cochranelibrary.com/ko/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013631.pub2&amp;doi=10.1002/14651858.CD013631.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ko-KR" rel="alternate"/> <link href="https://www.cochranelibrary.com/ms/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013631.pub2&amp;doi=10.1002/14651858.CD013631.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ms-MY" rel="alternate"/> <link href="https://www.cochranelibrary.com/fa/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013631.pub2&amp;doi=10.1002/14651858.CD013631.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="fa-IR" rel="alternate"/> <link href="https://www.cochranelibrary.com/pl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013631.pub2&amp;doi=10.1002/14651858.CD013631.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="pl-PL" rel="alternate"/> <link href="https://www.cochranelibrary.com/pt/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013631.pub2&amp;doi=10.1002/14651858.CD013631.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="pt-PT" rel="alternate"/> <link href="https://www.cochranelibrary.com/ro/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013631.pub2&amp;doi=10.1002/14651858.CD013631.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ro-RO" rel="alternate"/> <link href="https://www.cochranelibrary.com/ru/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013631.pub2&amp;doi=10.1002/14651858.CD013631.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ru-RU" rel="alternate"/> <link href="https://www.cochranelibrary.com/es/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013631.pub2&amp;doi=10.1002/14651858.CD013631.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="es-ES" rel="alternate"/> <link href="https://www.cochranelibrary.com/ta/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013631.pub2&amp;doi=10.1002/14651858.CD013631.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ta-IN" rel="alternate"/> <link href="https://www.cochranelibrary.com/th/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013631.pub2&amp;doi=10.1002/14651858.CD013631.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="th-TH" rel="alternate"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/aui.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <link href="/html/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772874000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/scolaris-content-display/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/notifications-portlet/notifications/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772751000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/html/portlet/login/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772901000" rel="stylesheet" type="text/css"/> <script type="text/javascript">var Liferay={Browser:{acceptsGzip:function(){return false},getMajorVersion:function(){return 80},getRevision:function(){return"537.36"},getVersion:function(){return"80.0"},isAir:function(){return false},isChrome:function(){return true},isFirefox:function(){return false},isGecko:function(){return true},isIe:function(){return false},isIphone:function(){return false},isLinux:function(){return true},isMac:function(){return false},isMobile:function(){return false},isMozilla:function(){return false},isOpera:function(){return false},isRtf:function(){return true},isSafari:function(){return true},isSun:function(){return false},isWap:function(){return false},isWapXhtml:function(){return false},isWebKit:function(){return true},isWindows:function(){return false},isWml:function(){return false}},Data:{NAV_SELECTOR:"#navigation",isCustomizationView:function(){return false},notices:[null]},ThemeDisplay:{getLayoutId:function(){return"7"},getLayoutURL:function(){return"https://www.cochranelibrary.com/en/content"},getParentLayoutId:function(){return"0"},isPrivateLayout:function(){return"false"},isVirtualLayout:function(){return false},getBCP47LanguageId:function(){return"en-US"},getCDNBaseURL:function(){return"https://www.cochranelibrary.com"},getCDNDynamicResourcesHost:function(){return""},getCDNHost:function(){return""},getCompanyId:function(){return"20155"},getCompanyGroupId:function(){return"20195"},getDefaultLanguageId:function(){return"en_US"},getDoAsUserIdEncoded:function(){return""},getLanguageId:function(){return"en_US"},getParentGroupId:function(){return"20182"},getPathContext:function(){return""},getPathImage:function(){return"/image"},getPathJavaScript:function(){return"/html/js"},getPathMain:function(){return"/en/c"},getPathThemeImages:function(){return"https://www.cochranelibrary.com/cochrane-theme/images"},getPathThemeRoot:function(){return"/cochrane-theme"},getPlid:function(){return"20757"},getPortalURL:function(){return"https://www.cochranelibrary.com"},getPortletSetupShowBordersDefault:function(){return true},getScopeGroupId:function(){return"20182"},getScopeGroupIdOrLiveGroupId:function(){return"20182"},getSessionId:function(){return""},getSiteGroupId:function(){return"20182"},getURLControlPanel:function(){return"/group/control_panel?refererPlid=20757"},getURLHome:function(){return"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane"},getUserId:function(){return"20159"},getUserName:function(){return""},isAddSessionIdToURL:function(){return false},isFreeformLayout:function(){return false},isImpersonated:function(){return false},isSignedIn:function(){return false},isStateExclusive:function(){return false},isStateMaximized:function(){return false},isStatePopUp:function(){return false}},PropsValues:{NTLM_AUTH_ENABLED:false}};var themeDisplay=Liferay.ThemeDisplay;Liferay.AUI={getAvailableLangPath:function(){return"available_languages.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513679709000"},getCombine:function(){return true},getComboPath:function(){return"/combo/?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513679709000&"},getFilter:function(){return"min"},getJavaScriptRootPath:function(){return"/html/js"},getLangPath:function(){return"aui_lang.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513679709000"},getStaticResourceURLParams:function(){return"?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513679709000"}};Liferay.authToken="XHP2gG4h";Liferay.currentURL="\x2fweb\x2fcochrane\x2fcontent\x3ftemplateType\x3dfull\x26urlTitle\x3d\x2fcdsr\x2fdoi\x2f10\x2e1002\x2f14651858\x2eCD013631\x2epub2\x26doi\x3d10\x2e1002\x2f14651858\x2eCD013631\x2epub2\x26type\x3dcdsr\x26contentLanguage\x3d";Liferay.currentURLEncoded="\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD013631\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD013631\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D";</script> <script src="/html/js/barebone.jsp?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;colorSchemeId=01&amp;minifierType=js&amp;minifierBundleId=javascript.barebone.files&amp;languageId=en_US&amp;b=6210&amp;t=1513679709000" type="text/javascript"></script> <script type="text/javascript"></script> <script type="text/javascript">var o={database:"CDSR",page:{pageType:"Article Full Text HTML"},article:{availableLanguage:["en","es","zh_HANS","zh_HANT","ko","th","ms","ja","hr","fa","id","fr","pl"],languageCode:"en",accessStatus:"delayed-free",doi:"10.1002/14651858.CD013631.pub2",title:"Synbiotics, prebiotics and probiotics for people with chronic kidney disease",firstPublishedDate:"Oct 23, 2023 12:00:00 AM",isCurrentVersion:true,editorialGroup:"Cochrane Kidney and Transplant Group",availableParts:["PDF Full","PDF Standard","PDF Abstract","HTML","Comments","Information","References","Stats","Related Content"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/custom.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <style type="text/css"></style> <script async="" src="https://assets.adobedtm.com/59640f9fa510/7cad07cf7779/launch-a215d9c51521.min.js"></script> <!--[if lt IE 9]> <script src="/cochrane-theme/vendor/respond/dest/respond.min.js?t=1738734064000" type="text/javascript"></script> <![endif]--> </head> <body class="yui3-skin-sam controls-visible guest-site signed-out public-page site"> <div class="site-container"> <a href="#main-content" id="skip-to-content">Skip to Content</a> <div class="cookie-message cookie-message--hidden system-message-container" id="js-cookie-message"> <div class="container"> <a aria-label="Close cookies message" class="fa fa-times js-cookie-close pull-right" href="#"></a> <div class="system-message-wrapper container"> <i aria-hidden="true" class="fa fa-exclamation-triangle"></i> <div class="system-message-title">Cookies</div> <div class="system-message-description"> <p> Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off cookies if you wish to do so. By continuing to browse this site you agree to us using cookies as described in <a href="http://olabout.wiley.com/WileyCDA/Section/id-813473.html">About Cookies</a>. </p> <a class="btn secondary js-cookie-close js-cookie-accept" href="#">I accept</a> </div> </div> </div> </div> <script>document.body.className=document.body.className+" js_enabled";</script><header> <div class="container"> <div class="branding"> <h1 class="brand-container"> <a href="https://www.cochranelibrary.com/en/"> <span class="brand-name">The Cochrane Library</span> <img alt="Cochrane Library logo" class="brand-logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_logo.png" title="Cochrane Library"/> </a> </h1> <span class="additional-branding"> <p class="brand-message"> <em>Trusted evidence.</em> <em>Informed decisions.</em> <em>Better health.</em> </p> </span> </div> <div class="desktop-search basic-search-container"> <div class="desktop-search-form"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="owel__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=XHP2gG4h&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"/> <input name="facetDisplayName" type="hidden" value=""/> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD013631.pub2&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD013631.pub2';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<div class="search-tools-nav">
<a class="btn secondary" href="/en/browse-by-topic">Browse</a>
<a class="btn primary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
</div>
<a class="toggle-menu-switch" href="#"><i aria-hidden="true" class="fa fa-bars"></i> <div class="toggle-menu-text">Open menu</div></a>
</div>
<div class="auxiliary-container">
<div class="container">
<div class="header-auxiliary-menu">
<div class="auxiliary-menu-item language-selector">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="bvrs__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> Review language : English </a> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> Website language : English </a> </div> <div class="language-selector-modal-content" data-modal-title="Language selection" data-size="large" style="display: none;"> <div class="form-content language-selector-modal"> <div class="row-fluid"> <div> <table class="mytable" style="border: 1px solid #f0f0f0" width="90%"> <tbody> <tr class="row-box"> <td><i class="fa fa-file-text icon-size"></i></td> <td><h3>Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> </td> <td> <div> <select id="contentLanguageSelector" onchange="updateLang(this.value)"> <option class="content-language-option" data-languagecode="de" value="de"> Deutsch </option> <option class="content-language-option" data-languagecode="en" selected="" value="en"> English </option> <option class="content-language-option" data-languagecode="es" value="es"> Español </option> <option class="content-language-option" data-languagecode="fa" value="fa"> فارسی </option> <option class="content-language-option" data-languagecode="fr" value="fr"> Français </option> <option class="content-language-option" data-languagecode="hi" value="hi"> हिन्दी </option> <option class="content-language-option" data-languagecode="hr" value="hr"> Hrvatski </option> <option class="content-language-option" data-languagecode="id" value="id"> Bahasa Indonesia </option> <option class="content-language-option" data-languagecode="ja" value="ja"> 日本語 </option> <option class="content-language-option" data-languagecode="ko" value="ko"> 한국어 </option> <option class="content-language-option" data-languagecode="hu" value="hu"> Magyar </option> <option class="content-language-option" data-languagecode="ms" value="ms"> Bahasa Malaysia </option> <option class="content-language-option" data-languagecode="nl" value="nl"> Nederlands </option> <option class="content-language-option" data-languagecode="pl" value="pl"> Polski </option> <option class="content-language-option" data-languagecode="pt" value="pt"> Português </option> <option class="content-language-option" data-languagecode="ru" value="ru"> Русский </option> <option class="content-language-option" data-languagecode="ro" value="ro"> Română </option> <option class="content-language-option" data-languagecode="ta" value="ta"> தமிழ் </option> <option class="content-language-option" data-languagecode="th" value="th"> ภาษาไทย </option> <option class="content-language-option" data-languagecode="zh_HANT" value="zh_HANT"> 繁體中文 </option> <option class="content-language-option" data-languagecode="zh_HANS" value="zh_HANS"> 简体中文 </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> <tr class="row-box"> <td><i class="fa fa-globe icon-size"></i></td> <td> <div class="language-info"> <h3>Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> </div> </td> <td> <div class="language-dropdown"> <select id="portalLanguageSelector"> <option class="portal-language-selector" data-portallanguage="en" selected="" value="/en/cdsr/doi/10.1002/14651858.CD013631.pub2/full/en"> English </option> <option class="portal-language-selector" data-portallanguage="es" value="/es/cdsr/doi/10.1002/14651858.CD013631.pub2/full/es"> Español </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> </tbody> </table> </div> </div> <div style="text-align: right;"> <button class="btn primary btn-cancel" style="margin-left: 10px;" type="button">Cancel</button> <a class="btn secondary ok-btn" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<a class="auxiliary-menu-item signin last" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD013631.pub2%2Ffull" rel="nofollow">
<i class="icon fa fa-user"></i> Sign In
    </a>
<span class="auxiliary-container-extended"></span>
</div>
</div>
</div>
</header>
<div class="main-nav-wrapper">
<span class="main-nav-left-extended"></span>
<nav class="main container">
<ul>
<li class="nav-root-item parent">
<a href="#">Cochrane reviews<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_14" role="presentation">
<a aria-labelledby="layout_14" href="https://www.cochranelibrary.com/en/cdsr/reviews" role="menuitem">
            Search reviews (CDSR)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_15" role="presentation">
<a aria-labelledby="layout_15" href="https://www.cochranelibrary.com/en/cdsr/reviews/topics" role="menuitem">
            Browse reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_18" role="presentation">
<a aria-labelledby="layout_18" href="https://www.cochranelibrary.com/en/cdsr/table-of-contents" role="menuitem">
            Issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_17" role="presentation">
<a aria-labelledby="layout_17" href="https://www.cochranelibrary.com/en/cdsr/editorials" role="menuitem">
            Editorials
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_19" role="presentation">
<a aria-labelledby="layout_19" href="https://www.cochranelibrary.com/en/special-collections" role="menuitem">
            Special Collections
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_20" role="presentation">
<a aria-labelledby="layout_20" href="https://www.cochranelibrary.com/en/cdsr/supplements" role="menuitem">
            Supplements
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_121" role="presentation">
<a aria-labelledby="layout_121" href="https://www.cochranelibrary.com/en/about/about-cochrane-reviews" role="menuitem">
            About Cochrane reviews
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Searching for trials<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_254" role="presentation">
<a aria-labelledby="layout_254" href="https://www.cochranelibrary.com/en/search/releases" role="menuitem">
            What's new (search and CENTRAL)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_266" role="presentation">
<a aria-labelledby="layout_266" href="https://www.cochranelibrary.com/en/search-help" role="menuitem">
            Search help
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_252" role="presentation">
<a aria-labelledby="layout_252" href="https://www.cochranelibrary.com/en/search-help-quick-guides" role="menuitem">
            Search help quick guides
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_251" role="presentation">
<a aria-labelledby="layout_251" href="https://www.cochranelibrary.com/en/search-faqs" role="menuitem">
            Search FAQs
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_114" role="presentation">
<a aria-labelledby="layout_114" href="https://www.cochranelibrary.com/en/central/about-central" role="menuitem">
            About CENTRAL
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_115" role="presentation">
<a aria-labelledby="layout_115" href="https://www.cochranelibrary.com/en/central/central-creation" role="menuitem">
            How CENTRAL is created
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_241" role="presentation">
<a aria-labelledby="layout_241" href="https://www.cochranelibrary.com/en/retracted-trials" role="menuitem">
            Retracted publications in CENTRAL
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Clinical Answers<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_29" role="presentation">
<a aria-labelledby="layout_29" href="https://www.cochranelibrary.com/en/cca" role="menuitem">
            Browse Clinical Answers
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_91" role="presentation">
<a aria-labelledby="layout_91" href="https://www.cochranelibrary.com/en/cca/about" role="menuitem">
            About Clinical Answers
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">About<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_116" role="presentation">
<a aria-labelledby="layout_116" href="https://www.cochranelibrary.com/en/about/about-cochrane-library" role="menuitem">
            About the Cochrane Library
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_13" role="presentation">
<a aria-labelledby="layout_13" href="https://www.cochranelibrary.com/en/cdsr/about-cdsr" role="menuitem">
            Cochrane Database of Systematic reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_198" role="presentation">
<a aria-labelledby="layout_198" href="https://www.cochranelibrary.com/en/cdsr/editorial-policies" role="menuitem">
            Editorial policies
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_92" role="presentation">
<a aria-labelledby="layout_92" href="https://www.cochranelibrary.com/en/about/author-information" role="menuitem">
            Information for authors
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_212" role="presentation">
<a aria-labelledby="layout_212" href="https://www.cochranelibrary.com/en/about-pico" role="menuitem">
            About PICO
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_207" role="presentation">
<a aria-labelledby="layout_207" href="https://www.cochranelibrary.com/en/about/about-translations" role="menuitem">
            About translations
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_188" role="presentation">
<a aria-labelledby="layout_188" href="https://www.cochranelibrary.com/en/about/releases" role="menuitem">
            What's new
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_216" role="presentation">
<a aria-labelledby="layout_216" href="https://www.cochranelibrary.com/en/data" role="menuitem">
            Data reuse
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_235" role="presentation">
<a aria-labelledby="layout_235" href="https://www.cochranelibrary.com/en/about/about-cochrane-library/editorial-board" role="menuitem">
            Cochrane Library Editorial Board
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Help<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_259" role="presentation">
<a aria-labelledby="layout_259" href="https://m.info.wiley.com/webApp/cochranenewsletter?id=0" role="menuitem">
            Newsletter
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_177" role="presentation">
<a aria-labelledby="layout_177" href="https://www.wiley.com/en-us/customer-success/cochrane-library-training-hub" role="menuitem">
            Cochrane Library Training
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_44" role="presentation">
<a aria-labelledby="layout_44" href="https://www.cochranelibrary.com/en/help/access" role="menuitem">
            Access
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_150" role="presentation">
<a aria-labelledby="layout_150" href="https://www.cochranelibrary.com/en/help/permissions" role="menuitem">
            Permissions and reprints
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_93" role="presentation">
<a aria-labelledby="layout_93" href="https://www.cochranelibrary.com/en/help/media" role="menuitem">
            Media information
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_97" role="presentation">
<a aria-labelledby="layout_97" href="https://www.cochranelibrary.com/en/help/contact-us" role="menuitem">
            Contact us
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_125" role="presentation">
<a aria-labelledby="layout_125" href="https://www.cochranelibrary.com/en/about/terms-and-conditions" role="menuitem">
            Terms and conditions
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_176" role="presentation">
<a aria-labelledby="layout_176" href="https://cochranesupport.wiley.com/s/article/cochrane-library-known-issues" role="menuitem">
            Known issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_270" role="presentation">
<a aria-labelledby="layout_270" href="https://www.cochranelibrary.com/search-help" role="menuitem">
            Search help
        </a>
</li>
</ul>
</li>
<li class="about-link"><a href="https://www.cochrane.org/about-us" target="_blank"><span>About Cochrane</span><i class="fa fa-caret-right"></i></a></li>
</ul>
</nav>
</div>
<div class="portlet-boundary portlet-boundary_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_">
<span id="p_scolariscontentlanguagebanner_WAR_scolarislanguageportlet"></span>
<section class="portlet" id="portlet_scolariscontentlanguagebanner_WAR_scolarislanguageportlet">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Language\x20Banner\x20Portlet')">
<img alt="" id="etlj__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Language Banner Portlet</span> </span> <span class="portlet-title-text">Scolaris Content Language Banner Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentlanguagebanner_WAR_scolarislanguageportlet" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="" id="content">
<div class="columns-1" id="main-content" role="main">
<div class="portlet-layout row-fluid">
<div class="portlet-column portlet-column-only span12" id="column-1">
<div class="portlet-dropzone portlet-column-content portlet-column-content-only" id="layout-column_column-1">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="rjus__column1__0" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="publication cdsr container"> <div class="article-navigation-container" id="cdsr-nav"> <nav class="article-navigation"> <ul class="tools-row"> <li> <li class="tools pdf pulldown-menu readcube-menu closed en_US"> <a class="pulldown-menu-trigger" href="#0"> <span class="pdf-icon"> <i class="icon fa fa-file-pdf-o"></i> <span>Download PDF</span> </span> <i aria-hidden="true" class="fa fa-caret-down"></i> </a> <ul class="pulldown-menu-items"> <li class=""> <a class="download media pdf-link-full pdf-link" href="/cdsr/doi/10.1002/14651858.CD013631.pub2/pdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> <a class="download media pdf-link-full readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD013631.pub2/epdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> </li> <li class=""> <a class="download media pdf-link-abstract pdf-link" href="/cdsr/doi/10.1002/14651858.CD013631.pub2/pdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> <a class="download media pdf-link-abstract readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD013631.pub2/epdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> </li> </ul> </li> <li class="tools cite cite-article-link" data-article-id="CD013631.PUB2" data-modal-title="Cite this review"> <span><i aria-hidden="true" class="icon fa fa-share"></i></span> <span>Cite this review</span> </li> </li> </ul> <ul class="tools-row tools-secondary"> <li> <li class="tools print print-cdsr-link" data-content-language="en" data-indicator-tooltip="scolaris.print.modal.language.tooltip.en" data-print-options="[{&quot;param&quot;: &quot;abstract&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Abstract&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;چکیده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé scientifique&quot;},{&quot;language&quot;:&quot;ko&quot;,&quot;title&quot;:&quot;초록&quot;},{&quot;language&quot;:&quot;th&quot;,&quot;title&quot;:&quot;บทคัดย่อ&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;摘要&quot;}]},{&quot;param&quot;: &quot;pls&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen en términos sencillos&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;خلاصه به زبان ساده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé simplifié&quot;},{&quot;language&quot;:&quot;hr&quot;,&quot;title&quot;:&quot;Laički sažetak&quot;},{&quot;language&quot;:&quot;id&quot;,&quot;title&quot;:&quot;Saripati tinjauan sistematik&quot;},{&quot;language&quot;:&quot;ja&quot;,&quot;title&quot;:&quot;一般語訳&quot;},{&quot;language&quot;:&quot;ko&quot;,&quot;title&quot;:&quot;쉬운 말 요약&quot;},{&quot;language&quot;:&quot;ms&quot;,&quot;title&quot;:&quot;Ringkasan bahasa mudah&quot;},{&quot;language&quot;:&quot;pl&quot;,&quot;title&quot;:&quot;Streszczenie prostym językiem&quot;},{&quot;language&quot;:&quot;th&quot;,&quot;title&quot;:&quot;ข้อสรุปภาษาธรรมดา&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;简语概要&quot;},{&quot;language&quot;:&quot;zh_HANT&quot;,&quot;title&quot;:&quot;淺顯易懂的口語結論&quot;}]},{&quot;param&quot;: &quot;conclusions&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors' conclusions&quot;}]},{&quot;param&quot;: &quot;summaryOfFindings&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Summary of findings&quot;}]},{&quot;param&quot;: &quot;background&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Background&quot;}]},{&quot;param&quot;: &quot;objectives&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Objectives&quot;}]},{&quot;param&quot;: &quot;methods&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Methods&quot;}]},{&quot;param&quot;: &quot;results&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Results&quot;}]},{&quot;param&quot;: &quot;discussion&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Discussion&quot;}]},{&quot;param&quot;: &quot;references&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;References&quot;}]},{&quot;param&quot;: &quot;appendices&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Appendices&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Search strategies&quot;}]},{&quot;param&quot;: &quot;characteristics&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Characteristics of studies&quot;}]},{&quot;param&quot;: &quot;data&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Analyses&quot;}]},{&quot;param&quot;: &quot;information&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Information&quot;}]},{&quot;param&quot;: &quot;authors&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors&quot;}]},{&quot;param&quot;: &quot;history&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;}]}]" data-print-urlbase="/cdsr/doi/10.1002/14651858.CD013631.pub2/print"> <span><i class="icon fa fa-print"></i></span> <span>Print</span> </li> <li class="js-old-version-modal-trigger tools comments comment-on-review" data-article-id="CD013631.PUB2" data-english-only-message="Please note, that commenting is available in English only. Apologies for any inconvenience." data-href="/cdsr/doi/10.1002/14651858.CD013631.pub2/read-comments" data-new-version="" id="comment-on-review"> <span class="comment-icon"><i class="icon fa fa-comment"></i></span> <span class="comments-count">0</span> <span>Comment</span> </li> <li class="tools share-cdsr-link" data-share-url="/cdsr/doi/10.1002/14651858.CD013631.pub2/full"> <span><i class="icon fa fa-share-alt"></i></span> <span>Share</span> </li> <li class="tools follow"> <span class="article-not-followed cochrane-link signin follow-wrapper"> <span> <i class="icon fa fa-plus"></i> </span> <span> Follow </span> </span> </li> </li> </ul> <div class="metrics-wrapper"> <div class="metrics-count"> <span>Full text views: </span> <span>4394 <i class="icon fa fa-info-circle custom-tooltip" style="padding-left: 2px;color: #962d91;" title="Usage represents full text views on Cochrane Library since January 2022 or 2023. For articles published after this date, the usage represents views since the article was first published on Cochrane Library."> </i> </span> </div> </div> <div class="metrics-wrapper nav-link-section"> <div class="altmetric-embed" data-badge-type="1" data-condensed="true" data-doi="10.1002/14651858.CD013631.pub2" data-link-target="_blank"></div> <div class="inline-status-wrapper guidelines-count" data-count-plural="Cited in $1 guidelines" data-count-single="Cited in 1 guideline"> <a href="related-content#guidelines_data" title="Guidelines"></a> </div> </div> <ul class="nav-section-header"> <li> <h3>Contents</h3> </li> </ul> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013631.pub2/full"> Abstract </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013631.pub2/full#pico"> PICOs </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013631.pub2/full#CD013631-abs-0002"> Plain language summary </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013631.pub2/full#CD013631-sec-0148"> Authors' conclusions </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013631.pub2/full#CD013631-sec-0008"> Summary of findings </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013631.pub2/full#CD013631-sec-0009"> Background </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013631.pub2/full#CD013631-sec-0019"> Objectives </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013631.pub2/full#CD013631-sec-0020"> Methods </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013631.pub2/full#CD013631-sec-0047"> Results </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013631.pub2/full#CD013631-sec-0142"> Discussion </a> </li> <li class="cdsr-nav-link"> <a class="figures-and-tables-link" href="/cdsr/doi/10.1002/14651858.CD013631.pub2/#"> Figures and tables </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013631.pub2/references"> References </a> </li> </ul> <div class="nav-section-header"> <h3>Supplementary materials</h3> </div> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013631.pub2/appendices#CD013631-sec-0153"> Search strategies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013631.pub2/references#characteristicStudies"> Characteristics of studies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013631.pub2/references#dataAndAnalyses"> Analyses </a> </li> <li class="cdsr-nav-link download-stats-data-link" data-download-href="/cdsr/doi/10.1002/14651858.CD013631.pub2/media/CDSR/CD013631/supinfo/CD013631-dataPackage.zip?content-disposition=attachment&amp;mime-type=application/octet-stream"> <a href="/cdsr/doi/10.1002/14651858.CD013631.pub2/media/CDSR/CD013631/supinfo/CD013631-dataPackage.zip?content-disposition=attachment&amp;mime-type=application/octet-stream"> Download data </a> </li> </ul> <ul class="tools-row"> <li> </li> </ul> <ul class="nav-section-header"> <li><h3>Related</h3></li> </ul> <ul class="linked-content linked-content-dropdown" id="linked-content-articles" tabindex="0"> <li class="linked-cca" data-type="cca"> <div class="linked-content-section"> <span class="linked-type">Cochrane Clinical Answers<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-editorials" data-type="editorial"> <div class="linked-content-section"> <span class="linked-type">Editorials<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-podcasts" data-type="podcast"> <div class="linked-content-section"> <span class="linked-type">Podcasts<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-sc" data-type="sc"> <div class="linked-content-section"> <span class="linked-type">Special Collections<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> </ul> <div class="nav-section-header"> <h3>About this review</h3> </div> <ul class="nav-long-form nav-info nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013631.pub2/information"> <i> <svg viewbox="0 0 24 24"> <path d="M11,9H13V7H11M12,20C7.59,20 4,16.41 4,12C4,7.59 7.59,4 12,4C16.41,4 20,7.59 20,12C20,16.41 16.41,20 12,20M12,2A10,10 0 0,0 2,12A10,10 0 0,0 12,22A10,10 0 0,0 22,12A10,10 0 0,0 12,2M11,17H13V11H11V17Z"></path> </svg> </i> Information </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013631.pub2/information#authors"> <i> <svg viewbox="0 0 24 24"> <path d="M12,5.5A3.5,3.5 0 0,1 15.5,9A3.5,3.5 0 0,1 12,12.5A3.5,3.5 0 0,1 8.5,9A3.5,3.5 0 0,1 12,5.5M5,8C5.56,8 6.08,8.15 6.53,8.42C6.38,9.85 6.8,11.27 7.66,12.38C7.16,13.34 6.16,14 5,14A3,3 0 0,1 2,11A3,3 0 0,1 5,8M19,8A3,3 0 0,1 22,11A3,3 0 0,1 19,14C17.84,14 16.84,13.34 16.34,12.38C17.2,11.27 17.62,9.85 17.47,8.42C17.92,8.15 18.44,8 19,8M5.5,18.25C5.5,16.18 8.41,14.5 12,14.5C15.59,14.5 18.5,16.18 18.5,18.25V20H5.5V18.25M0,20V18.5C0,17.11 1.89,15.94 4.45,15.6C3.86,16.28 3.5,17.22 3.5,18.25V20H0M24,20H20.5V18.25C20.5,17.22 20.14,16.28 19.55,15.6C22.11,15.94 24,17.11 24,18.5V20Z"></path> </svg> </i> Authors </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013631.pub2/information#history"> <i> <svg viewbox="0 0 24 24"> <path d="M13.5,8H12V13L16.28,15.54L17,14.33L13.5,12.25V8M13,3A9,9 0 0,0 4,12H1L4.96,16.03L9,12H6A7,7 0 0,1 13,5A7,7 0 0,1 20,12A7,7 0 0,1 13,19C11.07,19 9.32,18.21 8.06,16.94L6.64,18.36C8.27,20 10.5,21 13,21A9,9 0 0,0 22,12A9,9 0 0,0 13,3"></path> </svg> </i> Version history </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD013631.pub2/information#keywords"> <i> <svg viewbox="0 0 24 24"> <path d="M11 3C10.18 3 9.44 3.5 9.14 4.27L3.64 18.27C3.12 19.58 4.09 21 5.5 21H7.75C8.59 21 9.33 20.5 9.62 19.7L10.26 18H13.74L14.38 19.7C14.67 20.5 15.42 21 16.25 21H18.5C19.91 21 20.88 19.58 20.36 18.27L14.86 4.27C14.56 3.5 13.82 3 13 3M11 5H13L18.5 19H16.25L15.12 16H8.87L7.75 19H5.5M12 7.67L9.62 14H14.37Z"></path> </svg> </i> Keywords (MeSH, PICOs) </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD013631.pub2/related-content"> <i class="icon fa fa-sitemap fa-rotate-270"></i> Related content </a> </li> <li class="cdsr-nav-link translation-notes-link"> <a href="/cdsr/doi/10.1002/14651858.CD013631.pub2/#"> <i> <svg viewbox="0 0 24 24"> <path d="M12.87,15.07L10.33,12.56L10.36,12.53C12.1,10.59 13.34,8.36 14.07,6H17V4H10V2H8V4H1V6H12.17C11.5,7.92 10.44,9.75 9,11.35C8.07,10.32 7.3,9.19 6.69,8H4.69C5.42,9.63 6.42,11.17 7.67,12.56L2.58,17.58L4,19L9,14L12.11,17.11L12.87,15.07M18.5,10H16.5L12,22H14L15.12,19H19.87L21,22H23L18.5,10M15.88,17L17.5,12.67L19.12,17H15.88Z"></path> </svg> </i> Translation notes </a> </li> <li class="cdsr-nav-link"> <a class="request-permissions" data-copyright="Copyright © 2023 The Cochrane Collaboration. Published by John Wiley &amp; Sons, Ltd." data-creative-commons="false" href="/cdsr/doi/10.1002/14651858.CD013631.pub2/#"> <span class="request-permissions-icon"></span> Request permissions </a> </li> <li class="cdsr-nav-link"> <a href="/data"> <i class="icon fa fa-database"></i> Request data reuse </a> </li> </ul> </nav> </div> <article> <div class="cdsr-header-top"> <div class="cdsr-header-left"> <a class="publish-database" href="/">Cochrane Database of Systematic reviews</a> <span class="publish-type">Review - Intervention</span> </div> <div class="cdsr-header-right"> </div> </div> <header class="publication-header"> <h1 class="publication-title" lang="en">Synbiotics, prebiotics and probiotics for people with chronic kidney disease</h1> <div class="publication-metadata-block"> <div class="publication-authors"> <div class="publish-meta-wrapper"> <ul class="authors"> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD013631.pub2/information#CD013631-cr-0004"><i class="icon corresponding-author fa fa-envelope"></i>Tess E Cooper</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD013631.pub2/information#CD013631-cr-0005">Rabia Khalid</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD013631.pub2/information#CD013631-cr-0006">Samuel Chan</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD013631.pub2/information#CD013631-cr-0007">Jonathan C Craig</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD013631.pub2/information#CD013631-cr-0008">Carmel M Hawley</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD013631.pub2/information#CD013631-cr-0009">Martin Howell</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD013631.pub2/information#CD013631-cr-0010">David W Johnson</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD013631.pub2/information#CD013631-cr-0011">Allison Jaure</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD013631.pub2/information#CD013631-cr-0012">Armando Teixeira-Pinto</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD013631.pub2/information#CD013631-cr-0013">Germaine Wong</a></li> </ul> <span class="author declaration"> <a class="declarationsOfInterestLink" href="/cdsr/doi/10.1002/14651858.CD013631.pub2/information/en#CD013631-sec-0162">Authors' declarations of interest</a> </span> </div> </div> </div> <div class="publication-metadata-block"> <p> <span class="publish-date">Version published: 23 October 2023 </span> <a class="whatsNewLink" href="/cdsr/doi/10.1002/14651858.CD013631.pub2/information/en#versionTable">Version history</a> </p> <div class="doi-header"> <a href="https://doi.org/10.1002/14651858.CD013631.pub2">https://doi.org/10.1002/14651858.CD013631.pub2</a> </div> </div> </header> <div class="publication-control-bar"> <span class="publication-control-button publication-control-collapse"> Collapse all </span> <span class="publication-control-button publication-control-expand"> Expand all </span> </div> <section class="abstract"> <div class="section-header section-collapse-header" id="CD013631-abs-0001" lang="en"> <h2 class="title section-collapse-title"> Abstract <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD013631-abs-0001">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD013631-abs-0019">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD013631-abs-0013">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD013631-abs-0016">Français</a> </li> <li class="section-language"> <a class="" href="full/ko#CD013631-abs-0006">한국어</a> </li> <li class="section-language"> <a class="" href="full/th#CD013631-abs-0008">ภาษาไทย</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD013631-abs-0003">简体中文</a> </li> </nav> </div> </div> <div class="abstract full_abstract" id="CD013631-abs-0001" lang="en"> <section id="CD013631-sec-0001"> <h3 class="title" id="CD013631-sec-0001">Background</h3> <p>Chronic kidney disease (CKD) is a major public health problem affecting 13% of the global population. Prior research has indicated that CKD is associated with gut dysbiosis. Gut dysbiosis may lead to the development and/or progression of CKD, which in turn may in turn lead to gut dysbiosis as a result of uraemic toxins, intestinal wall oedema, metabolic acidosis, prolonged intestinal transit times, polypharmacy (frequent antibiotic exposures) and dietary restrictions used to treat CKD. Interventions such as synbiotics, prebiotics, and probiotics may improve the balance of the gut flora by altering intestinal pH, improving gut microbiota balance and enhancing gut barrier function (i.e. reducing gut permeability). </p> </section> <section id="CD013631-sec-0002"> <h3 class="title" id="CD013631-sec-0002">Objectives</h3> <p>This review aimed to evaluate the benefits and harms of synbiotics, prebiotics, and probiotics for people with CKD. </p> </section> <section id="CD013631-sec-0003"> <h3 class="title" id="CD013631-sec-0003">Search methods</h3> <p>We searched the Cochrane Kidney and Transplant Register of Studies up to 9 October 2023 through contact with the Information Specialist using search terms relevant to this review. Studies in the Register are identified through searches of CENTRAL, MEDLINE, and EMBASE, conference proceedings, the International Clinical Trials Registry Platform (ICTRP) Search Portal and ClinicalTrials.gov. </p> </section> <section id="CD013631-sec-0004"> <h3 class="title" id="CD013631-sec-0004">Selection criteria</h3> <p>We included randomised controlled trials (RCTs) measuring and reporting the effects of synbiotics, prebiotics, or probiotics in any combination and any formulation given to people with CKD (CKD stages 1 to 5, including dialysis and kidney transplant). Two authors independently assessed the retrieved titles and abstracts and, where necessary, the full text to determine which satisfied the inclusion criteria. </p> </section> <section id="CD013631-sec-0005"> <h3 class="title" id="CD013631-sec-0005">Data collection and analysis</h3> <p>Data extraction was independently carried out by two authors using a standard data extraction form. Summary estimates of effect were obtained using a random‐effects model, and results were expressed as risk ratios (RR) and their 95% confidence intervals (CI) for dichotomous outcomes, and mean difference (MD) or standardised mean difference (SMD) and 95% CI for continuous outcomes. The methodological quality of the included studies was assessed using the Cochrane risk of bias tool. Data entry was carried out by one author and cross‐checked by another. Confidence in the evidence was assessed using the Grading of Recommendations Assessment, Development and Evaluation (GRADE) approach. </p> </section> <section id="CD013631-sec-0006"> <h3 class="title" id="CD013631-sec-0006">Main results</h3> <p>Forty‐five studies (2266 randomised participants) were included in this review. Study participants were adults (two studies in children) with CKD ranging from stages 1 to 5, with patients receiving and not receiving dialysis, of whom half also had diabetes and hypertension. </p> <p>No studies investigated the same synbiotic, prebiotic or probiotic of similar strains, doses, or frequencies. Most studies were judged to be low risk for selection bias, performance bias and reporting bias, unclear risk for detection bias and for control of confounding factors, and high risk for attrition and other biases. </p> <p>Compared to prebiotics, it is uncertain whether synbiotics improve estimated glomerular filtration rate (eGFR) at four weeks (1 study, 34 participants: MD ‐3.80 mL/min/1.73 m², 95% CI ‐17.98 to 10.38), indoxyl sulfate at four weeks (1 study, 42 participants: MD 128.30 ng/mL, 95% CI ‐242.77 to 499.37), change in gastrointestinal (GI) upset (borborymgi) at four weeks (1 study, 34 participants: RR 15.26, 95% CI 0.99 to 236.23), or change in GI upset (Gastrointestinal Symptom Rating Scale) at 12 months (1 study, 56 participants: MD 0.00, 95% CI ‐0.27 to 0.27), because the certainty of the evidence was very low. </p> <p>Compared to certain strains of prebiotics, it is uncertain whether a different strain of prebiotics improves eGFR at 12 weeks (1 study, 50 participants: MD 0.00 mL/min, 95% CI ‐1.73 to 1.73), indoxyl sulfate at six weeks (2 studies, 64 participants: MD ‐0.20 μg/mL, 95% CI ‐1.01 to 0.61; I² = 0%) or change in any GI upset, intolerance or microbiota composition, because the certainty of the evidence was very low. </p> <p>Compared to certain strains of probiotics, it is uncertain whether a different strain of probiotic improves eGFR at eight weeks (1 study, 30 participants: MD ‐0.64 mL/min, 95% CI ‐9.51 to 8.23; very low certainty evidence). </p> <p>Compared to placebo or no treatment, it is uncertain whether synbiotics improve eGFR at six or 12 weeks (2 studies, 98 participants: MD 1.42 mL/min, 95% CI 0.65 to 2.2) or change in any GI upset or intolerance at 12 weeks because the certainty of the evidence was very low. </p> <p>Compared to placebo or no treatment, it is uncertain whether prebiotics improves indoxyl sulfate at eight weeks (2 studies, 75 participants: SMD ‐0.14 mg/L, 95% CI ‐0.60 to 0.31; very low certainty evidence) or microbiota composition because the certainty of the evidence is very low. </p> <p>Compared to placebo or no treatment, it is uncertain whether probiotics improve eGFR at eight, 12 or 15 weeks (3 studies, 128 participants: MD 2.73 mL/min, 95% CI ‐2.28 to 7.75; I² = 78%), proteinuria at 12 or 24 weeks (1 study, 60 participants: MD ‐15.60 mg/dL, 95% CI ‐34.30 to 3.10), indoxyl sulfate at 12 or 24 weeks (2 studies, 83 participants: MD ‐4.42 mg/dL, 95% CI ‐9.83 to 1.35; I² = 0%), or any change in GI upset or intolerance because the certainty of the evidence was very low. Probiotics may have little or no effect on albuminuria at 12 or 24 weeks compared to placebo or no treatment (4 studies, 193 participants: MD 0.02 g/dL, 95% CI ‐0.08 to 0.13; I² = 0%; low certainty evidence). </p> <p>For all comparisons, adverse events were poorly reported and were minimal (flatulence, nausea, diarrhoea, abdominal pain) and non‐serious, and withdrawals were not related to the study treatment. </p> </section> <section id="CD013631-sec-0007"> <h3 class="title" id="CD013631-sec-0007">Authors' conclusions</h3> <p>We found very few studies that adequately test biotic supplementation as alternative treatments for improving kidney function, GI symptoms, dialysis outcomes, allograft function, patient‐reported outcomes, CVD, cancer, reducing uraemic toxins, and adverse effects. </p> <p>We are not certain whether synbiotics, prebiotics, or probiotics are more or less effective compared to one another, antibiotics, or standard care for improving patient outcomes in people with CKD. Adverse events were uncommon and mild. </p> </section> </div> </section> <section class="pico-section" id="pico"> <h2 class="title section-collapse-title">PICOs <i class="icon fa fa-info-circle" title="The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome."></i> <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-content" style="display: block;"> <h3 class="keyword-heading">PICOs</h3> <div class="pico-table"> <div class="pico-column Population"> <h6>Population<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Intervention"> <h6>Intervention<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Comparison"> <h6>Comparison<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Outcome"> <h6>Outcome<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> </div> <div class="pico-information"> <p><i class="icon fa fa-info-circle"></i> The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome.</p> <p>See more on using PICO in the <a href="https://training.cochrane.org/handbook/current/chapter-02#section-2-3">Cochrane Handbook</a>.</p> </div> </div> </section> <section class="pls"> <div class="section-header section-collapse-header" id="CD013631-abs-0002" lang="en"> <h2 class="title section-collapse-title"> Plain language summary <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD013631-abs-0002">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD013631-abs-0020">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD013631-abs-0014">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD013631-abs-0017">Français</a> </li> <li class="section-language"> <a class="" href="full/hr#CD013631-abs-0012">Hrvatski</a> </li> <li class="section-language"> <a class="" href="full/id#CD013631-abs-0015">Bahasa Indonesia</a> </li> <li class="section-language"> <a class="" href="full/ja#CD013631-abs-0011">日本語</a> </li> <li class="section-language"> <a class="" href="full/ko#CD013631-abs-0007">한국어</a> </li> <li class="section-language"> <a class="" href="full/ms#CD013631-abs-0010">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="full/pl#CD013631-abs-0018">Polski</a> </li> <li class="section-language"> <a class="" href="full/th#CD013631-abs-0009">ภาษาไทย</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD013631-abs-0004">简体中文</a> </li> <li class="section-language"> <a class="" href="full/zh_HANT#CD013631-abs-0005">繁體中文</a> </li> </nav> </div> </div> <div class="abstract abstract_plainLanguageSummary" id="CD013631-abs-0002" lang="en"> <h3>Prebiotics (dietary fibre), probiotics (good bacteria) or synbiotics (prebiotics plus probiotics) for people with chronic kidney disease </h3> <p><b>Key messages</b> </p> <p>Chronic kidney disease (CKD) is a serious health problem that affects over 850 million people worldwide. People with kidney disease have an unhealthy balance of good and bad bacteria in their guts, called 'gut dysbiosis'. This imbalance arises because of the effects of reduced kidney function (retained toxic waste products, fluid retention causing the gut wall to swell), drugs frequently used in people with CKD (especially antibiotics), and dietary restrictions placed on people with CKD. </p> <p>Gut dysbiosis can, in turn, cause or worsen CKD because bacteria can produce toxins that cross the bowel wall and damage the kidneys. Gut dysbiosis can also cause stomach problems (like bloating, cramping, constipation and diarrhoea) and reduce quality of life. </p> <p>To improve the balance of the gut flora, good bacteria can be taken in tablets of high doses of prebiotics and probiotics. Prebiotics, or indigestible plant fibre, can encourage the growth of good bacteria. Synbiotics are a combination of prebiotics and probiotics. Some research suggests that taking high doses of the good bacteria can re‐balance the good bacteria in people's gut, thereby improving bowel symptoms and the conditions that lead to worsening of CKD. </p> <p><b>What did we do?</b> </p> <p>We reviewed all of the evidence on synbiotics, prebiotics and probiotics to see whether they can improve outcomes in people who have CKD (all stages 1 to 5). </p> <p><b>What did we find?</b> </p> <p>We found 45 studies randomising 2266 participants. Half of these looked at participants receiving dialysis (mostly haemodialysis), and the other half not receiving dialysis. Half also had diabetes and hypertension. </p> <p>We are uncertain whether synbiotics, prebiotics, or probiotics improve bowel outcomes, quality of life, kidney toxin levels or kidney function. </p> <p>The quality of the evidence that we found is low quality and very low certainty. All studies were conducted using moderate to poor‐quality methods with too few patients. </p> <p><b>Summary</b> </p> <p>Currently, we do not have enough information from trials to know whether synbiotics, prebiotics or probiotics work to improve bowel symptoms, quality of life, kidney toxin levels, or kidney function in people with CKD. Ten studies are currently ongoing; therefore, it is possible that findings may change with the inclusion of these studies in future updates. </p> <p>The evidence is up to date to 9 October 2023.</p> </div> </section> <section id="vls" style="display: none"> <div class="section-header section-collapse-header"> <h2 class="title section-collapse-title">Visual summary<i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i></h2> </div> <a href="" target="_blank"><img alt="visual summary" src=""/></a> </section> <section class="conclusions"> <div class="section-header section-collapse-header" id="CD013631-sec-0148" lang="en"> <h2 class="title section-collapse-title"> Authors' conclusions <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="authorsConclusions" lang="en"> <div class="section-header" id="CD013631-sec-0148"></div> <h3 class="title" id="CD013631-sec-0149">Implications for practice</h3> <section id="CD013631-sec-0149"> <p>We found very few studies that adequately test biotic supplementation as an alternative treatment to improve GI symptoms, kidney function, uraemic toxins, allograft function, dialysis outcomes, QoL, CVD, cancer, and adverse events for people with CKD. </p> <p>There is currently no evidence to support or refute the use of synbiotics, prebiotics, or probiotics in people with CKD, and findings should be viewed with caution. </p> <p>We are not certain whether synbiotics, prebiotics, or probiotics are more or less effective compared to one another, antibiotics, or standard care for improving patient outcomes in people with CKD. Adverse events were uncommon and mild. Twenty‐six studies are currently ongoing; therefore, it is possible findings may change with the inclusion of these studies in future updates. </p> </section> <h3 class="title" id="CD013631-sec-0150">Implications for research</h3> <section id="CD013631-sec-0150"> <p>To effectively examine the efficacy of synbiotics, prebiotics, or probiotics in people with CKD, future research in this field requires adequately powered, longer‐term RCTs comparing synbiotics, prebiotics, and probiotics separately (and with a placebo) measuring standardised strains, dosing and frequency as well as a standard set of core kidney transplant and core CKD outcomes (<a href="./references#CD013631-bbs2-0137" title="SONG Initiative. The SONG Handbook Version 1.0. www.songinitiative.org/reports-and-publications/2017.">SONG 2017</a>). </p> </section> </section> </section> <section class="summaryOfFindings"> <div class="section-header section-collapse-header" id="CD013631-sec-0008" lang="en"> <h2 class="title section-collapse-title"> Summary of findings <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="summaryOfFindings" lang="en"> <div class="section-header" id="CD013631-sec-0008"></div> <div class="table" id="CD013631-tbl-0001"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Synbiotic versus another synbiotic for people with chronic kidney disease</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Synbiotic versus another synbiotic for people with chronic kidney disease</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Patient or population:</b> people with CKD<br/><b>Setting:</b> hospital or primary care<br/><b>Intervention:</b> synbiotic 2<br/><b>Comparison:</b> synbiotic 1 </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>No. of participants<br/>(RCTs)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with synbiotic 1</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with synbiotic 2</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>eGFR</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Albuminuria or proteinuria</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Indoxyl sulfate</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Change in any GI upset or intolerance</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Microbiota composition</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Graft function</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Graft infection</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% CI) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><br/><b>CI:</b> confidence interval; <b>CKD:</b> chronic kidney disease; <b>eGFR:</b> (estimated) glomerular filtration rate; <b>GI:</b> gastrointestinal; RCT: randomised controlled trial; <b>RR:</b> risk ratio. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="6"> <div class="table-footnote"> <p>No data were reported for these outcomes under this comparison.</p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD013631-tbl-0002"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Synbiotic versus prebiotic for people with chronic kidney disease</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Synbiotic versus prebiotic for people with chronic kidney disease</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Patient or population:</b> people with CKD<br/><b>Setting:</b> hospital or primary care<br/><b>Intervention:</b> synbiotic<br/><b>Comparison:</b> prebiotic </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>No. of participants<br/>(RCTs)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with prebiotic</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with synbiotic</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>eGFR</b> </p> <p>(mL/min)</p> <p>Follow‐up: 4 weeks</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>CKD stage 3Ga (transplant)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>34 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/><b>very low<sup>1</sup> </b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>The mean eGFR was 3.8 mL/min lower (17.98 lower to 10.38 higher) with synbiotic compared prebiotic </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Albuminuria or proteinuria</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Indoxyl sulfate</b> </p> <p>(ng/mL)</p> <p>Follow‐up: 4 weeks</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>CKD stage G5D</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>42 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/><b>very low<sup>1</sup> </b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>The mean indoxyl sulfate was 128.3 ng/mL higher (242.77 lower to 499.37 higher) with synbiotic compared prebiotic </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Change in any GI upset (borborygmi)</b> </p> <p>Follow‐up: 4 weeks</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>CKD stage 3Ga (transplant)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 15.26<br/>(0.99 to 236.23) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>34 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/><b>very low<sup>1</sup> </b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0 per 1,000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0 per 1,000<br/>(0 to 0) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p><b>Change in any GI upset (GSRS total index)</b> </p> <p>Follow‐up: 12 months</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>CKD stage 3 to 4</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>56 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>⊕⊝⊝⊝<br/><b>very low<sup>1</sup> </b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p>The mean change in any GI upset was 0.00 (0.27 lower to 0.27 higher) with synbiotic compared prebiotic </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Microbiota composition</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Graft function</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Graft infection</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% CI) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><br/><b>CI:</b> confidence interval; <b>CKD:</b> chronic kidney disease; <b>eGFR:</b> estimated glomerular filtration rate; <b>GI:</b> gastrointestinal; <b>RR:</b> risk ratio; <b>RCT:</b> randomised controlled trial </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="6"> <div class="table-footnote"> <p><sup>1</sup> Downgraded twice for serious risk of bias, and once for sparse or small study data. </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD013631-tbl-0003"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">Prebiotic versus another prebiotic for people with chronic kidney disease</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Prebiotic versus another prebiotic for people with chronic kidney disease</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Patient or population:</b> people with CKD<br/><b>Setting:</b> hospital or primary care<br/><b>Intervention:</b> prebiotic 2<br/><b>Comparison:</b> prebiotic 1 </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>No. of participants<br/>(RCTs)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> </tr> <tr class="table-header separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with prebiotic 1</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with prebiotic 2</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>eGFR</b> </p> <p>(mL/min)</p> <p>Follow‐up: 12 weeks</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>CKD stage 3 to 5 (non‐dialysis)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>50 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/><b>very low<sup>1</sup> </b> </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>The mean eGFR was 0 mL/min lower (1.73 lower to 1.73 higher) with prebiotic 2 compared to prebiotic 1 </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Albuminuria or proteinuria</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Indoxyl sulfate</b> </p> <p>(μg/mL)</p> <p>Follow‐up: 6 weeks</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>CKD stage G5D with diabetes</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>64 (2)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/><b>very low<sup>1</sup> </b> </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>The mean indoxyl sulfate was 0.2 μg/mL lower (1.01 lower to 0.61 higher) with prebiotic 2 compared to prebiotic 1 </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Change in any GI upset or intolerance</b> </p> <p>Follow‐up: 4 weeks</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>CKD stage G5D with diabetes</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="8" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="8" valign="top"> <p>24 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="8" valign="top"> <p>⊕⊝⊝⊝<br/><b>very low<sup>1</sup> </b> </p> </td> </tr> <tr class="separated"> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Burping</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>The mean burping was 0.17 higher (0.5 lower to 0.84 higher) with prebiotic 2 compared to prebiotic 1 </p> </td> </tr> <tr class="separated"> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cramping</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>The mean cramping was 0.17 lower (0.5 lower to 0.16 higher) with prebiotic 2 compared to prebiotic 1 </p> </td> </tr> <tr class="separated"> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Distension</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>The mean distension was 0.33 higher (0.04 lower to 0.7 higher) with prebiotic 2 compared to prebiotic 1 </p> </td> </tr> <tr class="separated"> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Flatulence</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>The mean flatulence was 1 higher (0.25 higher to 1.75 higher) with prebiotic 2 compared to prebiotic 1 </p> </td> </tr> <tr class="separated"> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Nausea</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>The mean nausea was 0 (0 to 0 ) with prebiotic 2 compared to prebiotic 1</p> </td> </tr> <tr class="separated"> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Reflux</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>The mean reflux was 0 (0.5 lower to 0.5 higher) with prebiotic 2 compared to prebiotic 1 </p> </td> </tr> <tr class="separated"> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Rumblings</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>The mean rumblings was 0.5 higher (0.14 lower to 1.14 higher) with prebiotic 2 compared to prebiotic 1 </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Microbiota composition</b> </p> <p>Follow‐up: 4 weeks</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>CKD stage G5D with diabetes</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="14" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="14" valign="top"> <p>24 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="14" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><i>Actinobacteria</i> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>The mean <i>Actinobacteria</i> was 1.26 lower (4.46 lower to 1.94 higher) with prebiotic 2 compared to prebiotic 1 </p> </td> </tr> <tr class="separated"> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><i>Bacteriodetes</i> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>The mean <i>Bacteriodetes</i> was 3.23 higher (8.24 lower to 14.7 higher) with prebiotic 2 compared to prebiotic 1 </p> </td> </tr> <tr class="separated"> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><i>Proteobacteria</i> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>The mean <i>Proteobacteria</i> was 0.11 higher (1.61 lower to 1.83 higher) with prebiotic 2 compared to prebiotic 1 </p> </td> </tr> <tr class="separated"> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><i>Firmicutes</i> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>The mean <i>Firmicutes</i> was 2.44 lower (14.19 lower to 9.31 higher) with prebiotic 2 compared to prebiotic 1 </p> </td> </tr> <tr class="separated"> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><i>Synergistetes</i> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>The mean <i>Synergistetes</i> was MD 0.25 lower (0.89 lower to 0.39 higher) with prebiotic 2 compared to prebiotic 1 </p> </td> </tr> <tr class="separated"> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><i>Verrucomicrobia</i> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>The mean <i>Verrucomicrobia</i> was 0.96 higher (1.36 lower to 3.28 higher) with prebiotic 2 compared to prebiotic 1 </p> </td> </tr> <tr class="separated"> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Faecal acetate</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>The mean faecal acetate was 69.91 lower (203.95 lower to 64.13 higher) with prebiotic 2 compared to prebiotic 1 </p> </td> </tr> <tr class="separated"> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Faecal propionate</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>The mean faecal propionate was 19.35 lower (63.87 lower to 25.17 higher) with prebiotic 2 compared to prebiotic 1 </p> </td> </tr> <tr class="separated"> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Faecal butyrate</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>The mean faecal butyrate was 11.04 lower (39.57 lower to 17.49 higher) with prebiotic 2 compared to prebiotic 1 </p> </td> </tr> <tr class="separated"> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Faecal total short‐chain fatty acids</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>The mean faecal total short‐chain fatty acids were 104.71 lower (293.34 lower to 83.92 higher) with prebiotic 2 compared to prebiotic 1 </p> </td> </tr> <tr class="separated"> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Faecal total short‐chain fatty acids</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>The mean faecal total short‐chain fatty acids were 104.71 lower (293.34 lower to 83.92 higher) with prebiotic 2 compared to prebiotic 1 </p> </td> </tr> <tr class="separated"> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Faecal indoles</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>The mean faecal indoles were 2.71 higher (69.78 lower to 75.2 higher) with prebiotic 2 compared to prebiotic 1 </p> </td> </tr> <tr class="separated"> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Faecal P‐cresol</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>The mean faecal p‐cresol was 28.84 higher (105.07 lower to 162.75 higher) with prebiotic 2 compared to prebiotic 1 </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Graft function</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Graft infection</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% CI) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><br/><b>CKD:</b> chronic kidney disease; <b>CI:</b> confidence interval; <b>eGFR:</b> estimated glomerular filtration rate; <b>GI:</b> gastrointestinal; <b>RR:</b> risk ratio; <b>RCT:</b> randomised controlled trial </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="6"> <div class="table-footnote"> <p><sup>1</sup> Downgraded twice for serious risk of bias, and once for sparse or small study data. </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD013631-tbl-0004"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 4.</span> <span class="table-title">Prebiotic versus probiotic for people with chronic kidney disease</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>Prebiotic versus probiotic for people with chronic kidney disease</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>Patient or population:</b> people with CKD </p> <p><b>Settings:</b> hospital or primary care </p> <p><b>Intervention:</b> prebiotic </p> <p><b>Comparison:</b> probiotic </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>No. of participants<br/>(RCTs)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Quality of the evidence<br/>(GRADE)</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Assumed risk</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Corresponding risk</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with probiotic</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with prebiotic</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>eGFR</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Albuminuria or proteinuria</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Indoxyl sulfate</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Change in any GI upset or intolerance</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Microbiota composition</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Graft function</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Graft infection</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% CI) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). </p> <p><b>CKD:</b> chronic kidney disease; <b>CI:</b> confidence interval; <b>eGFR:</b> estimated glomerular filtration rate; <b>GI:</b> gastrointestinal; <b>RCT:</b> randomised controlled trial </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/><b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/><b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/><b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/><b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="6"> <div class="table-footnote"> <p>No data were reported for these outcomes under this comparison.</p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD013631-tbl-0005"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 5.</span> <span class="table-title">Probiotic versus another probiotic for people with chronic kidney disease</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Probiotic versus another probiotic for people with chronic kidney disease</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Patient or population:</b> people with CKD<br/><b>Setting:</b> hospital or primary care<br/><b>Intervention:</b> probiotic 2<br/><b>Comparison:</b> probiotic 1 </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>No. of participants<br/>(RCTs)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with probiotic 1</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with probiotic 2</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>eGFR</b> </p> <p>(mL/min)</p> <p>Follow‐up: 8 weeks</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>CKD stage G3 to G4</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>30 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/><b>very low<sup>1</sup> </b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>The mean eGFR was 0.64 mL/min lower (9.51 lower to 8.23 higher) with probiotic 2 than probiotic 1 </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Albuminuria or proteinuria</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Indoxyl sulfate</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Change in any GI upset or intolerance</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Microbiota composition</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Graft function</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Graft infection</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% CI) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><br/><b>CKD:</b> chronic kidney disease; <b>CI:</b> confidence interval; <b>eGFR:</b> estimated glomerular filtration rate; <b>GI:</b> gastrointestinal; <b>RR:</b> risk ratio; <b>RCT:</b> randomised controlled trial </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="6"> <div class="table-footnote"> <p><sup>1</sup> Downgraded twice for serious risk of bias, and once for sparse or small study data. </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD013631-tbl-0006"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 6.</span> <span class="table-title">Synbiotic versus placebo or no treatment for people with chronic kidney disease</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Synbiotic versus placebo or no treatment for people with chronic kidney disease</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Patient or population:</b> people with CKD<br/><b>Setting:</b> hospital or primary care<br/><b>Intervention:</b> synbiotic<br/><b>Comparison:</b> placebo or no treatment </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>No. of participants<br/>(RCTs)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> </tr> <tr class="table-header separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with placebo or no treatment</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with synbiotic</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>eGFR</b> </p> <p>(mL/min)</p> <p>Follow‐up: 6 or 12 weeks</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>CKD stage G3b</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>98 (2)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/><b>very low<sup>1</sup> </b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>The mean eGFR was 1.42 mL/min higher (0.65 higher to 2.2 higher) with synbiotic than placebo or no treatment </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Albuminuria or proteinuria</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Indoxyl sulfate</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Change in any GI upset or intolerance</b> </p> <p>(GSRS)</p> <p>Follow‐up: 12 weeks</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>CKD stage 3b</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="5" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="5" valign="top"> <p>23 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="5" valign="top"> <p>⊕⊝⊝⊝<br/><b>very low<sup>1</sup> </b> </p> </td> </tr> <tr class="separated"> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Rumbling</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>The mean rumbling was 0.54 GSRS lower (0.77 lower to 0.31 lower) with synbiotic than placebo or no treatment </p> </td> </tr> <tr class="separated"> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Hard stools</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>The mean hard stools was 0.09 GSRS lower (0.35 lower to 0.17 higher) with synbiotic than placebo or no treatment </p> </td> </tr> <tr class="separated"> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Abdominal pain</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>The mean abdominal pain was 0.22 GSRS higher (0.02 lower to 0.46 higher) with synbiotic than placebo or no treatment </p> </td> </tr> <tr class="separated"> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Constipation syndrome</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>The mean constipation syndrome was 0.17 GSRS lower (0.72 lower to 0.38 higher) with synbiotic than placebo or no treatment </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Microbiota composition</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Graft function</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Graft infection</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% CI) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><br/><b>CKD:</b> chronic kidney disease; <b>CI:</b> confidence interval; <b>eGFR:</b> estimated glomerular filtration rate; <b>GI:</b> gastrointestinal; <b>RR:</b> risk ratio; <b>RCT:</b> randomised controlled trial </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="6"> <div class="table-footnote"> <p><sup>1</sup> Downgraded twice for serious risk of bias, and once for sparse or small study data. </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD013631-tbl-0007"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 7.</span> <span class="table-title">Prebiotic versus placebo or no treatment for people with chronic kidney disease</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Prebiotic versus placebo or no treatment for people with chronic kidney disease</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Patient or population:</b> people with CKD<br/><b>Setting:</b> hospital or primary care<br/><b>Intervention:</b> prebiotic<br/><b>Comparison:</b> placebo or no treatment </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>No. of participants<br/>(RCTs)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> </tr> <tr class="table-header separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with placebo or no treatment</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with prebiotic</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>eGFR</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Albuminuria or proteinuria</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Indoxyl sulfate</b> </p> <p>(mg/L)</p> <p>Follow‐up: 8 weeks</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>CKD stage G5D</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>75 (2)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/><b>very low<sup>1</sup> </b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>The mean indoxyl sulfate was 0.14 mg/L lower (0.6 lower to 0.31 higher) with prebiotic than placebo or no treatment </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Any change in GI upset or intolerance</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Microbiota composition</b> </p> <p>Follow‐up: 8 weeks</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>CKD stage 5GD</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p>44 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p>⊕⊝⊝⊝<br/><b>very low<sup>1</sup> </b> </p> </td> </tr> <tr class="separated"> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><i>Faecalibacterium</i> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>The mean <i>Faecalibacterium</i> was 2.37 higher (0.23 higher to 4.51 higher) with prebiotic than placebo or no treatment </p> </td> </tr> <tr class="separated"> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><i>Parabacteroides</i> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>The mean <i>Parabacteroides</i> was 0.22 higher (0.06 higher to 0.38 higher) with prebiotic than placebo or no treatment </p> </td> </tr> <tr class="separated"> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><i>Bifidobacteria</i> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>The mean <i>Bifidobacteria</i> was 3.92 lower (9.83 lower to 1.99 higher) with prebiotic than placebo or no treatment </p> </td> </tr> <tr class="separated"> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><i>Ruminococcus</i> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>The mean <i>Ruminococcus</i> was 3.86 higher (0.32 lower to 8.04 higher) with prebiotic than placebo or no treatment </p> </td> </tr> <tr class="separated"> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><i>Prevotella</i> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>The mean <i>Prevotella</i> was 0.43 lower (1.45 lower to 0.59 higher) with prebiotic than placebo or no treatment </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Graft function</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Graft infection</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% CI) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><br/><b>CKD:</b> chronic kidney disease; <b>CI:</b> confidence interval; <b>eGFR:</b> estimated glomerular filtration rate; <b>GI:</b> gastrointestinal; <b>RR:</b> risk ratio; <b>RCT:</b> randomised controlled trial </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="6"> <div class="table-footnote"> <p><sup>1</sup> Downgraded twice for serious risk of bias, and once for sparse or small study data. </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD013631-tbl-0008"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 8.</span> <span class="table-title">Probiotic versus placebo or no treatment for people with chronic kidney disease</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Probiotic versus placebo or no treatment for people with chronic kidney disease</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Patient or population:</b> people with CKD<br/><b>Setting:</b> hospital or primary care<br/><b>Intervention:</b> probiotic<br/><b>Comparison:</b> placebo or no treatment </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>No. of participants<br/>(RCTs)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> </tr> <tr class="table-header separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with placebo or no treatment</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with probiotic</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p><b>eGFR</b> </p> <p>(mL/min)</p> <p>Follow‐up: 8, 12 or 15 weeks</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>CKD stage 1 with type 2 diabetes mellitus</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>40 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p>⊕⊝⊝⊝<br/><b>very low<sup>1</sup> </b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>The mean eGFR was 12.1 mL/min higher (4.19 higher to 20.01 higher) with probiotic than placebo or no treatment </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>CKD stage 3A with diabetes and hypertension</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>28 (1)</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>The mean eGFR mL/min was 0.4 higher (4.15 lower to 4.95 higher) with probiotic than placebo or no treatment </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>CKD stage G5D with diabetes and hypertension</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>60 (1)</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>The mean eGFR was 0.02 mL/min higher (0.63 lower to 0.67 higher) with probiotic than placebo or no treatment </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Albuminuria</b> </p> <p>(g/dL)</p> <p>Follow‐up: 12 or 24 weeks</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>CKD stage G5D</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>33 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊕⊝⊝<br/><b>low<sup>2</sup> </b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>The mean albuminuria was 0 g/dL (0.19 lower to 0.19 higher) with probiotic than placebo or no treatment </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>CKD stage G5D with diabetes and hypertension</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>160 (3)</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>The mean albuminuria was 0.03 g/dL higher (0.1 lower to 0.16 higher) with probiotic than placebo or no treatment </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Proteinuria</b> </p> <p>(mg/dL)</p> <p>Follow‐up: 12 or 24 weeks</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>CKD stages 1 to 5 with diabetic nephropathy</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>60 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/><b>very low<sup>1</sup> </b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p>The mean albuminuria was 15.6 g/dL (34.3 lower to 3.1 higher) with probiotic than placebo or no treatment </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Indoxyl sulfate</b> </p> <p>(mg/dL)</p> <p>Follow‐up: 12 or 24 weeks</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>CKD stage G5D</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>33 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/><b>very low<sup>1</sup> </b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>The mean indoxyl sulfate was 6 mg/dL lower (15.02 lower to 3.02 higher) with probiotic than placebo or no treatment </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>CKD stage G5D with diabetes and hypertension</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>50 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>⊕⊝⊝⊝<br/><b>very low<sup>1</sup> </b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>The mean indoxyl sulfate was 3.14 mg/dL lower (10.26 lower to 3.98 higher) with probiotic than placebo or no treatment </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Change in any GI upset or intolerance (abdominal pain/diarrhoea)</b> </p> <p>Follow‐up: 12 weeks</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>CKD stage G5D</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 2.13<br/>(0.21 to 21.22) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>33 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/><b>very low<sup>1</sup> </b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>59 per 1,000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>125 per 1,000<br/>(12 to 1,000) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Change in any GI upset or intolerance (constipation)</b> </p> <p>Follow‐up: 12 weeks</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>CKD stage G5D</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 3.18<br/>(0.14 to 72.75) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>33 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/><b>very low<sup>1</sup> </b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0 per 1,000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0 per 1,000<br/>(0 to 0) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Microbiota composition</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Graft function</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Graft infection</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% CI) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><br/><b>CKD:</b> chronic kidney disease; <b>CI:</b> confidence interval; <b>eGFR:</b> estimated glomerular filtration rate; <b>GI:</b> gastrointestinal; <b>RR:</b> risk ratio; <b>RCT:</b> randomised controlled trial </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="6"> <div class="table-footnote"> <p><sup>1</sup> Downgraded twice for serious risk of bias, and once for sparse or small study data. </p> <p><sup>2</sup> Downgraded twice for serious risk of bias. </p> </div> </td> </tr> </tfoot> </table> </div> </section> </section> <section class="background"> <div class="section-header section-collapse-header" id="CD013631-sec-0009" lang="en"> <h2 class="title section-collapse-title"> Background <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="background" lang="en"> <div class="section-header" id="CD013631-sec-0009"></div> <section id="CD013631-sec-0010"> <h3 class="title" id="CD013631-sec-0010">Description of the condition</h3> <section id="CD013631-sec-0011"> <h4 class="title">Chronic kidney disease</h4> <p>Chronic kidney disease (CKD) is defined as abnormalities of kidney structure or function, present for three months with implications for health (<a href="./references#CD013631-bbs2-0126" title="StevensPE , LevinA . Evaluation and management of chronic kidney disease: synopsis of the kidney disease: improving global outcomes 2012 clinical practice guideline. Annals of Internal Medicine2013;158(11):825-30. [MEDLINE: 23732715]">KDIGO 2013</a>). The current classification for CKD has five stages (<a href="./appendices#CD013631-sec-0154">Appendix 1</a>) classified based on two markers: (1) evidence of kidney damage (presence of proteinuria, microalbuminuria, or structural abnormality) and (2) the sustained impairment of estimated glomerular filtration rate (eGFR) for at least three months. Stages 1 to 3 are considered to be early CKD, at which point patients may have no or limited symptoms (with only urine or blood tests detecting the presence of kidney abnormality). Patients with CKD stages 4 and 5 have advanced‐stage kidney disease and may require or undergo dialysis or transplantation (<a href="./references#CD013631-bbs2-0126" title="StevensPE , LevinA . Evaluation and management of chronic kidney disease: synopsis of the kidney disease: improving global outcomes 2012 clinical practice guideline. Annals of Internal Medicine2013;158(11):825-30. [MEDLINE: 23732715]">KDIGO 2013</a>). </p> <p>The global prevalence of CKD is high, affecting 11% to 13% of the population (<a href="./references#CD013631-bbs2-0123" title="HillNR , FatobaST , OkeJL , HirstJA , O'CallaghanCA , LassersonDS , et al. Global prevalence of chronic kidney disease - a systematic review and meta-analysis. PLoS ONE [Electronic Resource]2016;11(7):e0158765. [MEDLINE: 27383068]">Hill 2016</a>). In 2017, an estimated 1.23 million people died from kidney failure, a 33.7% increase from 2007 (<a href="./references#CD013631-bbs2-0117" title="GBD 2017 Causes of Death Collaborators. Global, regional, and national age-sex-specific mortality for 282 causes of death in 195 countries and territories, 1980-2017: a systematic analysis for the Global Burden of Disease Study 2017 [Erratum in: Lancet. 2019 Jun 22;393(10190):e44; PMID: 31232379] [Erratum in: Lancet. 2018 Nov 17;392(10160):2170; PMID: 31329658]. Lancet2018;392(10159):1736-88. [MEDLINE: 30496103]">GBD 2017</a>). CKD predisposes the patient to a wide range of complications, including cardiovascular disease (CVD), infection, and cancer. Often CKD does not display symptoms until the disease is advanced (<a href="./references#CD013631-bbs2-0124" title="JhaV , Garcia-GarciaG , IsekiK , LiZ , NaickerS , PlattnerB , et al. Chronic kidney disease: global dimension and perspectives [Erratum in: Lancet. 2013 Jul 20;382(9888):208]. Lancet2013;382(9888):260-72. [MEDLINE: 23727169]">Jha 2013</a>) and is therefore often considered to be underestimated as a comorbidity, making the exact prevalence and burden difficult to calculate. </p> </section> <section id="CD013631-sec-0012"> <h4 class="title">The gut microbiome</h4> <p>The human microbiome is the collective genomes of the micro‐organisms in a particular environment (<a href="./references#CD013631-bbs2-0138" title="ValdesAM , WalterJ , SegalE , SpectorTD . Role of the gut microbiota in nutrition and health. BMJ2018;361:k2179. [MEDLINE: 29899036]">Valdes 2018</a>) and is of emerging high interest in chronic disease research. The human gut microbiota includes fungi, bacteria, archaea, protozoa, and viruses that all interact with each other and the host to affect the health and physiology of the host (<a href="./references#CD013631-bbs2-0107" title="AzadMA , SarkerM , LiT , YinJ . Probiotic species in the modulation of gut microbiota: an overview. BioMed Research International2018;2018:9478630. [MEDLINE: 29854813]">Azad 2018</a>). The human intestine contains more than 10 billion micro‐organisms, and the microbial composition changes from person to person, along both the digestive tract and within the urinary and kidney environments (<a href="./references#CD013631-bbs2-0106" title="Aron-WisnewskyJ , ClementK . The gut microbiome, diet, and links to cardiometabolic and chronic disorders. Nature Reviews Nephrology2016;12(3):169-81. [MEDLINE: 26616538]">Aron‐Wisnewsky 2016</a>). Recent culture‐independent studies that use high‐throughput sequencing have indicated that any microbial imbalances (otherwise known as gut dysbiosis or leaky gut) may be associated with cardiometabolic diseases in the long term (such as allergy, asthma, inflammatory bowel disease, celiac disease, systemic lupus erythematosus, arthritis, CKD, diabetes, obesity, and CVD) (<a href="./references#CD013631-bbs2-0106" title="Aron-WisnewskyJ , ClementK . The gut microbiome, diet, and links to cardiometabolic and chronic disorders. Nature Reviews Nephrology2016;12(3):169-81. [MEDLINE: 26616538]">Aron‐Wisnewsky 2016</a>; <a href="./references#CD013631-bbs2-0110" title="BrombergJS , FrickeWF , BrinkmanCC , SimonT , MongodinEF . Microbiota - implications for immunity and transplantation. Nature Reviews Nephrology2015;11(6):342-53. [MEDLINE: 25963591]">Bromberg 2015</a>). </p> <p>In people with advanced stages of CKD, uraemia and metabolic acidosis alter the biochemical milieu, promoting disturbances in gut microbiota, the community or micro‐organisms themselves (<a href="./references#CD013631-bbs2-0138" title="ValdesAM , WalterJ , SegalE , SpectorTD . Role of the gut microbiota in nutrition and health. BMJ2018;361:k2179. [MEDLINE: 29899036]">Valdes 2018</a>) and the intestinal barrier (<a href="./references#CD013631-bbs2-0130" title="MafraD , BorgesN , AlvarengaL , EsgalhadoM , CardozoL , LindholmB , et al. Dietary components that may influence the disturbed gut microbiota in chronic kidney disease. Nutrients2019;11(3):496. [MEDLINE: 30818761]">Mafra 2019</a>). These disturbances, referred to as gut dysbiosis, are further exacerbated by fluid retention with intestinal wall oedema, dietary restrictions and exposure to pharmacologic agents (particularly antibiotics) (<a href="./references#CD013631-bbs2-0134" title="Sampaio-MaiaB , Simões-SilvaL , PestanaM , AraujoR , Soares-SilvaIJ . The role of the gut microbiome on chronic kidney disease. Advances in Applied Microbiology2016;96:65-94. [PMID: 27565581]">Sampai‐Maia 2016</a>). Gut dysbiosis, in turn, frequently leads to gastrointestinal (GI) symptoms (<a href="./references#CD013631-bbs2-0112" title="ChanS , CaoC , PascoeEM , JohnsonDW , ShahA , HoltmanGA , et al. Patient-reported gastrointestinal symptoms and the association with quality of life following kidney transplantation. Kidney International Reports2020;6(1):138-45. [PMID: 33426393]">Chan 2020</a>) and has, in turn, been linked with the progression of CKD, in particular, the production of putative uraemic toxins (e.g. indoxyl sulfate, p‐cresol sulfate, phenylacetylglutamine, trimethylamine‐N‐oxide, kynurenine), increased gut permeability, and transmural movement of bacteria and endotoxins leading to inflammation and oxidative stress (<a href="./references#CD013631-bbs2-0109" title="BeerepootM , GeerlingsS . Non-antibiotic prophylaxis for urinary tract infections. Pathogens2016;5(2):36. [MEDLINE: 27092529]">Beerepoot 2016</a>; <a href="./references#CD013631-bbs2-0111" title="CaoC , ZhuH , YaoY , ZengR . Gut dysbiosis and kidney diseases. Frontiers in Medicine2022;3(9):829349. [PMID: 35308555]">Cao 2022</a>; <a href="./references#CD013631-bbs2-0114" title="CremonC , BarbaroMR , VenturaM , BarbaraG . Pre- and probiotic overview. Current Opinion in Pharmacology2018;43:87-92. [MEDLINE: 30219638]">Cremon 2018</a>; <a href="./references#CD013631-bbs2-0127" title="LehtoM , GroopPH . The gut-kidney axis: putative interconnections between gastrointestinal and renal disorders. Frontiers in Endocrinology2018;9:553. [MEDLINE: 30283404]">Lehto 2018</a>; <a href="./references#CD013631-bbs2-0129" title="LuyckxVA , TonelliM , StaniferJW . The global burden of kidney disease and the sustainable development goals. Bulletin of the World Health Organization2018;96(6):414-22D. [MEDLINE: 29904224]">Luyckx 2018</a>). </p> </section> </section> <section id="CD013631-sec-0013"> <h3 class="title" id="CD013631-sec-0013">Description of the intervention</h3> <p>Early observational and intervention studies have been investigating food‐intake patterns and various synbiotic interventions (antibiotics, prebiotics, or probiotics) to measure the effects on microbiota in treating cardiometabolic diseases, in particular CKD (<a href="./references#CD013631-bbs2-0106" title="Aron-WisnewskyJ , ClementK . The gut microbiome, diet, and links to cardiometabolic and chronic disorders. Nature Reviews Nephrology2016;12(3):169-81. [MEDLINE: 26616538]">Aron‐Wisnewsky 2016</a>). </p> <section id="CD013631-sec-0014"> <h4 class="title">Prebiotics</h4> <p>The International Scientific Association for Probiotics and Prebiotics (<a href="./references#CD013631-bbs2-0118" title="GibsonGR , HutkinsR , SandersME , PrescottSL , ReimerRA , SalminenSJ , et al. Expert consensus document: the International Scientific Association for Probiotics and Prebiotics (ISAPP) consensus statement on the definition and scope of prebiotics. Nature Reviews. Gastroenterology &amp; Hepatology2017;14(8):491-502. [MEDLINE: 28611480]">Gibson 2017</a>) defines prebiotics as substrates, or non‐digestible dietary substances, that are selectively utilised and fermented within the small intestine by host micro‐organisms. Modifying or diversifying the host microbiota may induce a health benefit to the host. </p> <p>Most types of prebiotics are subsets of carbohydrate groups and mostly oligosaccharide carbohydrates (<a href="./references#CD013631-bbs2-0115" title="Davani-DavariD , NegahdaripourM , KarimzadehI , SeifanM , MohkamM , MasoumiSJ , et al. Prebiotics: definition, types, sources, mechanisms, and clinical applications. Foods2019;8(3):92. [MEDLINE: 30857316]">Davani‐Davari 2019</a>). </p> <p> <ul id="CD013631-list-0001"> <li> <p>Fructans: inulin and fructo‐oligosaccharides (stimulate the enrichment of native probiotics <i>Lactobacilli</i> and <i>Bifidobacteria</i>) </p> </li> <li> <p>Galacto‐oligosaccharides (also known as trans‐galacto‐oligosaccharides): (stimulate the enrichment of native probiotics <i>Lactobacilli</i> , <i>Bifidobacteria</i> , <i>Enterobacteria</i> , <i>Bacteroidetes</i> , and <i>Firmicutes</i>) </p> </li> <li> <p>Starch and glucose‐derived oligosaccharides: resistant starch, polydextrose</p> </li> <li> <p>Other oligosaccharides: pectic‐oligosaccharide (from the polysaccharide pectin)</p> </li> <li> <p>Non‐carbohydrate oligosaccharides: cocoa‐derived flavanols.</p> </li> </ul> </p> <p>Natural sources of prebiotics can be obtained in peas, beans, cow's milk, human breast milk, soybean, rye, tomato, barley, wheat, honey, banana, onion, chicory, garlic, sugar beet, asparagus, and artichoke. </p> </section> <section id="CD013631-sec-0015"> <h4 class="title">Probiotics</h4> <p>The term probiotics is used to describe live micro‐organisms that are intended to confer health benefits on the host when administered in adequate quantities (<a href="./references#CD013631-bbs2-0116" title="Joint FAO/WHO Working Group Report on Drafting Guidelines for the Evaluation of Probiotics in Food London, Ontario, Canada, April 30 and May 1, 2002. Guidelines for the evaluation of probiotics in food. www.who.int/foodsafety/fs_management/en/probiotic_guidelines.pdf (last accessed 7 May 2020).">FAO/WHO 2002</a>). The living bacteria may modulate the existing composition of gut microbiota to improve the health of the GI tract, the immune system, the inflammatory state and the "bioavailability of micronutrients" (<a href="./references#CD013631-bbs2-0114" title="CremonC , BarbaroMR , VenturaM , BarbaraG . Pre- and probiotic overview. Current Opinion in Pharmacology2018;43:87-92. [MEDLINE: 30219638]">Cremon 2018</a>). </p> <p>The key microbial organisms often found in probiotic treatments are:</p> <p> <ul id="CD013631-list-0002"> <li> <p><i>Lactobacillus</i> </p> </li> <li> <p><i>Bifidobacterium</i> </p> </li> <li> <p><i>Saccharomyces</i> </p> </li> <li> <p><i>Streptococcus</i> </p> </li> <li> <p><i>Enterococcus</i> </p> </li> <li> <p><i>Escherichia</i> </p> </li> <li> <p><i>Bacillus</i> </p> </li> </ul> </p> <p>Natural sources of probiotics can be obtained in fermented foods such as yoghurt, kimchi, kombucha, sauerkraut, miso, pickles, raw apple cider vinegar, kefir, tempeh, some cheeses, and some sourdough breads. </p> </section> <section id="CD013631-sec-0016"> <h4 class="title">Synbiotics</h4> <p>Synbiotics are the combination of prebiotics and probiotics in one treatment with the intention of producing a superior effect compared to either agent alone (<a href="./references#CD013631-bbs2-0133" title="PanW , KangY . Gut microbiota and chronic kidney disease: implications for novel mechanistic insights and therapeutic strategies. International Urology &amp; Nephrology2018;50(2):289-99. [MEDLINE: 28849345]">Pan 2018</a>). The effect is currently unknown. </p> <p>Synthetic versions of synbiotics, prebiotics, and probiotics are available as oral capsules, tablets, liquids, or powder forms over‐the‐counter in most developed countries (<a href="./references#CD013631-bbs2-0114" title="CremonC , BarbaroMR , VenturaM , BarbaraG . Pre- and probiotic overview. Current Opinion in Pharmacology2018;43:87-92. [MEDLINE: 30219638]">Cremon 2018</a>). </p> </section> </section> <section id="CD013631-sec-0017"> <h3 class="title" id="CD013631-sec-0017">How the intervention might work</h3> <p>Growing research suggests that high doses of synbiotics, prebiotics, and probiotics are able to modify and improve dysbiosis of gut micro‐organisms by altering the population of the micro‐organisms. With the right balance of gut flora, a primary benefit is (believed to be) the suppression of pathogens through immunostimulation and gut barrier enhancement (reduced permeability of the gut) (<a href="./references#CD013631-bbs2-0114" title="CremonC , BarbaroMR , VenturaM , BarbaraG . Pre- and probiotic overview. Current Opinion in Pharmacology2018;43:87-92. [MEDLINE: 30219638]">Cremon 2018</a>). </p> <p>Gut microbiota ferments prebiotics and produces short‐chain fatty acids (lactic acid, butyric acid, propionic acid), which have positive effects on the airways and dendritic cells in the bone marrow, and decrease the pH of the colon (<a href="./references#CD013631-bbs2-0115" title="Davani-DavariD , NegahdaripourM , KarimzadehI , SeifanM , MohkamM , MasoumiSJ , et al. Prebiotics: definition, types, sources, mechanisms, and clinical applications. Foods2019;8(3):92. [MEDLINE: 30857316]">Davani‐Davari 2019</a>). Prebiotics also decrease the gut pH, resulting in the butyrogenic effect ‐ where a slight change in the unit of change in pH alters the entire composition or population of acid‐sensitive species (Bacterioides) and promotes butyrate formation of Firmicutes (<a href="./references#CD013631-bbs2-0115" title="Davani-DavariD , NegahdaripourM , KarimzadehI , SeifanM , MohkamM , MasoumiSJ , et al. Prebiotics: definition, types, sources, mechanisms, and clinical applications. Foods2019;8(3):92. [MEDLINE: 30857316]">Davani‐Davari 2019</a>). </p> <p>Probiotics alter the intestinal pH, inhibit pathogens (via the generation of antibacterial compounds, competitively eliminating pathogens in receptor binding sites and competing for available nutrients), inhibit the production of mutagenic and carcinogenic substances, and maintain the intestinal barrier (<a href="./references#CD013631-bbs2-0125" title="KatoS , ChmielewskiM , HondaH , Pecoits-FilhoR , MatsuoS , YuzawaY , et al. Aspects of immune dysfunction in end-stage renal disease. Clinical Journal of The American Society of Nephrology: CJASN2008;3(5):1526-33. [MEDLINE: 18701615]">Kato 2008</a>). </p> </section> <section id="CD013631-sec-0018"> <h3 class="title" id="CD013631-sec-0018">Why it is important to do this review</h3> <p>Prebiotics and probiotics are freely available as over‐the‐counter purchases in most high‐income countries and are being used as therapeutic supplements for improving the function and balance of gut microbiota in the general population. Whilst many positive effects have been identified, the exact mechanism of action by which these compounds exert their beneficial actions in humans is only partially understood (<a href="./references#CD013631-bbs2-0114" title="CremonC , BarbaroMR , VenturaM , BarbaraG . Pre- and probiotic overview. Current Opinion in Pharmacology2018;43:87-92. [MEDLINE: 30219638]">Cremon 2018</a>). In the general population, there is no definitive data to support the use of synbiotics, prebiotics, or probiotics. In CKD, there are uncertain effects in people with reduced kidney function because of the risk of catastrophic infections from the live micro‐organisms in patients who are immunocompromised. The efficacy of these interventions and the certainty of the evidence in CKD patients remains unknown, and it is imperative to synthesise the benefits and harms associated with these treatments. </p> </section> </section> </section> <section class="objectives"> <div class="section-header section-collapse-header" id="CD013631-sec-0019" lang="en"> <h2 class="title section-collapse-title"> Objectives <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="objectives" lang="en"> <div class="section-header" id="CD013631-sec-0019"></div> <p>This review aims to look at the benefits and harms of synbiotics, prebiotics, and probiotics for people with CKD. </p> </section> </section> <section class="methods"> <div class="section-header section-collapse-header" id="CD013631-sec-0020" lang="en"> <h2 class="title section-collapse-title"> Methods <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="methods" lang="en"> <div class="section-header" id="CD013631-sec-0020"></div> <section id="CD013631-sec-0021"> <h3 class="title">Criteria for considering studies for this review</h3> <section id="CD013631-sec-0022"> <h4 class="title">Types of studies</h4> <p>All randomised controlled trials (RCTs) and quasi‐RCTs (RCTs in which allocation to treatment was obtained by alternation, use of alternate medical records, date of birth or other predictable methods) and cluster RCTs were included. Unblinded, single and double‐blind studies were included. </p> <p>Cross‐over studies were included, and only data from the first phase was used for analysis. </p> <p>Full journal publication and peer review were required. Unpublished clinical studies with online results available were, however, included. </p> <p>Studies in any healthcare setting were included.</p> <p>Excluded study designs: abstracts, single‐arm studies, commentaries, editorials, and clinical observations. </p> </section> <section id="CD013631-sec-0023"> <h4 class="title">Types of participants</h4> <section id="CD013631-sec-0024"> <h5 class="title">Inclusion criteria</h5> <p> <ul id="CD013631-list-0003"> <li> <p>Adults and children with CKD (stages 1 to 5), receiving dialysis, and kidney transplant recipients. </p> </li> <li> <p>Studies of populations with altered GI function and diabetic kidney disease were included and analysed as subgroups. </p> </li> </ul> </p> </section> <section id="CD013631-sec-0025"> <h5 class="title">Exclusion criteria</h5> <p> <ul id="CD013631-list-0004"> <li> <p>Studies of populations receiving enteral nutrition.</p> </li> <li> <p>Adults and children who have signs of systemic illness (such as fever, loin pain, toxicity). </p> </li> </ul> </p> </section> </section> <section id="CD013631-sec-0026"> <h4 class="title">Types of interventions</h4> <p> <ul id="CD013631-list-0005"> <li> <p>Any synbiotic, prebiotic, or probiotic treatment compared to another, other pharmacological, non‐pharmacological, placebo, or no treatment </p> </li> <li> <p>Any route of administration, dose, duration, or frequency</p> </li> <li> <p>Formulations such as oral tablets and capsules, liquids, and powders</p> </li> <li> <p>Combination therapies of synbiotics, prebiotics, or probiotics with other pharmacological treatments or non‐pharmacological treatments were analysed as separate comparisons. </p> </li> </ul> </p> <p>Participants receiving concurrent pharmacological medications for co‐morbidities, such as blood glucose medications, blood pressure medications, and immunosuppressants, were included, and we planned to analyse these as subgroups. </p> <p>Studies of high‐dose prebiotics for the purpose of purgation and studies of dietary changes were excluded. </p> <section id="CD013631-sec-0027"> <h5 class="title">Comparison pairs for analysis</h5> <p> <ul id="CD013631-list-0006"> <li> <p>A synbiotic, prebiotic, or probiotic treatment versus another synbiotic, prebiotic, or probiotic </p> </li> <li> <p>A synbiotic, prebiotic, or probiotic treatment versus any other pharmacological comparator (antibiotics, immunosuppressants, other medicines) </p> </li> <li> <p>A synbiotic, prebiotic, or probiotic treatment versus another non‐pharmacological comparator (dietary, educational, behavioural, vitamin or herbal supplements, Traditional Chinese Medicine) </p> </li> <li> <p>Any synbiotic, prebiotic, or probiotic treatment versus placebo</p> </li> <li> <p>Any synbiotic, prebiotic, or probiotic treatment versus no treatment</p> </li> <li> <p>Any synbiotic, prebiotic, or probiotic treatment versus a combination treatment (any of the above) </p> </li> <li> <p>Any synbiotic, prebiotic, or probiotic treatment in combination with any of the above versus any of the above comparators. </p> </li> </ul> </p> <p>For each of these comparisons, synbiotics, prebiotics, and probiotics were analysed as separate comparisons. </p> </section> </section> <section id="CD013631-sec-0028"> <h4 class="title">Types of outcome measures</h4> <p>This review did not exclude studies based on non‐reporting of outcomes of interest.</p> <p>The outcomes selected include the relevant <a href="http://songinitiative.org/" target="_blank">SONG core outcome sets</a> as specified by the Standardised Outcomes in Nephrology initiative (<a href="./references#CD013631-bbs2-0137" title="SONG Initiative. The SONG Handbook Version 1.0. www.songinitiative.org/reports-and-publications/2017.">SONG 2017</a>). </p> <section id="CD013631-sec-0029"> <h5 class="title">Primary outcomes</h5> <p> <ol id="CD013631-list-0007"> <li> <p>Kidney function: eGFR; serum creatinine (SCr); albuminuria; proteinuria; infection (including pyelonephritis or urosepsis) </p> </li> <li> <p>Uraemic toxins: urea; indoxyl sulfate; p‐cresyl sulfate; trimethylamine N‐oxide; phenylacetylglutamine; kynurenine </p> </li> <li> <p>GI function: change in any GI upset or intolerance; microbiota composition; faecal characteristics (such as the Bristol Stool Chart) (<a href="./references#CD013631-bbs2-0128" title="LewisSJ , HeatonKW . Stool form scale as a useful guide to intestinal transit time. Scandinavian Journal of Gastroenterology1997;32(9):920-4. [MEDLINE: 9299672]">Lewis 1997</a>); colonic transit time. </p> </li> </ol> </p> </section> <section id="CD013631-sec-0030"> <h5 class="title">Secondary outcomes</h5> <p> <ol id="CD013631-list-0008"> <li> <p>Dialysis outcomes: peritoneal dialysis (PD) or haemodialysis (HD) infection; vascular access; technique survival; dialysis failure </p> </li> <li> <p>Transplant function: need for transplant; graft survival/health</p> </li> <li> <p>Patient‐reported outcomes: pain rating using any validated pain scale; quality of life (QoL) (using any validated scale); fatigue; life participation </p> </li> <li> <p>Adverse events: any adverse events (including infection); serious adverse events (including death); withdrawals due to adverse events. Potential (but not limited to) events include GI responses, nausea, vomiting, diarrhoea, and constipation </p> </li> <li> <p>CVD</p> </li> <li> <p>Cancer</p> </li> </ol> </p> </section> </section> </section> <section id="CD013631-sec-0031"> <h3 class="title">Search methods for identification of studies</h3> <section id="CD013631-sec-0032"> <h4 class="title">Electronic searches</h4> <p>We searched the <a href="http://kidneyandtransplant.cochrane.org/cochrane-kidney-and-transplant-specialised-register" target="_blank">Cochrane Kidney and Transplant Register of Studies</a> up to 9 October 2023 through contact with the Information Specialist using search terms relevant to this review. The Register contains studies identified from the following sources. </p> <p> <ol id="CD013631-list-0009"> <li> <p>Monthly searches of the Cochrane Central Register of Controlled Trials (CENTRAL)</p> </li> <li> <p>Weekly searches of MEDLINE OVID SP</p> </li> <li> <p>Searches of kidney and transplant journals and the proceedings and abstracts from major kidney and transplant conferences </p> </li> <li> <p>Searching of the current year of EMBASE OVID SP</p> </li> <li> <p>Weekly current awareness alerts for selected kidney and transplant journals</p> </li> <li> <p>Searches of the International Clinical Trials Registry Platform (ICTRP) Search Portal and ClinicalTrials.gov. </p> </li> </ol> </p> <p>Studies contained in the Register are identified through searches of CENTRAL, MEDLINE, and EMBASE based on the scope of Cochrane Kidney and Transplant. Details of search strategies, as well as a list of handsearched journals, conference proceedings and current awareness alerts, are available on the <a href="https://kidneyandtransplant.cochrane.org/cochrane-kidney-and-transplant-specialised-register" target="_blank">Cochrane Kidney and Transplant website</a>. </p> <p>See <a href="./appendices#CD013631-sec-0155">Appendix 2</a> for search terms used in strategies for this review. </p> </section> <section id="CD013631-sec-0033"> <h4 class="title">Searching other resources</h4> <p> <ol id="CD013631-list-0010"> <li> <p>Reference lists of review articles, relevant studies, and clinical practice guidelines.</p> </li> <li> <p>Contacting relevant individuals/organisations seeking information about unpublished or incomplete studies. </p> </li> <li> <p>Grey literature sources (e.g. abstracts, dissertations, and theses), in addition to those already included in the Cochrane Kidney and Transplant Register of Studies, were not searched. </p> </li> </ol> </p> </section> </section> <section id="CD013631-sec-0034"> <h3 class="title" id="CD013631-sec-0034">Data collection and analysis</h3> <section id="CD013631-sec-0035"> <h4 class="title">Selection of studies</h4> <p>The search strategy described was used to obtain titles and abstracts of studies that may be relevant to the review. The titles and abstracts were screened independently by two authors, who discarded studies that were not applicable; however, studies and reviews that might include relevant data or information on studies were retained initially. Two authors independently assessed the retrieved abstracts and, where necessary, the full text of these studies to determine which studies satisfied the inclusion criteria. Disagreements were resolved in consultation with a third author. </p> </section> <section id="CD013631-sec-0036"> <h4 class="title">Data extraction and management</h4> <p>Data extraction was carried out independently by two authors using standard data extraction forms. Disagreements were resolved in consultation with a third author. Studies reported in non‐English language journals were translated before assessment. Where more than one publication of one study existed, reports were grouped together, and the publication with the most complete data was used in the analyses. Where relevant outcomes were only published in earlier versions, these data were used. Any discrepancy between published versions was to be highlighted. </p> </section> <section id="CD013631-sec-0037"> <h4 class="title">Assessment of risk of bias in included studies</h4> <p>The following items were independently assessed by two authors using the risk of bias assessment tool (<a href="./references#CD013631-bbs2-0122" title="HigginsJP , ThomasJ , ChandlerJ , CumpstonM , LiT , PageMJ , et al. Cochrane Handbook for Systematic Reviews of Interventions version 6.3 (updated February 2022). Cochrane, 2022. Available from www.training.cochrane.org/handbook.">Higgins 2022</a>) (see <a href="./appendices#CD013631-sec-0156">Appendix 3</a>). </p> <p> <ul id="CD013631-list-0011"> <li> <p>Was there adequate sequence generation (selection bias)?</p> </li> <li> <p>Was allocation adequately concealed (selection bias)?</p> </li> <li> <p>Was knowledge of the allocated interventions adequately prevented during the study?</p> <ul id="CD013631-list-0012"> <li> <p>Participants and personnel (performance bias)</p> </li> <li> <p>Outcome assessors (detection bias)</p> </li> </ul> </li> <li> <p>Were incomplete outcome data adequately addressed (attrition bias)?</p> </li> <li> <p>Are reports of the study free of suggestion of selective outcome reporting (reporting bias)? </p> </li> <li> <p>Was the study apparently free of other problems that could put it at risk of bias?</p> </li> </ul> </p> </section> <section id="CD013631-sec-0038"> <h4 class="title">Measures of treatment effect</h4> <p>For dichotomous outcomes (e.g. progression to CKD stage), comparisons between groups were based on risk ratios (RR), the number needed to treat for an additional beneficial outcome (NNT) and pooled differences as absolute measures of effect with 95% confidence intervals (CI). </p> <p>Where continuous scales of measurement were used to assess the effects of treatment (e.g. pain or decline in kidney function), the mean difference (MD) was used, or the standardised mean difference (SMD) if different scales had been used. </p> <p>Where possible, we used the mean change score from baseline. We anticipated that some studies may only report the mean endpoint score of which we planned to use the final time point available. </p> </section> <section id="CD013631-sec-0039"> <h4 class="title">Unit of analysis issues</h4> <p>We only accepted randomisation of the individual participants. For multiple‐dose studies, we used data for the first dose only. For cross‐over studies, we used data from the first phase only. </p> </section> <section id="CD013631-sec-0040"> <h4 class="title">Dealing with missing data</h4> <p>Any further information required from the original author was requested by written correspondence (e.g. emailing the corresponding author), and any relevant information obtained in this manner was included in the review. Evaluation of important numerical data such as screened, randomised patients as well as intention‐to‐treat (ITT), as‐treated and per‐protocol population was carefully performed. Attrition rates, for example, drop‐outs, losses to follow‐up and withdrawals, were investigated. Issues of missing data and imputation methods (for example, last‐observation‐carried‐forward) were critically appraised (<a href="./references#CD013631-bbs2-0122" title="HigginsJP , ThomasJ , ChandlerJ , CumpstonM , LiT , PageMJ , et al. Cochrane Handbook for Systematic Reviews of Interventions version 6.3 (updated February 2022). Cochrane, 2022. Available from www.training.cochrane.org/handbook.">Higgins 2022</a>). </p> </section> <section id="CD013631-sec-0041"> <h4 class="title">Assessment of heterogeneity</h4> <p>We first assessed the heterogeneity by visual inspection of the forest plot. We quantified statistical heterogeneity using the I² statistic, which describes the percentage of total variation across studies that was due to heterogeneity rather than sampling error (<a href="./references#CD013631-bbs2-0121" title="HigginsJP , ThompsonSG , DeeksJJ , AltmanDG . Measuring inconsistency in meta-analyses. BMJ2003;327(7414):557-60. [MEDLINE: 12958120]">Higgins 2003</a>). A guide to the interpretation of I² values is as follows. </p> <p> <ul id="CD013631-list-0013"> <li> <p>0% to 40%: might not be important</p> </li> <li> <p>30% to 60%: may represent moderate heterogeneity</p> </li> <li> <p>50% to 90%: may represent substantial heterogeneity</p> </li> <li> <p>75% to 100%: considerable heterogeneity.</p> </li> </ul> </p> <p>The importance of the observed value of I² depends on the magnitude and direction of treatment effects and the strength of evidence for heterogeneity (e.g. P‐value from the Chi² test, or a CI for I²) (<a href="./references#CD013631-bbs2-0122" title="HigginsJP , ThomasJ , ChandlerJ , CumpstonM , LiT , PageMJ , et al. Cochrane Handbook for Systematic Reviews of Interventions version 6.3 (updated February 2022). Cochrane, 2022. Available from www.training.cochrane.org/handbook.">Higgins 2022</a>). </p> </section> <section id="CD013631-sec-0042"> <h4 class="title">Assessment of reporting biases</h4> <p>Where possible, funnel plots were planned to be used to assess for the potential existence of small study bias (<a href="./references#CD013631-bbs2-0122" title="HigginsJP , ThomasJ , ChandlerJ , CumpstonM , LiT , PageMJ , et al. Cochrane Handbook for Systematic Reviews of Interventions version 6.3 (updated February 2022). Cochrane, 2022. Available from www.training.cochrane.org/handbook.">Higgins 2022</a>). </p> </section> <section id="CD013631-sec-0043"> <h4 class="title">Data synthesis</h4> <p>Data were pooled using random‐effects models. Fixed‐effect models were also fitted to investigate potential discrepancies with the random‐effects models (e.g., the influence of large studies on the pooled estimates). </p> </section> <section id="CD013631-sec-0044"> <h4 class="title">Subgroup analysis and investigation of heterogeneity</h4> <p>Subgroup analysis and meta‐regression were planned to be used to explore possible sources of heterogeneity where there was sufficient data. Heterogeneity among participants could be related to the distribution of age, co‐morbidities, and cause of kidney disease. Heterogeneity in treatments could be related to prior agent(s) used and the agent, dose, and duration of therapy. Adverse effects were tabulated and assessed with descriptive techniques, as they were likely to be different for the various agents used (this was conducted as part of the meta‐analysis as adverse events were a secondary outcome). Where possible, the risk difference (RD) with 95% CI was calculated for each adverse event, either compared to no treatment or to another agent. </p> <p>Planned subgroups where sufficient data were available.</p> <p> <ul id="CD013631-list-0014"> <li> <p>CKD stage: 1 to 5 pre‐dialysis, dialysis, transplant, diabetes, hypertension</p> </li> <li> <p>Dose (to be determined upon presentation of available data)</p> </li> <li> <p>Timepoint: short‐term, long‐term (to be determined upon presentation of available data) </p> </li> <li> <p>Level of GI function or GI issues (to be determined upon presentation of available data) </p> </li> <li> <p>Age: children (&lt; 18 years), adults (&gt; 18 years).</p> </li> </ul> </p> </section> <section id="CD013631-sec-0045"> <h4 class="title">Sensitivity analysis</h4> <p>We planned to undertake sensitivity analyses (however, this was not possible) to explore the influence of the following factors on effect size. </p> <p> <ul id="CD013631-list-0015"> <li> <p>Repeating the analysis, excluding unpublished studies</p> </li> <li> <p>Repeating the analysis, taking account of the risk of bias, as specified</p> </li> <li> <p>Repeating the analysis, excluding any very long or large studies to establish how much they dominate the results </p> </li> <li> <p>Repeating the analysis excluding studies using the following filters: diagnostic criteria, language of publication, source of funding (industry versus other), and country. </p> </li> </ul> </p> </section> <section id="CD013631-sec-0046"> <h4 class="title">Summary of findings and assessment of the certainty of the evidence</h4> <p>We presented the main results of the review in 'Summary of findings' tables. These tables present key information concerning the certainty of the evidence, the magnitude of the effects of the interventions examined, and the sum of the available data for the main outcomes (<a href="./references#CD013631-bbs2-0135" title="SchünemannHJ , HigginsJP , VistGE , GlasziouP , AklEA , SkoetzN , et al. Chapter 14: Completing ‘Summary of findings’ tables and grading the certainty of the evidence. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA (editors). Cochrane Handbook for Systematic Reviews of Interventions version 6.3 (updated February 2022). Cochrane, 2022. www.training.cochrane.org/handbook.">Schünemann 2022a</a>). </p> <p>The 'Summary of findings' tables also include an overall grading of the evidence related to each of the main outcomes using the GRADE (Grades of Recommendation, Assessment, Development and Evaluation) approach (<a href="./references#CD013631-bbs2-0119" title="GuyattGH , OxmanAD , VistGE , KunzR , Falck-YtterY , Alonso-CoelloP , et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ2008;336(7650):924-6. [MEDLINE: 18436948]">GRADE 2008</a>; <a href="./references#CD013631-bbs2-0120" title="GuyattG , OxmanAD , AklEA , KunzR , VistG , BrozekJ , et al. GRADE guidelines: 1. Introduction-GRADE evidence profiles and summary of findings tables. Journal of Clinical Epidemiology2011;64(4):383-94. [MEDLINE: 21195583]">GRADE 2011</a>). The GRADE approach defines the certainty of a body of evidence as the extent to which one can be confident that an estimate of effect or association is close to the true quantity of specific interest. This was assessed by two authors. A summary of the assessment process is in <a href="./appendices#CD013631-sec-0157">Appendix 4</a>. The certainty of a body of evidence involves consideration of within‐trial risk of bias (methodological quality), directness of evidence, heterogeneity, precision of effect estimates and risk of publication bias (<a href="./references#CD013631-bbs2-0136" title="SchünemannHJ , VistGE , HigginsJP , SantessoN , DeeksJJ , GlasziouP , et al. Chapter 15: Interpreting results and drawing conclusions. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA (editors). Cochrane Handbook for Systematic Reviews of Interventions version 6.3 (updated February 2022). Cochrane, 2022. Available from www.training.cochrane.org/handbook.">Schünemann 2022b</a>). We planned to present the following outcomes in the 'Summary of findings' tables. </p> <p> <ul id="CD013631-list-0016"> <li> <p>Changes in kidney function: eGFR</p> </li> <li> <p>Changes in kidney function: kidney damage (albuminuria, proteinuria)</p> </li> <li> <p>Uraemic toxins: free and protein‐bound concentrations of serum indoxyl sulfate</p> </li> <li> <p>GI function: change in any GI upset or intolerance</p> </li> <li> <p>GI function: microbiota composition</p> </li> <li> <p>Transplant function: graft function</p> </li> <li> <p>Transplant function: graft infection</p> </li> </ul> </p> </section> </section> </section> </section> <section class="results"> <div class="section-header section-collapse-header" id="CD013631-sec-0047" lang="en"> <h2 class="title section-collapse-title"> Results <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="results" lang="en"> <div class="section-header" id="CD013631-sec-0047"></div> <section id="CD013631-sec-0048"> <h3 class="title">Description of studies</h3> <p>The following section contains broad descriptions of the studies considered in this review. For further details on each individual study, please see the characteristics of studies tables (<a href="./references#CD013631-sec-0168" title="">Characteristics of included studies</a>; <a href="./references#CD013631-sec-0169" title="">Characteristics of excluded studies</a>; <a href="./references#CD013631-sec-0170" title="">Characteristics of studies awaiting classification</a>; <a href="./references#CD013631-sec-0171" title="">Characteristics of ongoing studies</a>). </p> <section id="CD013631-sec-0049"> <h4 class="title">Results of the search</h4> <p>Our search of the Specialised Register up to 9 October 2023 identified a total of 161 records. After screening titles and abstracts and full‐text review, 45 studies (88 reports) were included, 21 studies (29 reports) were excluded, 12 studies were identified as ongoing, and 12 abstracts (17 reports) are awaiting classification. We will include ongoing and abstracts awaiting classification in a future update of this review (<a href="#CD013631-fig-0001">Figure 1</a>). </p> <div class="figure" id="CD013631-fig-0001"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 1</div> </div> <hr class="top"/><img alt="Study flow diagram." data-id="CD013631-fig-0001" src="/cdsr/doi/10.1002/14651858.CD013631.pub2/media/CDSR/CD013631/image_n/nCD013631-FIG-01.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Study flow diagram.</p> </div> </div> </div> </section> <section id="CD013631-sec-0050"> <h4 class="title">Included studies</h4> <p>Forty‐five studies, randomising 2274 participants, met our inclusion criteria (<a href="./references#CD013631-sec-0168" title="">Characteristics of included studies</a>). </p> <p>Thirty‐seven studies were single‐centre, and eight studies were multicentre. All studies took place in a research centre or hospital outpatient setting in Australia, Belgium, Brazil, Canada, China, France, Indonesia, Iran, Italy, Mexico, Saudi Arabia, South Africa, and the USA. </p> <p>Sample sizes ranged from 13 (<a href="./references#CD013631-bbs2-0002" title="BirueteA , CrossTL , AllenJM , KistlerBM , deLoorH , EvenepoelP , et al. Effect of dietary inulin supplementation on the gut microbiota composition and derived metabolites of individuals undergoing hemodialysis: a pilot study. Journal of Renal Nutrition2021;31(5):512-22. [MEDLINE: 34120835]BirueteA , KistlerB , AllenJ , BauerL , FaheyG , SwansonK , et al. Effect of inulin supplementation on mineral metabolism and short-chain fatty acid excretion in hemodialysis patients [abstract no: MP434]. Nephrology Dialysis Transplantation2017;32(Suppl 3):iii588-9. [EMBASE: 617289888]">Biruete 2017</a>) to 124 (<a href="./references#CD013631-bbs2-0046" title="XieLM , GeYY , HuangX , ZhangY , LiJX . Effects of fermentable dietary fiber supplementation on oxidative and inflammatory status in hemodialysis patients. International Journal of Clinical &amp; Experimental Medicine2015;8(1):1363-9. [EMBASE: 602272251]">Xie 2015a</a>) participants. </p> <p>Twenty‐five studies investigated participants with CKD stage 5D (dialysis), 18 studies investigated participants with stages 1 to 5 non‐dialysis, and two studies investigated kidney transplant or simultaneous pancreas‐kidney (SPK) transplant recipients (<a href="./references#CD013631-bbs2-0014" title="GuidaB , CataldiM , MemoliA , TrioR , di MaroM , GrumettoL , et al. Effect of a short-course treatment with synbiotics on plasma p-cresol concentration in kidney transplant recipients. Journal of the American College of Nutrition2017;36(7):586-91. [PMID: 28895794]">Guida 2017</a>; <a href="./references#CD013631-bbs2-0034" title="ChanS , HawleyCM , PascoeEM , CaoC , CampbellKL , CampbellSB , et al. PREBIOTIC: a study protocol of a randomised controlled trial to assess prebiotic supplementation in kidney transplant recipients for preventing infections and gastrointestinal upset — a feasibility study. Pilot &amp; Feasibility Studies2023;9(1):11. [DOI: 10.1186/s40814-023-01236-y]ChanS , HawleyCM , PascoeEM , CaoC , CampbellSB , CampbellKL , et al. Prebiotic supplementation in kidney transplant recipients for preventing infections and gastrointestinal upset: a randomized controlled feasibility study. Journal of Renal Nutrition2022;32(6):718-25. [MEDLINE: 35248721]ChanS , HawleyCM , PascoeEM , CaoCZ , CampbellSB , CampbellKL , et al. Prebiotic supplementation in kidney transplant recipients for preventing infections and gastrointestinal upset: a randomized controlled feasibility study. American Journal of Transplantation2022;22:783. [DOI: 10.1111/ajt.17073]">PREBIOTIC 2022</a>). Twenty‐nine studies included participants who had diabetes, and 24 studies included participants who had hypertension. </p> <p>Forty‐three studies investigated adults 18 years and older, and two studies investigated adults and children of all ages (<a href="./references#CD013631-bbs2-0030" title="MirzaeianS , Saraf-BankS , EntezariMH , HekmatdoostA , FeiziA , AtapourA . Effects of synbiotic supplementation on microbiota-derived protein-bound uremic toxins, systemic inflammation, and biochemical parameters in patients on hemodialysis: A double-blind, placebo-controlled, randomized clinical trial. Nutrition2020;73:110713. [MEDLINE: 32120316]">Mirzaeian 2020</a>; <a href="./references#CD013631-bbs2-0046" title="XieLM , GeYY , HuangX , ZhangY , LiJX . Effects of fermentable dietary fiber supplementation on oxidative and inflammatory status in hemodialysis patients. International Journal of Clinical &amp; Experimental Medicine2015;8(1):1363-9. [EMBASE: 602272251]">Xie 2015a</a>). </p> <p>Thirty‐two studies compared two parallel arms, three studies compared three parallel arms (<a href="./references#CD013631-bbs2-0011" title="ElaminS , AlkhawajaMJ , BukhamsinAY , IdrisMA , AbdelrahmanMM , AbutalebNK , et al. Gum Arabic reduces C-reactive protein in chronic kidney disease patients without affecting urea or indoxyl sulfate levels. International Journal of Nephrology2017;2017:9501470. [MEDLINE: 28589039]">Elamin 2017</a>; <a href="./references#CD013631-bbs2-0015" title="HaghighatN , MohammadshahiM , ShayanpourS , HaghighizadehMH , RahmdelS , RajaeiM . The effect of synbiotic and probiotic supplementation on mental health parameters in patients undergoing hemodialysis: A double-blind, randomized, placebo-controlled trial. Indian Journal of Nephrology2021;31(2):149-56. [EMBASE: 634933481]HaghighatN , MohammadshahiM , ShayanpourS , HaghighizadehMH . Effect of synbiotic and probiotic supplementation on serum levels of endothelial cell adhesion molecules in hemodialysis patients: a randomized control study. Probiotics &amp; Antimicrobial Proteins2019;11(4):1210-8. [MEDLINE: 30293208]HaghighatN , MohammadshahiM , ShayanpourS , HaghighizadehMH . Effects of synbiotics and probiotics supplementation on serum levels of endotoxin, heat shock protein 70 antibodies and inflammatory markers in hemodialysis patients: a randomized double-blinded controlled trial. Probiotics &amp; Antimicrobial Proteins2020;12(1):144-51. [MEDLINE: 30617950]HaghighatN , RajabiS , MohammadshahiM . Effect of synbiotic and probiotic supplementation on serum brain-derived neurotrophic factor level, depression and anxiety symptoms in hemodialysis patients: a randomized, double-blinded, clinical trial. Nutritional Neuroscience2019;24(6):490-9. [MEDLINE: 31379269]HaghighatN , RajabiS , MohammadshahiM . Effect of synbiotic and probiotic supplementation on serum brain-derived neurotrophic factor level, depression and anxiety symptoms in hemodialysis patients: a randomized, double-blinded, clinical trial. Nutritional Neuroscience2021;24(6):490-9. [MEDLINE: 31379269]">Haghighat 2019</a>; <a href="./references#CD013631-bbs2-0046" title="XieLM , GeYY , HuangX , ZhangY , LiJX . Effects of fermentable dietary fiber supplementation on oxidative and inflammatory status in hemodialysis patients. International Journal of Clinical &amp; Experimental Medicine2015;8(1):1363-9. [EMBASE: 602272251]">Xie 2015a</a>), 10 studies compared a cross‐over treatment with either a washout period (<a href="./references#CD013631-bbs2-0002" title="BirueteA , CrossTL , AllenJM , KistlerBM , deLoorH , EvenepoelP , et al. Effect of dietary inulin supplementation on the gut microbiota composition and derived metabolites of individuals undergoing hemodialysis: a pilot study. Journal of Renal Nutrition2021;31(5):512-22. [MEDLINE: 34120835]BirueteA , KistlerB , AllenJ , BauerL , FaheyG , SwansonK , et al. Effect of inulin supplementation on mineral metabolism and short-chain fatty acid excretion in hemodialysis patients [abstract no: MP434]. Nephrology Dialysis Transplantation2017;32(Suppl 3):iii588-9. [EMBASE: 617289888]">Biruete 2017</a>; <a href="./references#CD013631-bbs2-0006" title="deAndradeLS , SardaFA , PereiraNB , TeixeiraRR , RodriguesSD , deLimaJD , et al. Effect of unripe banana flour on gut-derived uremic toxins in individuals undergoing peritoneal dialysis: a randomized, double-blind, placebo-controlled, crossover trial. Nutrients2021;13(2):646. [MEDLINE: 33671166]">de Andrade 2021</a>; <a href="./references#CD013631-bbs2-0012" title="AzevedoR , EsgalhadoM , KempJA , RegisB , CardozoLF , NakaoLS , et al. Resistant starch supplementation effects on plasma indole 3-acetic acid and aryl hydrocarbon receptor mRNA expression in hemodialysis patients: Randomized, double blind and controlled clinical trial [Efeitos da suplementacao de amido resistente no acido indol-3-acetico plasmatico e na expressao do mRNA do receptor aril-hidrocarboneto em pacientesemhemodialise:ensaioclinicorandomizado,duplo-cegoecontrolado]. Jornal Brasileiro de Nefrologia2020;42(3):273-9. [MEDLINE: 32459282]EsgalhadoM , KempJA , AzevedoR , PaivaBR , Stockler-PintoMB , DolengaCJ , et al. Could resistant starch supplementation improve inflammatory and oxidative stress biomarkers and uremic toxins levels in hemodialysis patients? A pilot randomized controlled trial. Food &amp; Function2018;9(12):6508-16. [MEDLINE: 30468238]EsgalhadoM , KempJA , PaivaBR , BritoJS , CardozoLF , AzevedoR , et al. Resistant starch type-2 enriched cookies modulate uremic toxins and inflammation in hemodialysis patients: a randomized, double-blind, crossover and placebo-controlled trial. Food &amp; Function2020;11(3):2617-25. [MEDLINE: 32159187]KempJA , Dos SantosHF , deJesusHE , EsgalhadoM , dePaivaBR , AzevedoR , et al. Resistant starch type-2 supplementation does not decrease trimethylamine n-oxide (TMAO) plasma level in hemodialysis patients. Journal of the American Nutrition Association2022;41(8):788-95. [MEDLINE: 35512757]KempJA , Regis de PaivaB , Fragoso Dos SantosH , Emiliano de JesusH , CravenH , Z IjazU , et al. The impact of enriched resistant starch type-2 cookies on the gut microbiome in hemodialysis patients: a randomized controlled trial. Molecular Nutrition &amp; Food Research2021;65(19):e2100374. [MEDLINE: 34390604]MafraD , Ann KempJ , EsgalhadoM , PaivaB , De JesusHE , SantosHF . Effects of resistant starch (RS) type 2 cookies on gut microbiota profile in hemodialysis (HD) patients [abstract no: PO2051]. Journal of the American Society of Nephrology2020;31(Abstract Suppl):629-30. [EMBASE: 633701738]MafraD , Ann KempJ , SantosHF , De JesusHE , EsgalhadoM , PaivaB , et al. High-amylose resistant starch (RS) cookies supplementation does not decrease trimethylamine n-oxide (TMAO) plasma level in hemodialysis (HD) patients [abstract no: PO2039]. Journal of the American Society of Nephrology2020;31(Abstract Suppl):626-7. [EMBASE: 633701431]MafraD , EsgalhadoM , MacedoRD , KempJ , PaivaB , NakaoLS , et al. Resistant starch supplementation reduces indoxyl sulfate levels in hemodialysis patients: a randomized, double-blind, crossover, placebo-controlled study [abstract no: FR-OR127]. Journal of the American Society of Nephrology2018;29(Abstract Suppl):72. [EMBASE: 633737357]MafraD , EsgalhadoM , Stockler-PintoMB , BorgesNA , CardozoLF , PaivaB , et al. Effects of resistant starch supplementation on inflammatory and oxidative stress status in hemodialysis patients: a pilot randomized, double-blind, placebo-controlled clinical trial [abstract no: SA-PO149]. Journal of the American Society of Nephrology2017;28(Abstract Suppl):716. [EMBASE: 633701761]MafraD , MacedoRD , CardozoLF , BorgesNA , NakaoLS , JardimMZ , et al. Effect of resistant starch supplementation on the indole-3-acetic acid levels and aryl hydrocarbon receptor expression in hemodialysis patients [abstract no: FR-PO545]. Journal of the American Society of Nephrology2018;29(Abstract Suppl):561. [EMBASE: 633736002]MafraD , PaivaB , EsgalhadoM , BorgesNA , KempJA , CardozoLF , et al. Resistant starch supplementation attenuates inflammation in hemodialysis patients [abstract no: SA-PO818]. Journal of the American Society of Nephrology2019;30(Abstract Suppl):974. [EMBASE: 633769632]dePaivaBR , EsgalhadoM , BorgesNA , KempJA , AlvesG , LeitePE , et al. Resistant starch supplementation attenuates inflammation in hemodialysis patients: a pilot study. International Urology &amp; Nephrology2020;52(3):549-55. [MEDLINE: 32008198]">Esgalhado 2018</a>; <a href="./references#CD013631-bbs2-0017" title="HeS , XiongQ , TianC , LiL , ZhaoJ , LinX , et al. Inulin-type prebiotics reduce serum uric acid levels via gut microbiota modulation: a randomized, controlled crossover trial in peritoneal dialysis patients. European Journal of Nutrition2022;61(2):665-77. [MEDLINE: 34491388]">He 2022</a>; <a href="./references#CD013631-bbs2-0020" title="LiL , XiongQ , ZhaoJ , LinX , HeS , WuN , et al. Inulin-type fructan intervention restricts the increase in gut microbiome-generated indole in patients with peritoneal dialysis: a randomized crossover study [Erratum in: Am J Clin Nutr. 2022 Jun 7;115(6):1659]. American Journal of Clinical Nutrition2020;111(5):1087-99. [MEDLINE: 31942927]XiongQ , LiL , XiaoY , HeS , ZhaoJ , LinX , et al. The effect of inulin-type fructans on plasma trimethylamine n-oxide levels in peritoneal dialysis patients: a randomized crossover trial. Molecular Nutrition &amp; Food Research2023;67(9):e2200531. [DOI: 10.1002/mnfr.202200531]">Li 2020</a>; <a href="./references#CD013631-bbs2-0031" title="NatarajanR , PechenyakB , VyasU , RanganathanP , WeinbergA , LiangP , et al. Randomized controlled trial of strain-specific probiotic formulation (Renadyl) in dialysis patients. BioMed Research International2014;2014:568571. [MEDLINE: 25147806]">Natarajan 2014</a>; <a href="./references#CD013631-bbs2-0033" title="PoesenR , EvenepoelP , deLoorH , DelcourJA , CourtinCM , KuypersD , et al. The influence of prebiotic arabinoxylan oligosaccharides on microbiota derived uremic retention solutes in patients with chronic kidney disease: a randomized controlled trial. PLoS ONE {Electronic Resource]2016;11(4):e0153893. [MEDLINE: 27100399]">Poesen 2016</a>; <a href="./references#CD013631-bbs2-0042" title="RossiM , JohnsonD , PascoeE , CoombesJ , ForbesJ , SzetoCC , et al. Synbiotic therapy in pre-dialysis: a randomised controlled trial [abstract no: SAO029]. Nephrology Dialysis Transplantation2015;30(Suppl 3):iii38. [EMBASE: 72206363]RossiM , JohnsonDW , MorrisonM , PascoeE , CoombesJS , ForbesJM , et al. SYNbiotics Easing Renal failure by improving Gut microbiologY (SYNERGY): a protocol of placebo-controlled randomised cross-over trial. BMC Nephrology2014;15:106. [MEDLINE: 24996842]RossiM , JohnsonDW , MorrisonM , PascoeEM , CoombesJS , ForbesJM , et al. Synbiotics easing renal failure by improving gut microbiology (SYNERGY): a randomized trial. Clinical Journal of the American Society of Nephrology: CJASN2016;11(2):223-31. [MEDLINE: 26772193]RossiM , JohnsonDW , XuH , CarreroJJ , PascoeE , FrenchC , et al. Dietary protein-fiber ratio associates with circulating levels of indoxyl sulfate and p-cresyl sulfate in chronic kidney disease patients. Nutrition Metabolism &amp; Cardiovascular Diseases2015;25(9):860-5. [MEDLINE: 26026209]">SYNERGY 2014</a>) or no washout period (<a href="./references#CD013631-bbs2-0003" title="BlissDZ , SteinTP , SchleiferCR , SettleRG . Supplementation with gum arabic fiber increases fecal nitrogen excretion and lowers serum urea nitrogen concentration in chronic renal failure patients consuming a low-protein diet. American Journal of Clinical Nutrition1996;63(3):392-8. [MEDLINE: 8602598]BlissDZ . Effect of a gum Arabic supplement on the nitrogen excretion and serum urea nitrogen concentration of chronic renal failure patients on a low protein diet [PhD thesis]. University of Pennsylvania1992:1-206. [CINAHL: 109870911] ">Bliss 1992</a>; <a href="./references#CD013631-bbs2-0037" title="RanganathanN , FriedmanEA , TamP , RaoV , RanganathanP , DheerR . Probiotic dietary supplementation in patients with stage 3 and 4 chronic kidney disease: a 6-month pilot scale trial in Canada. Current Medical Research &amp; Opinion2009;25(8):1919-30. [MEDLINE: 19558344]RanganathanN , FriedmanEA , TamPY , RaoV , RanganathanPL . Dietary supplementation with a probiotic formulation (Kibow biotics) on CKD III and IV patients- a short term pilot scale study in Canada [abstract no: SA-PO2755]. Journal of the American Society of Nephrology2009;20(Abstract Suppl):741A. RanganathanN , RanganathanP , FriedmanEA , JosephA , DelanoB , GoldfarbDS , et al. Pilot study of probiotic dietary supplementation for promoting healthy kidney function in patients with chronic kidney disease. Advances in Therapy2010;27(9):634-47. [MEDLINE: 20721651]">Ranganathan 2009</a>). </p> <section id="CD013631-sec-0051"> <h5 class="title">Comparisons</h5> <p> <ul id="CD013631-list-0017"> <li> <p>One study investigated a synbiotic to another synbiotic (<a href="./references#CD013631-bbs2-0015" title="HaghighatN , MohammadshahiM , ShayanpourS , HaghighizadehMH , RahmdelS , RajaeiM . The effect of synbiotic and probiotic supplementation on mental health parameters in patients undergoing hemodialysis: A double-blind, randomized, placebo-controlled trial. Indian Journal of Nephrology2021;31(2):149-56. [EMBASE: 634933481]HaghighatN , MohammadshahiM , ShayanpourS , HaghighizadehMH . Effect of synbiotic and probiotic supplementation on serum levels of endothelial cell adhesion molecules in hemodialysis patients: a randomized control study. Probiotics &amp; Antimicrobial Proteins2019;11(4):1210-8. [MEDLINE: 30293208]HaghighatN , MohammadshahiM , ShayanpourS , HaghighizadehMH . Effects of synbiotics and probiotics supplementation on serum levels of endotoxin, heat shock protein 70 antibodies and inflammatory markers in hemodialysis patients: a randomized double-blinded controlled trial. Probiotics &amp; Antimicrobial Proteins2020;12(1):144-51. [MEDLINE: 30617950]HaghighatN , RajabiS , MohammadshahiM . Effect of synbiotic and probiotic supplementation on serum brain-derived neurotrophic factor level, depression and anxiety symptoms in hemodialysis patients: a randomized, double-blinded, clinical trial. Nutritional Neuroscience2019;24(6):490-9. [MEDLINE: 31379269]HaghighatN , RajabiS , MohammadshahiM . Effect of synbiotic and probiotic supplementation on serum brain-derived neurotrophic factor level, depression and anxiety symptoms in hemodialysis patients: a randomized, double-blinded, clinical trial. Nutritional Neuroscience2021;24(6):490-9. [MEDLINE: 31379269]">Haghighat 2019</a>) </p> </li> <li> <p>Seven studies investigated a synbiotic to a prebiotic (<a href="./references#CD013631-bbs2-0013" title="GuidaB , GermanoR , TrioR , RussoD , MemoliB , GrumettoL , et al. Effect of short-term synbiotic treatment on plasma p-cresol levels in patients with chronic renal failure: a randomized clinical trial. Nutrition Metabolism &amp; Cardiovascular Diseases2014;24(9):1043-9. [MEDLINE: 24929795]">Guida 2014</a>; <a href="./references#CD013631-bbs2-0014" title="GuidaB , CataldiM , MemoliA , TrioR , di MaroM , GrumettoL , et al. Effect of a short-course treatment with synbiotics on plasma p-cresol concentration in kidney transplant recipients. Journal of the American College of Nutrition2017;36(7):586-91. [PMID: 28895794]">Guida 2017</a>; <a href="./references#CD013631-bbs2-0015" title="HaghighatN , MohammadshahiM , ShayanpourS , HaghighizadehMH , RahmdelS , RajaeiM . The effect of synbiotic and probiotic supplementation on mental health parameters in patients undergoing hemodialysis: A double-blind, randomized, placebo-controlled trial. Indian Journal of Nephrology2021;31(2):149-56. [EMBASE: 634933481]HaghighatN , MohammadshahiM , ShayanpourS , HaghighizadehMH . Effect of synbiotic and probiotic supplementation on serum levels of endothelial cell adhesion molecules in hemodialysis patients: a randomized control study. Probiotics &amp; Antimicrobial Proteins2019;11(4):1210-8. [MEDLINE: 30293208]HaghighatN , MohammadshahiM , ShayanpourS , HaghighizadehMH . Effects of synbiotics and probiotics supplementation on serum levels of endotoxin, heat shock protein 70 antibodies and inflammatory markers in hemodialysis patients: a randomized double-blinded controlled trial. Probiotics &amp; Antimicrobial Proteins2020;12(1):144-51. [MEDLINE: 30617950]HaghighatN , RajabiS , MohammadshahiM . Effect of synbiotic and probiotic supplementation on serum brain-derived neurotrophic factor level, depression and anxiety symptoms in hemodialysis patients: a randomized, double-blinded, clinical trial. Nutritional Neuroscience2019;24(6):490-9. [MEDLINE: 31379269]HaghighatN , RajabiS , MohammadshahiM . Effect of synbiotic and probiotic supplementation on serum brain-derived neurotrophic factor level, depression and anxiety symptoms in hemodialysis patients: a randomized, double-blinded, clinical trial. Nutritional Neuroscience2021;24(6):490-9. [MEDLINE: 31379269]">Haghighat 2019</a>; <a href="./references#CD013631-bbs2-0023" title="LopesRC , TheodoroJM , da SilvaBP , QueirozVA , deCastro MoreiraME , MantovaniHC , et al. Synbiotic meal decreases uremic toxins in hemodialysis individuals: a placebo-controlled trial. Food Research International2019;116:241-8. [MEDLINE: 30716942]LopesRC , deLimaSL , da SilvaBP , ToledoRC , MoreiraME , AnunciacaoPC , et al. Evaluation of the health benefits of consumption of extruded tannin sorghum with unfermented probiotic milk in individuals with chronic kidney disease. Food Research International2018;107:629-38. [MEDLINE: 29580529]">Lopes 2018</a>; <a href="./references#CD013631-bbs2-0030" title="MirzaeianS , Saraf-BankS , EntezariMH , HekmatdoostA , FeiziA , AtapourA . Effects of synbiotic supplementation on microbiota-derived protein-bound uremic toxins, systemic inflammation, and biochemical parameters in patients on hemodialysis: A double-blind, placebo-controlled, randomized clinical trial. Nutrition2020;73:110713. [MEDLINE: 32120316]">Mirzaeian 2020</a>; <a href="./references#CD013631-bbs2-0042" title="RossiM , JohnsonD , PascoeE , CoombesJ , ForbesJ , SzetoCC , et al. Synbiotic therapy in pre-dialysis: a randomised controlled trial [abstract no: SAO029]. Nephrology Dialysis Transplantation2015;30(Suppl 3):iii38. [EMBASE: 72206363]RossiM , JohnsonDW , MorrisonM , PascoeE , CoombesJS , ForbesJM , et al. SYNbiotics Easing Renal failure by improving Gut microbiologY (SYNERGY): a protocol of placebo-controlled randomised cross-over trial. BMC Nephrology2014;15:106. [MEDLINE: 24996842]RossiM , JohnsonDW , MorrisonM , PascoeEM , CoombesJS , ForbesJM , et al. Synbiotics easing renal failure by improving gut microbiology (SYNERGY): a randomized trial. Clinical Journal of the American Society of Nephrology: CJASN2016;11(2):223-31. [MEDLINE: 26772193]RossiM , JohnsonDW , XuH , CarreroJJ , PascoeE , FrenchC , et al. Dietary protein-fiber ratio associates with circulating levels of indoxyl sulfate and p-cresyl sulfate in chronic kidney disease patients. Nutrition Metabolism &amp; Cardiovascular Diseases2015;25(9):860-5. [MEDLINE: 26026209]">SYNERGY 2014</a>; <a href="./references#CD013631-bbs2-0043" title="McFarlaneC , KrishnasamyR , StantonT , SavillE , SnelsonM , MihalaG , et al. Synbiotics easing renal failure by improving gut microbiology II (SYNERGY II): a feasibility randomized controlled trial. Nutrients2021;13(12):4481. [PMID: 34960037]">SYNERGY II 2021</a>) </p> </li> <li> <p>Nine studies investigated a prebiotic to a prebiotic (<a href="./references#CD013631-bbs2-0002" title="BirueteA , CrossTL , AllenJM , KistlerBM , deLoorH , EvenepoelP , et al. Effect of dietary inulin supplementation on the gut microbiota composition and derived metabolites of individuals undergoing hemodialysis: a pilot study. Journal of Renal Nutrition2021;31(5):512-22. [MEDLINE: 34120835]BirueteA , KistlerB , AllenJ , BauerL , FaheyG , SwansonK , et al. Effect of inulin supplementation on mineral metabolism and short-chain fatty acid excretion in hemodialysis patients [abstract no: MP434]. Nephrology Dialysis Transplantation2017;32(Suppl 3):iii588-9. [EMBASE: 617289888]">Biruete 2017</a>; <a href="./references#CD013631-bbs2-0003" title="BlissDZ , SteinTP , SchleiferCR , SettleRG . Supplementation with gum arabic fiber increases fecal nitrogen excretion and lowers serum urea nitrogen concentration in chronic renal failure patients consuming a low-protein diet. American Journal of Clinical Nutrition1996;63(3):392-8. [MEDLINE: 8602598]BlissDZ . Effect of a gum Arabic supplement on the nitrogen excretion and serum urea nitrogen concentration of chronic renal failure patients on a low protein diet [PhD thesis]. University of Pennsylvania1992:1-206. [CINAHL: 109870911] ">Bliss 1992</a>; <a href="./references#CD013631-bbs2-0011" title="ElaminS , AlkhawajaMJ , BukhamsinAY , IdrisMA , AbdelrahmanMM , AbutalebNK , et al. Gum Arabic reduces C-reactive protein in chronic kidney disease patients without affecting urea or indoxyl sulfate levels. International Journal of Nephrology2017;2017:9501470. [MEDLINE: 28589039]">Elamin 2017</a>; <a href="./references#CD013631-bbs2-0017" title="HeS , XiongQ , TianC , LiL , ZhaoJ , LinX , et al. Inulin-type prebiotics reduce serum uric acid levels via gut microbiota modulation: a randomized, controlled crossover trial in peritoneal dialysis patients. European Journal of Nutrition2022;61(2):665-77. [MEDLINE: 34491388]">He 2022</a>; <a href="./references#CD013631-bbs2-0020" title="LiL , XiongQ , ZhaoJ , LinX , HeS , WuN , et al. Inulin-type fructan intervention restricts the increase in gut microbiome-generated indole in patients with peritoneal dialysis: a randomized crossover study [Erratum in: Am J Clin Nutr. 2022 Jun 7;115(6):1659]. American Journal of Clinical Nutrition2020;111(5):1087-99. [MEDLINE: 31942927]XiongQ , LiL , XiaoY , HeS , ZhaoJ , LinX , et al. The effect of inulin-type fructans on plasma trimethylamine n-oxide levels in peritoneal dialysis patients: a randomized crossover trial. Molecular Nutrition &amp; Food Research2023;67(9):e2200531. [DOI: 10.1002/mnfr.202200531]">Li 2020</a>; <a href="./references#CD013631-bbs2-0033" title="PoesenR , EvenepoelP , deLoorH , DelcourJA , CourtinCM , KuypersD , et al. The influence of prebiotic arabinoxylan oligosaccharides on microbiota derived uremic retention solutes in patients with chronic kidney disease: a randomized controlled trial. PLoS ONE {Electronic Resource]2016;11(4):e0153893. [MEDLINE: 27100399]">Poesen 2016</a>; <a href="./references#CD013631-bbs2-0036" title="ArmaniR , IshikawaC , HongV , BortolottoLA , CassiolattoJL , KlassenA , et al. Effect of frutooligosaccharide on endothelial function in CKD patients: a randomized controlled trial [abstract no: SAT-206]. Kidney International Reports2019;4(7 Suppl):S93. [EMBASE: 2002179674]ArmaniRG , CarvalhoAB , RamosCI , HongV , BortolottoLA , CassiolatoJL , et al. Effect of fructooligosaccharide on endothelial function in CKD patients: a randomized controlled trial. Nephrology Dialysis Transplantation2021;37(1):85-91. [MEDLINE: 33411910]ArmaniRG , RamosCI , CuppariL , CanzianiME . Effect of fructooligosaccharide on endothelium function in CKD patients: a randomized controlled trial [abstract no: TH-PO1138]. Journal of the American Society of Nephrology2018;29(Abstract Suppl):417. [EMBASE: 633736090]RamosCI , ArmaniRG , CanzianiMEF , DalboniMA , DolengaCJR , NakaoLS , et al. Effect of prebiotic (fructooligosaccharide) on uremic toxins of chronic kidney disease patients: a randomized controlled trial. Nephrology Dialysis Transplantation2019;34(11):1876-84. [MEDLINE: 29939302]RamosCI , ArmaniRG , NakaoLS , CanzianiMEF , CampbellKL , CuppariL . Effect of fructooligosaccharide on microbiota-derived uremic toxins in predialysis patients: a randomized controlled trial [abstract no: SA-PO161]. Journal of the American Society of Nephrology2017;28(Abstract Suppl):720. [EMBASE: 633702127]">Ramos 2019</a>; <a href="./references#CD013631-bbs2-0039" title="SirichTL , PlummerN , HostetterTH , MeyerT . Increasing dietary fiber reduces plasma levels of colon-derived uremic solutes in hemodialysis patients [abstract no: FR-PO793]. Journal of the American Society of Nephrology2013;24(Abstract Suppl):545A. [MEDLINE: 25147155]SirichTL , PlummerNS , GardnerCD , HostetterTH , MeyerTW . Effect of increasing dietary fiber on plasma levels of colon-derived solutes in hemodialysis patients. Clinical Journal of the American Society of Nephrology: CJASN2014;9(9):1603-10. [MEDLINE: 25147155]">Sirich 2014</a>; <a href="./references#CD013631-bbs2-0046" title="XieLM , GeYY , HuangX , ZhangY , LiJX . Effects of fermentable dietary fiber supplementation on oxidative and inflammatory status in hemodialysis patients. International Journal of Clinical &amp; Experimental Medicine2015;8(1):1363-9. [EMBASE: 602272251]">Xie 2015a</a>) </p> </li> <li> <p>Two studies investigated a prebiotic to a probiotic (<a href="./references#CD013631-bbs2-0031" title="NatarajanR , PechenyakB , VyasU , RanganathanP , WeinbergA , LiangP , et al. Randomized controlled trial of strain-specific probiotic formulation (Renadyl) in dialysis patients. BioMed Research International2014;2014:568571. [MEDLINE: 25147806]">Natarajan 2014</a>; <a href="./references#CD013631-bbs2-0045" title="WangIK , WuYY , YangYF , TingIW , LinCC , YenTH , et al. The effect of probiotics on serum levels of cytokine and endotoxin in peritoneal dialysis patients: a randomised, double-blind, placebo-controlled trial. Beneficial Microbes2015;6(4):423-30. [MEDLINE: 25609654]">Wang 2015a</a>) </p> </li> <li> <p>One study investigated a probiotic to another probiotic (<a href="./references#CD013631-bbs2-0029" title="Miranda AlatristePV , UrbinaAR , Gomez EspinosaCO , Espinosa CuevasML . Effect of probiotics on human blood urea levels in patients with chronic renal failure. Nutricion Hospitalaria2014;29(3):582-90. [MEDLINE: 24559003]">Miranda Alatriste 2014</a>) </p> </li> <li> <p>Six studies compared a synbiotic to placebo (<a href="./references#CD013631-bbs2-0005" title="CosolaC , RocchettiMT , di BariI , AcquavivaPM , MaranzanoV , CorciuloS , et al. An innovative synbiotic formulation decreases free serum indoxyl sulfate, small intestine permeability and ameliorates gastrointestinal symptoms in a randomized pilot trial in stage IIIb-IV CKD patients. Toxins2021;13(5):334. [MEDLINE: 34063068]">Cosola 2021</a>; <a href="./references#CD013631-bbs2-0008" title="DehghaniH , HeidariF , Mozaffari-KhosraviH , Nouri-MajelanN , DehghaniA . Synbiotic supplementations for azotemia in patients with chronic kidney disease: a randomized controlled trial. Iranian Journal of Kidney Diseases2016;10(6):351-7. [MEDLINE: 27903994]">Dehghani 2016</a>; <a href="./references#CD013631-bbs2-0019" title="KooshkiA , TofighiyanT , MiriM . A synbiotic supplement for inflammation and oxidative stress and lipid abnormalities in hemodialysis patients. Hemodialysis International2019;23(2):254-60. [MEDLINE: 30821897]">Kooshki 2019</a>; <a href="./references#CD013631-bbs2-0024" title="LydiaA , IndraTA , RizkaA , AbdullahM . The effects of synbiotics on indoxyl sulphate level, constipation, and quality of life associated with constipation in chronic haemodialysis patients: a randomized controlled trial. BMC Nephrology2022;23(1):259. [MEDLINE: 35869437]">Lydia 2022</a>; <a href="./references#CD013631-bbs2-0040" title="SoleimaniA , Zarrati MojarradM , BahmaniF , TaghizadehM , RamezaniM , Tajabadi-EbrahimiM , et al. Probiotic supplementation in diabetic hemodialysis patients has beneficial metabolic effects. Kidney International2017;91(2):435-42. [MEDLINE: 27927601]">Soleimani 2017</a>; <a href="./references#CD013631-bbs2-0044" title="Viramontes-HornerD , Marquez-SandovalF , Martin-del-CampoF , Vizmanos-LamotteB , Sandoval-RodriguezA , Armendariz-BorundaJ , et al. Effect of a symbiotic gel (Lactobacillus acidophilus + Bifidobacterium lactis + inulin) on presence and severity of gastrointestinal symptoms in hemodialysis patients. Journal of Renal Nutrition2015;25(3):284-91. [MEDLINE: 25455039]">Viramontes‐Horner 2015</a>) </p> </li> <li> <p>Six studies investigated a prebiotic to placebo (<a href="./references#CD013631-bbs2-0006" title="deAndradeLS , SardaFA , PereiraNB , TeixeiraRR , RodriguesSD , deLimaJD , et al. Effect of unripe banana flour on gut-derived uremic toxins in individuals undergoing peritoneal dialysis: a randomized, double-blind, placebo-controlled, crossover trial. Nutrients2021;13(2):646. [MEDLINE: 33671166]">de Andrade 2021</a>; <a href="./references#CD013631-bbs2-0012" title="AzevedoR , EsgalhadoM , KempJA , RegisB , CardozoLF , NakaoLS , et al. Resistant starch supplementation effects on plasma indole 3-acetic acid and aryl hydrocarbon receptor mRNA expression in hemodialysis patients: Randomized, double blind and controlled clinical trial [Efeitos da suplementacao de amido resistente no acido indol-3-acetico plasmatico e na expressao do mRNA do receptor aril-hidrocarboneto em pacientesemhemodialise:ensaioclinicorandomizado,duplo-cegoecontrolado]. Jornal Brasileiro de Nefrologia2020;42(3):273-9. [MEDLINE: 32459282]EsgalhadoM , KempJA , AzevedoR , PaivaBR , Stockler-PintoMB , DolengaCJ , et al. Could resistant starch supplementation improve inflammatory and oxidative stress biomarkers and uremic toxins levels in hemodialysis patients? A pilot randomized controlled trial. Food &amp; Function2018;9(12):6508-16. [MEDLINE: 30468238]EsgalhadoM , KempJA , PaivaBR , BritoJS , CardozoLF , AzevedoR , et al. Resistant starch type-2 enriched cookies modulate uremic toxins and inflammation in hemodialysis patients: a randomized, double-blind, crossover and placebo-controlled trial. Food &amp; Function2020;11(3):2617-25. [MEDLINE: 32159187]KempJA , Dos SantosHF , deJesusHE , EsgalhadoM , dePaivaBR , AzevedoR , et al. Resistant starch type-2 supplementation does not decrease trimethylamine n-oxide (TMAO) plasma level in hemodialysis patients. Journal of the American Nutrition Association2022;41(8):788-95. [MEDLINE: 35512757]KempJA , Regis de PaivaB , Fragoso Dos SantosH , Emiliano de JesusH , CravenH , Z IjazU , et al. The impact of enriched resistant starch type-2 cookies on the gut microbiome in hemodialysis patients: a randomized controlled trial. Molecular Nutrition &amp; Food Research2021;65(19):e2100374. [MEDLINE: 34390604]MafraD , Ann KempJ , EsgalhadoM , PaivaB , De JesusHE , SantosHF . Effects of resistant starch (RS) type 2 cookies on gut microbiota profile in hemodialysis (HD) patients [abstract no: PO2051]. Journal of the American Society of Nephrology2020;31(Abstract Suppl):629-30. [EMBASE: 633701738]MafraD , Ann KempJ , SantosHF , De JesusHE , EsgalhadoM , PaivaB , et al. High-amylose resistant starch (RS) cookies supplementation does not decrease trimethylamine n-oxide (TMAO) plasma level in hemodialysis (HD) patients [abstract no: PO2039]. Journal of the American Society of Nephrology2020;31(Abstract Suppl):626-7. [EMBASE: 633701431]MafraD , EsgalhadoM , MacedoRD , KempJ , PaivaB , NakaoLS , et al. Resistant starch supplementation reduces indoxyl sulfate levels in hemodialysis patients: a randomized, double-blind, crossover, placebo-controlled study [abstract no: FR-OR127]. Journal of the American Society of Nephrology2018;29(Abstract Suppl):72. [EMBASE: 633737357]MafraD , EsgalhadoM , Stockler-PintoMB , BorgesNA , CardozoLF , PaivaB , et al. Effects of resistant starch supplementation on inflammatory and oxidative stress status in hemodialysis patients: a pilot randomized, double-blind, placebo-controlled clinical trial [abstract no: SA-PO149]. Journal of the American Society of Nephrology2017;28(Abstract Suppl):716. [EMBASE: 633701761]MafraD , MacedoRD , CardozoLF , BorgesNA , NakaoLS , JardimMZ , et al. Effect of resistant starch supplementation on the indole-3-acetic acid levels and aryl hydrocarbon receptor expression in hemodialysis patients [abstract no: FR-PO545]. Journal of the American Society of Nephrology2018;29(Abstract Suppl):561. [EMBASE: 633736002]MafraD , PaivaB , EsgalhadoM , BorgesNA , KempJA , CardozoLF , et al. Resistant starch supplementation attenuates inflammation in hemodialysis patients [abstract no: SA-PO818]. Journal of the American Society of Nephrology2019;30(Abstract Suppl):974. [EMBASE: 633769632]dePaivaBR , EsgalhadoM , BorgesNA , KempJA , AlvesG , LeitePE , et al. Resistant starch supplementation attenuates inflammation in hemodialysis patients: a pilot study. International Urology &amp; Nephrology2020;52(3):549-55. [MEDLINE: 32008198]">Esgalhado 2018</a>; <a href="./references#CD013631-bbs2-0018" title="KhosroshahiHT , AbediB , GhojazadehM , SamadiA , JouybanA . Effects of fermentable high fiber diet supplementation on gut derived and conventional nitrogenous product in patients on maintenance hemodialysis: a randomized controlled trial. Nutrition &amp; Metabolism2019;16:18. [MEDLINE: 30911321]LaffinMR , Tayebi KhosroshahiH , ParkH , LaffinLJ , MadsenK , KafilHS , et al. Amylose resistant starch (HAM-RS2) supplementation increases the proportion of Faecalibacterium bacteria in end-stage renal disease patients: microbial analysis from a randomized placebo-controlled trial. Hemodialysis International2019;23(3):343-7. [MEDLINE: 30924310]Tayebi Khosroshahi H, VaziriND , AbediB , AslBH , GhojazadehM , JingW , et al. Effect of high amylose resistant starch (HAM-RS2) supplementation on biomarkers of inflammation and oxidative stress in hemodialysis patients: a randomized clinical trial. Hemodialysis International2018;22(4):492-500. [MEDLINE: 29532981]">Khosroshahi 2018</a>; <a href="./references#CD013631-bbs2-0032" title="PanY , YangL , DaiB , LinB , LinS , LinE . Effects of probiotics on malnutrition and health-related quality of life in patients undergoing peritoneal dialysis: a randomized controlled trial. Journal of Renal Nutrition2021;31(2):199-205. [MEDLINE: 32620335]">Pan 2021</a>; <a href="./references#CD013631-bbs2-0034" title="ChanS , HawleyCM , PascoeEM , CaoC , CampbellKL , CampbellSB , et al. PREBIOTIC: a study protocol of a randomised controlled trial to assess prebiotic supplementation in kidney transplant recipients for preventing infections and gastrointestinal upset — a feasibility study. Pilot &amp; Feasibility Studies2023;9(1):11. [DOI: 10.1186/s40814-023-01236-y]ChanS , HawleyCM , PascoeEM , CaoC , CampbellSB , CampbellKL , et al. Prebiotic supplementation in kidney transplant recipients for preventing infections and gastrointestinal upset: a randomized controlled feasibility study. Journal of Renal Nutrition2022;32(6):718-25. [MEDLINE: 35248721]ChanS , HawleyCM , PascoeEM , CaoCZ , CampbellSB , CampbellKL , et al. Prebiotic supplementation in kidney transplant recipients for preventing infections and gastrointestinal upset: a randomized controlled feasibility study. American Journal of Transplantation2022;22:783. [DOI: 10.1111/ajt.17073]">PREBIOTIC 2022</a>; <a href="./references#CD013631-bbs2-0046" title="XieLM , GeYY , HuangX , ZhangY , LiJX . Effects of fermentable dietary fiber supplementation on oxidative and inflammatory status in hemodialysis patients. International Journal of Clinical &amp; Experimental Medicine2015;8(1):1363-9. [EMBASE: 602272251]">Xie 2015a</a>) </p> </li> <li> <p>Ten studies investigated a probiotic to placebo (<a href="./references#CD013631-bbs2-0004" title="BorgesNA , CarmoFL , Stockler-PintoMB , deBritoJS , DolengaCJ , FerreiraDC , et al. Probiotic supplementation in chronic kidney disease: a double-blind, randomized, placebo-controlled trial. Journal of Renal Nutrition2018;28(1):28-36. [MEDLINE: 28888762]BorgesNA , StenvinkelP , BergmanP , QureshiAR , LindholmB , MoraesC , et al. Effects of probiotic supplementation on trimethylamine-N-oxide plasma levels in hemodialysis patients: a pilot study. Probiotics &amp; Antimicrobial Proteins2019;11(2):648-54. [MEDLINE: 29651635]MafraD , BorgesNA , MoraesC , Stockler-PintoMB , BergmanP , StenvinkelP . Effects of probiotic supplementation on trimethylamine-N-oxide plasma levels in chronic kidney disease patients [abstract no: TH-PO764]. Journal of the American Society of Nephrology2016;27(Abstract Suppl):270A. [EMBASE: 641135082]MafraD , BorgesNA , NakauL , DolengaC , BergmanP , StenvinkelP . Effects of probiotic supplementation on uremic toxins levels in non-dialysis CKD patients [abstract no: MP431]. Nephrology Dialysis Transplantation2017;32(Suppl 3):iii587-8. [EMBASE: 617289825]MafraD , BorgesNA , Stockler-PintoMB , FouqueD , BarrosAF . Does a probiotic supplementation alter the indoxyl sulfate levels in non-dialysis chronic kidney disease patients? A randomized placebo-controlled clinical trial [abstract no: FR-PO862]. Journal of the American Society of Nephrology2015;26(Abstract Suppl):563A. [EMBASE: 641102246]">Borges 2018</a>; <a href="./references#CD013631-bbs2-0007" title="De AraujoEM , MenesesGC , MartinsAM , De Francesco DaherE , Da Silva JuniorGB . Effect of probiotic supplementation on endothelial injury and inflammation biomarkers among patients with chronic kidney diseases on hemodialysis [abstract no: MO584]. Nephrology Dialysis Transplantation2022;37(Suppl 3):i429. [DOI: 10.1093/ndt/gfac074.029]deAraujoEM , MenesesGC , CariocaAA , MartinsAM , DaherEF , da Silva JuniorGB . Use of probiotics in patients with chronic kidney disease on hemodialysis: a randomized clinical trial. Jornal Brasileiro de Nefrologia2022;45(2):152-61. [MEDLINE: 36112723]">de Araujo 2022</a>; <a href="./references#CD013631-bbs2-0010" title="EidiF , Poor-RezaGF , OstadrahimiA , DaliliN , SamadianF , BarzegariA . Effect of Lactobacillus rhamnosus on serum uremic toxins (phenol and P-cresol) in hemodialysis patients: A double blind randomized clinical trial. Clinical Nutrition ESPEN2018;28:158-64. [MEDLINE: 30390875]GholiFP , DaliliN , EidiF , OstadrahimiA . Effect of lactobacillus rhamnosus on serum uremic toxins in hemodialysis patients [abstract no: SP705]. Nephrology Dialysis Transplantation2017;32(Suppl 3):iii375. [EMBASE: 617290088]">Eidi 2018</a>; <a href="./references#CD013631-bbs2-0021" title="LimPS , WangHF , LeeMC , ChiuLS , WuMY , ChangWC , et al. The efficacy of lactobacillus-containing probiotic supplementation in hemodialysis patients: a randomized, double-blind, placebo-controlled trial. Journal of Renal Nutrition2021;31(2):189-98. [MEDLINE: 32900583]">Lim 2021</a>; <a href="./references#CD013631-bbs2-0022" title="LiuS , LiuH , ChenL , LiangSS , ShiK , MengW , et al. Effect of probiotics on the intestinal microbiota of hemodialysis patients: a randomized trial. European Journal of Nutrition2020;59(8):3755-66. [MEDLINE: 32112136]">Liu 2020</a>; <a href="./references#CD013631-bbs2-0025" title="MafiA , NamaziG , SoleimaniA , BahmaniF , AghadavodE , AsemiZ . Metabolic and genetic response to probiotics supplementation in patients with diabetic nephropathy: a randomized, double-blind, placebo-controlled trial [Expression of Concern in: Food Funct. 2022 Apr 4;13(7):4229]. Food &amp; Function2018;9(9):4763-70. [MEDLINE: 30113051]">Mafi 2018</a>; <a href="./references#CD013631-bbs2-0026" title="Mazruei AraniN , Emam-DjomehZ , TavakolipourH , Sharafati-ChaleshtoriR , SoleimaniA , AsemiZ . The effects of probiotic honey consumption on metabolic status in patients with diabetic nephropathy: a randomized, double-blind, controlled trial. Probiotics &amp; Antimicrobial Proteins2019;11(4):1195-201. [MEDLINE: 30218286]">Mazruei Arani 2019</a>; <a href="./references#CD013631-bbs2-0037" title="RanganathanN , FriedmanEA , TamP , RaoV , RanganathanP , DheerR . Probiotic dietary supplementation in patients with stage 3 and 4 chronic kidney disease: a 6-month pilot scale trial in Canada. Current Medical Research &amp; Opinion2009;25(8):1919-30. [MEDLINE: 19558344]RanganathanN , FriedmanEA , TamPY , RaoV , RanganathanPL . Dietary supplementation with a probiotic formulation (Kibow biotics) on CKD III and IV patients- a short term pilot scale study in Canada [abstract no: SA-PO2755]. Journal of the American Society of Nephrology2009;20(Abstract Suppl):741A. RanganathanN , RanganathanP , FriedmanEA , JosephA , DelanoB , GoldfarbDS , et al. Pilot study of probiotic dietary supplementation for promoting healthy kidney function in patients with chronic kidney disease. Advances in Therapy2010;27(9):634-47. [MEDLINE: 20721651]">Ranganathan 2009</a>; <a href="./references#CD013631-bbs2-0038" title="ShariatyZ , Mahmoodi ShanGR , FarajollahiM , AmerianM , BehnamPN . The effects of probiotic supplement on hemoglobin in chronic renal failure patients under hemodialysis: a randomized clinical trial. Journal of Research in Medical Sciences2017;22:74. [MEDLINE: 28717371]">Shariaty 2017</a>; <a href="./references#CD013631-bbs2-0040" title="SoleimaniA , Zarrati MojarradM , BahmaniF , TaghizadehM , RamezaniM , Tajabadi-EbrahimiM , et al. Probiotic supplementation in diabetic hemodialysis patients has beneficial metabolic effects. Kidney International2017;91(2):435-42. [MEDLINE: 27927601]">Soleimani 2017</a>) </p> </li> <li> <p>Two studies investigated a prebiotic to no treatment (<a href="./references#CD013631-bbs2-0009" title="EbrahimZ , ProostS , TitoRY , RaesJ , GlorieuxG , MoosaMR , et al. The effect of s-glucan prebiotic on kidney function, uremic toxins and gut microbiome in stage 3 to 5 chronic kidney disease (CKD) predialysis participants: a randomized controlled trial. Nutrients2022;14(4):805. [MEDLINE: 35215453]">Ebrahim 2022</a>; <a href="./references#CD013631-bbs2-0027" title="MengY , BaiH , YuQ , YanJ , ZhaoL , WangS , et al. High-resistant starch, low-protein flour intervention on patients with early type 2 diabetic nephropathy: a randomized trial. Journal of Renal Nutrition2019;29(5):386-93. [MEDLINE: 30982743]">Meng 2019</a>) </p> </li> <li> <p>Two studies investigated a probiotic to no treatment (<a href="./references#CD013631-bbs2-0001" title="AbbasiB , GhiasvandR , MirlohiM . Kidney function improvement by soy milk containing lactobacillus plantarum A7 in type 2 diabetic patients with nephropathy: a double-blinded randomized controlled trial. Iranian Journal of Kidney Diseases2017;11(1):36-43. [MEDLINE: 28174351]AbbasiB , MirlohiM , DanialiM , GhiasvandR . Effects of probiotic soy milk on lipid panel in type 2 diabetic patients with nephropathy: a double-blind randomized clinical trial. Progress in Nutrition2018;20:70-8. [EMBASE: 2001649336]">Abbasi 2017</a>; <a href="./references#CD013631-bbs2-0028" title="MiraghajaniM , ZaghianN , DehkohnehA , MirlohiM , GhiasvandR . Probiotic soy milk consumption and renal function among type 2 diabetic patients with nephropathy: a randomized controlled clinical trial. Probiotics &amp; Antimicrobial Proteins2019;11(1):124-32. [MEDLINE: 28884306]MiraghajaniM , ZaghianN , MirlohiM , FeiziA , GhiasvandR . Impact of probiotic soy milk consumption on oxidative stress among type 2 diabetic kidney disease patients: a randomized controlled clinical trial. Journal of Renal Nutrition2017;27(5):317-24. [MEDLINE: 28579313]">Miraghajani 2017</a>) </p> </li> </ul> </p> <p>Twenty‐eight studies contributed data to our meta‐analyses, 11 studies did not report data for our planned outcomes or data was not reported in a useable way to be meta‐analysed (<a href="./references#CD013631-bbs2-0007" title="De AraujoEM , MenesesGC , MartinsAM , De Francesco DaherE , Da Silva JuniorGB . Effect of probiotic supplementation on endothelial injury and inflammation biomarkers among patients with chronic kidney diseases on hemodialysis [abstract no: MO584]. Nephrology Dialysis Transplantation2022;37(Suppl 3):i429. [DOI: 10.1093/ndt/gfac074.029]deAraujoEM , MenesesGC , CariocaAA , MartinsAM , DaherEF , da Silva JuniorGB . Use of probiotics in patients with chronic kidney disease on hemodialysis: a randomized clinical trial. Jornal Brasileiro de Nefrologia2022;45(2):152-61. [MEDLINE: 36112723]">de Araujo 2022</a>; <a href="./references#CD013631-bbs2-0009" title="EbrahimZ , ProostS , TitoRY , RaesJ , GlorieuxG , MoosaMR , et al. The effect of s-glucan prebiotic on kidney function, uremic toxins and gut microbiome in stage 3 to 5 chronic kidney disease (CKD) predialysis participants: a randomized controlled trial. Nutrients2022;14(4):805. [MEDLINE: 35215453]">Ebrahim 2022</a>; <a href="./references#CD013631-bbs2-0011" title="ElaminS , AlkhawajaMJ , BukhamsinAY , IdrisMA , AbdelrahmanMM , AbutalebNK , et al. Gum Arabic reduces C-reactive protein in chronic kidney disease patients without affecting urea or indoxyl sulfate levels. International Journal of Nephrology2017;2017:9501470. [MEDLINE: 28589039]">Elamin 2017</a>; <a href="./references#CD013631-bbs2-0019" title="KooshkiA , TofighiyanT , MiriM . A synbiotic supplement for inflammation and oxidative stress and lipid abnormalities in hemodialysis patients. Hemodialysis International2019;23(2):254-60. [MEDLINE: 30821897]">Kooshki 2019</a>; <a href="./references#CD013631-bbs2-0024" title="LydiaA , IndraTA , RizkaA , AbdullahM . The effects of synbiotics on indoxyl sulphate level, constipation, and quality of life associated with constipation in chronic haemodialysis patients: a randomized controlled trial. BMC Nephrology2022;23(1):259. [MEDLINE: 35869437]">Lydia 2022</a>; <a href="./references#CD013631-bbs2-0028" title="MiraghajaniM , ZaghianN , DehkohnehA , MirlohiM , GhiasvandR . Probiotic soy milk consumption and renal function among type 2 diabetic patients with nephropathy: a randomized controlled clinical trial. Probiotics &amp; Antimicrobial Proteins2019;11(1):124-32. [MEDLINE: 28884306]MiraghajaniM , ZaghianN , MirlohiM , FeiziA , GhiasvandR . Impact of probiotic soy milk consumption on oxidative stress among type 2 diabetic kidney disease patients: a randomized controlled clinical trial. Journal of Renal Nutrition2017;27(5):317-24. [MEDLINE: 28579313]">Miraghajani 2017</a>; <a href="./references#CD013631-bbs2-0133" title="PanW , KangY . Gut microbiota and chronic kidney disease: implications for novel mechanistic insights and therapeutic strategies. International Urology &amp; Nephrology2018;50(2):289-99. [MEDLINE: 28849345]">Pan 2018</a>; <a href="./references#CD013631-bbs2-0034" title="ChanS , HawleyCM , PascoeEM , CaoC , CampbellKL , CampbellSB , et al. PREBIOTIC: a study protocol of a randomised controlled trial to assess prebiotic supplementation in kidney transplant recipients for preventing infections and gastrointestinal upset — a feasibility study. Pilot &amp; Feasibility Studies2023;9(1):11. [DOI: 10.1186/s40814-023-01236-y]ChanS , HawleyCM , PascoeEM , CaoC , CampbellSB , CampbellKL , et al. Prebiotic supplementation in kidney transplant recipients for preventing infections and gastrointestinal upset: a randomized controlled feasibility study. Journal of Renal Nutrition2022;32(6):718-25. [MEDLINE: 35248721]ChanS , HawleyCM , PascoeEM , CaoCZ , CampbellSB , CampbellKL , et al. Prebiotic supplementation in kidney transplant recipients for preventing infections and gastrointestinal upset: a randomized controlled feasibility study. American Journal of Transplantation2022;22:783. [DOI: 10.1111/ajt.17073]">PREBIOTIC 2022</a>; <a href="./references#CD013631-bbs2-0038" title="ShariatyZ , Mahmoodi ShanGR , FarajollahiM , AmerianM , BehnamPN . The effects of probiotic supplement on hemoglobin in chronic renal failure patients under hemodialysis: a randomized clinical trial. Journal of Research in Medical Sciences2017;22:74. [MEDLINE: 28717371]">Shariaty 2017</a>; <a href="./references#CD013631-bbs2-0040" title="SoleimaniA , Zarrati MojarradM , BahmaniF , TaghizadehM , RamezaniM , Tajabadi-EbrahimiM , et al. Probiotic supplementation in diabetic hemodialysis patients has beneficial metabolic effects. Kidney International2017;91(2):435-42. [MEDLINE: 27927601]">Soleimani 2017</a>; <a href="./references#CD013631-bbs2-0046" title="XieLM , GeYY , HuangX , ZhangY , LiJX . Effects of fermentable dietary fiber supplementation on oxidative and inflammatory status in hemodialysis patients. International Journal of Clinical &amp; Experimental Medicine2015;8(1):1363-9. [EMBASE: 602272251]">Xie 2015a</a>), and six were cross‐over studies and did not report separate data for the first phase of the study (<a href="./references#CD013631-bbs2-0006" title="deAndradeLS , SardaFA , PereiraNB , TeixeiraRR , RodriguesSD , deLimaJD , et al. Effect of unripe banana flour on gut-derived uremic toxins in individuals undergoing peritoneal dialysis: a randomized, double-blind, placebo-controlled, crossover trial. Nutrients2021;13(2):646. [MEDLINE: 33671166]">de Andrade 2021</a>; <a href="./references#CD013631-bbs2-0017" title="HeS , XiongQ , TianC , LiL , ZhaoJ , LinX , et al. Inulin-type prebiotics reduce serum uric acid levels via gut microbiota modulation: a randomized, controlled crossover trial in peritoneal dialysis patients. European Journal of Nutrition2022;61(2):665-77. [MEDLINE: 34491388]">He 2022</a>; <a href="./references#CD013631-bbs2-0031" title="NatarajanR , PechenyakB , VyasU , RanganathanP , WeinbergA , LiangP , et al. Randomized controlled trial of strain-specific probiotic formulation (Renadyl) in dialysis patients. BioMed Research International2014;2014:568571. [MEDLINE: 25147806]">Natarajan 2014</a>; <a href="./references#CD013631-bbs2-0033" title="PoesenR , EvenepoelP , deLoorH , DelcourJA , CourtinCM , KuypersD , et al. The influence of prebiotic arabinoxylan oligosaccharides on microbiota derived uremic retention solutes in patients with chronic kidney disease: a randomized controlled trial. PLoS ONE {Electronic Resource]2016;11(4):e0153893. [MEDLINE: 27100399]">Poesen 2016</a>; <a href="./references#CD013631-bbs2-0037" title="RanganathanN , FriedmanEA , TamP , RaoV , RanganathanP , DheerR . Probiotic dietary supplementation in patients with stage 3 and 4 chronic kidney disease: a 6-month pilot scale trial in Canada. Current Medical Research &amp; Opinion2009;25(8):1919-30. [MEDLINE: 19558344]RanganathanN , FriedmanEA , TamPY , RaoV , RanganathanPL . Dietary supplementation with a probiotic formulation (Kibow biotics) on CKD III and IV patients- a short term pilot scale study in Canada [abstract no: SA-PO2755]. Journal of the American Society of Nephrology2009;20(Abstract Suppl):741A. RanganathanN , RanganathanP , FriedmanEA , JosephA , DelanoB , GoldfarbDS , et al. Pilot study of probiotic dietary supplementation for promoting healthy kidney function in patients with chronic kidney disease. Advances in Therapy2010;27(9):634-47. [MEDLINE: 20721651]">Ranganathan 2009</a>; <a href="./references#CD013631-bbs2-0042" title="RossiM , JohnsonD , PascoeE , CoombesJ , ForbesJ , SzetoCC , et al. Synbiotic therapy in pre-dialysis: a randomised controlled trial [abstract no: SAO029]. Nephrology Dialysis Transplantation2015;30(Suppl 3):iii38. [EMBASE: 72206363]RossiM , JohnsonDW , MorrisonM , PascoeE , CoombesJS , ForbesJM , et al. SYNbiotics Easing Renal failure by improving Gut microbiologY (SYNERGY): a protocol of placebo-controlled randomised cross-over trial. BMC Nephrology2014;15:106. [MEDLINE: 24996842]RossiM , JohnsonDW , MorrisonM , PascoeEM , CoombesJS , ForbesJM , et al. Synbiotics easing renal failure by improving gut microbiology (SYNERGY): a randomized trial. Clinical Journal of the American Society of Nephrology: CJASN2016;11(2):223-31. [MEDLINE: 26772193]RossiM , JohnsonDW , XuH , CarreroJJ , PascoeE , FrenchC , et al. Dietary protein-fiber ratio associates with circulating levels of indoxyl sulfate and p-cresyl sulfate in chronic kidney disease patients. Nutrition Metabolism &amp; Cardiovascular Diseases2015;25(9):860-5. [MEDLINE: 26026209]">SYNERGY 2014</a>). </p> </section> </section> <section id="CD013631-sec-0052"> <h4 class="title">Excluded studies</h4> <p>Following full‐text review, we excluded 21 studies (<a href="./references#CD013631-sec-0169" title="">Characteristics of excluded studies</a>). Eleven studies were undertaken in the wrong population, nine studies investigated the wrong intervention, and one study was of ineligible study design. </p> </section> <section id="CD013631-sec-0053"> <h4 class="title">Ongoing studies and studies awaiting classification</h4> <p>Twenty‐six ongoing studies were identified on trial registries or had published an a priori protocol (<a href="./references#CD013631-sec-0171" title="">Characteristics of ongoing studies</a>), and 12 abstracts were identified (<a href="./references#CD013631-sec-0170" title="">Characteristics of studies awaiting classification</a>). These studies will be assessed in a future update of this review. </p> </section> </section> <section id="CD013631-sec-0054"> <h3 class="title">Risk of bias in included studies</h3> <p>See <a href="#CD013631-fig-0002">Figure 2</a> for a graphical summary of the risk of bias assessment within each study. </p> <div class="figure" id="CD013631-fig-0002"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 2</div> </div> <hr class="top"/><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study." data-id="CD013631-fig-0002" src="/cdsr/doi/10.1002/14651858.CD013631.pub2/media/CDSR/CD013631/image_n/nCD013631-FIG-02.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> </div> <p>Most studies were characterised by an unclear risk of bias across most domains due to the lack of information and detail provided to permit judgement. </p> <p>Using funnel plots to detect publication bias was not feasible due to the lack of available data to analyse quantitatively. </p> <section id="CD013631-sec-0055"> <h4 class="title">Allocation</h4> <section id="CD013631-sec-0056"> <h5 class="title">Random sequence generation</h5> <p>Thirty‐six studies were judged to have a low risk of bias for providing an adequate description of how their randomisation methods were undertaken. </p> <p>Nine studies were judged to have an unclear risk of bias due to a lack of information provided on their randomisation methods, although stated to be randomised. </p> </section> <section id="CD013631-sec-0057"> <h5 class="title">Allocation concealment</h5> <p>Twenty‐four studies were judged to have a low risk of bias for providing an adequate description of how allocations were concealed. </p> <p>Two studies were judged to be at high risk of bias due to being open‐label and appeared to have no approach to concealing allocation (<a href="./references#CD013631-bbs2-0009" title="EbrahimZ , ProostS , TitoRY , RaesJ , GlorieuxG , MoosaMR , et al. The effect of s-glucan prebiotic on kidney function, uremic toxins and gut microbiome in stage 3 to 5 chronic kidney disease (CKD) predialysis participants: a randomized controlled trial. Nutrients2022;14(4):805. [MEDLINE: 35215453]">Ebrahim 2022</a>; <a href="./references#CD013631-bbs2-0027" title="MengY , BaiH , YuQ , YanJ , ZhaoL , WangS , et al. High-resistant starch, low-protein flour intervention on patients with early type 2 diabetic nephropathy: a randomized trial. Journal of Renal Nutrition2019;29(5):386-93. [MEDLINE: 30982743]">Meng 2019</a>). </p> <p>Nineteen studies were judged to have an unclear risk of bias due to a lack of information provided on how allocations were concealed. </p> </section> </section> <section id="CD013631-sec-0058"> <h4 class="title">Blinding</h4> <section id="CD013631-sec-0059"> <h5 class="title">Performance bias</h5> <p>Twenty‐six studies were judged to have a low risk of bias for clearly reporting how both the study participants were kept blind to treatments as well as the study personnel. </p> <p>Ten studies were judged to be at high risk of bias due to being open‐label (<a href="./references#CD013631-bbs2-0003" title="BlissDZ , SteinTP , SchleiferCR , SettleRG . Supplementation with gum arabic fiber increases fecal nitrogen excretion and lowers serum urea nitrogen concentration in chronic renal failure patients consuming a low-protein diet. American Journal of Clinical Nutrition1996;63(3):392-8. [MEDLINE: 8602598]BlissDZ . Effect of a gum Arabic supplement on the nitrogen excretion and serum urea nitrogen concentration of chronic renal failure patients on a low protein diet [PhD thesis]. University of Pennsylvania1992:1-206. [CINAHL: 109870911] ">Bliss 1992</a>; <a href="./references#CD013631-bbs2-0005" title="CosolaC , RocchettiMT , di BariI , AcquavivaPM , MaranzanoV , CorciuloS , et al. An innovative synbiotic formulation decreases free serum indoxyl sulfate, small intestine permeability and ameliorates gastrointestinal symptoms in a randomized pilot trial in stage IIIb-IV CKD patients. Toxins2021;13(5):334. [MEDLINE: 34063068]">Cosola 2021</a>; <a href="./references#CD013631-bbs2-0009" title="EbrahimZ , ProostS , TitoRY , RaesJ , GlorieuxG , MoosaMR , et al. The effect of s-glucan prebiotic on kidney function, uremic toxins and gut microbiome in stage 3 to 5 chronic kidney disease (CKD) predialysis participants: a randomized controlled trial. Nutrients2022;14(4):805. [MEDLINE: 35215453]">Ebrahim 2022</a>; <a href="./references#CD013631-bbs2-0011" title="ElaminS , AlkhawajaMJ , BukhamsinAY , IdrisMA , AbdelrahmanMM , AbutalebNK , et al. Gum Arabic reduces C-reactive protein in chronic kidney disease patients without affecting urea or indoxyl sulfate levels. International Journal of Nephrology2017;2017:9501470. [MEDLINE: 28589039]">Elamin 2017</a>; <a href="./references#CD013631-bbs2-0023" title="LopesRC , TheodoroJM , da SilvaBP , QueirozVA , deCastro MoreiraME , MantovaniHC , et al. Synbiotic meal decreases uremic toxins in hemodialysis individuals: a placebo-controlled trial. Food Research International2019;116:241-8. [MEDLINE: 30716942]LopesRC , deLimaSL , da SilvaBP , ToledoRC , MoreiraME , AnunciacaoPC , et al. Evaluation of the health benefits of consumption of extruded tannin sorghum with unfermented probiotic milk in individuals with chronic kidney disease. Food Research International2018;107:629-38. [MEDLINE: 29580529]">Lopes 2018</a>; <a href="./references#CD013631-bbs2-0027" title="MengY , BaiH , YuQ , YanJ , ZhaoL , WangS , et al. High-resistant starch, low-protein flour intervention on patients with early type 2 diabetic nephropathy: a randomized trial. Journal of Renal Nutrition2019;29(5):386-93. [MEDLINE: 30982743]">Meng 2019</a>; <a href="./references#CD013631-bbs2-0029" title="Miranda AlatristePV , UrbinaAR , Gomez EspinosaCO , Espinosa CuevasML . Effect of probiotics on human blood urea levels in patients with chronic renal failure. Nutricion Hospitalaria2014;29(3):582-90. [MEDLINE: 24559003]">Miranda Alatriste 2014</a>; <a href="./references#CD013631-bbs2-0032" title="PanY , YangL , DaiB , LinB , LinS , LinE . Effects of probiotics on malnutrition and health-related quality of life in patients undergoing peritoneal dialysis: a randomized controlled trial. Journal of Renal Nutrition2021;31(2):199-205. [MEDLINE: 32620335]">Pan 2021</a>; <a href="./references#CD013631-bbs2-0035" title="SimeoniM , CianfroneP , CapriaM , DeodatoF , CitraroM , CerantonioA , et al. ProbiotiCKD: A monocentric, randomized, openlabel, placebo-controlled study to reveal and correct gut dysbiosis in early CKD stages [abstract no: SP367]. Nephrology Dialysis Transplantation2018;33(Suppl 1):i469-70. [EMBASE: 622605912]SimeoniM , CitraroML , CerantonioA , DeodatoF , ProvenzanoM , CianfroneP , et al. An open-label, randomized, placebo-controlled study on the effectiveness of a novel probiotics administration protocol (ProbiotiCKD) in patients with mild renal insufficiency (stage 3a of CKD) [Erratum in: Eur J Nutr. 2018 58(5):2157]. European Journal of Nutrition2019;58(5):2145-56. [MEDLINE: 30076458]SimeoniM , CitraroML , CerantonioA , DeodatoF , ProvenzanoM , CianfroneP , et al. Correction to: An open-label, randomized, placebo-controlled study on the effectiveness of a novel probiotics administration protocol (ProbiotiCKD) in patients with mild renal insufficiency (stage 3a of CKD) (European Journal of Nutrition, (2019), 58, 5, (2145-2156), 10.1007/s00394-018-1785-z). European Journal of Nutrition2019;58(5):2157. [MEDLINE: 30302543]">ProbiotiCKD 2019</a>; <a href="./references#CD013631-bbs2-0046" title="XieLM , GeYY , HuangX , ZhangY , LiJX . Effects of fermentable dietary fiber supplementation on oxidative and inflammatory status in hemodialysis patients. International Journal of Clinical &amp; Experimental Medicine2015;8(1):1363-9. [EMBASE: 602272251]">Xie 2015a</a>). </p> <p>Nine studies were judged to have an unclear risk of bias due to a lack of information provided on blinding methods, although stated to be double‐blind. </p> </section> <section id="CD013631-sec-0060"> <h5 class="title">Detection bias</h5> <p>Fifteen studies were judged to have a low risk of bias for clearly reporting how the outcomes were kept blind to treatments. </p> <p>Nine studies were judged to be at high risk of bias due to being open‐label (<a href="./references#CD013631-bbs2-0003" title="BlissDZ , SteinTP , SchleiferCR , SettleRG . Supplementation with gum arabic fiber increases fecal nitrogen excretion and lowers serum urea nitrogen concentration in chronic renal failure patients consuming a low-protein diet. American Journal of Clinical Nutrition1996;63(3):392-8. [MEDLINE: 8602598]BlissDZ . Effect of a gum Arabic supplement on the nitrogen excretion and serum urea nitrogen concentration of chronic renal failure patients on a low protein diet [PhD thesis]. University of Pennsylvania1992:1-206. [CINAHL: 109870911] ">Bliss 1992</a>; <a href="./references#CD013631-bbs2-0005" title="CosolaC , RocchettiMT , di BariI , AcquavivaPM , MaranzanoV , CorciuloS , et al. An innovative synbiotic formulation decreases free serum indoxyl sulfate, small intestine permeability and ameliorates gastrointestinal symptoms in a randomized pilot trial in stage IIIb-IV CKD patients. Toxins2021;13(5):334. [MEDLINE: 34063068]">Cosola 2021</a>; <a href="./references#CD013631-bbs2-0011" title="ElaminS , AlkhawajaMJ , BukhamsinAY , IdrisMA , AbdelrahmanMM , AbutalebNK , et al. Gum Arabic reduces C-reactive protein in chronic kidney disease patients without affecting urea or indoxyl sulfate levels. International Journal of Nephrology2017;2017:9501470. [MEDLINE: 28589039]">Elamin 2017</a>; <a href="./references#CD013631-bbs2-0023" title="LopesRC , TheodoroJM , da SilvaBP , QueirozVA , deCastro MoreiraME , MantovaniHC , et al. Synbiotic meal decreases uremic toxins in hemodialysis individuals: a placebo-controlled trial. Food Research International2019;116:241-8. [MEDLINE: 30716942]LopesRC , deLimaSL , da SilvaBP , ToledoRC , MoreiraME , AnunciacaoPC , et al. Evaluation of the health benefits of consumption of extruded tannin sorghum with unfermented probiotic milk in individuals with chronic kidney disease. Food Research International2018;107:629-38. [MEDLINE: 29580529]">Lopes 2018</a>; <a href="./references#CD013631-bbs2-0027" title="MengY , BaiH , YuQ , YanJ , ZhaoL , WangS , et al. High-resistant starch, low-protein flour intervention on patients with early type 2 diabetic nephropathy: a randomized trial. Journal of Renal Nutrition2019;29(5):386-93. [MEDLINE: 30982743]">Meng 2019</a>; <a href="./references#CD013631-bbs2-0029" title="Miranda AlatristePV , UrbinaAR , Gomez EspinosaCO , Espinosa CuevasML . Effect of probiotics on human blood urea levels in patients with chronic renal failure. Nutricion Hospitalaria2014;29(3):582-90. [MEDLINE: 24559003]">Miranda Alatriste 2014</a>; <a href="./references#CD013631-bbs2-0032" title="PanY , YangL , DaiB , LinB , LinS , LinE . Effects of probiotics on malnutrition and health-related quality of life in patients undergoing peritoneal dialysis: a randomized controlled trial. Journal of Renal Nutrition2021;31(2):199-205. [MEDLINE: 32620335]">Pan 2021</a>; <a href="./references#CD013631-bbs2-0035" title="SimeoniM , CianfroneP , CapriaM , DeodatoF , CitraroM , CerantonioA , et al. ProbiotiCKD: A monocentric, randomized, openlabel, placebo-controlled study to reveal and correct gut dysbiosis in early CKD stages [abstract no: SP367]. Nephrology Dialysis Transplantation2018;33(Suppl 1):i469-70. [EMBASE: 622605912]SimeoniM , CitraroML , CerantonioA , DeodatoF , ProvenzanoM , CianfroneP , et al. An open-label, randomized, placebo-controlled study on the effectiveness of a novel probiotics administration protocol (ProbiotiCKD) in patients with mild renal insufficiency (stage 3a of CKD) [Erratum in: Eur J Nutr. 2018 58(5):2157]. European Journal of Nutrition2019;58(5):2145-56. [MEDLINE: 30076458]SimeoniM , CitraroML , CerantonioA , DeodatoF , ProvenzanoM , CianfroneP , et al. Correction to: An open-label, randomized, placebo-controlled study on the effectiveness of a novel probiotics administration protocol (ProbiotiCKD) in patients with mild renal insufficiency (stage 3a of CKD) (European Journal of Nutrition, (2019), 58, 5, (2145-2156), 10.1007/s00394-018-1785-z). European Journal of Nutrition2019;58(5):2157. [MEDLINE: 30302543]">ProbiotiCKD 2019</a>; <a href="./references#CD013631-bbs2-0046" title="XieLM , GeYY , HuangX , ZhangY , LiJX . Effects of fermentable dietary fiber supplementation on oxidative and inflammatory status in hemodialysis patients. International Journal of Clinical &amp; Experimental Medicine2015;8(1):1363-9. [EMBASE: 602272251]">Xie 2015a</a>). <a href="./references#CD013631-bbs2-0009" title="EbrahimZ , ProostS , TitoRY , RaesJ , GlorieuxG , MoosaMR , et al. The effect of s-glucan prebiotic on kidney function, uremic toxins and gut microbiome in stage 3 to 5 chronic kidney disease (CKD) predialysis participants: a randomized controlled trial. Nutrients2022;14(4):805. [MEDLINE: 35215453]">Ebrahim 2022</a> was blinded to investigators and therefore judged unclear rather than high risk. </p> <p>Twenty‐one studies were judged to have an unclear risk of bias due to a lack of information provided on blinding methods for outcome assessors, although stated to be double‐blind. </p> </section> </section> <section id="CD013631-sec-0061"> <h4 class="title">Incomplete outcome data</h4> <p>Eleven studies were judged to be at low risk of bias for adequately accounting for all participants throughout the study, providing reasons for withdrawals, having low attrition rates, and undertaking an ITT analysis. </p> <p>Thirty‐one studies were judged to be at high risk of bias due to either not accounting for all participants throughout the study and providing reasons for withdrawals, high attrition rates (ranging from 40% to 50% and higher), or for not undertaking an ITT analysis. </p> <p>Three studies were judged to have unclear risk of bias as no information about withdrawals, attrition, or ITT analysis could be identified in the available text (<a href="./references#CD013631-bbs2-0011" title="ElaminS , AlkhawajaMJ , BukhamsinAY , IdrisMA , AbdelrahmanMM , AbutalebNK , et al. Gum Arabic reduces C-reactive protein in chronic kidney disease patients without affecting urea or indoxyl sulfate levels. International Journal of Nephrology2017;2017:9501470. [MEDLINE: 28589039]">Elamin 2017</a>; <a href="./references#CD013631-bbs2-0012" title="AzevedoR , EsgalhadoM , KempJA , RegisB , CardozoLF , NakaoLS , et al. Resistant starch supplementation effects on plasma indole 3-acetic acid and aryl hydrocarbon receptor mRNA expression in hemodialysis patients: Randomized, double blind and controlled clinical trial [Efeitos da suplementacao de amido resistente no acido indol-3-acetico plasmatico e na expressao do mRNA do receptor aril-hidrocarboneto em pacientesemhemodialise:ensaioclinicorandomizado,duplo-cegoecontrolado]. Jornal Brasileiro de Nefrologia2020;42(3):273-9. [MEDLINE: 32459282]EsgalhadoM , KempJA , AzevedoR , PaivaBR , Stockler-PintoMB , DolengaCJ , et al. Could resistant starch supplementation improve inflammatory and oxidative stress biomarkers and uremic toxins levels in hemodialysis patients? A pilot randomized controlled trial. Food &amp; Function2018;9(12):6508-16. [MEDLINE: 30468238]EsgalhadoM , KempJA , PaivaBR , BritoJS , CardozoLF , AzevedoR , et al. Resistant starch type-2 enriched cookies modulate uremic toxins and inflammation in hemodialysis patients: a randomized, double-blind, crossover and placebo-controlled trial. Food &amp; Function2020;11(3):2617-25. [MEDLINE: 32159187]KempJA , Dos SantosHF , deJesusHE , EsgalhadoM , dePaivaBR , AzevedoR , et al. Resistant starch type-2 supplementation does not decrease trimethylamine n-oxide (TMAO) plasma level in hemodialysis patients. Journal of the American Nutrition Association2022;41(8):788-95. [MEDLINE: 35512757]KempJA , Regis de PaivaB , Fragoso Dos SantosH , Emiliano de JesusH , CravenH , Z IjazU , et al. The impact of enriched resistant starch type-2 cookies on the gut microbiome in hemodialysis patients: a randomized controlled trial. Molecular Nutrition &amp; Food Research2021;65(19):e2100374. [MEDLINE: 34390604]MafraD , Ann KempJ , EsgalhadoM , PaivaB , De JesusHE , SantosHF . Effects of resistant starch (RS) type 2 cookies on gut microbiota profile in hemodialysis (HD) patients [abstract no: PO2051]. Journal of the American Society of Nephrology2020;31(Abstract Suppl):629-30. [EMBASE: 633701738]MafraD , Ann KempJ , SantosHF , De JesusHE , EsgalhadoM , PaivaB , et al. High-amylose resistant starch (RS) cookies supplementation does not decrease trimethylamine n-oxide (TMAO) plasma level in hemodialysis (HD) patients [abstract no: PO2039]. Journal of the American Society of Nephrology2020;31(Abstract Suppl):626-7. [EMBASE: 633701431]MafraD , EsgalhadoM , MacedoRD , KempJ , PaivaB , NakaoLS , et al. Resistant starch supplementation reduces indoxyl sulfate levels in hemodialysis patients: a randomized, double-blind, crossover, placebo-controlled study [abstract no: FR-OR127]. Journal of the American Society of Nephrology2018;29(Abstract Suppl):72. [EMBASE: 633737357]MafraD , EsgalhadoM , Stockler-PintoMB , BorgesNA , CardozoLF , PaivaB , et al. Effects of resistant starch supplementation on inflammatory and oxidative stress status in hemodialysis patients: a pilot randomized, double-blind, placebo-controlled clinical trial [abstract no: SA-PO149]. Journal of the American Society of Nephrology2017;28(Abstract Suppl):716. [EMBASE: 633701761]MafraD , MacedoRD , CardozoLF , BorgesNA , NakaoLS , JardimMZ , et al. Effect of resistant starch supplementation on the indole-3-acetic acid levels and aryl hydrocarbon receptor expression in hemodialysis patients [abstract no: FR-PO545]. Journal of the American Society of Nephrology2018;29(Abstract Suppl):561. [EMBASE: 633736002]MafraD , PaivaB , EsgalhadoM , BorgesNA , KempJA , CardozoLF , et al. Resistant starch supplementation attenuates inflammation in hemodialysis patients [abstract no: SA-PO818]. Journal of the American Society of Nephrology2019;30(Abstract Suppl):974. [EMBASE: 633769632]dePaivaBR , EsgalhadoM , BorgesNA , KempJA , AlvesG , LeitePE , et al. Resistant starch supplementation attenuates inflammation in hemodialysis patients: a pilot study. International Urology &amp; Nephrology2020;52(3):549-55. [MEDLINE: 32008198]">Esgalhado 2018</a>; <a href="./references#CD013631-bbs2-0019" title="KooshkiA , TofighiyanT , MiriM . A synbiotic supplement for inflammation and oxidative stress and lipid abnormalities in hemodialysis patients. Hemodialysis International2019;23(2):254-60. [MEDLINE: 30821897]">Kooshki 2019</a>). </p> </section> <section id="CD013631-sec-0062"> <h4 class="title">Selective reporting</h4> <p>Twenty‐six studies were judged to be at low risk of bias for providing a trial registration number or had an a priori published protocol. </p> <p>Five studies were judged to be at high risk of bias due to serious changes to study outcomes and analyses that were not explained (<a href="./references#CD013631-bbs2-0001" title="AbbasiB , GhiasvandR , MirlohiM . Kidney function improvement by soy milk containing lactobacillus plantarum A7 in type 2 diabetic patients with nephropathy: a double-blinded randomized controlled trial. Iranian Journal of Kidney Diseases2017;11(1):36-43. [MEDLINE: 28174351]AbbasiB , MirlohiM , DanialiM , GhiasvandR . Effects of probiotic soy milk on lipid panel in type 2 diabetic patients with nephropathy: a double-blind randomized clinical trial. Progress in Nutrition2018;20:70-8. [EMBASE: 2001649336]">Abbasi 2017</a>; <a href="./references#CD013631-bbs2-0005" title="CosolaC , RocchettiMT , di BariI , AcquavivaPM , MaranzanoV , CorciuloS , et al. An innovative synbiotic formulation decreases free serum indoxyl sulfate, small intestine permeability and ameliorates gastrointestinal symptoms in a randomized pilot trial in stage IIIb-IV CKD patients. Toxins2021;13(5):334. [MEDLINE: 34063068]">Cosola 2021</a>; <a href="./references#CD013631-bbs2-0008" title="DehghaniH , HeidariF , Mozaffari-KhosraviH , Nouri-MajelanN , DehghaniA . Synbiotic supplementations for azotemia in patients with chronic kidney disease: a randomized controlled trial. Iranian Journal of Kidney Diseases2016;10(6):351-7. [MEDLINE: 27903994]">Dehghani 2016</a>; <a href="./references#CD013631-bbs2-0029" title="Miranda AlatristePV , UrbinaAR , Gomez EspinosaCO , Espinosa CuevasML . Effect of probiotics on human blood urea levels in patients with chronic renal failure. Nutricion Hospitalaria2014;29(3):582-90. [MEDLINE: 24559003]">Miranda Alatriste 2014</a>; <a href="./references#CD013631-bbs2-0044" title="Viramontes-HornerD , Marquez-SandovalF , Martin-del-CampoF , Vizmanos-LamotteB , Sandoval-RodriguezA , Armendariz-BorundaJ , et al. Effect of a symbiotic gel (Lactobacillus acidophilus + Bifidobacterium lactis + inulin) on presence and severity of gastrointestinal symptoms in hemodialysis patients. Journal of Renal Nutrition2015;25(3):284-91. [MEDLINE: 25455039]">Viramontes‐Horner 2015</a>). </p> <p>Fourteen studies were judged to have an unclear risk of bias as no information was available about trial registration or an a priori published protocol. </p> </section> <section id="CD013631-sec-0063"> <h4 class="title">Other potential sources of bias</h4> <section id="CD013631-sec-0064"> <h5 class="title">Control for confounding factors</h5> <p>Seventeen studies were judged to be at low risk of bias for adequately describing control for standardising dietary intake and/or ingesting synbiotics, prebiotics, or probiotics where possible for the pre‐study run‐in and during study periods. </p> <p>Twenty‐eight studies were judged to have an unclear risk of bias for not reporting any information about whether diet or medications were controlled for pre‐ or during study periods. </p> </section> <section id="CD013631-sec-0065"> <h5 class="title">Other biases</h5> <p>Seventeen studies were judged to be at low risk of bias due to providing information on funding (non‐conflicting) and reporting disclosures (non‐conflicting). </p> <p>Twenty‐two studies were judged to be at high risk of bias due to conflicting funding (industry or otherwise). </p> <p>Six studies were judged to have unclear risk of bias as no information was available about funding or disclosures, or only information about one of these was provided. </p> </section> </section> </section> <section id="CD013631-sec-0066"> <h3 class="title" id="CD013631-sec-0066">Effects of interventions</h3> <p>See: <a href="./full#CD013631-tbl-0001"><b>Summary of findings 1</b> Synbiotic versus another synbiotic for people with chronic kidney disease</a>; <a href="./full#CD013631-tbl-0002"><b>Summary of findings 2</b> Synbiotic versus prebiotic for people with chronic kidney disease</a>; <a href="./full#CD013631-tbl-0003"><b>Summary of findings 3</b> Prebiotic versus another prebiotic for people with chronic kidney disease</a>; <a href="./full#CD013631-tbl-0004"><b>Summary of findings 4</b> Prebiotic versus probiotic for people with chronic kidney disease</a>; <a href="./full#CD013631-tbl-0005"><b>Summary of findings 5</b> Probiotic versus another probiotic for people with chronic kidney disease</a>; <a href="./full#CD013631-tbl-0006"><b>Summary of findings 6</b> Synbiotic versus placebo or no treatment for people with chronic kidney disease</a>; <a href="./full#CD013631-tbl-0007"><b>Summary of findings 7</b> Prebiotic versus placebo or no treatment for people with chronic kidney disease</a>; <a href="./full#CD013631-tbl-0008"><b>Summary of findings 8</b> Probiotic versus placebo or no treatment for people with chronic kidney disease</a> </p> <p>Adverse events are reported in <a href="./appendices#CD013631-sec-0158">Appendix 5</a>. </p> <section id="CD013631-sec-0067"> <h4 class="title">1: Synbiotic versus synbiotic</h4> <p><a href="./references#CD013631-bbs2-0015" title="HaghighatN , MohammadshahiM , ShayanpourS , HaghighizadehMH , RahmdelS , RajaeiM . The effect of synbiotic and probiotic supplementation on mental health parameters in patients undergoing hemodialysis: A double-blind, randomized, placebo-controlled trial. Indian Journal of Nephrology2021;31(2):149-56. [EMBASE: 634933481]HaghighatN , MohammadshahiM , ShayanpourS , HaghighizadehMH . Effect of synbiotic and probiotic supplementation on serum levels of endothelial cell adhesion molecules in hemodialysis patients: a randomized control study. Probiotics &amp; Antimicrobial Proteins2019;11(4):1210-8. [MEDLINE: 30293208]HaghighatN , MohammadshahiM , ShayanpourS , HaghighizadehMH . Effects of synbiotics and probiotics supplementation on serum levels of endotoxin, heat shock protein 70 antibodies and inflammatory markers in hemodialysis patients: a randomized double-blinded controlled trial. Probiotics &amp; Antimicrobial Proteins2020;12(1):144-51. [MEDLINE: 30617950]HaghighatN , RajabiS , MohammadshahiM . Effect of synbiotic and probiotic supplementation on serum brain-derived neurotrophic factor level, depression and anxiety symptoms in hemodialysis patients: a randomized, double-blinded, clinical trial. Nutritional Neuroscience2019;24(6):490-9. [MEDLINE: 31379269]HaghighatN , RajabiS , MohammadshahiM . Effect of synbiotic and probiotic supplementation on serum brain-derived neurotrophic factor level, depression and anxiety symptoms in hemodialysis patients: a randomized, double-blinded, clinical trial. Nutritional Neuroscience2021;24(6):490-9. [MEDLINE: 31379269]">Haghighat 2019</a> compared the same probiotics (<i>Lactobacillusacidophilus</i> T16, <i>Bifidobacteriumbifidum</i> BIA‐6, <i>Bifidobacteriumlactis</i> BIA‐6, and <i>Bifidobacteriumlongum</i> LAF‐5) with two different prebiotics (fructo‐oligosaccharides plus galacto‐oligosaccharides plus inulin compared to maltodextrin). </p> <section id="CD013631-sec-0068"> <h5 class="title">Patient‐reported outcomes</h5> <section id="CD013631-sec-0069"> <h6 class="title">Health‐related quality of life</h6> <p><a href="./references#CD013631-bbs2-0015" title="HaghighatN , MohammadshahiM , ShayanpourS , HaghighizadehMH , RahmdelS , RajaeiM . The effect of synbiotic and probiotic supplementation on mental health parameters in patients undergoing hemodialysis: A double-blind, randomized, placebo-controlled trial. Indian Journal of Nephrology2021;31(2):149-56. [EMBASE: 634933481]HaghighatN , MohammadshahiM , ShayanpourS , HaghighizadehMH . Effect of synbiotic and probiotic supplementation on serum levels of endothelial cell adhesion molecules in hemodialysis patients: a randomized control study. Probiotics &amp; Antimicrobial Proteins2019;11(4):1210-8. [MEDLINE: 30293208]HaghighatN , MohammadshahiM , ShayanpourS , HaghighizadehMH . Effects of synbiotics and probiotics supplementation on serum levels of endotoxin, heat shock protein 70 antibodies and inflammatory markers in hemodialysis patients: a randomized double-blinded controlled trial. Probiotics &amp; Antimicrobial Proteins2020;12(1):144-51. [MEDLINE: 30617950]HaghighatN , RajabiS , MohammadshahiM . Effect of synbiotic and probiotic supplementation on serum brain-derived neurotrophic factor level, depression and anxiety symptoms in hemodialysis patients: a randomized, double-blinded, clinical trial. Nutritional Neuroscience2019;24(6):490-9. [MEDLINE: 31379269]HaghighatN , RajabiS , MohammadshahiM . Effect of synbiotic and probiotic supplementation on serum brain-derived neurotrophic factor level, depression and anxiety symptoms in hemodialysis patients: a randomized, double-blinded, clinical trial. Nutritional Neuroscience2021;24(6):490-9. [MEDLINE: 31379269]">Haghighat 2019</a> reported no difference in health‐related QoL (HRQoL‐14) at 12 weeks in patients receiving synbiotics compared to another synbiotic of a different dose (<a href="./references#CD013631-fig-0003" title="">Analysis 1.1</a> (1 study, 46 participants): MD 1.98, 95% CI ‐11.2 to 15.08; very low certainty evidence). </p> </section> </section> <section id="CD013631-sec-0070"> <h5 class="title">Adverse events</h5> <p>Adverse events were minimal and non‐serious, and withdrawals were not related to the study interventions (see <a href="./appendices#CD013631-sec-0158">Appendix 5</a>). </p> <p>The studies in this comparison did not report data on our remaining primary and secondary outcomes. </p> <p>There were no subgroups to analyse for this comparison.</p> </section> </section> <section id="CD013631-sec-0071"> <h4 class="title">2: Synbiotic versus prebiotic</h4> <p>Six studies contributed to this comparison.</p> <p> <ul id="CD013631-list-0018"> <li> <p><a href="./references#CD013631-bbs2-0013" title="GuidaB , GermanoR , TrioR , RussoD , MemoliB , GrumettoL , et al. Effect of short-term synbiotic treatment on plasma p-cresol levels in patients with chronic renal failure: a randomized clinical trial. Nutrition Metabolism &amp; Cardiovascular Diseases2014;24(9):1043-9. [MEDLINE: 24929795]">Guida 2014</a> </p> <ul id="CD013631-list-0019"> <li> <p>Synbiotic: <i>Lactobacillusplantarum</i> , <i>Lactobacilluscasei</i> subsp. <i>rhamnosus, Lactobacillus gasseri</i> , <i>Bifidobacteriuminfantis,Bifidobactetriumlongum</i> , <i>Lactobacillusacidophilus</i> , <i>Lactobacillussalivarius,Lactobacillussporogenes</i> and <i>Streptococcusthermophilus</i> plus prebiotics inulin and tapioca‐resistant starch </p> </li> <li> <p>Prebiotic: tapioca‐resistant starch</p> </li> </ul> </li> <li> <p><a href="./references#CD013631-bbs2-0014" title="GuidaB , CataldiM , MemoliA , TrioR , di MaroM , GrumettoL , et al. Effect of a short-course treatment with synbiotics on plasma p-cresol concentration in kidney transplant recipients. Journal of the American College of Nutrition2017;36(7):586-91. [PMID: 28895794]">Guida 2017</a> </p> <ul id="CD013631-list-0020"> <li> <p>Synbiotic: <i>Lactobacillusplantarum,Lactobacilluscasei subsp. rhamnosus,</i> <i>Lactobacillusgasseri</i> , <i>Bifidobacteriuminfantis,Bifidobacteriumlongum</i> , <i>Lactobacillusacidophilus</i> , <i>Lactobacillussalivarius, Lactobacillussporogenes, Streptococcusthermophilus</i> plus inulin and tapioca‐resistant starch </p> </li> <li> <p>Prebiotic: cellulose</p> </li> </ul> </li> <li> <p><a href="./references#CD013631-bbs2-0015" title="HaghighatN , MohammadshahiM , ShayanpourS , HaghighizadehMH , RahmdelS , RajaeiM . The effect of synbiotic and probiotic supplementation on mental health parameters in patients undergoing hemodialysis: A double-blind, randomized, placebo-controlled trial. Indian Journal of Nephrology2021;31(2):149-56. [EMBASE: 634933481]HaghighatN , MohammadshahiM , ShayanpourS , HaghighizadehMH . Effect of synbiotic and probiotic supplementation on serum levels of endothelial cell adhesion molecules in hemodialysis patients: a randomized control study. Probiotics &amp; Antimicrobial Proteins2019;11(4):1210-8. [MEDLINE: 30293208]HaghighatN , MohammadshahiM , ShayanpourS , HaghighizadehMH . Effects of synbiotics and probiotics supplementation on serum levels of endotoxin, heat shock protein 70 antibodies and inflammatory markers in hemodialysis patients: a randomized double-blinded controlled trial. Probiotics &amp; Antimicrobial Proteins2020;12(1):144-51. [MEDLINE: 30617950]HaghighatN , RajabiS , MohammadshahiM . Effect of synbiotic and probiotic supplementation on serum brain-derived neurotrophic factor level, depression and anxiety symptoms in hemodialysis patients: a randomized, double-blinded, clinical trial. Nutritional Neuroscience2019;24(6):490-9. [MEDLINE: 31379269]HaghighatN , RajabiS , MohammadshahiM . Effect of synbiotic and probiotic supplementation on serum brain-derived neurotrophic factor level, depression and anxiety symptoms in hemodialysis patients: a randomized, double-blinded, clinical trial. Nutritional Neuroscience2021;24(6):490-9. [MEDLINE: 31379269]">Haghighat 2019</a> </p> <ul id="CD013631-list-0021"> <li> <p>Synbiotic 1: <i>Lactobacillusacidophilus</i> T16, <i>Bifidobacteriumbifidum</i> BIA‐6, <i>Bifidobacteriumlactis</i> BIA‐6, and <i>Bifidobacteriumlongum</i> LAF‐5 plus fructo‐oligosaccharides, galacto‐oligosaccharides and inulin </p> </li> <li> <p>Synbiotic 2: <i>Lactobacillusacidophilus</i> T16, <i>Bifidobacteriumbifidum</i> BIA‐6, <i>Bifidobacteriumlactis</i> BIA‐6, and <i>Bifidobacteriumlongum</i> LAF‐5 plus maltodextrin </p> </li> <li> <p>Prebiotic: maltodextrin</p> </li> </ul> </li> <li> <p><a href="./references#CD013631-bbs2-0023" title="LopesRC , TheodoroJM , da SilvaBP , QueirozVA , deCastro MoreiraME , MantovaniHC , et al. Synbiotic meal decreases uremic toxins in hemodialysis individuals: a placebo-controlled trial. Food Research International2019;116:241-8. [MEDLINE: 30716942]LopesRC , deLimaSL , da SilvaBP , ToledoRC , MoreiraME , AnunciacaoPC , et al. Evaluation of the health benefits of consumption of extruded tannin sorghum with unfermented probiotic milk in individuals with chronic kidney disease. Food Research International2018;107:629-38. [MEDLINE: 29580529]">Lopes 2018</a> </p> <ul id="CD013631-list-0022"> <li> <p>Synbiotic: <i>Bifidobacterium longum</i> BL‐G301 plus extruded sorghum flakes </p> </li> <li> <p>Prebiotic: extruded corn flakes</p> </li> </ul> </li> <li> <p><a href="./references#CD013631-bbs2-0030" title="MirzaeianS , Saraf-BankS , EntezariMH , HekmatdoostA , FeiziA , AtapourA . Effects of synbiotic supplementation on microbiota-derived protein-bound uremic toxins, systemic inflammation, and biochemical parameters in patients on hemodialysis: A double-blind, placebo-controlled, randomized clinical trial. Nutrition2020;73:110713. [MEDLINE: 32120316]">Mirzaeian 2020</a> </p> <ul id="CD013631-list-0023"> <li> <p>Synbiotic: <i>Lactobacillus casei</i> , <i>Lactobacillus acidophilus</i> , <i>Lactobacillus rhamnosus</i> , <i>Lactobacillus bulgaricus</i> , <i>Bifidobacterium breve</i> , <i>Bifidobacterium longum</i> , and <i>Streptococcus thermophiles</i> plus fructo‐oligosaccharide lactose </p> </li> <li> <p>Prebiotic: maltodextrin</p> </li> </ul> </li> <li> <p><a href="./references#CD013631-bbs2-0043" title="McFarlaneC , KrishnasamyR , StantonT , SavillE , SnelsonM , MihalaG , et al. Synbiotics easing renal failure by improving gut microbiology II (SYNERGY II): a feasibility randomized controlled trial. Nutrients2021;13(12):4481. [PMID: 34960037]">SYNERGY II 2021</a> </p> <ul id="CD013631-list-0024"> <li> <p>Synbiotic: <i>Lactobacillus</i> , <i>Bifidobacteria</i> , and <i>Streptococcus</i> plus high‐resistant starch fibre supplement </p> </li> <li> <p>Prebiotic: maltodextrin.</p> </li> </ul> </li> </ul> </p> <section id="CD013631-sec-0072"> <h5 class="title">Kidney function</h5> <section id="CD013631-sec-0073"> <h6 class="title">Estimated glomerular filtration rate</h6> <p><a href="./references#CD013631-bbs2-0014" title="GuidaB , CataldiM , MemoliA , TrioR , di MaroM , GrumettoL , et al. Effect of a short-course treatment with synbiotics on plasma p-cresol concentration in kidney transplant recipients. Journal of the American College of Nutrition2017;36(7):586-91. [PMID: 28895794]">Guida 2017</a> reported no difference in eGFR at four weeks in patients receiving synbiotics compared to prebiotics (<a href="./references#CD013631-fig-0004" title="">Analysis 2.1</a>(1 study, 34 participants): MD ‐3.80 mL/min/1.73 m², 95% CI ‐17.98 to 10.38; very low certainty evidence). </p> <p><a href="./references#CD013631-bbs2-0043" title="McFarlaneC , KrishnasamyR , StantonT , SavillE , SnelsonM , MihalaG , et al. Synbiotics easing renal failure by improving gut microbiology II (SYNERGY II): a feasibility randomized controlled trial. Nutrients2021;13(12):4481. [PMID: 34960037]">SYNERGY II 2021</a> reported that patients receiving synbiotic supplementation resulted in a mean reduction in eGFR of ‐3.14 mL/min/1.73 m<sup>2</sup> (95% CI ‐6.23 to ‐0.06) at 12 months from baseline (prebiotics had a mean increase of 2.61 mL/min/1.73 m<sup>2</sup>; 95% CI ‐0.41 to 5.63) (n = 56; P &lt; 0.01). </p> </section> <section id="CD013631-sec-0074"> <h6 class="title">Serum creatinine</h6> <p><a href="./references#CD013631-bbs2-0030" title="MirzaeianS , Saraf-BankS , EntezariMH , HekmatdoostA , FeiziA , AtapourA . Effects of synbiotic supplementation on microbiota-derived protein-bound uremic toxins, systemic inflammation, and biochemical parameters in patients on hemodialysis: A double-blind, placebo-controlled, randomized clinical trial. Nutrition2020;73:110713. [MEDLINE: 32120316]">Mirzaeian 2020</a> reported no difference in SCr at eight weeks in patients receiving synbiotics compared to prebiotics (<a href="./references#CD013631-fig-0005" title="">Analysis 2.2</a> (1 study, 42 participants): MD ‐0.20 mg/dL, 95% CI ‐1.50 to 1.10; very low certainty evidence). </p> <p><a href="./references#CD013631-bbs2-0043" title="McFarlaneC , KrishnasamyR , StantonT , SavillE , SnelsonM , MihalaG , et al. Synbiotics easing renal failure by improving gut microbiology II (SYNERGY II): a feasibility randomized controlled trial. Nutrients2021;13(12):4481. [PMID: 34960037]">SYNERGY II 2021</a> reported synbiotic supplementation resulted in a mean increase in SCr concentration of 20.8 μmol (95% CI 2.97 to 38.5) at 12 months from baseline (prebiotics had a mean decrease of ‐9.79 μmol; 95% CI 21.7 to 2.09) (n = 56; P &lt; 0.01). </p> </section> </section> <section id="CD013631-sec-0075"> <h5 class="title">Uraemic toxins</h5> <section id="CD013631-sec-0076"> <h6 class="title">Urea</h6> <p><a href="./references#CD013631-bbs2-0030" title="MirzaeianS , Saraf-BankS , EntezariMH , HekmatdoostA , FeiziA , AtapourA . Effects of synbiotic supplementation on microbiota-derived protein-bound uremic toxins, systemic inflammation, and biochemical parameters in patients on hemodialysis: A double-blind, placebo-controlled, randomized clinical trial. Nutrition2020;73:110713. [MEDLINE: 32120316]">Mirzaeian 2020</a> reported no difference in urea at four weeks in patients receiving synbiotics compared to prebiotics (<a href="./references#CD013631-fig-0006" title="">Analysis 2.3</a> (1 study, 42 participants): MD ‐2.10 mg/dL, 95% CI ‐13.93 to 9.73; very low certainty evidence). </p> </section> <section id="CD013631-sec-0077"> <h6 class="title">Indoxyl sulfate</h6> <p><a href="./references#CD013631-bbs2-0030" title="MirzaeianS , Saraf-BankS , EntezariMH , HekmatdoostA , FeiziA , AtapourA . Effects of synbiotic supplementation on microbiota-derived protein-bound uremic toxins, systemic inflammation, and biochemical parameters in patients on hemodialysis: A double-blind, placebo-controlled, randomized clinical trial. Nutrition2020;73:110713. [MEDLINE: 32120316]">Mirzaeian 2020</a> reported no difference in indoxyl sulfate at four weeks in patients receiving synbiotics compared to prebiotics (<a href="./references#CD013631-fig-0007" title="">Analysis 2.4</a> (1 study, 42 participants): MD 128.30 ng/mL, 95% CI ‐242.77 to 499.37; very low certainty evidence). </p> <p><a href="./references#CD013631-bbs2-0043" title="McFarlaneC , KrishnasamyR , StantonT , SavillE , SnelsonM , MihalaG , et al. Synbiotics easing renal failure by improving gut microbiology II (SYNERGY II): a feasibility randomized controlled trial. Nutrients2021;13(12):4481. [PMID: 34960037]">SYNERGY II 2021</a> reported no difference in total indoxyl sulfate at 12 months in patients receiving synbiotic supplementation (mean change 1.5 μmol/L; 95% CI ‐3.25 to 6.26) compared to prebiotics (mean change ‐3.07 μmol/L; 95% CI ‐9.14 to 2.99) mean change from baseline (n = 56; P = 0.96). </p> <p><a href="./references#CD013631-bbs2-0043" title="McFarlaneC , KrishnasamyR , StantonT , SavillE , SnelsonM , MihalaG , et al. Synbiotics easing renal failure by improving gut microbiology II (SYNERGY II): a feasibility randomized controlled trial. Nutrients2021;13(12):4481. [PMID: 34960037]">SYNERGY II 2021</a> reported no difference in free indoxyl sulfate at 12 months in patients receiving synbiotic supplementation (mean change 0.1 μmol/L; 95% CI ‐0.14 to 0.34) compared to prebiotics (mean change ‐0.09 μmol/L; 95% CI ‐0.34 to 0.17) mean change from baseline (n = 56; p = 0.25). </p> </section> <section id="CD013631-sec-0078"> <h6 class="title">P‐cresyl sulfate</h6> <p><a href="./references#CD013631-bbs2-0013" title="GuidaB , GermanoR , TrioR , RussoD , MemoliB , GrumettoL , et al. Effect of short-term synbiotic treatment on plasma p-cresol levels in patients with chronic renal failure: a randomized clinical trial. Nutrition Metabolism &amp; Cardiovascular Diseases2014;24(9):1043-9. [MEDLINE: 24929795]">Guida 2014</a> reported p‐cresyl sulfate was lower at four weeks in patients receiving synbiotics compared to prebiotics (<a href="./references#CD013631-fig-0008" title="">Analysis 2.5</a> (1 study, 34 participants): MD ‐2.10 μg/mL, 95% CI ‐3.92 to ‐0.28; very low certainty evidence). </p> <p><a href="./references#CD013631-bbs2-0043" title="McFarlaneC , KrishnasamyR , StantonT , SavillE , SnelsonM , MihalaG , et al. Synbiotics easing renal failure by improving gut microbiology II (SYNERGY II): a feasibility randomized controlled trial. Nutrients2021;13(12):4481. [PMID: 34960037]">SYNERGY II 2021</a> reported no difference in total p‐cresyl sulfate at 12 months in patients receiving synbiotic supplementation (mean change 28.8 μmol/L; 95% CI ‐6.32 to 64.0) compared to prebiotics (mean change ‐17.2 μmol/L; 95% CI ‐49.8 to 15.3) mean change from baseline (n = 56; P = 0.15). </p> <p><a href="./references#CD013631-bbs2-0043" title="McFarlaneC , KrishnasamyR , StantonT , SavillE , SnelsonM , MihalaG , et al. Synbiotics easing renal failure by improving gut microbiology II (SYNERGY II): a feasibility randomized controlled trial. Nutrients2021;13(12):4481. [PMID: 34960037]">SYNERGY II 2021</a> reported no difference in free p‐cresyl sulfate at 12 months in patients receiving synbiotic supplementation (mean change 0.98 μmol/L; 95% CI 0.17 to 1.79) compared to prebiotics (mean change ‐0.17 μmol/L; 95% CI ‐1.18 to 0.84) mean change from baseline (n = 56; P = 0.08). </p> </section> </section> <section id="CD013631-sec-0079"> <h5 class="title">Gastrointestinal function</h5> <section id="CD013631-sec-0080"> <h6 class="title">Change in any gastrointestinal upset or intolerance</h6> <p><a href="./references#CD013631-bbs2-0014" title="GuidaB , CataldiM , MemoliA , TrioR , di MaroM , GrumettoL , et al. Effect of a short-course treatment with synbiotics on plasma p-cresol concentration in kidney transplant recipients. Journal of the American College of Nutrition2017;36(7):586-91. [PMID: 28895794]">Guida 2017</a> reported prebiotics decreased borborygmi at four weeks compared to synbiotics (<a href="./references#CD013631-fig-0009" title="">Analysis 2.6</a> (1 study, 34 participants): RR 15.26, 95% CI 0.99 to 236.23; very low certainty evidence). </p> <p><a href="./references#CD013631-bbs2-0043" title="McFarlaneC , KrishnasamyR , StantonT , SavillE , SnelsonM , MihalaG , et al. Synbiotics easing renal failure by improving gut microbiology II (SYNERGY II): a feasibility randomized controlled trial. Nutrients2021;13(12):4481. [PMID: 34960037]">SYNERGY II 2021</a> reported no difference in change in GI symptoms according to the Gastrointestinal Symptom Rating Scale (GSRS) Total Index (scale of 1 to 7, a higher score indicates worse discomfort) at 12 months in patients receiving synbiotics compared to prebiotics (<a href="./references#CD013631-fig-0010" title="">Analysis 2.7</a> (1 study, 56 participants): MD 0.00, 95% CI ‐0.27 to 0.27; very low certainty evidence). <a href="./references#CD013631-bbs2-0043" title="McFarlaneC , KrishnasamyR , StantonT , SavillE , SnelsonM , MihalaG , et al. Synbiotics easing renal failure by improving gut microbiology II (SYNERGY II): a feasibility randomized controlled trial. Nutrients2021;13(12):4481. [PMID: 34960037]">SYNERGY II 2021</a> also reported no difference in the subdomains of the GSRS in patients receiving synbiotics compared to prebiotics, respectively (mean score ± SD): reflux (1.4 ± 0.8, 1.3 ± 0.4); abdominal pain (1.2 ± 0.4, 1.3 ± 0.4); indigestion (1.7 ± 0.9, 1.6 ± 0.5); constipation (1.4 ± 1.0, 1.5 ± 0.8); diarrhoea (1.3 ± 0.5, 1.2 ± 0.4). </p> </section> <section id="CD013631-sec-0081"> <h6 class="title">Microbiota composition</h6> <p><a href="./references#CD013631-bbs2-0043" title="McFarlaneC , KrishnasamyR , StantonT , SavillE , SnelsonM , MihalaG , et al. Synbiotics easing renal failure by improving gut microbiology II (SYNERGY II): a feasibility randomized controlled trial. Nutrients2021;13(12):4481. [PMID: 34960037]">SYNERGY II 2021</a> reported no difference in change in microbiota composition (Richness and Shannon's index) at 12 months in patients receiving synbiotics compared to prebiotics (n = 56). <a href="./references#CD013631-bbs2-0043" title="McFarlaneC , KrishnasamyR , StantonT , SavillE , SnelsonM , MihalaG , et al. Synbiotics easing renal failure by improving gut microbiology II (SYNERGY II): a feasibility randomized controlled trial. Nutrients2021;13(12):4481. [PMID: 34960037]">SYNERGY II 2021</a> reported, "The coverage of the microbiota diversity for all samples was high with a rarefied sequencing depth of 4 million reads with 298 species identified". </p> </section> <section id="CD013631-sec-0082"> <h6 class="title">Faecal characteristics</h6> <p><a href="./references#CD013631-bbs2-0023" title="LopesRC , TheodoroJM , da SilvaBP , QueirozVA , deCastro MoreiraME , MantovaniHC , et al. Synbiotic meal decreases uremic toxins in hemodialysis individuals: a placebo-controlled trial. Food Research International2019;116:241-8. [MEDLINE: 30716942]LopesRC , deLimaSL , da SilvaBP , ToledoRC , MoreiraME , AnunciacaoPC , et al. Evaluation of the health benefits of consumption of extruded tannin sorghum with unfermented probiotic milk in individuals with chronic kidney disease. Food Research International2018;107:629-38. [MEDLINE: 29580529]">Lopes 2018</a> reported faecal pH at seven weeks was lower in patients receiving synbiotics compared to prebiotics (<a href="./references#CD013631-fig-0011" title="">Analysis 2.8</a> (1 study, 58 participants): MD ‐0.63, 95% CI ‐1.13 to ‐0.13; very low certainty evidence). </p> <p><a href="./references#CD013631-bbs2-0014" title="GuidaB , CataldiM , MemoliA , TrioR , di MaroM , GrumettoL , et al. Effect of a short-course treatment with synbiotics on plasma p-cresol concentration in kidney transplant recipients. Journal of the American College of Nutrition2017;36(7):586-91. [PMID: 28895794]">Guida 2017</a> reported no difference in stool shape and characteristics on the Bristol Stool Chart (scale of 1 to 7) at four weeks in patients receiving synbiotics compared to prebiotics (<a href="./references#CD013631-fig-0012" title="">Analysis 2.9</a> (1 study, 34 participants): MD ‐0.50, 95% CI ‐1.15 to 0.15; very low certainty evidence). </p> <p><a href="./references#CD013631-bbs2-0043" title="McFarlaneC , KrishnasamyR , StantonT , SavillE , SnelsonM , MihalaG , et al. Synbiotics easing renal failure by improving gut microbiology II (SYNERGY II): a feasibility randomized controlled trial. Nutrients2021;13(12):4481. [PMID: 34960037]">SYNERGY II 2021</a> reported no difference in stool consistency on the Bristol Stool Chart at 12 months in patients receiving synbiotics compared to prebiotics (<a href="./references#CD013631-fig-0013" title="">Analysis 2.10</a> (1 study, 56 participants): MD 0.50, 95% CI ‐0.18 to 1.18; very low certainty evidence). </p> <p><a href="./references#CD013631-bbs2-0043" title="McFarlaneC , KrishnasamyR , StantonT , SavillE , SnelsonM , MihalaG , et al. Synbiotics easing renal failure by improving gut microbiology II (SYNERGY II): a feasibility randomized controlled trial. Nutrients2021;13(12):4481. [PMID: 34960037]">SYNERGY II 2021</a> reported no difference in stool frequency (patient‐reported number of times their bowels opened in the previous 24‐hour period) at 12 months in patients receiving synbiotics compared to prebiotics, respectively (1.8 ± 1.0, 1.6 ± 0.9; n = 56). </p> </section> </section> <section id="CD013631-sec-0083"> <h5 class="title">Patient‐reported outcomes</h5> <section id="CD013631-sec-0084"> <h6 class="title">Health‐related quality of life</h6> <p><a href="./references#CD013631-bbs2-0015" title="HaghighatN , MohammadshahiM , ShayanpourS , HaghighizadehMH , RahmdelS , RajaeiM . The effect of synbiotic and probiotic supplementation on mental health parameters in patients undergoing hemodialysis: A double-blind, randomized, placebo-controlled trial. Indian Journal of Nephrology2021;31(2):149-56. [EMBASE: 634933481]HaghighatN , MohammadshahiM , ShayanpourS , HaghighizadehMH . Effect of synbiotic and probiotic supplementation on serum levels of endothelial cell adhesion molecules in hemodialysis patients: a randomized control study. Probiotics &amp; Antimicrobial Proteins2019;11(4):1210-8. [MEDLINE: 30293208]HaghighatN , MohammadshahiM , ShayanpourS , HaghighizadehMH . Effects of synbiotics and probiotics supplementation on serum levels of endotoxin, heat shock protein 70 antibodies and inflammatory markers in hemodialysis patients: a randomized double-blinded controlled trial. Probiotics &amp; Antimicrobial Proteins2020;12(1):144-51. [MEDLINE: 30617950]HaghighatN , RajabiS , MohammadshahiM . Effect of synbiotic and probiotic supplementation on serum brain-derived neurotrophic factor level, depression and anxiety symptoms in hemodialysis patients: a randomized, double-blinded, clinical trial. Nutritional Neuroscience2019;24(6):490-9. [MEDLINE: 31379269]HaghighatN , RajabiS , MohammadshahiM . Effect of synbiotic and probiotic supplementation on serum brain-derived neurotrophic factor level, depression and anxiety symptoms in hemodialysis patients: a randomized, double-blinded, clinical trial. Nutritional Neuroscience2021;24(6):490-9. [MEDLINE: 31379269]">Haghighat 2019</a> reported no difference in HRQoL (HRQoL‐14) scores at 12 weeks in patients receiving synbiotics compared to prebiotics (<a href="./references#CD013631-fig-0014" title="">Analysis 2.11</a> (2 studies, 65 participants): MD 6.38, 95% CI ‐4.88 to 17.64; very low certainty evidence). </p> <p><a href="./references#CD013631-bbs2-0043" title="McFarlaneC , KrishnasamyR , StantonT , SavillE , SnelsonM , MihalaG , et al. Synbiotics easing renal failure by improving gut microbiology II (SYNERGY II): a feasibility randomized controlled trial. Nutrients2021;13(12):4481. [PMID: 34960037]">SYNERGY II 2021</a> reported no difference in HRQoL (Assessment of Quality of Life‐4 Dimension, 5‐point scale (AQoL‐4D)) at 12 months in patients receiving synbiotics compared to prebiotics, respectively (median (IQR): 16.0 (13.0 to 18.0), 15.0 (13.0 to 17.0); n = 56). </p> </section> </section> <section id="CD013631-sec-0085"> <h5 class="title">Adverse events</h5> <p>It is uncertain whether synbiotics decreased adverse events compared to prebiotics (<a href="./references#CD013631-fig-0015" title="">Analysis 2.12</a> (5 studies, 279 participants): very low certainty evidence). It is uncertain whether synbiotics decreased withdrawals due to adverse events compared to prebiotics (<a href="./references#CD013631-fig-0016" title="">Analysis 2.13</a> (4 studies, 211 participants): very low certainty evidence). </p> <p><a href="./references#CD013631-bbs2-0030" title="MirzaeianS , Saraf-BankS , EntezariMH , HekmatdoostA , FeiziA , AtapourA . Effects of synbiotic supplementation on microbiota-derived protein-bound uremic toxins, systemic inflammation, and biochemical parameters in patients on hemodialysis: A double-blind, placebo-controlled, randomized clinical trial. Nutrition2020;73:110713. [MEDLINE: 32120316]">Mirzaeian 2020</a> reported one death in each arm; however, they were not related to the study interventions. </p> <p>The remaining adverse events were minimal and non‐serious, and withdrawals were not related to study treatment (see <a href="./appendices#CD013631-sec-0158">Appendix 5</a>). </p> <p>The studies in this comparison did not report data on our remaining primary and secondary outcomes. </p> <p>Subgroups were not estimable for the remaining analyses in this comparison. In <a href="./references#CD013631-fig-0015" title="">Analysis 2.12</a> and <a href="./references#CD013631-fig-0016" title="">Analysis 2.13</a>, totals were turned off due to zero event rate data and are also not estimable. </p> </section> </section> <section id="CD013631-sec-0086"> <h4 class="title">3: Prebiotic versus prebiotic</h4> <p>Five studies contributed to this comparison.</p> <p> <ul id="CD013631-list-0025"> <li> <p><a href="./references#CD013631-bbs2-0002" title="BirueteA , CrossTL , AllenJM , KistlerBM , deLoorH , EvenepoelP , et al. Effect of dietary inulin supplementation on the gut microbiota composition and derived metabolites of individuals undergoing hemodialysis: a pilot study. Journal of Renal Nutrition2021;31(5):512-22. [MEDLINE: 34120835]BirueteA , KistlerB , AllenJ , BauerL , FaheyG , SwansonK , et al. Effect of inulin supplementation on mineral metabolism and short-chain fatty acid excretion in hemodialysis patients [abstract no: MP434]. Nephrology Dialysis Transplantation2017;32(Suppl 3):iii588-9. [EMBASE: 617289888]">Biruete 2017</a> compared inulin to maltodextrin </p> </li> <li> <p><a href="./references#CD013631-bbs2-0003" title="BlissDZ , SteinTP , SchleiferCR , SettleRG . Supplementation with gum arabic fiber increases fecal nitrogen excretion and lowers serum urea nitrogen concentration in chronic renal failure patients consuming a low-protein diet. American Journal of Clinical Nutrition1996;63(3):392-8. [MEDLINE: 8602598]BlissDZ . Effect of a gum Arabic supplement on the nitrogen excretion and serum urea nitrogen concentration of chronic renal failure patients on a low protein diet [PhD thesis]. University of Pennsylvania1992:1-206. [CINAHL: 109870911] ">Bliss 1992</a> compared gum Arabic to pectin </p> </li> <li> <p><a href="./references#CD013631-bbs2-0020" title="LiL , XiongQ , ZhaoJ , LinX , HeS , WuN , et al. Inulin-type fructan intervention restricts the increase in gut microbiome-generated indole in patients with peritoneal dialysis: a randomized crossover study [Erratum in: Am J Clin Nutr. 2022 Jun 7;115(6):1659]. American Journal of Clinical Nutrition2020;111(5):1087-99. [MEDLINE: 31942927]XiongQ , LiL , XiaoY , HeS , ZhaoJ , LinX , et al. The effect of inulin-type fructans on plasma trimethylamine n-oxide levels in peritoneal dialysis patients: a randomized crossover trial. Molecular Nutrition &amp; Food Research2023;67(9):e2200531. [DOI: 10.1002/mnfr.202200531]">Li 2020</a> compared 50:50 inulin plus oligofructose to maltodextrin </p> </li> <li> <p><a href="./references#CD013631-bbs2-0036" title="ArmaniR , IshikawaC , HongV , BortolottoLA , CassiolattoJL , KlassenA , et al. Effect of frutooligosaccharide on endothelial function in CKD patients: a randomized controlled trial [abstract no: SAT-206]. Kidney International Reports2019;4(7 Suppl):S93. [EMBASE: 2002179674]ArmaniRG , CarvalhoAB , RamosCI , HongV , BortolottoLA , CassiolatoJL , et al. Effect of fructooligosaccharide on endothelial function in CKD patients: a randomized controlled trial. Nephrology Dialysis Transplantation2021;37(1):85-91. [MEDLINE: 33411910]ArmaniRG , RamosCI , CuppariL , CanzianiME . Effect of fructooligosaccharide on endothelium function in CKD patients: a randomized controlled trial [abstract no: TH-PO1138]. Journal of the American Society of Nephrology2018;29(Abstract Suppl):417. [EMBASE: 633736090]RamosCI , ArmaniRG , CanzianiMEF , DalboniMA , DolengaCJR , NakaoLS , et al. Effect of prebiotic (fructooligosaccharide) on uremic toxins of chronic kidney disease patients: a randomized controlled trial. Nephrology Dialysis Transplantation2019;34(11):1876-84. [MEDLINE: 29939302]RamosCI , ArmaniRG , NakaoLS , CanzianiMEF , CampbellKL , CuppariL . Effect of fructooligosaccharide on microbiota-derived uremic toxins in predialysis patients: a randomized controlled trial [abstract no: SA-PO161]. Journal of the American Society of Nephrology2017;28(Abstract Suppl):720. [EMBASE: 633702127]">Ramos 2019</a> compared fructo‐oligosaccharide to maltodextrin </p> </li> <li> <p><a href="./references#CD013631-bbs2-0039" title="SirichTL , PlummerN , HostetterTH , MeyerT . Increasing dietary fiber reduces plasma levels of colon-derived uremic solutes in hemodialysis patients [abstract no: FR-PO793]. Journal of the American Society of Nephrology2013;24(Abstract Suppl):545A. [MEDLINE: 25147155]SirichTL , PlummerNS , GardnerCD , HostetterTH , MeyerTW . Effect of increasing dietary fiber on plasma levels of colon-derived solutes in hemodialysis patients. Clinical Journal of the American Society of Nephrology: CJASN2014;9(9):1603-10. [MEDLINE: 25147155]">Sirich 2014</a> compared high‐amylose corn starch to high‐amylopectin starch. </p> </li> </ul> </p> <section id="CD013631-sec-0087"> <h5 class="title">Kidney function</h5> <section id="CD013631-sec-0088"> <h6 class="title">Estimated glomerular filtration rate</h6> <p><a href="./references#CD013631-bbs2-0036" title="ArmaniR , IshikawaC , HongV , BortolottoLA , CassiolattoJL , KlassenA , et al. Effect of frutooligosaccharide on endothelial function in CKD patients: a randomized controlled trial [abstract no: SAT-206]. Kidney International Reports2019;4(7 Suppl):S93. [EMBASE: 2002179674]ArmaniRG , CarvalhoAB , RamosCI , HongV , BortolottoLA , CassiolatoJL , et al. Effect of fructooligosaccharide on endothelial function in CKD patients: a randomized controlled trial. Nephrology Dialysis Transplantation2021;37(1):85-91. [MEDLINE: 33411910]ArmaniRG , RamosCI , CuppariL , CanzianiME . Effect of fructooligosaccharide on endothelium function in CKD patients: a randomized controlled trial [abstract no: TH-PO1138]. Journal of the American Society of Nephrology2018;29(Abstract Suppl):417. [EMBASE: 633736090]RamosCI , ArmaniRG , CanzianiMEF , DalboniMA , DolengaCJR , NakaoLS , et al. Effect of prebiotic (fructooligosaccharide) on uremic toxins of chronic kidney disease patients: a randomized controlled trial. Nephrology Dialysis Transplantation2019;34(11):1876-84. [MEDLINE: 29939302]RamosCI , ArmaniRG , NakaoLS , CanzianiMEF , CampbellKL , CuppariL . Effect of fructooligosaccharide on microbiota-derived uremic toxins in predialysis patients: a randomized controlled trial [abstract no: SA-PO161]. Journal of the American Society of Nephrology2017;28(Abstract Suppl):720. [EMBASE: 633702127]">Ramos 2019</a> reported no difference in eGFR at 12 weeks in patients receiving fructo‐oligosaccharide compared to maltodextrin of a different dose (<a href="./references#CD013631-fig-0017" title="">Analysis 3.1</a> (1 study, 50 participants): MD 0.00 mL/min, 95% CI ‐1.73 to 1.73; very low certainty evidence). </p> </section> </section> <section id="CD013631-sec-0089"> <h5 class="title">Uraemic toxins</h5> <section id="CD013631-sec-0090"> <h6 class="title">Indoxyl sulfate</h6> <p>It is uncertain whether prebiotic 1 (inulin or high‐amylose corn starch) improves indoxyl sulfate at six weeks compared to prebiotic 2 (maltodextrin or high‐amylopectin starch) (<a href="./references#CD013631-fig-0018" title="">Analysis 3.2</a> (2 studies, 64 participants): MD ‐0.20 μg/mL, 95% CI ‐1.01 to 0.61; I² = 0%; very low certainty evidence). </p> </section> </section> <section id="CD013631-sec-0091"> <h5 class="title">Uraemic toxins</h5> <section id="CD013631-sec-0092"> <h6 class="title">P‐cresyl sulfate</h6> <p>It is uncertain whether prebiotic 1 (inulin or high‐amylose corn starch) improves indoxyl sulfate at six weeks compared to prebiotic 2 (maltodextrin or high‐amylopectin starch) (<a href="./references#CD013631-fig-0019" title="">Analysis 3.3</a> (2 studies, 64 participants): SMD ‐0.04 μg/mL, 95% CI ‐0.53 to 0.45; I² = 0%; very low certainty evidence). </p> </section> </section> <section id="CD013631-sec-0093"> <h5 class="title">Gastrointestinal function</h5> <section id="CD013631-sec-0094"> <h6 class="title">Change in any gastrointestinal upset or intolerance</h6> <p>In very low certainty evidence, <a href="./references#CD013631-bbs2-0002" title="BirueteA , CrossTL , AllenJM , KistlerBM , deLoorH , EvenepoelP , et al. Effect of dietary inulin supplementation on the gut microbiota composition and derived metabolites of individuals undergoing hemodialysis: a pilot study. Journal of Renal Nutrition2021;31(5):512-22. [MEDLINE: 34120835]BirueteA , KistlerB , AllenJ , BauerL , FaheyG , SwansonK , et al. Effect of inulin supplementation on mineral metabolism and short-chain fatty acid excretion in hemodialysis patients [abstract no: MP434]. Nephrology Dialysis Transplantation2017;32(Suppl 3):iii588-9. [EMBASE: 617289888]">Biruete 2017</a> reported no difference in patients receiving inulin compared to maltodextrin at four weeks for burping (<a href="./references#CD013631-fig-0020" title="">Analysis 3.4</a> (1 study, 24 participants): MD 0.17, 95% CI ‐0.50 to 0.84), cramping (<a href="./references#CD013631-fig-0021" title="">Analysis 3.5</a> (1 study, 24 participants): MD ‐0.17, 95% CI ‐0.50 to 0.16), distension (<a href="./references#CD013631-fig-0022" title="">Analysis 3.6</a> (1 study, 24 participants): MD 0.33, 95% CI ‐0.04 to 0.70), flatulence (<a href="./references#CD013631-fig-0023" title="">Analysis 3.7</a> (1 study, 24 participants): MD 1.00, 95% CI 0.25 to 1.75), nausea (<a href="./references#CD013631-fig-0024" title="">Analysis 3.8</a> (1 study, 24 participants): MD 0.00, 95% CI ‐0.00 to 0.00), reflux (<a href="./references#CD013631-fig-0025" title="">Analysis 3.9</a> (1 study, 24 participants): MD 0.00, 95% CI ‐0.50 to 0.50), and rumbling (<a href="./references#CD013631-fig-0026" title="">Analysis 3.10</a> (1 study, 24 participants): MD 0.50, 95% CI ‐0.14 to 1.14). </p> </section> <section id="CD013631-sec-0095"> <h6 class="title">Microbiota composition</h6> <p>In very low certainty evidence, <a href="./references#CD013631-bbs2-0002" title="BirueteA , CrossTL , AllenJM , KistlerBM , deLoorH , EvenepoelP , et al. Effect of dietary inulin supplementation on the gut microbiota composition and derived metabolites of individuals undergoing hemodialysis: a pilot study. Journal of Renal Nutrition2021;31(5):512-22. [MEDLINE: 34120835]BirueteA , KistlerB , AllenJ , BauerL , FaheyG , SwansonK , et al. Effect of inulin supplementation on mineral metabolism and short-chain fatty acid excretion in hemodialysis patients [abstract no: MP434]. Nephrology Dialysis Transplantation2017;32(Suppl 3):iii588-9. [EMBASE: 617289888]">Biruete 2017</a> reported no difference in patients receiving inulin compared to maltodextrin at four weeks for actinobacteria <a href="./references#CD013631-fig-0027" title="">Analysis 3.11</a> (1 study, 24 participants): MD ‐1.26, 95% CI ‐4.46 to 1.94), bacteriodetes (<a href="./references#CD013631-fig-0028" title="">Analysis 3.12</a> (1 study, 24 participants): MD 3.23, 95% CI ‐8.24 to 14.70), proteobacteria (<a href="./references#CD013631-fig-0029" title="">Analysis 3.13</a> (1 study, 24 participants): MD 0.11, 95% CI ‐1.61 to 1.83), firmicutes (<a href="./references#CD013631-fig-0030" title="">Analysis 3.14</a> (1 study, 24 participants): MD ‐2.44, 95% CI ‐14.19 to 9.31), synergistetes (<a href="./references#CD013631-fig-0031" title="">Analysis 3.15</a> (1 study, 24 participants): MD ‐0.25, 95% CI ‐0.89 to 0.39), verrucomicrobia (<a href="./references#CD013631-fig-0032" title="">Analysis 3.16</a> (1 study, 24 participants): MD 0.96, 95% CI ‐1.36 to 3.28), faceal acetate (<a href="./references#CD013631-fig-0033" title="">Analysis 3.17</a> (1 study, 24 participants): MD ‐69.91, 95% CI ‐203.95 to 64.13), faecal propionate (<a href="./references#CD013631-fig-0034" title="">Analysis 3.18</a> (1 study, 24 participants): MD ‐19.35, 95% CI ‐63.87 to 25.17), faecal butyrate (<a href="./references#CD013631-fig-0035" title="">Analysis 3.19</a> (1 study, 24 participants): MD ‐11.04, 95% CI ‐39.57 to 17.49), faecal total short‐chain fatty acids (<a href="./references#CD013631-fig-0036" title="">Analysis 3.20</a> (1 study, 24 participants): MD ‐104.71, 95% CI ‐293.34 to 83.92), faecal indoles (<a href="./references#CD013631-fig-0037" title="">Analysis 3.21</a> (1 study, 24 participants): MD 2.71, 95% CI ‐69.78 to 75.20), and faecal p‐cresol (<a href="./references#CD013631-fig-0038" title="">Analysis 3.22</a> (1 study, 24 participants): MD 28.84, 95% CI ‐105.07 to 162.75). </p> </section> <section id="CD013631-sec-0096"> <h6 class="title">Faecal characteristics</h6> <p>In very low certainty evidence, <a href="./references#CD013631-bbs2-0002" title="BirueteA , CrossTL , AllenJM , KistlerBM , deLoorH , EvenepoelP , et al. Effect of dietary inulin supplementation on the gut microbiota composition and derived metabolites of individuals undergoing hemodialysis: a pilot study. Journal of Renal Nutrition2021;31(5):512-22. [MEDLINE: 34120835]BirueteA , KistlerB , AllenJ , BauerL , FaheyG , SwansonK , et al. Effect of inulin supplementation on mineral metabolism and short-chain fatty acid excretion in hemodialysis patients [abstract no: MP434]. Nephrology Dialysis Transplantation2017;32(Suppl 3):iii588-9. [EMBASE: 617289888]">Biruete 2017</a> reported no difference in patients receiving inulin compared to maltodextrin at four weeks for bowel movements (<a href="./references#CD013631-fig-0039" title="">Analysis 3.23</a> (1 study, 24 participants): MD ‐0.27, 95% CI ‐1.23 to 0.69), ease of passage (<a href="./references#CD013631-fig-0040" title="">Analysis 3.24</a> (1 study, 24 participants): MD 0.00, 95% CI ‐0.90 to 0.90; very low certainty evidence), and consistency (<a href="./references#CD013631-fig-0041" title="">Analysis 3.25</a> (1 study, 24 participants): MD ‐0.19, 95% CI‐1.34 to 0.96). </p> </section> </section> <section id="CD013631-sec-0097"> <h5 class="title">Adverse events and withdrawals</h5> <p>It is uncertain whether prebiotic 1 (gum Arabic or inulin plus oligofructose) decreased adverse events compared to prebiotic 2 (pectin or maltodextrin) (<a href="./references#CD013631-fig-0042" title="">Analysis 3.26</a> (2 studies, 79 participants): RR 2.92, 95% CI 0.10 to 88.03; I² = 77%; very low certainty evidence). </p> <p>It is uncertain whether inulin plus oligofructose decreased withdrawals due to adverse events compared to maltodextrin (<a href="./references#CD013631-fig-0043" title="">Analysis 3.27</a> (1 study, 39 participants): RR 0.70, 95% CI 0.13 to 3.75; very low certainty evidence). </p> <p>Adverse events were minimal and non‐serious, and withdrawals were not related to the study interventions (see <a href="./appendices#CD013631-sec-0158">Appendix 5</a>). </p> <p>The studies in this comparison did not report data on our remaining primary and secondary outcomes. </p> <p>There were no subgroups to analyse for this comparison.</p> </section> </section> <section id="CD013631-sec-0098"> <h4 class="title">4: Prebiotic versus probiotic</h4> <p>Two studies contributed to this comparison.</p> <p> <ul id="CD013631-list-0026"> <li> <p><a href="./references#CD013631-bbs2-0031" title="NatarajanR , PechenyakB , VyasU , RanganathanP , WeinbergA , LiangP , et al. Randomized controlled trial of strain-specific probiotic formulation (Renadyl) in dialysis patients. BioMed Research International2014;2014:568571. [MEDLINE: 25147806]">Natarajan 2014</a> compared a 1:1 blend of cream of wheat and psyllium husk to <i>Streptococcus thermophilus</i> KB19, <i>Lactobacillus acidophilus</i> KB 27, and <i>Bifidobacteriumlongum</i> KB 31. </p> </li> <li> <p><a href="./references#CD013631-bbs2-0045" title="WangIK , WuYY , YangYF , TingIW , LinCC , YenTH , et al. The effect of probiotics on serum levels of cytokine and endotoxin in peritoneal dialysis patients: a randomised, double-blind, placebo-controlled trial. Beneficial Microbes2015;6(4):423-30. [MEDLINE: 25609654]">Wang 2015a</a> compared maltodextrin to <i>Bifidobacteriumbifidum</i> A218, <i>Bifidobacteriumcatenulatum</i> A302, <i>Bifidobacteriumlongum</i> A101, <i>Lactobacillusplantarum</i> A87. </p> </li> </ul> </p> <section id="CD013631-sec-0099"> <h5 class="title">Dialysis outcomes</h5> <section id="CD013631-sec-0100"> <h6 class="title">Peritonitis</h6> <p><a href="./references#CD013631-bbs2-0045" title="WangIK , WuYY , YangYF , TingIW , LinCC , YenTH , et al. The effect of probiotics on serum levels of cytokine and endotoxin in peritoneal dialysis patients: a randomised, double-blind, placebo-controlled trial. Beneficial Microbes2015;6(4):423-30. [MEDLINE: 25609654]">Wang 2015a</a> reported no difference in the occurrence of peritonitis at eight weeks in patients receiving prebiotics compared to probiotics (<a href="./references#CD013631-fig-0044" title="">Analysis 4.1</a> (1 study, 47 participants): very low certainty evidence). </p> </section> </section> <section id="CD013631-sec-0101"> <h5 class="title">Adverse events</h5> <p><a href="./references#CD013631-bbs2-0031" title="NatarajanR , PechenyakB , VyasU , RanganathanP , WeinbergA , LiangP , et al. Randomized controlled trial of strain-specific probiotic formulation (Renadyl) in dialysis patients. BioMed Research International2014;2014:568571. [MEDLINE: 25147806]">Natarajan 2014</a> reported one death not related to the study intervention: myocardial infarction at home from underlying cardiovascular conditions. Cross‐over numbers and denominators are unclear. <a href="./references#CD013631-bbs2-0045" title="WangIK , WuYY , YangYF , TingIW , LinCC , YenTH , et al. The effect of probiotics on serum levels of cytokine and endotoxin in peritoneal dialysis patients: a randomised, double-blind, placebo-controlled trial. Beneficial Microbes2015;6(4):423-30. [MEDLINE: 25609654]">Wang 2015a</a> reported one patient in the placebo group died due to a head injury. </p> <p>The remaining adverse events were minimal and non‐serious, and withdrawals were not related to the study interventions (see <a href="./appendices#CD013631-sec-0158">Appendix 5</a>). </p> <p>The studies in this comparison did not report data on our remaining primary and secondary outcomes. </p> <p>There were no subgroups to analyse for this comparison.</p> </section> </section> <section id="CD013631-sec-0102"> <h4 class="title">5: Low versus high dose probiotic</h4> <p><a href="./references#CD013631-bbs2-0029" title="Miranda AlatristePV , UrbinaAR , Gomez EspinosaCO , Espinosa CuevasML . Effect of probiotics on human blood urea levels in patients with chronic renal failure. Nutricion Hospitalaria2014;29(3):582-90. [MEDLINE: 24559003]">Miranda Alatriste 2014</a> compared a low dose of <i>Lactobacillus casei Shirota</i> (8 x 10<sup>9</sup> CFU) to a higher dose of <i>Lactobacillus casei Shirota</i> (16 x 10<sup>9</sup> CFU). </p> <section id="CD013631-sec-0103"> <h5 class="title">Kidney function</h5> <section id="CD013631-sec-0104"> <h6 class="title">Estimated glomerular filtration rate</h6> <p><a href="./references#CD013631-bbs2-0029" title="Miranda AlatristePV , UrbinaAR , Gomez EspinosaCO , Espinosa CuevasML . Effect of probiotics on human blood urea levels in patients with chronic renal failure. Nutricion Hospitalaria2014;29(3):582-90. [MEDLINE: 24559003]">Miranda Alatriste 2014</a> reported no difference in eGFR at eight weeks in patients receiving a low dose of <i>Lactobacillus casei Shirota</i> compared to a higher dose (<a href="./references#CD013631-fig-0045" title="">Analysis 5.1</a> (1 study, 30 participants): MD ‐0.64 mL/min, 95% CI ‐9.51 to 8.23; very low certainty evidence). </p> </section> <section id="CD013631-sec-0105"> <h6 class="title">Serum creatinine</h6> <p><a href="./references#CD013631-bbs2-0029" title="Miranda AlatristePV , UrbinaAR , Gomez EspinosaCO , Espinosa CuevasML . Effect of probiotics on human blood urea levels in patients with chronic renal failure. Nutricion Hospitalaria2014;29(3):582-90. [MEDLINE: 24559003]">Miranda Alatriste 2014</a> reported no difference in SCr at eight weeks in patients receiving a low dose of <i>Lactobacillus casei Shirota</i> compared to a higher dose (<a href="./references#CD013631-fig-0046" title="">Analysis 5.2</a> (1 study, 30 participants): MD ‐0.13 mg/dL, 95% CI ‐0.89 to 0.63; very low certainty evidence). </p> </section> <section id="CD013631-sec-0106"> <h6 class="title">Urea</h6> <p><a href="./references#CD013631-bbs2-0029" title="Miranda AlatristePV , UrbinaAR , Gomez EspinosaCO , Espinosa CuevasML . Effect of probiotics on human blood urea levels in patients with chronic renal failure. Nutricion Hospitalaria2014;29(3):582-90. [MEDLINE: 24559003]">Miranda Alatriste 2014</a> reported no difference in urea rate at eight weeks in patients receiving a low dose of <i>Lactobacillus casei Shirota</i> compared to a higher dose (<a href="./references#CD013631-fig-0047" title="">Analysis 5.3</a> (1 study, 30 participants): MD 4.57 mg/dL, 95% CI ‐9.52 to 18.66; very low certainty evidence). </p> </section> </section> <section id="CD013631-sec-0107"> <h5 class="title">Adverse events</h5> <p>Adverse events were minimal and non‐serious, and withdrawals were not related to the study treatment (see <a href="./appendices#CD013631-sec-0158">Appendix 5</a>). </p> <p>The studies in this comparison did not report data on our remaining primary and secondary outcomes. </p> <p>There were no subgroups to analyse for this comparison.</p> </section> </section> <section id="CD013631-sec-0108"> <h4 class="title">6: Synbiotic versus placebo or no treatment</h4> <p>Three studies contributed to this comparison.</p> <p> <ul id="CD013631-list-0027"> <li> <p><a href="./references#CD013631-bbs2-0005" title="CosolaC , RocchettiMT , di BariI , AcquavivaPM , MaranzanoV , CorciuloS , et al. An innovative synbiotic formulation decreases free serum indoxyl sulfate, small intestine permeability and ameliorates gastrointestinal symptoms in a randomized pilot trial in stage IIIb-IV CKD patients. Toxins2021;13(5):334. [MEDLINE: 34063068]">Cosola 2021</a> compared a synbiotic (<i>Lactobacillus</i> c<i>asei</i> LC4P1, <i>Bifidobacteriumanimalis</i> BLC1 plus fructo‐oligosaccharides, inulin and natural antioxidants) to a placebo. </p> </li> <li> <p><a href="./references#CD013631-bbs2-0008" title="DehghaniH , HeidariF , Mozaffari-KhosraviH , Nouri-MajelanN , DehghaniA . Synbiotic supplementations for azotemia in patients with chronic kidney disease: a randomized controlled trial. Iranian Journal of Kidney Diseases2016;10(6):351-7. [MEDLINE: 27903994]">Dehghani 2016</a> compared a synbiotic (<i>Lactobacilluscasei</i> , <i>Lactobacillusacidophilus</i> , <i>Lactobacillusbulgaricus</i> , <i>Lactobacillusrhamnosus</i> , <i>Bifidobacteriumbreve</i> , <i>Bifidobacterium longum</i> , <i>Streptococcusthermophilus</i> plus fructo‐oligosaccharides) to a placebo. </p> </li> <li> <p><a href="./references#CD013631-bbs2-0044" title="Viramontes-HornerD , Marquez-SandovalF , Martin-del-CampoF , Vizmanos-LamotteB , Sandoval-RodriguezA , Armendariz-BorundaJ , et al. Effect of a symbiotic gel (Lactobacillus acidophilus + Bifidobacterium lactis + inulin) on presence and severity of gastrointestinal symptoms in hemodialysis patients. Journal of Renal Nutrition2015;25(3):284-91. [MEDLINE: 25455039]">Viramontes‐Horner 2015</a> compared a synbiotic (<i>Lactobacillus acidophilus</i> , <i>Bifidobacteriumlactis</i> Bi‐07 plus inulin, omega‐3 fatty acids and vitamins) to a placebo. </p> </li> </ul> </p> <section id="CD013631-sec-0109"> <h5 class="title">Kidney function</h5> <section id="CD013631-sec-0110"> <h6 class="title">Estimated glomerular filtration rate</h6> <p>It is uncertain whether synbiotics improve eGFR at six or 12 weeks compared to placebo (<a href="./references#CD013631-fig-0048" title="">Analysis 6.1</a> (2 studies, 98 participants): MD 1.42 mL/min, 95% CI 0.65 to 2.2; very low certainty evidence). </p> </section> <section id="CD013631-sec-0111"> <h6 class="title">Serum creatinine</h6> <p>It is uncertain whether synbiotics improve SCr at six or 12 weeks compared to placebo (<a href="./references#CD013631-fig-0049" title="">Analysis 6.2</a> (2 studies, 98 participants): MD ‐0.57 mg/dL, 95% CI ‐1.08 to 0.07; very low certainty evidence). </p> </section> </section> <section id="CD013631-sec-0112"> <h5 class="title">Uraemic toxins</h5> <section id="CD013631-sec-0113"> <h6 class="title">Urea</h6> <p>It is uncertain whether synbiotics improve urea at six or 12 weeks compared to placebo, with no differences found between subgroups (<a href="./references#CD013631-fig-0050" title="">Analysis 6.3</a> (2 studies, 117 participants): MD 3.34 mg/dL, 95% CI ‐15.65 to 22.32; very low certainty evidence; test for subgroup differences P = 0.15). </p> </section> </section> <section id="CD013631-sec-0114"> <h5 class="title">Gastrointestinal function</h5> <section id="CD013631-sec-0115"> <h6 class="title">Change in any gastrointestinal upset or intolerance</h6> <p>In very low certainty evidence, <a href="./references#CD013631-bbs2-0005" title="CosolaC , RocchettiMT , di BariI , AcquavivaPM , MaranzanoV , CorciuloS , et al. An innovative synbiotic formulation decreases free serum indoxyl sulfate, small intestine permeability and ameliorates gastrointestinal symptoms in a randomized pilot trial in stage IIIb-IV CKD patients. Toxins2021;13(5):334. [MEDLINE: 34063068]">Cosola 2021</a> reported no difference at 12 weeks in patients receiving synbiotics compared to placebo on the GSRS scale for rumbling (<a href="./references#CD013631-fig-0051" title="">Analysis 6.4</a> (1 study, 23 participants): MD ‐0.54, 95% CI ‐0.77 to ‐0.31), hard stools (<a href="./references#CD013631-fig-0052" title="">Analysis 6.5</a> (1 study, 23 participants): MD ‐0.09, 95% CI ‐0.35 to 0.17), abdominal pain (<a href="./references#CD013631-fig-0053" title="">Analysis 6.6</a> (1 study, 23 participants): MD 0.22, 95% CI ‐0.02 to 0.46) or constipation syndrome (<a href="./references#CD013631-fig-0054" title="">Analysis 6.7</a> (1 study, 23 participants): MD ‐0.17, 95% CI ‐0.72 to 0.38). </p> </section> </section> <section id="CD013631-sec-0116"> <h5 class="title">Adverse events</h5> <p>Adverse events were minimal and non‐serious, and withdrawals were not related to the study interventions (see <a href="./appendices#CD013631-sec-0158">Appendix 5</a>). </p> <p>The studies in this comparison did not report data on our remaining primary and secondary outcomes. </p> <p>There were no subgroups to analyse for the remaining analyses other than <a href="./references#CD013631-fig-0050" title="">Analysis 6.3</a>. </p> </section> </section> <section id="CD013631-sec-0117"> <h4 class="title">7: Prebiotic versus placebo or no treatment</h4> <p>Three studies contributed to this comparison.</p> <p> <ul id="CD013631-list-0028"> <li> <p><a href="./references#CD013631-bbs2-0027" title="MengY , BaiH , YuQ , YanJ , ZhaoL , WangS , et al. High-resistant starch, low-protein flour intervention on patients with early type 2 diabetic nephropathy: a randomized trial. Journal of Renal Nutrition2019;29(5):386-93. [MEDLINE: 30982743]">Meng 2019</a> compared a high‐resistant starch, low‐protein flour to no treatment. </p> </li> <li> <p><a href="./references#CD013631-bbs2-0012" title="AzevedoR , EsgalhadoM , KempJA , RegisB , CardozoLF , NakaoLS , et al. Resistant starch supplementation effects on plasma indole 3-acetic acid and aryl hydrocarbon receptor mRNA expression in hemodialysis patients: Randomized, double blind and controlled clinical trial [Efeitos da suplementacao de amido resistente no acido indol-3-acetico plasmatico e na expressao do mRNA do receptor aril-hidrocarboneto em pacientesemhemodialise:ensaioclinicorandomizado,duplo-cegoecontrolado]. Jornal Brasileiro de Nefrologia2020;42(3):273-9. [MEDLINE: 32459282]EsgalhadoM , KempJA , AzevedoR , PaivaBR , Stockler-PintoMB , DolengaCJ , et al. Could resistant starch supplementation improve inflammatory and oxidative stress biomarkers and uremic toxins levels in hemodialysis patients? A pilot randomized controlled trial. Food &amp; Function2018;9(12):6508-16. [MEDLINE: 30468238]EsgalhadoM , KempJA , PaivaBR , BritoJS , CardozoLF , AzevedoR , et al. Resistant starch type-2 enriched cookies modulate uremic toxins and inflammation in hemodialysis patients: a randomized, double-blind, crossover and placebo-controlled trial. Food &amp; Function2020;11(3):2617-25. [MEDLINE: 32159187]KempJA , Dos SantosHF , deJesusHE , EsgalhadoM , dePaivaBR , AzevedoR , et al. Resistant starch type-2 supplementation does not decrease trimethylamine n-oxide (TMAO) plasma level in hemodialysis patients. Journal of the American Nutrition Association2022;41(8):788-95. [MEDLINE: 35512757]KempJA , Regis de PaivaB , Fragoso Dos SantosH , Emiliano de JesusH , CravenH , Z IjazU , et al. The impact of enriched resistant starch type-2 cookies on the gut microbiome in hemodialysis patients: a randomized controlled trial. Molecular Nutrition &amp; Food Research2021;65(19):e2100374. [MEDLINE: 34390604]MafraD , Ann KempJ , EsgalhadoM , PaivaB , De JesusHE , SantosHF . Effects of resistant starch (RS) type 2 cookies on gut microbiota profile in hemodialysis (HD) patients [abstract no: PO2051]. Journal of the American Society of Nephrology2020;31(Abstract Suppl):629-30. [EMBASE: 633701738]MafraD , Ann KempJ , SantosHF , De JesusHE , EsgalhadoM , PaivaB , et al. High-amylose resistant starch (RS) cookies supplementation does not decrease trimethylamine n-oxide (TMAO) plasma level in hemodialysis (HD) patients [abstract no: PO2039]. Journal of the American Society of Nephrology2020;31(Abstract Suppl):626-7. [EMBASE: 633701431]MafraD , EsgalhadoM , MacedoRD , KempJ , PaivaB , NakaoLS , et al. Resistant starch supplementation reduces indoxyl sulfate levels in hemodialysis patients: a randomized, double-blind, crossover, placebo-controlled study [abstract no: FR-OR127]. Journal of the American Society of Nephrology2018;29(Abstract Suppl):72. [EMBASE: 633737357]MafraD , EsgalhadoM , Stockler-PintoMB , BorgesNA , CardozoLF , PaivaB , et al. Effects of resistant starch supplementation on inflammatory and oxidative stress status in hemodialysis patients: a pilot randomized, double-blind, placebo-controlled clinical trial [abstract no: SA-PO149]. Journal of the American Society of Nephrology2017;28(Abstract Suppl):716. [EMBASE: 633701761]MafraD , MacedoRD , CardozoLF , BorgesNA , NakaoLS , JardimMZ , et al. Effect of resistant starch supplementation on the indole-3-acetic acid levels and aryl hydrocarbon receptor expression in hemodialysis patients [abstract no: FR-PO545]. Journal of the American Society of Nephrology2018;29(Abstract Suppl):561. [EMBASE: 633736002]MafraD , PaivaB , EsgalhadoM , BorgesNA , KempJA , CardozoLF , et al. Resistant starch supplementation attenuates inflammation in hemodialysis patients [abstract no: SA-PO818]. Journal of the American Society of Nephrology2019;30(Abstract Suppl):974. [EMBASE: 633769632]dePaivaBR , EsgalhadoM , BorgesNA , KempJA , AlvesG , LeitePE , et al. Resistant starch supplementation attenuates inflammation in hemodialysis patients: a pilot study. International Urology &amp; Nephrology2020;52(3):549-55. [MEDLINE: 32008198]">Esgalhado 2018</a> compared a resistant starch to a placebo. </p> </li> <li> <p><a href="./references#CD013631-bbs2-0018" title="KhosroshahiHT , AbediB , GhojazadehM , SamadiA , JouybanA . Effects of fermentable high fiber diet supplementation on gut derived and conventional nitrogenous product in patients on maintenance hemodialysis: a randomized controlled trial. Nutrition &amp; Metabolism2019;16:18. [MEDLINE: 30911321]LaffinMR , Tayebi KhosroshahiH , ParkH , LaffinLJ , MadsenK , KafilHS , et al. Amylose resistant starch (HAM-RS2) supplementation increases the proportion of Faecalibacterium bacteria in end-stage renal disease patients: microbial analysis from a randomized placebo-controlled trial. Hemodialysis International2019;23(3):343-7. [MEDLINE: 30924310]Tayebi Khosroshahi H, VaziriND , AbediB , AslBH , GhojazadehM , JingW , et al. Effect of high amylose resistant starch (HAM-RS2) supplementation on biomarkers of inflammation and oxidative stress in hemodialysis patients: a randomized clinical trial. Hemodialysis International2018;22(4):492-500. [MEDLINE: 29532981]">Khosroshahi 2018</a> compared high‐amylose maize‐resistant starch to a placebo. </p> </li> </ul> </p> <section id="CD013631-sec-0118"> <h5 class="title">Kidney function</h5> <section id="CD013631-sec-0119"> <h6 class="title">Serum creatinine</h6> <p>It is uncertain whether prebiotics improves SCr at eight or 12 weeks compared to placebo or no treatment (<a href="./references#CD013631-fig-0055" title="">Analysis 7.1</a> (3 studies, 145 participants): MD 0.52 mg/dL, 95% CI ‐2.39 to 3.44; very low certainty evidence). </p> <p>A difference was identified across subgroups by CKD stage. Participants receiving placebo or no treatment showed increased SCr in patients with CKD stage A2 with diabetic nephropathy (70 participants) compared to CKD stage G5D (75 participants); however, heterogeneity was very high I² = 79% (P = 0.03). </p> </section> </section> <section id="CD013631-sec-0120"> <h5 class="title">Uraemic toxins</h5> <section id="CD013631-sec-0121"> <h6 class="title">Urea</h6> <p><a href="./references#CD013631-bbs2-0027" title="MengY , BaiH , YuQ , YanJ , ZhaoL , WangS , et al. High-resistant starch, low-protein flour intervention on patients with early type 2 diabetic nephropathy: a randomized trial. Journal of Renal Nutrition2019;29(5):386-93. [MEDLINE: 30982743]">Meng 2019</a> reported no difference no difference to urea at 12 weeks in patients receiving prebiotics compared to no treatment (<a href="./references#CD013631-fig-0056" title="">Analysis 7.2</a> (1 study, 70 participants): MD ‐0.40 mmol/L, 95% CI ‐0.86 to 0.06; very low certainty evidence). </p> </section> <section id="CD013631-sec-0122"> <h6 class="title">Indoxyl sulfate</h6> <p>It is uncertain whether prebiotics improve indoxyl sulfate at eight weeks compared to placebo or no treatment (<a href="./references#CD013631-fig-0057" title="">Analysis 7.3</a> (2 studies, 75 participants): SMD ‐0.14 mg/L, 95% CI ‐0.60 to 0.31; very low certainty evidence). </p> </section> <section id="CD013631-sec-0123"> <h6 class="title">P‐cresyl sulfate</h6> <p><a href="./references#CD013631-bbs2-0018" title="KhosroshahiHT , AbediB , GhojazadehM , SamadiA , JouybanA . Effects of fermentable high fiber diet supplementation on gut derived and conventional nitrogenous product in patients on maintenance hemodialysis: a randomized controlled trial. Nutrition &amp; Metabolism2019;16:18. [MEDLINE: 30911321]LaffinMR , Tayebi KhosroshahiH , ParkH , LaffinLJ , MadsenK , KafilHS , et al. Amylose resistant starch (HAM-RS2) supplementation increases the proportion of Faecalibacterium bacteria in end-stage renal disease patients: microbial analysis from a randomized placebo-controlled trial. Hemodialysis International2019;23(3):343-7. [MEDLINE: 30924310]Tayebi Khosroshahi H, VaziriND , AbediB , AslBH , GhojazadehM , JingW , et al. Effect of high amylose resistant starch (HAM-RS2) supplementation on biomarkers of inflammation and oxidative stress in hemodialysis patients: a randomized clinical trial. Hemodialysis International2018;22(4):492-500. [MEDLINE: 29532981]">Khosroshahi 2018</a> reported no difference in p‐cresyl sulfate at eight weeks in patients receiving prebiotics compared to placebo (<a href="./references#CD013631-fig-0058" title="">Analysis 7.4</a> (1 study, 44 participants): MD ‐1.68 mg/L, 95% CI ‐14.30 to 10.94; very low certainty evidence). </p> </section> </section> <section id="CD013631-sec-0124"> <h5 class="title">Gastrointestinal function</h5> <section id="CD013631-sec-0125"> <h6 class="title">Microbiota composition</h6> <p>In very low certainty evidence, <a href="./references#CD013631-bbs2-0018" title="KhosroshahiHT , AbediB , GhojazadehM , SamadiA , JouybanA . Effects of fermentable high fiber diet supplementation on gut derived and conventional nitrogenous product in patients on maintenance hemodialysis: a randomized controlled trial. Nutrition &amp; Metabolism2019;16:18. [MEDLINE: 30911321]LaffinMR , Tayebi KhosroshahiH , ParkH , LaffinLJ , MadsenK , KafilHS , et al. Amylose resistant starch (HAM-RS2) supplementation increases the proportion of Faecalibacterium bacteria in end-stage renal disease patients: microbial analysis from a randomized placebo-controlled trial. Hemodialysis International2019;23(3):343-7. [MEDLINE: 30924310]Tayebi Khosroshahi H, VaziriND , AbediB , AslBH , GhojazadehM , JingW , et al. Effect of high amylose resistant starch (HAM-RS2) supplementation on biomarkers of inflammation and oxidative stress in hemodialysis patients: a randomized clinical trial. Hemodialysis International2018;22(4):492-500. [MEDLINE: 29532981]">Khosroshahi 2018</a> reported no difference at eight weeks in prebiotics compared to placebo to the microbiota compositions of <i>Facealibacterium</i> (<a href="./references#CD013631-fig-0059" title="">Analysis 7.5</a> (1 study, 44 participants): MD 2.37, 95% CI 0.23 to 4.51), <i>Parabacteroides</i> (<a href="./references#CD013631-fig-0060" title="">Analysis 7.6</a> (1 study 44 participants): MD 0.22, 95% CI 0.06 to 0.38), <i>Bifidobacteria</i> (<a href="./references#CD013631-fig-0061" title="">Analysis 7.7</a> (1 study 44 participants): MD ‐3.92, 95% CI ‐9.83 to 1.99), <i>Ruminococcus</i> (<a href="./references#CD013631-fig-0062" title="">Analysis 7.8</a> (1 study 44 participants): MD 3.86, 95% CI ‐0.32 to 8.04), and <i>Prevotella</i> (<a href="./references#CD013631-fig-0063" title="">Analysis 7.9</a> (1 study 44 participants): MD ‐0.43, 95% CI ‐1.45 to 0.59). </p> </section> </section> <section id="CD013631-sec-0126"> <h5 class="title">Adverse events</h5> <p><a href="./references#CD013631-bbs2-0018" title="KhosroshahiHT , AbediB , GhojazadehM , SamadiA , JouybanA . Effects of fermentable high fiber diet supplementation on gut derived and conventional nitrogenous product in patients on maintenance hemodialysis: a randomized controlled trial. Nutrition &amp; Metabolism2019;16:18. [MEDLINE: 30911321]LaffinMR , Tayebi KhosroshahiH , ParkH , LaffinLJ , MadsenK , KafilHS , et al. Amylose resistant starch (HAM-RS2) supplementation increases the proportion of Faecalibacterium bacteria in end-stage renal disease patients: microbial analysis from a randomized placebo-controlled trial. Hemodialysis International2019;23(3):343-7. [MEDLINE: 30924310]Tayebi Khosroshahi H, VaziriND , AbediB , AslBH , GhojazadehM , JingW , et al. Effect of high amylose resistant starch (HAM-RS2) supplementation on biomarkers of inflammation and oxidative stress in hemodialysis patients: a randomized clinical trial. Hemodialysis International2018;22(4):492-500. [MEDLINE: 29532981]">Khosroshahi 2018</a> reported no difference in any adverse events (number of participants reporting an event) in patients receiving prebiotics compared to placebo (<a href="./references#CD013631-fig-0064" title="">Analysis 7.10</a> (1 study, 50 participants): RR 2.50, 95% CI 0.53 to 11.70; very low certainty evidence). </p> <p><a href="./references#CD013631-bbs2-0018" title="KhosroshahiHT , AbediB , GhojazadehM , SamadiA , JouybanA . Effects of fermentable high fiber diet supplementation on gut derived and conventional nitrogenous product in patients on maintenance hemodialysis: a randomized controlled trial. Nutrition &amp; Metabolism2019;16:18. [MEDLINE: 30911321]LaffinMR , Tayebi KhosroshahiH , ParkH , LaffinLJ , MadsenK , KafilHS , et al. Amylose resistant starch (HAM-RS2) supplementation increases the proportion of Faecalibacterium bacteria in end-stage renal disease patients: microbial analysis from a randomized placebo-controlled trial. Hemodialysis International2019;23(3):343-7. [MEDLINE: 30924310]Tayebi Khosroshahi H, VaziriND , AbediB , AslBH , GhojazadehM , JingW , et al. Effect of high amylose resistant starch (HAM-RS2) supplementation on biomarkers of inflammation and oxidative stress in hemodialysis patients: a randomized clinical trial. Hemodialysis International2018;22(4):492-500. [MEDLINE: 29532981]">Khosroshahi 2018</a> reported no difference in withdrawals due to adverse events in patients receiving prebiotics compared to placebo (<a href="./references#CD013631-fig-0065" title="">Analysis 7.11</a> (1 study, 50 participants): RR 3.0, 95% CI 0.13 to 70.30; very low certainty evidence). </p> <p>Adverse events were minimal and non‐serious, and withdrawals were not related to the study interventions (see <a href="./appendices#CD013631-sec-0158">Appendix 5</a>). </p> <p>The studies in this comparison did not report data on our remaining primary and secondary outcomes. </p> <p>There were no subgroups to analyse for the remaining analyses.</p> </section> </section> <section id="CD013631-sec-0127"> <h4 class="title">8: Probiotic versus placebo or no treatment</h4> <p>Nine studies contributed to this comparison.</p> <p> <ul id="CD013631-list-0029"> <li> <p><a href="./references#CD013631-bbs2-0001" title="AbbasiB , GhiasvandR , MirlohiM . Kidney function improvement by soy milk containing lactobacillus plantarum A7 in type 2 diabetic patients with nephropathy: a double-blinded randomized controlled trial. Iranian Journal of Kidney Diseases2017;11(1):36-43. [MEDLINE: 28174351]AbbasiB , MirlohiM , DanialiM , GhiasvandR . Effects of probiotic soy milk on lipid panel in type 2 diabetic patients with nephropathy: a double-blind randomized clinical trial. Progress in Nutrition2018;20:70-8. [EMBASE: 2001649336]">Abbasi 2017</a> compared soy milk plus <i>Lactobacillusplantarum</i> A7 to soy milk. </p> </li> <li> <p><a href="./references#CD013631-bbs2-0004" title="BorgesNA , CarmoFL , Stockler-PintoMB , deBritoJS , DolengaCJ , FerreiraDC , et al. Probiotic supplementation in chronic kidney disease: a double-blind, randomized, placebo-controlled trial. Journal of Renal Nutrition2018;28(1):28-36. [MEDLINE: 28888762]BorgesNA , StenvinkelP , BergmanP , QureshiAR , LindholmB , MoraesC , et al. Effects of probiotic supplementation on trimethylamine-N-oxide plasma levels in hemodialysis patients: a pilot study. Probiotics &amp; Antimicrobial Proteins2019;11(2):648-54. [MEDLINE: 29651635]MafraD , BorgesNA , MoraesC , Stockler-PintoMB , BergmanP , StenvinkelP . Effects of probiotic supplementation on trimethylamine-N-oxide plasma levels in chronic kidney disease patients [abstract no: TH-PO764]. Journal of the American Society of Nephrology2016;27(Abstract Suppl):270A. [EMBASE: 641135082]MafraD , BorgesNA , NakauL , DolengaC , BergmanP , StenvinkelP . Effects of probiotic supplementation on uremic toxins levels in non-dialysis CKD patients [abstract no: MP431]. Nephrology Dialysis Transplantation2017;32(Suppl 3):iii587-8. [EMBASE: 617289825]MafraD , BorgesNA , Stockler-PintoMB , FouqueD , BarrosAF . Does a probiotic supplementation alter the indoxyl sulfate levels in non-dialysis chronic kidney disease patients? A randomized placebo-controlled clinical trial [abstract no: FR-PO862]. Journal of the American Society of Nephrology2015;26(Abstract Suppl):563A. [EMBASE: 641102246]">Borges 2018</a> compared <i>Streptococcusthermophilus</i> , <i>Lactobacillusacidophilus</i> , and <i>Bifidobacterialongum</i> strains to a placebo. </p> </li> <li> <p><a href="./references#CD013631-bbs2-0010" title="EidiF , Poor-RezaGF , OstadrahimiA , DaliliN , SamadianF , BarzegariA . Effect of Lactobacillus rhamnosus on serum uremic toxins (phenol and P-cresol) in hemodialysis patients: A double blind randomized clinical trial. Clinical Nutrition ESPEN2018;28:158-64. [MEDLINE: 30390875]GholiFP , DaliliN , EidiF , OstadrahimiA . Effect of lactobacillus rhamnosus on serum uremic toxins in hemodialysis patients [abstract no: SP705]. Nephrology Dialysis Transplantation2017;32(Suppl 3):iii375. [EMBASE: 617290088]">Eidi 2018</a> compared <i>LactobacillusRhamnosus</i> to infant formula. </p> </li> <li> <p><a href="./references#CD013631-bbs2-0021" title="LimPS , WangHF , LeeMC , ChiuLS , WuMY , ChangWC , et al. The efficacy of lactobacillus-containing probiotic supplementation in hemodialysis patients: a randomized, double-blind, placebo-controlled trial. Journal of Renal Nutrition2021;31(2):189-98. [MEDLINE: 32900583]">Lim 2021</a> compared <i>Lactococcuslactis</i> subspecies (<i>Lactis</i> LL358, <i>Lactobacillussalivarius</i> LS159, and <i>Lactobaccilluspentosus</i> LPE588) to a placebo. </p> </li> <li> <p><a href="./references#CD013631-bbs2-0022" title="LiuS , LiuH , ChenL , LiangSS , ShiK , MengW , et al. Effect of probiotics on the intestinal microbiota of hemodialysis patients: a randomized trial. European Journal of Nutrition2020;59(8):3755-66. [MEDLINE: 32112136]">Liu 2020</a> compared <i>Bifidobacteriumlongum</i> NQ1501, <i>Lactobacillusacidophilus</i> YIT2004 and <i>Enterococcifaecalis</i> YIT0072 to a placebo. </p> </li> <li> <p><a href="./references#CD013631-bbs2-0025" title="MafiA , NamaziG , SoleimaniA , BahmaniF , AghadavodE , AsemiZ . Metabolic and genetic response to probiotics supplementation in patients with diabetic nephropathy: a randomized, double-blind, placebo-controlled trial [Expression of Concern in: Food Funct. 2022 Apr 4;13(7):4229]. Food &amp; Function2018;9(9):4763-70. [MEDLINE: 30113051]">Mafi 2018</a> compared <i>Lactobacillusacidophilus</i> , <i>Bifidobacteriumbifidum</i> ZT‐B1, <i>Lactobacillusreuteri</i> ZT‐Lre and <i>Lactobacillusfermentum</i> ZT‐L3 to a placebo </p> </li> <li> <p><a href="./references#CD013631-bbs2-0026" title="Mazruei AraniN , Emam-DjomehZ , TavakolipourH , Sharafati-ChaleshtoriR , SoleimaniA , AsemiZ . The effects of probiotic honey consumption on metabolic status in patients with diabetic nephropathy: a randomized, double-blind, controlled trial. Probiotics &amp; Antimicrobial Proteins2019;11(4):1195-201. [MEDLINE: 30218286]">Mazruei Arani 2019</a> compared honey containing a viable and heat‐resistant probiotic <i>Bacillus coagulans</i> T4 (IBRC‐N10791) to control honey. </p> </li> <li> <p><a href="./references#CD013631-bbs2-0035" title="SimeoniM , CianfroneP , CapriaM , DeodatoF , CitraroM , CerantonioA , et al. ProbiotiCKD: A monocentric, randomized, openlabel, placebo-controlled study to reveal and correct gut dysbiosis in early CKD stages [abstract no: SP367]. Nephrology Dialysis Transplantation2018;33(Suppl 1):i469-70. [EMBASE: 622605912]SimeoniM , CitraroML , CerantonioA , DeodatoF , ProvenzanoM , CianfroneP , et al. An open-label, randomized, placebo-controlled study on the effectiveness of a novel probiotics administration protocol (ProbiotiCKD) in patients with mild renal insufficiency (stage 3a of CKD) [Erratum in: Eur J Nutr. 2018 58(5):2157]. European Journal of Nutrition2019;58(5):2145-56. [MEDLINE: 30076458]SimeoniM , CitraroML , CerantonioA , DeodatoF , ProvenzanoM , CianfroneP , et al. Correction to: An open-label, randomized, placebo-controlled study on the effectiveness of a novel probiotics administration protocol (ProbiotiCKD) in patients with mild renal insufficiency (stage 3a of CKD) (European Journal of Nutrition, (2019), 58, 5, (2145-2156), 10.1007/s00394-018-1785-z). European Journal of Nutrition2019;58(5):2157. [MEDLINE: 30302543]">ProbiotiCKD 2019</a> compared different probiotics over different weeks (week 1, weeks 2 to 3, weeks 4 to 15) to placebo. </p> </li> <li> <p><a href="./references#CD013631-bbs2-0040" title="SoleimaniA , Zarrati MojarradM , BahmaniF , TaghizadehM , RamezaniM , Tajabadi-EbrahimiM , et al. Probiotic supplementation in diabetic hemodialysis patients has beneficial metabolic effects. Kidney International2017;91(2):435-42. [MEDLINE: 27927601]">Soleimani 2017</a> compared <i>Lactobacillus acidophilus</i> , <i>Lactobacillus casei</i> , and <i>Bifidobacteria bifidum</i> to a placebo. </p> </li> </ul> </p> <section id="CD013631-sec-0128"> <h5 class="title">Kidney function</h5> <section id="CD013631-sec-0129"> <h6 class="title">Estimated glomerular filtration rate</h6> <p>It is uncertain whether probiotics improve eGFR at eight, 12, or 15 weeks compared to placebo or no treatment (<a href="./references#CD013631-fig-0066" title="">Analysis 8.1</a> (3 studies, 128 participants): MD 2.73 mL/min, 95% CI ‐2.28 to 7.75; I² = 78%; very low certainty evidence). A difference was identified across subgroups by CKD stage. Participants receiving placebo or no treatment showed decreased eGFR in patients with CKD stage 1 with type 2 diabetes mellitus (40 participants) compared to CKD stage 3A with diabetes and hypertension (28 participants) and CKD stage G5D with diabetes and hypertension (60 participants); however, heterogeneity was very high I² = 77.6% (P = 0.01). </p> </section> <section id="CD013631-sec-0130"> <h6 class="title">Serum creatinine</h6> <p>Probiotics may have little or no effect on SCr at eight, 12, or 24 weeks compared to placebo or no treatment, with no difference found between subgroups (<a href="./references#CD013631-fig-0067" title="">Analysis 8.2</a> (6 studies, 303 participants): MD ‐0.51 mg/dL, 95% CI ‐1.06 to 0.04; I² = 96%; low certainty evidence; test for subgroup differences P = 0.55). </p> </section> <section id="CD013631-sec-0131"> <h6 class="title">Albuminuria</h6> <p>Probiotics may have little or no effect on albuminuria at eight, 12, or 24 weeks compared to placebo or no treatment, with no difference found between subgroups (<a href="./references#CD013631-fig-0068" title="">Analysis 8.3</a> (4 studies, 193 participants): MD 0.02 g/dL, 95% CI ‐0.08 to 0.13; I² = 0%; low certainty evidence; test for subgroup differences P = 0.80). </p> </section> <section id="CD013631-sec-0132"> <h6 class="title">Proteinuria</h6> <p><a href="./references#CD013631-bbs2-0025" title="MafiA , NamaziG , SoleimaniA , BahmaniF , AghadavodE , AsemiZ . Metabolic and genetic response to probiotics supplementation in patients with diabetic nephropathy: a randomized, double-blind, placebo-controlled trial [Expression of Concern in: Food Funct. 2022 Apr 4;13(7):4229]. Food &amp; Function2018;9(9):4763-70. [MEDLINE: 30113051]">Mafi 2018</a> reported no difference in proteinuria at 12 weeks in patients receiving probiotics compared to placebo or no treatment (<a href="./references#CD013631-fig-0069" title="">Analysis 8.4</a> (1 study, 60 participants): MD ‐15.60 mg/dL, 95% CI ‐34.30 to 3.10; very low certainty evidence). </p> </section> </section> <section id="CD013631-sec-0133"> <h5 class="title">Uraemic toxins</h5> <section id="CD013631-sec-0134"> <h6 class="title">Urea</h6> <p>Probiotics may have little or no effect on urea at 12 or 24 weeks compared to placebo or no treatment, with no difference found between subgroups (<a href="./references#CD013631-fig-0070" title="">Analysis 8.5</a> (5 studies, 263 participants): MD ‐1.11 mg/dL, 95% CI ‐2.58 to 0.35; I² = 0%; low certainty evidence; test for subgroup differences P = 0.73). </p> </section> <section id="CD013631-sec-0135"> <h6 class="title">Indoxyl sulfate</h6> <p>It is uncertain whether probiotics improved indoxyl sulfate at 12 or 24 weeks compared to placebo or no treatment, with no difference found between subgroups (<a href="./references#CD013631-fig-0071" title="">Analysis 8.6</a> (2 studies, 83 participants): MD ‐4.42 mg/dL, 95% CI ‐9.83 to 1.35; I² = 0%; very low certainty evidence; test for subgroup differences P = 0.63). </p> </section> <section id="CD013631-sec-0136"> <h6 class="title">P‐cresyl sulfate</h6> <p>It is uncertain whether probiotics improved p‐cresyl sulfate at four, 12 or 24 weeks compared to placebo or no treatment, with no difference found between subgroups (<a href="./references#CD013631-fig-0072" title="">Analysis 8.7</a> (3 studies, 125 participants): MD ‐2.12 mg/dL, 95% CI ‐5.19 to 0.95; I² = 16%; very low certainty evidence; test for subgroup differences P = 0.21). </p> </section> <section id="CD013631-sec-0137"> <h6 class="title">Indole‐3‐acetic acid</h6> <p><a href="./references#CD013631-bbs2-0004" title="BorgesNA , CarmoFL , Stockler-PintoMB , deBritoJS , DolengaCJ , FerreiraDC , et al. Probiotic supplementation in chronic kidney disease: a double-blind, randomized, placebo-controlled trial. Journal of Renal Nutrition2018;28(1):28-36. [MEDLINE: 28888762]BorgesNA , StenvinkelP , BergmanP , QureshiAR , LindholmB , MoraesC , et al. Effects of probiotic supplementation on trimethylamine-N-oxide plasma levels in hemodialysis patients: a pilot study. Probiotics &amp; Antimicrobial Proteins2019;11(2):648-54. [MEDLINE: 29651635]MafraD , BorgesNA , MoraesC , Stockler-PintoMB , BergmanP , StenvinkelP . Effects of probiotic supplementation on trimethylamine-N-oxide plasma levels in chronic kidney disease patients [abstract no: TH-PO764]. Journal of the American Society of Nephrology2016;27(Abstract Suppl):270A. [EMBASE: 641135082]MafraD , BorgesNA , NakauL , DolengaC , BergmanP , StenvinkelP . Effects of probiotic supplementation on uremic toxins levels in non-dialysis CKD patients [abstract no: MP431]. Nephrology Dialysis Transplantation2017;32(Suppl 3):iii587-8. [EMBASE: 617289825]MafraD , BorgesNA , Stockler-PintoMB , FouqueD , BarrosAF . Does a probiotic supplementation alter the indoxyl sulfate levels in non-dialysis chronic kidney disease patients? A randomized placebo-controlled clinical trial [abstract no: FR-PO862]. Journal of the American Society of Nephrology2015;26(Abstract Suppl):563A. [EMBASE: 641102246]">Borges 2018</a> reported no difference in indole‐3‐acetic acid at 12 weeks in patients receiving probiotics compared to placebo or no treatment (<a href="./references#CD013631-fig-0073" title="">Analysis 8.8</a> (1 study, 33 participants): MD ‐288.10 μg/L, 95% CI ‐464.41 to ‐111.79; very low certainty evidence). </p> </section> </section> <section id="CD013631-sec-0138"> <h5 class="title">Gastrointestinal function</h5> <section id="CD013631-sec-0139"> <h6 class="title">Change in any gastrointestinal upset or intolerance</h6> <p><a href="./references#CD013631-bbs2-0004" title="BorgesNA , CarmoFL , Stockler-PintoMB , deBritoJS , DolengaCJ , FerreiraDC , et al. Probiotic supplementation in chronic kidney disease: a double-blind, randomized, placebo-controlled trial. Journal of Renal Nutrition2018;28(1):28-36. [MEDLINE: 28888762]BorgesNA , StenvinkelP , BergmanP , QureshiAR , LindholmB , MoraesC , et al. Effects of probiotic supplementation on trimethylamine-N-oxide plasma levels in hemodialysis patients: a pilot study. Probiotics &amp; Antimicrobial Proteins2019;11(2):648-54. [MEDLINE: 29651635]MafraD , BorgesNA , MoraesC , Stockler-PintoMB , BergmanP , StenvinkelP . Effects of probiotic supplementation on trimethylamine-N-oxide plasma levels in chronic kidney disease patients [abstract no: TH-PO764]. Journal of the American Society of Nephrology2016;27(Abstract Suppl):270A. [EMBASE: 641135082]MafraD , BorgesNA , NakauL , DolengaC , BergmanP , StenvinkelP . Effects of probiotic supplementation on uremic toxins levels in non-dialysis CKD patients [abstract no: MP431]. Nephrology Dialysis Transplantation2017;32(Suppl 3):iii587-8. [EMBASE: 617289825]MafraD , BorgesNA , Stockler-PintoMB , FouqueD , BarrosAF . Does a probiotic supplementation alter the indoxyl sulfate levels in non-dialysis chronic kidney disease patients? A randomized placebo-controlled clinical trial [abstract no: FR-PO862]. Journal of the American Society of Nephrology2015;26(Abstract Suppl):563A. [EMBASE: 641102246]">Borges 2018</a> reported no difference at 12 weeks in patients receiving probiotics compared to placebo or no treatment for abdominal pain or diarrhoea (<a href="./references#CD013631-fig-0074" title="">Analysis 8.9</a> (1 study, 33 participants): RR 2.13, 95% CI 0.21 to 21.22; very low certainty evidence), or constipation (<a href="./references#CD013631-fig-0075" title="">Analysis 8.10</a> (1 study, 33 participants): RR 3.18, 95% CI 0.14 to 72.75; very low certainty evidence). </p> </section> <section id="CD013631-sec-0140"> <h6 class="title">Faecal characteristics</h6> <p><a href="./references#CD013631-bbs2-0004" title="BorgesNA , CarmoFL , Stockler-PintoMB , deBritoJS , DolengaCJ , FerreiraDC , et al. Probiotic supplementation in chronic kidney disease: a double-blind, randomized, placebo-controlled trial. Journal of Renal Nutrition2018;28(1):28-36. [MEDLINE: 28888762]BorgesNA , StenvinkelP , BergmanP , QureshiAR , LindholmB , MoraesC , et al. Effects of probiotic supplementation on trimethylamine-N-oxide plasma levels in hemodialysis patients: a pilot study. Probiotics &amp; Antimicrobial Proteins2019;11(2):648-54. [MEDLINE: 29651635]MafraD , BorgesNA , MoraesC , Stockler-PintoMB , BergmanP , StenvinkelP . Effects of probiotic supplementation on trimethylamine-N-oxide plasma levels in chronic kidney disease patients [abstract no: TH-PO764]. Journal of the American Society of Nephrology2016;27(Abstract Suppl):270A. [EMBASE: 641135082]MafraD , BorgesNA , NakauL , DolengaC , BergmanP , StenvinkelP . Effects of probiotic supplementation on uremic toxins levels in non-dialysis CKD patients [abstract no: MP431]. Nephrology Dialysis Transplantation2017;32(Suppl 3):iii587-8. [EMBASE: 617289825]MafraD , BorgesNA , Stockler-PintoMB , FouqueD , BarrosAF . Does a probiotic supplementation alter the indoxyl sulfate levels in non-dialysis chronic kidney disease patients? A randomized placebo-controlled clinical trial [abstract no: FR-PO862]. Journal of the American Society of Nephrology2015;26(Abstract Suppl):563A. [EMBASE: 641102246]">Borges 2018</a> reported no difference in faecal pH at 12 weeks in patients receiving probiotics compared to placebo or no treatment (<a href="./references#CD013631-fig-0076" title="">Analysis 8.11</a> (1 study, 20 participants): MD ‐2.10, 95% CI ‐7.28 to 3.08; very low certainty evidence). </p> </section> </section> <section id="CD013631-sec-0141"> <h5 class="title">Adverse events</h5> <p>It is uncertain whether probiotics decrease adverse events compared to placebo or no treatment, with no difference found between subgroups (<a href="./references#CD013631-fig-0077" title="">Analysis 8.12</a> (4 studies, 205 participants): RR 1.96, 95% CI 0.63 to 6.12; I² = 13%; very low certainty evidence; test for subgroup differences P = 0.17), and withdrawals due to adverse events, with no difference found between subgroups (<a href="./references#CD013631-fig-0078" title="">Analysis 8.13</a> (4 studies, 205 participants): RR 4.96, 95% CI 1.13 to 21.77; I² = 0%; very low certainty evidence; test for subgroup differences P = 1.00). </p> <p><a href="./references#CD013631-bbs2-0021" title="LimPS , WangHF , LeeMC , ChiuLS , WuMY , ChangWC , et al. The efficacy of lactobacillus-containing probiotic supplementation in hemodialysis patients: a randomized, double-blind, placebo-controlled trial. Journal of Renal Nutrition2021;31(2):189-98. [MEDLINE: 32900583]">Lim 2021</a> reported one death in each arm but not related to the study treatment, "No significant gastrointestinal side effects were reported or recorded throughout the study in either group." </p> <p>The remaining adverse events were minimal and non‐serious, and withdrawals were not related to study treatment (see <a href="./appendices#CD013631-sec-0158">Appendix 5</a>). </p> <p>The studies in this comparison did not report data on our remaining primary and secondary outcomes. </p> </section> </section> </section> </section> </section> <section class="discussion"> <div class="section-header section-collapse-header" id="CD013631-sec-0142" lang="en"> <h2 class="title section-collapse-title"> Discussion <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="discussion" lang="en"> <div class="section-header" id="CD013631-sec-0142"></div> <section id="CD013631-sec-0143"> <h3 class="title" id="CD013631-sec-0143">Summary of main results</h3> <p>Forty‐five studies (2266 randomised participants) were included in this review. Study participants were predominantly adults (two studies included children) with CKD ranging from stages 1 to 5, with patients receiving and not receiving dialysis, of whom half also had diabetes and hypertension. </p> <p>No studies investigated the same synbiotic, prebiotic or probiotic of similar strains, doses, or frequencies. The risk of bias in the included studies varied between low, unclear or high risk across each of the domains. </p> <p> <ul id="CD013631-list-0030"> <li> <p>Synbiotics versus synbiotics: compared to synbiotics of a different dose, it is uncertain whether synbiotics improve HRQoL because the certainty of the evidence was very low. </p> </li> <li> <p>Synbiotics versus prebiotics: compared to prebiotics, it is uncertain whether synbiotics improve eGFR, SCr, urea, indoxyl sulfate, p‐cresyl sulfate, change in any GI upset or intolerance, microbiota composition, faecal characteristics, or HRQoL because the certainty of the evidence was very low. </p> </li> <li> <p>Prebiotics versus prebiotics: compared to prebiotics of a different dose, it is uncertain whether prebiotics improves eGFR, indoxyl sulfate, p‐cresyl sulfate, change in any GI upset or intolerance, microbiota composition, or faecal characteristics because the certainty of the evidence was very low. </p> </li> <li> <p>Prebiotics versus probiotics: compared to probiotics, it is uncertain whether prebiotics prevent peritonitis because the certainty of the evidence was very low. </p> </li> <li> <p>Probiotics versus probiotics: compared to probiotics of a different dose, it is uncertain whether probiotics improve eGFR, SCr, or urea because the certainty of the evidence was very low. </p> </li> <li> <p>Synbiotics versus placebo or no treatment: compared to placebo or no treatment, it is uncertain whether synbiotics improve eGFR, SCr, urea, or change in any GI upset or intolerance because the certainty of the evidence was very low. </p> </li> <li> <p>Prebiotics versus placebo or no treatment: compared to placebo or no treatment, it is uncertain whether prebiotics improve SCr, urea, indoxyl sulfate, p‐cresyl sulfate, or microbiota composition because the certainty of the evidence is very low. For SCr, a difference was identified across subgroups by CKD stage. Participants receiving placebo or no treatment showed an increase in SCr in patients with CKD stage A2 with diabetic nephropathy (70 participants) compared to CKD stage G5D (75 participants); however, heterogeneity was very high I² = 79% (P = 0.03). </p> </li> <li> <p>Probiotics versus placebo or no treatment: compared to placebo or no treatment, it is uncertain whether probiotics improve eGFR, proteinuria, indoxyl sulfate, p‐cresyl sulfate, indole‐3‐acetic acid, change in any GI upset or intolerance, or faecal characteristics because the certainty of the evidence is very low. For eGFR, a difference was identified across subgroups by CKD stage. Participants receiving placebo or no treatment showed decreased eGFR in patients with CKD stage 1 with type 2 diabetes mellitus (40 participants) compared to CKD stage 3A with diabetes and hypertension (28 participants) and CKD stage G5D with diabetes and hypertension (60 participants); however, heterogeneity was very high I² = 77.6% (P = 0.01). Probiotics may have little or no effect on SCr, albuminuria, or urea compared to placebo or no treatment, as the certainty of the evidence is low. </p> </li> </ul> </p> <p>For all comparisons, adverse events were poorly reported and were minimal (flatulence, nausea, diarrhoea, abdominal pain) and non‐serious, and withdrawals were not related to the study treatment. </p> </section> <section id="CD013631-sec-0144"> <h3 class="title" id="CD013631-sec-0144">Overall completeness and applicability of evidence</h3> <p>This review identified a substantial number of RCTs testing the efficacy of synbiotics, prebiotics or probiotics in people with CKD. However, the severe lack of congruence across the studies highlights the lack of high‐quality RCTs testing similar biotics, doses, strains, frequencies, and standardised outcomes. </p> <p>This field contains emerging trials of diverse and assorted interventions. No studies investigated the same synbiotic, prebiotic or probiotic of similar strains or doses. </p> <p>We have identified significant gaps in the evidence with the meta‐analyses undertaken containing limited data from small studies. It is critically important for this emerging field to conduct trials of alternative interventions in a standardised way to help better inform whether these agents favourably modify gut dysbiosis and its associated morbidity and QoL in people with CKD. </p> <p>The four major issues around the completeness of the evidence were:</p> <p> <ol id="CD013631-list-0031"> <li> <p>Limited sample size and insufficient power</p> </li> <li> <p>Standardised dosing of synbiotics, prebiotics or probiotics</p> </li> <li> <p>Standardised measuring</p> </li> <li> <p>Reporting of outcomes.</p> </li> </ol> </p> <p>The three major issues around the applicability of the evidence were:</p> <p> <ol id="CD013631-list-0032"> <li> <p>Participant criteria: the spread of patients across CKD stages 1 to 5, dialysis and non‐dialysis, diabetes, and hypertension </p> </li> <li> <p>Outcome measures varied greatly by definition of units, scale, and time points.</p> </li> <li> <p>Lack of patient‐important and patient‐centred outcomes.</p> </li> </ol> </p> </section> <section id="CD013631-sec-0145"> <h3 class="title" id="CD013631-sec-0145">Quality of the evidence</h3> <p>Overall, the quality of the evidence was low to very low. Studies were judged to have a spread of low to unclear to high risks of bias across most domains (<a href="#CD013631-fig-0002">Figure 2</a>). Of the available evidence, meta‐analyses undertaken were of limited data from small studies. Data were sparse and addressed few primary and secondary outcomes. </p> <p>Across all comparisons, GRADE evaluations were judged to be low or very low certainty evidence. This evidence was downgraded primarily due to the risk of bias and sparse data from small study sizes. The evidence was also downgraded to very low for single‐study data or incomplete or no data reported for an outcome. </p> <p>Very low certainty evidence implies that we are very uncertain about results (not estimable due to lack of data or poor quality). We have no evidence to support or refute the use of synbiotics, prebiotics, or probiotics in people with CKD, and findings should be viewed with caution. </p> </section> <section id="CD013631-sec-0146"> <h3 class="title" id="CD013631-sec-0146">Potential biases in the review process</h3> <p>This review was conducted as per the protocol following prespecified inclusion criteria and used comprehensive literature searches to find all relevant studies. We do not believe there are any other potential biases in this review process. </p> </section> <section id="CD013631-sec-0147"> <h3 class="title" id="CD013631-sec-0147">Agreements and disagreements with other studies or reviews</h3> <p>This review is the most up‐to‐date synthesis of the evidence that examines synbiotics, prebiotics, and probiotics in people with CKD. </p> <p>A recent systematic review has identified similar RCTs to those of an earlier search date (<a href="./references#CD013631-bbs2-0132" title="McFarlaneC , RamosCI , JohnsonDW , CampbellKL . Prebiotic, probiotic, and synbiotic supplementation in chronic kidney disease: a systematic review and meta-analysis. Journal of Renal Nutrition2019;9(3):209-20. [PMID: 30366767]">McFarlane 2019</a>). The included studies are similar, and the results of the meta‐analyses also found, from very low certainty evidence, that synbiotic, prebiotic or probiotic interventions made little or no difference to some uraemic toxins (urea, indoxyl sulfate, p‐cresyl sulfate). Similarly, the review concludes that further high‐quality, standardised trials are needed to develop answers within this emerging field. </p> <p>In contrast, <a href="./references#CD013631-bbs2-0139" title="ZhengJH , GuoJ , WangQ , WangL , WangY , ZhangF , et al. Probiotics, prebiotics, and synbiotics for the improvement of metabolic profiles in patients with chronic kidney disease: A systematic review and meta-analysis of randomized controlled trials. Critical Reviews in Food Science &amp; Nutrition2020;61(4):577–98. [PMID: 32329633]">Zheng 2020</a> and colleagues identified improvement in lipids, oxidative stress and inflammatory biomarkers from treatment with biotic supplementation. The meta‐analysis appears to have combined synbiotics, prebiotics and probiotics involving entirely different treatment options, doses and strains. Further to this, the included studies have been rated as mostly low risk of bias across the domains. Our review disagrees with this quality assessment. GRADE rating was also not used for assessing the certainty of the evidence. <a href="./references#CD013631-bbs2-0139" title="ZhengJH , GuoJ , WangQ , WangL , WangY , ZhangF , et al. Probiotics, prebiotics, and synbiotics for the improvement of metabolic profiles in patients with chronic kidney disease: A systematic review and meta-analysis of randomized controlled trials. Critical Reviews in Food Science &amp; Nutrition2020;61(4):577–98. [PMID: 32329633]">Zheng 2020</a> and colleagues may prematurely promote the use of biotic interventions in this population. </p> <p>A further two systematic reviews focus on patients receiving dialysis and conclude similar results. <a href="./references#CD013631-bbs2-0113" title="ChenC , WangJ , LiJ , ZhangW , OuS . Probiotics, prebiotics, and synbiotics for patients on dialysis: a systematic review and meta-analysis of randomized controlled trials. Journal of Renal Nutrition2023;33(1):129-39. [DOI: 35452837]">Chen 2022</a> and colleagues found from low‐quality evidence that supplementation with biotics may reduce some inflammatory biomarkers (C‐reactive protein, interleukin‐6), and uraemic toxins (indoxyl sulfate) and increase HDL in dialysis patients. <a href="./references#CD013631-bbs2-0131" title="MarchDS , JonesAW , BishopNC , BurtonJO . The efficacy of prebiotic, probiotic, and synbiotic supplementation in modulating gut-derived circulatory particles associated with cardiovascular disease in individuals receiving dialysis: a systematic review and meta-analysis of randomized controlled trials. Journal of Renal Nutrition2020;30(4):347-59. [PMID: 31607550]">March 2020</a> and colleagues have similarly reported that supplementation with biotics may reduce endotoxins, uraemic toxins (indoxyl‐sulphate, p‐cresyl sulfate), and reduced GI symptoms. However, the review correctly identifies that these were low‐quality, high‐risk of bias studies. </p> </section> </section> </section> <div class="figures-list"> <div class="figure" id="CD013631-fig-0001"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013631.pub2/media/CDSR/CD013631/urn:x-wiley:14651858:media:CD013631:CD013631-FIG-01" target="_blank"><b></b></a></p> </div><img alt="Study flow diagram." data-id="CD013631-fig-0001" src="/cdsr/doi/10.1002/14651858.CD013631.pub2/media/CDSR/CD013631/image_n/nCD013631-FIG-01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013631.pub2/media/CDSR/CD013631/image_t/tCD013631-FIG-01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 1</div> <div class="figure-caption"> <p>Study flow diagram.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013631.pub2/full#CD013631-fig-0001">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013631.pub2/media/CDSR/CD013631/image_n/nCD013631-FIG-01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013631-fig-0002"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013631.pub2/media/CDSR/CD013631/urn:x-wiley:14651858:media:CD013631:CD013631-FIG-02" target="_blank"><b></b></a></p> </div><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study." data-id="CD013631-fig-0002" src="/cdsr/doi/10.1002/14651858.CD013631.pub2/media/CDSR/CD013631/image_n/nCD013631-FIG-02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013631.pub2/media/CDSR/CD013631/image_t/tCD013631-FIG-02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 2</div> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013631.pub2/full#CD013631-fig-0002">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013631.pub2/media/CDSR/CD013631/image_n/nCD013631-FIG-02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013631-fig-0003"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013631.pub2/media/CDSR/CD013631/urn:x-wiley:14651858:media:CD013631:CD013631-CMP-001.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Synbiotic versus synbiotic, Outcome 1: Patient‐reported outcomes: HRQoL at 12 weeks" data-id="CD013631-fig-0003" src="/cdsr/doi/10.1002/14651858.CD013631.pub2/media/CDSR/CD013631/image_n/nCD013631-CMP-001.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013631.pub2/media/CDSR/CD013631/image_t/tCD013631-CMP-001.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.1</div> <div class="figure-caption"> <p>Comparison 1: Synbiotic versus synbiotic, Outcome 1: Patient‐reported outcomes: HRQoL at 12 weeks </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013631.pub2/references#CD013631-fig-0003">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013631.pub2/media/CDSR/CD013631/image_n/nCD013631-CMP-001.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013631-fig-0004"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013631.pub2/media/CDSR/CD013631/urn:x-wiley:14651858:media:CD013631:CD013631-CMP-002.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Synbiotic versus prebiotic, Outcome 1: Kidney function: eGFR at 4 weeks" data-id="CD013631-fig-0004" src="/cdsr/doi/10.1002/14651858.CD013631.pub2/media/CDSR/CD013631/image_n/nCD013631-CMP-002.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013631.pub2/media/CDSR/CD013631/image_t/tCD013631-CMP-002.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.1</div> <div class="figure-caption"> <p>Comparison 2: Synbiotic versus prebiotic, Outcome 1: Kidney function: eGFR at 4 weeks</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013631.pub2/references#CD013631-fig-0004">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013631.pub2/media/CDSR/CD013631/image_n/nCD013631-CMP-002.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013631-fig-0005"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013631.pub2/media/CDSR/CD013631/urn:x-wiley:14651858:media:CD013631:CD013631-CMP-002.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Synbiotic versus prebiotic, Outcome 2: Kidney function: serum creatinine at 8 weeks" data-id="CD013631-fig-0005" src="/cdsr/doi/10.1002/14651858.CD013631.pub2/media/CDSR/CD013631/image_n/nCD013631-CMP-002.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013631.pub2/media/CDSR/CD013631/image_t/tCD013631-CMP-002.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.2</div> <div class="figure-caption"> <p>Comparison 2: Synbiotic versus prebiotic, Outcome 2: Kidney function: serum creatinine at 8 weeks </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013631.pub2/references#CD013631-fig-0005">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013631.pub2/media/CDSR/CD013631/image_n/nCD013631-CMP-002.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013631-fig-0006"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013631.pub2/media/CDSR/CD013631/urn:x-wiley:14651858:media:CD013631:CD013631-CMP-002.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Synbiotic versus prebiotic, Outcome 3: Uraemic toxins: urea at 4 weeks" data-id="CD013631-fig-0006" src="/cdsr/doi/10.1002/14651858.CD013631.pub2/media/CDSR/CD013631/image_n/nCD013631-CMP-002.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013631.pub2/media/CDSR/CD013631/image_t/tCD013631-CMP-002.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.3</div> <div class="figure-caption"> <p>Comparison 2: Synbiotic versus prebiotic, Outcome 3: Uraemic toxins: urea at 4 weeks</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013631.pub2/references#CD013631-fig-0006">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013631.pub2/media/CDSR/CD013631/image_n/nCD013631-CMP-002.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013631-fig-0007"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013631.pub2/media/CDSR/CD013631/urn:x-wiley:14651858:media:CD013631:CD013631-CMP-002.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Synbiotic versus prebiotic, Outcome 4: Uraemic toxins: indoxyl sulfate at 4 weeks" data-id="CD013631-fig-0007" src="/cdsr/doi/10.1002/14651858.CD013631.pub2/media/CDSR/CD013631/image_n/nCD013631-CMP-002.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013631.pub2/media/CDSR/CD013631/image_t/tCD013631-CMP-002.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.4</div> <div class="figure-caption"> <p>Comparison 2: Synbiotic versus prebiotic, Outcome 4: Uraemic toxins: indoxyl sulfate at 4 weeks </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013631.pub2/references#CD013631-fig-0007">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013631.pub2/media/CDSR/CD013631/image_n/nCD013631-CMP-002.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013631-fig-0008"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013631.pub2/media/CDSR/CD013631/urn:x-wiley:14651858:media:CD013631:CD013631-CMP-002.05" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Synbiotic versus prebiotic, Outcome 5: Uraemic toxins: p‐cresol sulfate at 4 weeks" data-id="CD013631-fig-0008" src="/cdsr/doi/10.1002/14651858.CD013631.pub2/media/CDSR/CD013631/image_n/nCD013631-CMP-002.05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013631.pub2/media/CDSR/CD013631/image_t/tCD013631-CMP-002.05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.5</div> <div class="figure-caption"> <p>Comparison 2: Synbiotic versus prebiotic, Outcome 5: Uraemic toxins: p‐cresol sulfate at 4 weeks </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013631.pub2/references#CD013631-fig-0008">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013631.pub2/media/CDSR/CD013631/image_n/nCD013631-CMP-002.05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013631-fig-0009"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013631.pub2/media/CDSR/CD013631/urn:x-wiley:14651858:media:CD013631:CD013631-CMP-002.06" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Synbiotic versus prebiotic, Outcome 6: GI function: change in any GI upset or intolerance (prevalence of borborygmi) at 4 weeks" data-id="CD013631-fig-0009" src="/cdsr/doi/10.1002/14651858.CD013631.pub2/media/CDSR/CD013631/image_n/nCD013631-CMP-002.06.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013631.pub2/media/CDSR/CD013631/image_t/tCD013631-CMP-002.06.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.6</div> <div class="figure-caption"> <p>Comparison 2: Synbiotic versus prebiotic, Outcome 6: GI function: change in any GI upset or intolerance (prevalence of borborygmi) at 4 weeks </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013631.pub2/references#CD013631-fig-0009">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013631.pub2/media/CDSR/CD013631/image_n/nCD013631-CMP-002.06.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013631-fig-0010"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013631.pub2/media/CDSR/CD013631/urn:x-wiley:14651858:media:CD013631:CD013631-CMP-002.07" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Synbiotic versus prebiotic, Outcome 7: GI function: change in any GI upset or intolerance (GSRS Total Index at 12 months)" data-id="CD013631-fig-0010" src="/cdsr/doi/10.1002/14651858.CD013631.pub2/media/CDSR/CD013631/image_n/nCD013631-CMP-002.07.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013631.pub2/media/CDSR/CD013631/image_t/tCD013631-CMP-002.07.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.7</div> <div class="figure-caption"> <p>Comparison 2: Synbiotic versus prebiotic, Outcome 7: GI function: change in any GI upset or intolerance (GSRS Total Index at 12 months) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013631.pub2/references#CD013631-fig-0010">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013631.pub2/media/CDSR/CD013631/image_n/nCD013631-CMP-002.07.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013631-fig-0011"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013631.pub2/media/CDSR/CD013631/urn:x-wiley:14651858:media:CD013631:CD013631-CMP-002.08" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Synbiotic versus prebiotic, Outcome 8: GI function: faecal pH at 7 weeks" data-id="CD013631-fig-0011" src="/cdsr/doi/10.1002/14651858.CD013631.pub2/media/CDSR/CD013631/image_n/nCD013631-CMP-002.08.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013631.pub2/media/CDSR/CD013631/image_t/tCD013631-CMP-002.08.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.8</div> <div class="figure-caption"> <p>Comparison 2: Synbiotic versus prebiotic, Outcome 8: GI function: faecal pH at 7 weeks</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013631.pub2/references#CD013631-fig-0011">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013631.pub2/media/CDSR/CD013631/image_n/nCD013631-CMP-002.08.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013631-fig-0012"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013631.pub2/media/CDSR/CD013631/urn:x-wiley:14651858:media:CD013631:CD013631-CMP-002.09" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Synbiotic versus prebiotic, Outcome 9: GI function: faecal characteristics (Bristol Stool Chart) at 4 weeks" data-id="CD013631-fig-0012" src="/cdsr/doi/10.1002/14651858.CD013631.pub2/media/CDSR/CD013631/image_n/nCD013631-CMP-002.09.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013631.pub2/media/CDSR/CD013631/image_t/tCD013631-CMP-002.09.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.9</div> <div class="figure-caption"> <p>Comparison 2: Synbiotic versus prebiotic, Outcome 9: GI function: faecal characteristics (Bristol Stool Chart) at 4 weeks </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013631.pub2/references#CD013631-fig-0012">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013631.pub2/media/CDSR/CD013631/image_n/nCD013631-CMP-002.09.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013631-fig-0013"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013631.pub2/media/CDSR/CD013631/urn:x-wiley:14651858:media:CD013631:CD013631-CMP-002.10" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Synbiotic versus prebiotic, Outcome 10: GI function: faecal characteristics (Bristol Stool Chart) at 12 months" data-id="CD013631-fig-0013" src="/cdsr/doi/10.1002/14651858.CD013631.pub2/media/CDSR/CD013631/image_n/nCD013631-CMP-002.10.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013631.pub2/media/CDSR/CD013631/image_t/tCD013631-CMP-002.10.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.10</div> <div class="figure-caption"> <p>Comparison 2: Synbiotic versus prebiotic, Outcome 10: GI function: faecal characteristics (Bristol Stool Chart) at 12 months </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013631.pub2/references#CD013631-fig-0013">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013631.pub2/media/CDSR/CD013631/image_n/nCD013631-CMP-002.10.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013631-fig-0014"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013631.pub2/media/CDSR/CD013631/urn:x-wiley:14651858:media:CD013631:CD013631-CMP-002.11" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Synbiotic versus prebiotic, Outcome 11: Patient‐reported outcomes: HRQoL at 24 weeks" data-id="CD013631-fig-0014" src="/cdsr/doi/10.1002/14651858.CD013631.pub2/media/CDSR/CD013631/image_n/nCD013631-CMP-002.11.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013631.pub2/media/CDSR/CD013631/image_t/tCD013631-CMP-002.11.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.11</div> <div class="figure-caption"> <p>Comparison 2: Synbiotic versus prebiotic, Outcome 11: Patient‐reported outcomes: HRQoL at 24 weeks </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013631.pub2/references#CD013631-fig-0014">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013631.pub2/media/CDSR/CD013631/image_n/nCD013631-CMP-002.11.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013631-fig-0015"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013631.pub2/media/CDSR/CD013631/urn:x-wiley:14651858:media:CD013631:CD013631-CMP-002.12" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Synbiotic versus prebiotic, Outcome 12: Adverse events: any adverse event" data-id="CD013631-fig-0015" src="/cdsr/doi/10.1002/14651858.CD013631.pub2/media/CDSR/CD013631/image_n/nCD013631-CMP-002.12.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013631.pub2/media/CDSR/CD013631/image_t/tCD013631-CMP-002.12.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.12</div> <div class="figure-caption"> <p>Comparison 2: Synbiotic versus prebiotic, Outcome 12: Adverse events: any adverse event </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013631.pub2/references#CD013631-fig-0015">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013631.pub2/media/CDSR/CD013631/image_n/nCD013631-CMP-002.12.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013631-fig-0016"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013631.pub2/media/CDSR/CD013631/urn:x-wiley:14651858:media:CD013631:CD013631-CMP-002.13" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Synbiotic versus prebiotic, Outcome 13: Withdrawals due to adverse events" data-id="CD013631-fig-0016" src="/cdsr/doi/10.1002/14651858.CD013631.pub2/media/CDSR/CD013631/image_n/nCD013631-CMP-002.13.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013631.pub2/media/CDSR/CD013631/image_t/tCD013631-CMP-002.13.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.13</div> <div class="figure-caption"> <p>Comparison 2: Synbiotic versus prebiotic, Outcome 13: Withdrawals due to adverse events</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013631.pub2/references#CD013631-fig-0016">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013631.pub2/media/CDSR/CD013631/image_n/nCD013631-CMP-002.13.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013631-fig-0017"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013631.pub2/media/CDSR/CD013631/urn:x-wiley:14651858:media:CD013631:CD013631-CMP-003.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Prebiotic versus prebiotic, Outcome 1: Kidney function: eGFR at 12 weeks" data-id="CD013631-fig-0017" src="/cdsr/doi/10.1002/14651858.CD013631.pub2/media/CDSR/CD013631/image_n/nCD013631-CMP-003.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013631.pub2/media/CDSR/CD013631/image_t/tCD013631-CMP-003.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.1</div> <div class="figure-caption"> <p>Comparison 3: Prebiotic versus prebiotic, Outcome 1: Kidney function: eGFR at 12 weeks</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013631.pub2/references#CD013631-fig-0017">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013631.pub2/media/CDSR/CD013631/image_n/nCD013631-CMP-003.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013631-fig-0018"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013631.pub2/media/CDSR/CD013631/urn:x-wiley:14651858:media:CD013631:CD013631-CMP-003.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Prebiotic versus prebiotic, Outcome 2: Uraemic toxins: indoxyl sulfate at 6 weeks" data-id="CD013631-fig-0018" src="/cdsr/doi/10.1002/14651858.CD013631.pub2/media/CDSR/CD013631/image_n/nCD013631-CMP-003.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013631.pub2/media/CDSR/CD013631/image_t/tCD013631-CMP-003.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.2</div> <div class="figure-caption"> <p>Comparison 3: Prebiotic versus prebiotic, Outcome 2: Uraemic toxins: indoxyl sulfate at 6 weeks </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013631.pub2/references#CD013631-fig-0018">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013631.pub2/media/CDSR/CD013631/image_n/nCD013631-CMP-003.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013631-fig-0019"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013631.pub2/media/CDSR/CD013631/urn:x-wiley:14651858:media:CD013631:CD013631-CMP-003.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Prebiotic versus prebiotic, Outcome 3: Uraemic toxins: p‐cresol sulfate at 6 weeks" data-id="CD013631-fig-0019" src="/cdsr/doi/10.1002/14651858.CD013631.pub2/media/CDSR/CD013631/image_n/nCD013631-CMP-003.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013631.pub2/media/CDSR/CD013631/image_t/tCD013631-CMP-003.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.3</div> <div class="figure-caption"> <p>Comparison 3: Prebiotic versus prebiotic, Outcome 3: Uraemic toxins: p‐cresol sulfate at 6 weeks </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013631.pub2/references#CD013631-fig-0019">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013631.pub2/media/CDSR/CD013631/image_n/nCD013631-CMP-003.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013631-fig-0020"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013631.pub2/media/CDSR/CD013631/urn:x-wiley:14651858:media:CD013631:CD013631-CMP-003.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Prebiotic versus prebiotic, Outcome 4: GI function: change in any GI upset or intolerance (burping) at 4 weeks" data-id="CD013631-fig-0020" src="/cdsr/doi/10.1002/14651858.CD013631.pub2/media/CDSR/CD013631/image_n/nCD013631-CMP-003.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013631.pub2/media/CDSR/CD013631/image_t/tCD013631-CMP-003.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.4</div> <div class="figure-caption"> <p>Comparison 3: Prebiotic versus prebiotic, Outcome 4: GI function: change in any GI upset or intolerance (burping) at 4 weeks </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013631.pub2/references#CD013631-fig-0020">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013631.pub2/media/CDSR/CD013631/image_n/nCD013631-CMP-003.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013631-fig-0021"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013631.pub2/media/CDSR/CD013631/urn:x-wiley:14651858:media:CD013631:CD013631-CMP-003.05" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Prebiotic versus prebiotic, Outcome 5: GI function: change in any GI upset or intolerance (cramping) at 4 weeks" data-id="CD013631-fig-0021" src="/cdsr/doi/10.1002/14651858.CD013631.pub2/media/CDSR/CD013631/image_n/nCD013631-CMP-003.05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013631.pub2/media/CDSR/CD013631/image_t/tCD013631-CMP-003.05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.5</div> <div class="figure-caption"> <p>Comparison 3: Prebiotic versus prebiotic, Outcome 5: GI function: change in any GI upset or intolerance (cramping) at 4 weeks </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013631.pub2/references#CD013631-fig-0021">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013631.pub2/media/CDSR/CD013631/image_n/nCD013631-CMP-003.05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013631-fig-0022"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013631.pub2/media/CDSR/CD013631/urn:x-wiley:14651858:media:CD013631:CD013631-CMP-003.06" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Prebiotic versus prebiotic, Outcome 6: GI function: change in any GI upset or intolerance (distension) at 4 weeks" data-id="CD013631-fig-0022" src="/cdsr/doi/10.1002/14651858.CD013631.pub2/media/CDSR/CD013631/image_n/nCD013631-CMP-003.06.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013631.pub2/media/CDSR/CD013631/image_t/tCD013631-CMP-003.06.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.6</div> <div class="figure-caption"> <p>Comparison 3: Prebiotic versus prebiotic, Outcome 6: GI function: change in any GI upset or intolerance (distension) at 4 weeks </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013631.pub2/references#CD013631-fig-0022">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013631.pub2/media/CDSR/CD013631/image_n/nCD013631-CMP-003.06.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013631-fig-0023"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013631.pub2/media/CDSR/CD013631/urn:x-wiley:14651858:media:CD013631:CD013631-CMP-003.07" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Prebiotic versus prebiotic, Outcome 7: GI function: change in any GI upset or intolerance (flatulence) at 4 weeks" data-id="CD013631-fig-0023" src="/cdsr/doi/10.1002/14651858.CD013631.pub2/media/CDSR/CD013631/image_n/nCD013631-CMP-003.07.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013631.pub2/media/CDSR/CD013631/image_t/tCD013631-CMP-003.07.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.7</div> <div class="figure-caption"> <p>Comparison 3: Prebiotic versus prebiotic, Outcome 7: GI function: change in any GI upset or intolerance (flatulence) at 4 weeks </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013631.pub2/references#CD013631-fig-0023">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013631.pub2/media/CDSR/CD013631/image_n/nCD013631-CMP-003.07.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013631-fig-0024"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013631.pub2/media/CDSR/CD013631/urn:x-wiley:14651858:media:CD013631:CD013631-CMP-003.08" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Prebiotic versus prebiotic, Outcome 8: GI function: change in any GI upset or intolerance (nausea) at 4 weeks" data-id="CD013631-fig-0024" src="/cdsr/doi/10.1002/14651858.CD013631.pub2/media/CDSR/CD013631/image_n/nCD013631-CMP-003.08.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013631.pub2/media/CDSR/CD013631/image_t/tCD013631-CMP-003.08.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.8</div> <div class="figure-caption"> <p>Comparison 3: Prebiotic versus prebiotic, Outcome 8: GI function: change in any GI upset or intolerance (nausea) at 4 weeks </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013631.pub2/references#CD013631-fig-0024">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013631.pub2/media/CDSR/CD013631/image_n/nCD013631-CMP-003.08.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013631-fig-0025"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013631.pub2/media/CDSR/CD013631/urn:x-wiley:14651858:media:CD013631:CD013631-CMP-003.09" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Prebiotic versus prebiotic, Outcome 9: GI function: change in any GI upset or intolerance (reflux) at 4 weeks" data-id="CD013631-fig-0025" src="/cdsr/doi/10.1002/14651858.CD013631.pub2/media/CDSR/CD013631/image_n/nCD013631-CMP-003.09.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013631.pub2/media/CDSR/CD013631/image_t/tCD013631-CMP-003.09.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.9</div> <div class="figure-caption"> <p>Comparison 3: Prebiotic versus prebiotic, Outcome 9: GI function: change in any GI upset or intolerance (reflux) at 4 weeks </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013631.pub2/references#CD013631-fig-0025">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013631.pub2/media/CDSR/CD013631/image_n/nCD013631-CMP-003.09.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013631-fig-0026"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013631.pub2/media/CDSR/CD013631/urn:x-wiley:14651858:media:CD013631:CD013631-CMP-003.10" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Prebiotic versus prebiotic, Outcome 10: GI function: change in any GI upset or intolerance (rumblings) at 4 weeks" data-id="CD013631-fig-0026" src="/cdsr/doi/10.1002/14651858.CD013631.pub2/media/CDSR/CD013631/image_n/nCD013631-CMP-003.10.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013631.pub2/media/CDSR/CD013631/image_t/tCD013631-CMP-003.10.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.10</div> <div class="figure-caption"> <p>Comparison 3: Prebiotic versus prebiotic, Outcome 10: GI function: change in any GI upset or intolerance (rumblings) at 4 weeks </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013631.pub2/references#CD013631-fig-0026">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013631.pub2/media/CDSR/CD013631/image_n/nCD013631-CMP-003.10.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013631-fig-0027"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013631.pub2/media/CDSR/CD013631/urn:x-wiley:14651858:media:CD013631:CD013631-CMP-003.11" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Prebiotic versus prebiotic, Outcome 11: GI function: microbiota composition (Actinobacteria) at 4 weeks" data-id="CD013631-fig-0027" src="/cdsr/doi/10.1002/14651858.CD013631.pub2/media/CDSR/CD013631/image_n/nCD013631-CMP-003.11.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013631.pub2/media/CDSR/CD013631/image_t/tCD013631-CMP-003.11.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.11</div> <div class="figure-caption"> <p>Comparison 3: Prebiotic versus prebiotic, Outcome 11: GI function: microbiota composition (Actinobacteria) at 4 weeks </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013631.pub2/references#CD013631-fig-0027">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013631.pub2/media/CDSR/CD013631/image_n/nCD013631-CMP-003.11.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013631-fig-0028"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013631.pub2/media/CDSR/CD013631/urn:x-wiley:14651858:media:CD013631:CD013631-CMP-003.12" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Prebiotic versus prebiotic, Outcome 12: GI function: microbiota composition (Bacteriodetes) at 4 weeks" data-id="CD013631-fig-0028" src="/cdsr/doi/10.1002/14651858.CD013631.pub2/media/CDSR/CD013631/image_n/nCD013631-CMP-003.12.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013631.pub2/media/CDSR/CD013631/image_t/tCD013631-CMP-003.12.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.12</div> <div class="figure-caption"> <p>Comparison 3: Prebiotic versus prebiotic, Outcome 12: GI function: microbiota composition (Bacteriodetes) at 4 weeks </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013631.pub2/references#CD013631-fig-0028">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013631.pub2/media/CDSR/CD013631/image_n/nCD013631-CMP-003.12.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013631-fig-0029"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013631.pub2/media/CDSR/CD013631/urn:x-wiley:14651858:media:CD013631:CD013631-CMP-003.13" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Prebiotic versus prebiotic, Outcome 13: GI function: microbiota composition (Proteobacteria) at 4 weeks" data-id="CD013631-fig-0029" src="/cdsr/doi/10.1002/14651858.CD013631.pub2/media/CDSR/CD013631/image_n/nCD013631-CMP-003.13.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013631.pub2/media/CDSR/CD013631/image_t/tCD013631-CMP-003.13.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.13</div> <div class="figure-caption"> <p>Comparison 3: Prebiotic versus prebiotic, Outcome 13: GI function: microbiota composition (Proteobacteria) at 4 weeks </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013631.pub2/references#CD013631-fig-0029">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013631.pub2/media/CDSR/CD013631/image_n/nCD013631-CMP-003.13.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013631-fig-0030"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013631.pub2/media/CDSR/CD013631/urn:x-wiley:14651858:media:CD013631:CD013631-CMP-003.14" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Prebiotic versus prebiotic, Outcome 14: GI function: microbiota composition (Firmicutes) at 4 weeks" data-id="CD013631-fig-0030" src="/cdsr/doi/10.1002/14651858.CD013631.pub2/media/CDSR/CD013631/image_n/nCD013631-CMP-003.14.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013631.pub2/media/CDSR/CD013631/image_t/tCD013631-CMP-003.14.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.14</div> <div class="figure-caption"> <p>Comparison 3: Prebiotic versus prebiotic, Outcome 14: GI function: microbiota composition (Firmicutes) at 4 weeks </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013631.pub2/references#CD013631-fig-0030">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013631.pub2/media/CDSR/CD013631/image_n/nCD013631-CMP-003.14.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013631-fig-0031"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013631.pub2/media/CDSR/CD013631/urn:x-wiley:14651858:media:CD013631:CD013631-CMP-003.15" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Prebiotic versus prebiotic, Outcome 15: GI function: microbiota composition (Synergistetes) at 4 weeks" data-id="CD013631-fig-0031" src="/cdsr/doi/10.1002/14651858.CD013631.pub2/media/CDSR/CD013631/image_n/nCD013631-CMP-003.15.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013631.pub2/media/CDSR/CD013631/image_t/tCD013631-CMP-003.15.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.15</div> <div class="figure-caption"> <p>Comparison 3: Prebiotic versus prebiotic, Outcome 15: GI function: microbiota composition (Synergistetes) at 4 weeks </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013631.pub2/references#CD013631-fig-0031">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013631.pub2/media/CDSR/CD013631/image_n/nCD013631-CMP-003.15.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013631-fig-0032"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013631.pub2/media/CDSR/CD013631/urn:x-wiley:14651858:media:CD013631:CD013631-CMP-003.16" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Prebiotic versus prebiotic, Outcome 16: GI function: microbiota composition (Verrucomicrobia) at 4 weeks" data-id="CD013631-fig-0032" src="/cdsr/doi/10.1002/14651858.CD013631.pub2/media/CDSR/CD013631/image_n/nCD013631-CMP-003.16.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013631.pub2/media/CDSR/CD013631/image_t/tCD013631-CMP-003.16.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.16</div> <div class="figure-caption"> <p>Comparison 3: Prebiotic versus prebiotic, Outcome 16: GI function: microbiota composition (Verrucomicrobia) at 4 weeks </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013631.pub2/references#CD013631-fig-0032">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013631.pub2/media/CDSR/CD013631/image_n/nCD013631-CMP-003.16.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013631-fig-0033"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013631.pub2/media/CDSR/CD013631/urn:x-wiley:14651858:media:CD013631:CD013631-CMP-003.17" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Prebiotic versus prebiotic, Outcome 17: GI function: microbiota composition (faecal acetate) at 4 weeks" data-id="CD013631-fig-0033" src="/cdsr/doi/10.1002/14651858.CD013631.pub2/media/CDSR/CD013631/image_n/nCD013631-CMP-003.17.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013631.pub2/media/CDSR/CD013631/image_t/tCD013631-CMP-003.17.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.17</div> <div class="figure-caption"> <p>Comparison 3: Prebiotic versus prebiotic, Outcome 17: GI function: microbiota composition (faecal acetate) at 4 weeks </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013631.pub2/references#CD013631-fig-0033">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013631.pub2/media/CDSR/CD013631/image_n/nCD013631-CMP-003.17.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013631-fig-0034"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013631.pub2/media/CDSR/CD013631/urn:x-wiley:14651858:media:CD013631:CD013631-CMP-003.18" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Prebiotic versus prebiotic, Outcome 18: GI function: microbiota composition (faecal propionate) at 4 weeks" data-id="CD013631-fig-0034" src="/cdsr/doi/10.1002/14651858.CD013631.pub2/media/CDSR/CD013631/image_n/nCD013631-CMP-003.18.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013631.pub2/media/CDSR/CD013631/image_t/tCD013631-CMP-003.18.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.18</div> <div class="figure-caption"> <p>Comparison 3: Prebiotic versus prebiotic, Outcome 18: GI function: microbiota composition (faecal propionate) at 4 weeks </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013631.pub2/references#CD013631-fig-0034">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013631.pub2/media/CDSR/CD013631/image_n/nCD013631-CMP-003.18.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013631-fig-0035"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013631.pub2/media/CDSR/CD013631/urn:x-wiley:14651858:media:CD013631:CD013631-CMP-003.19" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Prebiotic versus prebiotic, Outcome 19: GI function: microbiota composition (faecal butyrate) at 4 weeks" data-id="CD013631-fig-0035" src="/cdsr/doi/10.1002/14651858.CD013631.pub2/media/CDSR/CD013631/image_n/nCD013631-CMP-003.19.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013631.pub2/media/CDSR/CD013631/image_t/tCD013631-CMP-003.19.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.19</div> <div class="figure-caption"> <p>Comparison 3: Prebiotic versus prebiotic, Outcome 19: GI function: microbiota composition (faecal butyrate) at 4 weeks </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013631.pub2/references#CD013631-fig-0035">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013631.pub2/media/CDSR/CD013631/image_n/nCD013631-CMP-003.19.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013631-fig-0036"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013631.pub2/media/CDSR/CD013631/urn:x-wiley:14651858:media:CD013631:CD013631-CMP-003.20" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Prebiotic versus prebiotic, Outcome 20: GI function: microbiota composition (faecal total short‐chain fatty acids) at 4 weeks" data-id="CD013631-fig-0036" src="/cdsr/doi/10.1002/14651858.CD013631.pub2/media/CDSR/CD013631/image_n/nCD013631-CMP-003.20.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013631.pub2/media/CDSR/CD013631/image_t/tCD013631-CMP-003.20.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.20</div> <div class="figure-caption"> <p>Comparison 3: Prebiotic versus prebiotic, Outcome 20: GI function: microbiota composition (faecal total short‐chain fatty acids) at 4 weeks </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013631.pub2/references#CD013631-fig-0036">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013631.pub2/media/CDSR/CD013631/image_n/nCD013631-CMP-003.20.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013631-fig-0037"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013631.pub2/media/CDSR/CD013631/urn:x-wiley:14651858:media:CD013631:CD013631-CMP-003.21" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Prebiotic versus prebiotic, Outcome 21: GI function: microbiota composition (faecal indoles) at 4 weeks" data-id="CD013631-fig-0037" src="/cdsr/doi/10.1002/14651858.CD013631.pub2/media/CDSR/CD013631/image_n/nCD013631-CMP-003.21.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013631.pub2/media/CDSR/CD013631/image_t/tCD013631-CMP-003.21.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.21</div> <div class="figure-caption"> <p>Comparison 3: Prebiotic versus prebiotic, Outcome 21: GI function: microbiota composition (faecal indoles) at 4 weeks </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013631.pub2/references#CD013631-fig-0037">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013631.pub2/media/CDSR/CD013631/image_n/nCD013631-CMP-003.21.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013631-fig-0038"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013631.pub2/media/CDSR/CD013631/urn:x-wiley:14651858:media:CD013631:CD013631-CMP-003.22" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Prebiotic versus prebiotic, Outcome 22: GI function: microbiota composition (faecal p‐cresol) at 4 weeks" data-id="CD013631-fig-0038" src="/cdsr/doi/10.1002/14651858.CD013631.pub2/media/CDSR/CD013631/image_n/nCD013631-CMP-003.22.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013631.pub2/media/CDSR/CD013631/image_t/tCD013631-CMP-003.22.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.22</div> <div class="figure-caption"> <p>Comparison 3: Prebiotic versus prebiotic, Outcome 22: GI function: microbiota composition (faecal p‐cresol) at 4 weeks </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013631.pub2/references#CD013631-fig-0038">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013631.pub2/media/CDSR/CD013631/image_n/nCD013631-CMP-003.22.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013631-fig-0039"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013631.pub2/media/CDSR/CD013631/urn:x-wiley:14651858:media:CD013631:CD013631-CMP-003.23" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Prebiotic versus prebiotic, Outcome 23: GI function: faecal characteristics (bowel movements) at 4 weeks" data-id="CD013631-fig-0039" src="/cdsr/doi/10.1002/14651858.CD013631.pub2/media/CDSR/CD013631/image_n/nCD013631-CMP-003.23.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013631.pub2/media/CDSR/CD013631/image_t/tCD013631-CMP-003.23.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.23</div> <div class="figure-caption"> <p>Comparison 3: Prebiotic versus prebiotic, Outcome 23: GI function: faecal characteristics (bowel movements) at 4 weeks </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013631.pub2/references#CD013631-fig-0039">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013631.pub2/media/CDSR/CD013631/image_n/nCD013631-CMP-003.23.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013631-fig-0040"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013631.pub2/media/CDSR/CD013631/urn:x-wiley:14651858:media:CD013631:CD013631-CMP-003.24" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Prebiotic versus prebiotic, Outcome 24: GI function: faecal characteristics (ease of passage) at 4 weeks" data-id="CD013631-fig-0040" src="/cdsr/doi/10.1002/14651858.CD013631.pub2/media/CDSR/CD013631/image_n/nCD013631-CMP-003.24.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013631.pub2/media/CDSR/CD013631/image_t/tCD013631-CMP-003.24.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.24</div> <div class="figure-caption"> <p>Comparison 3: Prebiotic versus prebiotic, Outcome 24: GI function: faecal characteristics (ease of passage) at 4 weeks </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013631.pub2/references#CD013631-fig-0040">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013631.pub2/media/CDSR/CD013631/image_n/nCD013631-CMP-003.24.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013631-fig-0041"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013631.pub2/media/CDSR/CD013631/urn:x-wiley:14651858:media:CD013631:CD013631-CMP-003.25" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Prebiotic versus prebiotic, Outcome 25: GI function: faecal characteristics (consistency) at 4 weeks" data-id="CD013631-fig-0041" src="/cdsr/doi/10.1002/14651858.CD013631.pub2/media/CDSR/CD013631/image_n/nCD013631-CMP-003.25.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013631.pub2/media/CDSR/CD013631/image_t/tCD013631-CMP-003.25.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.25</div> <div class="figure-caption"> <p>Comparison 3: Prebiotic versus prebiotic, Outcome 25: GI function: faecal characteristics (consistency) at 4 weeks </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013631.pub2/references#CD013631-fig-0041">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013631.pub2/media/CDSR/CD013631/image_n/nCD013631-CMP-003.25.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013631-fig-0042"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013631.pub2/media/CDSR/CD013631/urn:x-wiley:14651858:media:CD013631:CD013631-CMP-003.26" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Prebiotic versus prebiotic, Outcome 26: Adverse events: number participants reporting an event" data-id="CD013631-fig-0042" src="/cdsr/doi/10.1002/14651858.CD013631.pub2/media/CDSR/CD013631/image_n/nCD013631-CMP-003.26.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013631.pub2/media/CDSR/CD013631/image_t/tCD013631-CMP-003.26.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.26</div> <div class="figure-caption"> <p>Comparison 3: Prebiotic versus prebiotic, Outcome 26: Adverse events: number participants reporting an event </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013631.pub2/references#CD013631-fig-0042">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013631.pub2/media/CDSR/CD013631/image_n/nCD013631-CMP-003.26.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013631-fig-0043"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013631.pub2/media/CDSR/CD013631/urn:x-wiley:14651858:media:CD013631:CD013631-CMP-003.27" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Prebiotic versus prebiotic, Outcome 27: Withdrawals due to adverse events" data-id="CD013631-fig-0043" src="/cdsr/doi/10.1002/14651858.CD013631.pub2/media/CDSR/CD013631/image_n/nCD013631-CMP-003.27.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013631.pub2/media/CDSR/CD013631/image_t/tCD013631-CMP-003.27.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.27</div> <div class="figure-caption"> <p>Comparison 3: Prebiotic versus prebiotic, Outcome 27: Withdrawals due to adverse events</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013631.pub2/references#CD013631-fig-0043">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013631.pub2/media/CDSR/CD013631/image_n/nCD013631-CMP-003.27.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013631-fig-0044"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013631.pub2/media/CDSR/CD013631/urn:x-wiley:14651858:media:CD013631:CD013631-CMP-004.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 4: Prebiotic versus probiotic, Outcome 1: Dialysis outcomes: peritonitis at 24 weeks" data-id="CD013631-fig-0044" src="/cdsr/doi/10.1002/14651858.CD013631.pub2/media/CDSR/CD013631/image_n/nCD013631-CMP-004.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013631.pub2/media/CDSR/CD013631/image_t/tCD013631-CMP-004.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.1</div> <div class="figure-caption"> <p>Comparison 4: Prebiotic versus probiotic, Outcome 1: Dialysis outcomes: peritonitis at 24 weeks </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013631.pub2/references#CD013631-fig-0044">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013631.pub2/media/CDSR/CD013631/image_n/nCD013631-CMP-004.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013631-fig-0045"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013631.pub2/media/CDSR/CD013631/urn:x-wiley:14651858:media:CD013631:CD013631-CMP-005.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 5: Low versus high dose probiotic, Outcome 1: Kidney function: GFR at 8 weeks" data-id="CD013631-fig-0045" src="/cdsr/doi/10.1002/14651858.CD013631.pub2/media/CDSR/CD013631/image_n/nCD013631-CMP-005.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013631.pub2/media/CDSR/CD013631/image_t/tCD013631-CMP-005.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.1</div> <div class="figure-caption"> <p>Comparison 5: Low versus high dose probiotic, Outcome 1: Kidney function: GFR at 8 weeks </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013631.pub2/references#CD013631-fig-0045">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013631.pub2/media/CDSR/CD013631/image_n/nCD013631-CMP-005.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013631-fig-0046"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013631.pub2/media/CDSR/CD013631/urn:x-wiley:14651858:media:CD013631:CD013631-CMP-005.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 5: Low versus high dose probiotic, Outcome 2: Kidney function: serum creatinine at 8 weeks" data-id="CD013631-fig-0046" src="/cdsr/doi/10.1002/14651858.CD013631.pub2/media/CDSR/CD013631/image_n/nCD013631-CMP-005.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013631.pub2/media/CDSR/CD013631/image_t/tCD013631-CMP-005.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.2</div> <div class="figure-caption"> <p>Comparison 5: Low versus high dose probiotic, Outcome 2: Kidney function: serum creatinine at 8 weeks </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013631.pub2/references#CD013631-fig-0046">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013631.pub2/media/CDSR/CD013631/image_n/nCD013631-CMP-005.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013631-fig-0047"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013631.pub2/media/CDSR/CD013631/urn:x-wiley:14651858:media:CD013631:CD013631-CMP-005.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 5: Low versus high dose probiotic, Outcome 3: Uraemic toxins: urea at 8 weeks" data-id="CD013631-fig-0047" src="/cdsr/doi/10.1002/14651858.CD013631.pub2/media/CDSR/CD013631/image_n/nCD013631-CMP-005.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013631.pub2/media/CDSR/CD013631/image_t/tCD013631-CMP-005.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.3</div> <div class="figure-caption"> <p>Comparison 5: Low versus high dose probiotic, Outcome 3: Uraemic toxins: urea at 8 weeks </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013631.pub2/references#CD013631-fig-0047">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013631.pub2/media/CDSR/CD013631/image_n/nCD013631-CMP-005.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013631-fig-0048"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013631.pub2/media/CDSR/CD013631/urn:x-wiley:14651858:media:CD013631:CD013631-CMP-006.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 6: Synbiotic versus placebo, Outcome 1: Kidney function: eGFR at 6 or 12 weeks" data-id="CD013631-fig-0048" src="/cdsr/doi/10.1002/14651858.CD013631.pub2/media/CDSR/CD013631/image_n/nCD013631-CMP-006.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013631.pub2/media/CDSR/CD013631/image_t/tCD013631-CMP-006.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.1</div> <div class="figure-caption"> <p>Comparison 6: Synbiotic versus placebo, Outcome 1: Kidney function: eGFR at 6 or 12 weeks </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013631.pub2/references#CD013631-fig-0048">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013631.pub2/media/CDSR/CD013631/image_n/nCD013631-CMP-006.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013631-fig-0049"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013631.pub2/media/CDSR/CD013631/urn:x-wiley:14651858:media:CD013631:CD013631-CMP-006.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 6: Synbiotic versus placebo, Outcome 2: Kidney function: SrCr at 6 or 12 weeks" data-id="CD013631-fig-0049" src="/cdsr/doi/10.1002/14651858.CD013631.pub2/media/CDSR/CD013631/image_n/nCD013631-CMP-006.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013631.pub2/media/CDSR/CD013631/image_t/tCD013631-CMP-006.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.2</div> <div class="figure-caption"> <p>Comparison 6: Synbiotic versus placebo, Outcome 2: Kidney function: SrCr at 6 or 12 weeks </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013631.pub2/references#CD013631-fig-0049">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013631.pub2/media/CDSR/CD013631/image_n/nCD013631-CMP-006.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013631-fig-0050"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013631.pub2/media/CDSR/CD013631/urn:x-wiley:14651858:media:CD013631:CD013631-CMP-006.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 6: Synbiotic versus placebo, Outcome 3: Uraemic toxins: urea at 6 or 12 weeks" data-id="CD013631-fig-0050" src="/cdsr/doi/10.1002/14651858.CD013631.pub2/media/CDSR/CD013631/image_n/nCD013631-CMP-006.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013631.pub2/media/CDSR/CD013631/image_t/tCD013631-CMP-006.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.3</div> <div class="figure-caption"> <p>Comparison 6: Synbiotic versus placebo, Outcome 3: Uraemic toxins: urea at 6 or 12 weeks </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013631.pub2/references#CD013631-fig-0050">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013631.pub2/media/CDSR/CD013631/image_n/nCD013631-CMP-006.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013631-fig-0051"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013631.pub2/media/CDSR/CD013631/urn:x-wiley:14651858:media:CD013631:CD013631-CMP-006.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 6: Synbiotic versus placebo, Outcome 4: GI function: GSRS Item 6 (rumbling) at 12 weeks" data-id="CD013631-fig-0051" src="/cdsr/doi/10.1002/14651858.CD013631.pub2/media/CDSR/CD013631/image_n/nCD013631-CMP-006.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013631.pub2/media/CDSR/CD013631/image_t/tCD013631-CMP-006.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.4</div> <div class="figure-caption"> <p>Comparison 6: Synbiotic versus placebo, Outcome 4: GI function: GSRS Item 6 (rumbling) at 12 weeks </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013631.pub2/references#CD013631-fig-0051">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013631.pub2/media/CDSR/CD013631/image_n/nCD013631-CMP-006.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013631-fig-0052"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013631.pub2/media/CDSR/CD013631/urn:x-wiley:14651858:media:CD013631:CD013631-CMP-006.05" target="_blank"><b></b></a></p> </div><img alt="Comparison 6: Synbiotic versus placebo, Outcome 5: GI function: GSRS Item 13 (hard stools) at 12 weeks" data-id="CD013631-fig-0052" src="/cdsr/doi/10.1002/14651858.CD013631.pub2/media/CDSR/CD013631/image_n/nCD013631-CMP-006.05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013631.pub2/media/CDSR/CD013631/image_t/tCD013631-CMP-006.05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.5</div> <div class="figure-caption"> <p>Comparison 6: Synbiotic versus placebo, Outcome 5: GI function: GSRS Item 13 (hard stools) at 12 weeks </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013631.pub2/references#CD013631-fig-0052">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013631.pub2/media/CDSR/CD013631/image_n/nCD013631-CMP-006.05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013631-fig-0053"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013631.pub2/media/CDSR/CD013631/urn:x-wiley:14651858:media:CD013631:CD013631-CMP-006.06" target="_blank"><b></b></a></p> </div><img alt="Comparison 6: Synbiotic versus placebo, Outcome 6: GI function: abdominal pain at 12 weeks" data-id="CD013631-fig-0053" src="/cdsr/doi/10.1002/14651858.CD013631.pub2/media/CDSR/CD013631/image_n/nCD013631-CMP-006.06.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013631.pub2/media/CDSR/CD013631/image_t/tCD013631-CMP-006.06.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.6</div> <div class="figure-caption"> <p>Comparison 6: Synbiotic versus placebo, Outcome 6: GI function: abdominal pain at 12 weeks </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013631.pub2/references#CD013631-fig-0053">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013631.pub2/media/CDSR/CD013631/image_n/nCD013631-CMP-006.06.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013631-fig-0054"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013631.pub2/media/CDSR/CD013631/urn:x-wiley:14651858:media:CD013631:CD013631-CMP-006.07" target="_blank"><b></b></a></p> </div><img alt="Comparison 6: Synbiotic versus placebo, Outcome 7: GI function: constipation syndrome at 12 weeks" data-id="CD013631-fig-0054" src="/cdsr/doi/10.1002/14651858.CD013631.pub2/media/CDSR/CD013631/image_n/nCD013631-CMP-006.07.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013631.pub2/media/CDSR/CD013631/image_t/tCD013631-CMP-006.07.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.7</div> <div class="figure-caption"> <p>Comparison 6: Synbiotic versus placebo, Outcome 7: GI function: constipation syndrome at 12 weeks </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013631.pub2/references#CD013631-fig-0054">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013631.pub2/media/CDSR/CD013631/image_n/nCD013631-CMP-006.07.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013631-fig-0055"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013631.pub2/media/CDSR/CD013631/urn:x-wiley:14651858:media:CD013631:CD013631-CMP-007.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 7: Prebiotic versus placebo or no treatment, Outcome 1: Kidney function: serum creatinine at 8 or 12 weeks" data-id="CD013631-fig-0055" src="/cdsr/doi/10.1002/14651858.CD013631.pub2/media/CDSR/CD013631/image_n/nCD013631-CMP-007.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013631.pub2/media/CDSR/CD013631/image_t/tCD013631-CMP-007.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.1</div> <div class="figure-caption"> <p>Comparison 7: Prebiotic versus placebo or no treatment, Outcome 1: Kidney function: serum creatinine at 8 or 12 weeks </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013631.pub2/references#CD013631-fig-0055">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013631.pub2/media/CDSR/CD013631/image_n/nCD013631-CMP-007.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013631-fig-0056"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013631.pub2/media/CDSR/CD013631/urn:x-wiley:14651858:media:CD013631:CD013631-CMP-007.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 7: Prebiotic versus placebo or no treatment, Outcome 2: Uraemic toxins: urea at 12 weeks" data-id="CD013631-fig-0056" src="/cdsr/doi/10.1002/14651858.CD013631.pub2/media/CDSR/CD013631/image_n/nCD013631-CMP-007.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013631.pub2/media/CDSR/CD013631/image_t/tCD013631-CMP-007.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.2</div> <div class="figure-caption"> <p>Comparison 7: Prebiotic versus placebo or no treatment, Outcome 2: Uraemic toxins: urea at 12 weeks </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013631.pub2/references#CD013631-fig-0056">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013631.pub2/media/CDSR/CD013631/image_n/nCD013631-CMP-007.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013631-fig-0057"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013631.pub2/media/CDSR/CD013631/urn:x-wiley:14651858:media:CD013631:CD013631-CMP-007.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 7: Prebiotic versus placebo or no treatment, Outcome 3: Uraemic toxins: indoxyl sulfate at 8 weeks" data-id="CD013631-fig-0057" src="/cdsr/doi/10.1002/14651858.CD013631.pub2/media/CDSR/CD013631/image_n/nCD013631-CMP-007.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013631.pub2/media/CDSR/CD013631/image_t/tCD013631-CMP-007.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.3</div> <div class="figure-caption"> <p>Comparison 7: Prebiotic versus placebo or no treatment, Outcome 3: Uraemic toxins: indoxyl sulfate at 8 weeks </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013631.pub2/references#CD013631-fig-0057">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013631.pub2/media/CDSR/CD013631/image_n/nCD013631-CMP-007.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013631-fig-0058"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013631.pub2/media/CDSR/CD013631/urn:x-wiley:14651858:media:CD013631:CD013631-CMP-007.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 7: Prebiotic versus placebo or no treatment, Outcome 4: Uraemic toxins: p‐cresyl sulfate at 8 weeks" data-id="CD013631-fig-0058" src="/cdsr/doi/10.1002/14651858.CD013631.pub2/media/CDSR/CD013631/image_n/nCD013631-CMP-007.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013631.pub2/media/CDSR/CD013631/image_t/tCD013631-CMP-007.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.4</div> <div class="figure-caption"> <p>Comparison 7: Prebiotic versus placebo or no treatment, Outcome 4: Uraemic toxins: p‐cresyl sulfate at 8 weeks </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013631.pub2/references#CD013631-fig-0058">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013631.pub2/media/CDSR/CD013631/image_n/nCD013631-CMP-007.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013631-fig-0059"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013631.pub2/media/CDSR/CD013631/urn:x-wiley:14651858:media:CD013631:CD013631-CMP-007.05" target="_blank"><b></b></a></p> </div><img alt="Comparison 7: Prebiotic versus placebo or no treatment, Outcome 5: GI function: microbiota composition (Facealibacterium) at 8 weeks" data-id="CD013631-fig-0059" src="/cdsr/doi/10.1002/14651858.CD013631.pub2/media/CDSR/CD013631/image_n/nCD013631-CMP-007.05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013631.pub2/media/CDSR/CD013631/image_t/tCD013631-CMP-007.05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.5</div> <div class="figure-caption"> <p>Comparison 7: Prebiotic versus placebo or no treatment, Outcome 5: GI function: microbiota composition (Facealibacterium) at 8 weeks </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013631.pub2/references#CD013631-fig-0059">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013631.pub2/media/CDSR/CD013631/image_n/nCD013631-CMP-007.05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013631-fig-0060"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013631.pub2/media/CDSR/CD013631/urn:x-wiley:14651858:media:CD013631:CD013631-CMP-007.06" target="_blank"><b></b></a></p> </div><img alt="Comparison 7: Prebiotic versus placebo or no treatment, Outcome 6: GI function: microbiota composition (Parabacteroides) at 8 weeks" data-id="CD013631-fig-0060" src="/cdsr/doi/10.1002/14651858.CD013631.pub2/media/CDSR/CD013631/image_n/nCD013631-CMP-007.06.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013631.pub2/media/CDSR/CD013631/image_t/tCD013631-CMP-007.06.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.6</div> <div class="figure-caption"> <p>Comparison 7: Prebiotic versus placebo or no treatment, Outcome 6: GI function: microbiota composition (Parabacteroides) at 8 weeks </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013631.pub2/references#CD013631-fig-0060">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013631.pub2/media/CDSR/CD013631/image_n/nCD013631-CMP-007.06.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013631-fig-0061"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013631.pub2/media/CDSR/CD013631/urn:x-wiley:14651858:media:CD013631:CD013631-CMP-007.07" target="_blank"><b></b></a></p> </div><img alt="Comparison 7: Prebiotic versus placebo or no treatment, Outcome 7: GI function: microbiota composition (Bifidobacteria) at 8 weeks" data-id="CD013631-fig-0061" src="/cdsr/doi/10.1002/14651858.CD013631.pub2/media/CDSR/CD013631/image_n/nCD013631-CMP-007.07.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013631.pub2/media/CDSR/CD013631/image_t/tCD013631-CMP-007.07.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.7</div> <div class="figure-caption"> <p>Comparison 7: Prebiotic versus placebo or no treatment, Outcome 7: GI function: microbiota composition (Bifidobacteria) at 8 weeks </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013631.pub2/references#CD013631-fig-0061">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013631.pub2/media/CDSR/CD013631/image_n/nCD013631-CMP-007.07.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013631-fig-0062"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013631.pub2/media/CDSR/CD013631/urn:x-wiley:14651858:media:CD013631:CD013631-CMP-007.08" target="_blank"><b></b></a></p> </div><img alt="Comparison 7: Prebiotic versus placebo or no treatment, Outcome 8: GI function: microbiota composition (Ruminococcus) at 8 weeks" data-id="CD013631-fig-0062" src="/cdsr/doi/10.1002/14651858.CD013631.pub2/media/CDSR/CD013631/image_n/nCD013631-CMP-007.08.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013631.pub2/media/CDSR/CD013631/image_t/tCD013631-CMP-007.08.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.8</div> <div class="figure-caption"> <p>Comparison 7: Prebiotic versus placebo or no treatment, Outcome 8: GI function: microbiota composition (Ruminococcus) at 8 weeks </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013631.pub2/references#CD013631-fig-0062">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013631.pub2/media/CDSR/CD013631/image_n/nCD013631-CMP-007.08.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013631-fig-0063"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013631.pub2/media/CDSR/CD013631/urn:x-wiley:14651858:media:CD013631:CD013631-CMP-007.09" target="_blank"><b></b></a></p> </div><img alt="Comparison 7: Prebiotic versus placebo or no treatment, Outcome 9: GI function: microbiota composition (Prevotella) at 8 weeks" data-id="CD013631-fig-0063" src="/cdsr/doi/10.1002/14651858.CD013631.pub2/media/CDSR/CD013631/image_n/nCD013631-CMP-007.09.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013631.pub2/media/CDSR/CD013631/image_t/tCD013631-CMP-007.09.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.9</div> <div class="figure-caption"> <p>Comparison 7: Prebiotic versus placebo or no treatment, Outcome 9: GI function: microbiota composition (Prevotella) at 8 weeks </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013631.pub2/references#CD013631-fig-0063">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013631.pub2/media/CDSR/CD013631/image_n/nCD013631-CMP-007.09.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013631-fig-0064"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013631.pub2/media/CDSR/CD013631/urn:x-wiley:14651858:media:CD013631:CD013631-CMP-007.10" target="_blank"><b></b></a></p> </div><img alt="Comparison 7: Prebiotic versus placebo or no treatment, Outcome 10: Adverse events: any adverse event (number of participants)" data-id="CD013631-fig-0064" src="/cdsr/doi/10.1002/14651858.CD013631.pub2/media/CDSR/CD013631/image_n/nCD013631-CMP-007.10.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013631.pub2/media/CDSR/CD013631/image_t/tCD013631-CMP-007.10.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.10</div> <div class="figure-caption"> <p>Comparison 7: Prebiotic versus placebo or no treatment, Outcome 10: Adverse events: any adverse event (number of participants) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013631.pub2/references#CD013631-fig-0064">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013631.pub2/media/CDSR/CD013631/image_n/nCD013631-CMP-007.10.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013631-fig-0065"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013631.pub2/media/CDSR/CD013631/urn:x-wiley:14651858:media:CD013631:CD013631-CMP-007.11" target="_blank"><b></b></a></p> </div><img alt="Comparison 7: Prebiotic versus placebo or no treatment, Outcome 11: Withdrawals due to adverse events" data-id="CD013631-fig-0065" src="/cdsr/doi/10.1002/14651858.CD013631.pub2/media/CDSR/CD013631/image_n/nCD013631-CMP-007.11.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013631.pub2/media/CDSR/CD013631/image_t/tCD013631-CMP-007.11.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.11</div> <div class="figure-caption"> <p>Comparison 7: Prebiotic versus placebo or no treatment, Outcome 11: Withdrawals due to adverse events </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013631.pub2/references#CD013631-fig-0065">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013631.pub2/media/CDSR/CD013631/image_n/nCD013631-CMP-007.11.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013631-fig-0066"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013631.pub2/media/CDSR/CD013631/urn:x-wiley:14651858:media:CD013631:CD013631-CMP-008.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 8: Probiotic versus placebo or no treatment, Outcome 1: Kidney function: GFR at 8, 12 or 15 weeks" data-id="CD013631-fig-0066" src="/cdsr/doi/10.1002/14651858.CD013631.pub2/media/CDSR/CD013631/image_n/nCD013631-CMP-008.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013631.pub2/media/CDSR/CD013631/image_t/tCD013631-CMP-008.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 8.1</div> <div class="figure-caption"> <p>Comparison 8: Probiotic versus placebo or no treatment, Outcome 1: Kidney function: GFR at 8, 12 or 15 weeks </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013631.pub2/references#CD013631-fig-0066">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013631.pub2/media/CDSR/CD013631/image_n/nCD013631-CMP-008.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013631-fig-0067"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013631.pub2/media/CDSR/CD013631/urn:x-wiley:14651858:media:CD013631:CD013631-CMP-008.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 8: Probiotic versus placebo or no treatment, Outcome 2: Kidney function: serum creatinine at 8, 12 or 24 weeks" data-id="CD013631-fig-0067" src="/cdsr/doi/10.1002/14651858.CD013631.pub2/media/CDSR/CD013631/image_n/nCD013631-CMP-008.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013631.pub2/media/CDSR/CD013631/image_t/tCD013631-CMP-008.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 8.2</div> <div class="figure-caption"> <p>Comparison 8: Probiotic versus placebo or no treatment, Outcome 2: Kidney function: serum creatinine at 8, 12 or 24 weeks </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013631.pub2/references#CD013631-fig-0067">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013631.pub2/media/CDSR/CD013631/image_n/nCD013631-CMP-008.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013631-fig-0068"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013631.pub2/media/CDSR/CD013631/urn:x-wiley:14651858:media:CD013631:CD013631-CMP-008.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 8: Probiotic versus placebo or no treatment, Outcome 3: Kidney function: albuminuria at 12 or 24 weeks" data-id="CD013631-fig-0068" src="/cdsr/doi/10.1002/14651858.CD013631.pub2/media/CDSR/CD013631/image_n/nCD013631-CMP-008.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013631.pub2/media/CDSR/CD013631/image_t/tCD013631-CMP-008.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 8.3</div> <div class="figure-caption"> <p>Comparison 8: Probiotic versus placebo or no treatment, Outcome 3: Kidney function: albuminuria at 12 or 24 weeks </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013631.pub2/references#CD013631-fig-0068">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013631.pub2/media/CDSR/CD013631/image_n/nCD013631-CMP-008.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013631-fig-0069"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013631.pub2/media/CDSR/CD013631/urn:x-wiley:14651858:media:CD013631:CD013631-CMP-008.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 8: Probiotic versus placebo or no treatment, Outcome 4: Kidney function: proteinuria at 12 weeks" data-id="CD013631-fig-0069" src="/cdsr/doi/10.1002/14651858.CD013631.pub2/media/CDSR/CD013631/image_n/nCD013631-CMP-008.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013631.pub2/media/CDSR/CD013631/image_t/tCD013631-CMP-008.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 8.4</div> <div class="figure-caption"> <p>Comparison 8: Probiotic versus placebo or no treatment, Outcome 4: Kidney function: proteinuria at 12 weeks </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013631.pub2/references#CD013631-fig-0069">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013631.pub2/media/CDSR/CD013631/image_n/nCD013631-CMP-008.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013631-fig-0070"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013631.pub2/media/CDSR/CD013631/urn:x-wiley:14651858:media:CD013631:CD013631-CMP-008.05" target="_blank"><b></b></a></p> </div><img alt="Comparison 8: Probiotic versus placebo or no treatment, Outcome 5: Uraemic toxins: urea at 12 or 24 weeks" data-id="CD013631-fig-0070" src="/cdsr/doi/10.1002/14651858.CD013631.pub2/media/CDSR/CD013631/image_n/nCD013631-CMP-008.05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013631.pub2/media/CDSR/CD013631/image_t/tCD013631-CMP-008.05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 8.5</div> <div class="figure-caption"> <p>Comparison 8: Probiotic versus placebo or no treatment, Outcome 5: Uraemic toxins: urea at 12 or 24 weeks </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013631.pub2/references#CD013631-fig-0070">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013631.pub2/media/CDSR/CD013631/image_n/nCD013631-CMP-008.05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013631-fig-0071"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013631.pub2/media/CDSR/CD013631/urn:x-wiley:14651858:media:CD013631:CD013631-CMP-008.06" target="_blank"><b></b></a></p> </div><img alt="Comparison 8: Probiotic versus placebo or no treatment, Outcome 6: Uraemic toxins: indoxyl sulfate at 12 or 24 weeks" data-id="CD013631-fig-0071" src="/cdsr/doi/10.1002/14651858.CD013631.pub2/media/CDSR/CD013631/image_n/nCD013631-CMP-008.06.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013631.pub2/media/CDSR/CD013631/image_t/tCD013631-CMP-008.06.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 8.6</div> <div class="figure-caption"> <p>Comparison 8: Probiotic versus placebo or no treatment, Outcome 6: Uraemic toxins: indoxyl sulfate at 12 or 24 weeks </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013631.pub2/references#CD013631-fig-0071">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013631.pub2/media/CDSR/CD013631/image_n/nCD013631-CMP-008.06.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013631-fig-0072"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013631.pub2/media/CDSR/CD013631/urn:x-wiley:14651858:media:CD013631:CD013631-CMP-008.07" target="_blank"><b></b></a></p> </div><img alt="Comparison 8: Probiotic versus placebo or no treatment, Outcome 7: Uraemic toxins: p‐cresyl sulfate at 4, 12 or 24 weeks" data-id="CD013631-fig-0072" src="/cdsr/doi/10.1002/14651858.CD013631.pub2/media/CDSR/CD013631/image_n/nCD013631-CMP-008.07.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013631.pub2/media/CDSR/CD013631/image_t/tCD013631-CMP-008.07.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 8.7</div> <div class="figure-caption"> <p>Comparison 8: Probiotic versus placebo or no treatment, Outcome 7: Uraemic toxins: p‐cresyl sulfate at 4, 12 or 24 weeks </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013631.pub2/references#CD013631-fig-0072">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013631.pub2/media/CDSR/CD013631/image_n/nCD013631-CMP-008.07.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013631-fig-0073"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013631.pub2/media/CDSR/CD013631/urn:x-wiley:14651858:media:CD013631:CD013631-CMP-008.08" target="_blank"><b></b></a></p> </div><img alt="Comparison 8: Probiotic versus placebo or no treatment, Outcome 8: Uraemic toxins: indole‐3‐acetic acid acid at 12 weeks" data-id="CD013631-fig-0073" src="/cdsr/doi/10.1002/14651858.CD013631.pub2/media/CDSR/CD013631/image_n/nCD013631-CMP-008.08.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013631.pub2/media/CDSR/CD013631/image_t/tCD013631-CMP-008.08.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 8.8</div> <div class="figure-caption"> <p>Comparison 8: Probiotic versus placebo or no treatment, Outcome 8: Uraemic toxins: indole‐3‐acetic acid acid at 12 weeks </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013631.pub2/references#CD013631-fig-0073">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013631.pub2/media/CDSR/CD013631/image_n/nCD013631-CMP-008.08.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013631-fig-0074"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013631.pub2/media/CDSR/CD013631/urn:x-wiley:14651858:media:CD013631:CD013631-CMP-008.09" target="_blank"><b></b></a></p> </div><img alt="Comparison 8: Probiotic versus placebo or no treatment, Outcome 9: GI function: any GI upset or intolerance (abdominal pain/diarrhoea) at 12 weeks" data-id="CD013631-fig-0074" src="/cdsr/doi/10.1002/14651858.CD013631.pub2/media/CDSR/CD013631/image_n/nCD013631-CMP-008.09.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013631.pub2/media/CDSR/CD013631/image_t/tCD013631-CMP-008.09.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 8.9</div> <div class="figure-caption"> <p>Comparison 8: Probiotic versus placebo or no treatment, Outcome 9: GI function: any GI upset or intolerance (abdominal pain/diarrhoea) at 12 weeks </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013631.pub2/references#CD013631-fig-0074">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013631.pub2/media/CDSR/CD013631/image_n/nCD013631-CMP-008.09.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013631-fig-0075"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013631.pub2/media/CDSR/CD013631/urn:x-wiley:14651858:media:CD013631:CD013631-CMP-008.10" target="_blank"><b></b></a></p> </div><img alt="Comparison 8: Probiotic versus placebo or no treatment, Outcome 10: GI function: any GI upset or intolerance (constipation) at 12 weeks" data-id="CD013631-fig-0075" src="/cdsr/doi/10.1002/14651858.CD013631.pub2/media/CDSR/CD013631/image_n/nCD013631-CMP-008.10.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013631.pub2/media/CDSR/CD013631/image_t/tCD013631-CMP-008.10.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 8.10</div> <div class="figure-caption"> <p>Comparison 8: Probiotic versus placebo or no treatment, Outcome 10: GI function: any GI upset or intolerance (constipation) at 12 weeks </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013631.pub2/references#CD013631-fig-0075">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013631.pub2/media/CDSR/CD013631/image_n/nCD013631-CMP-008.10.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013631-fig-0076"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013631.pub2/media/CDSR/CD013631/urn:x-wiley:14651858:media:CD013631:CD013631-CMP-008.11" target="_blank"><b></b></a></p> </div><img alt="Comparison 8: Probiotic versus placebo or no treatment, Outcome 11: GI function: faecal pH at 12 weeks" data-id="CD013631-fig-0076" src="/cdsr/doi/10.1002/14651858.CD013631.pub2/media/CDSR/CD013631/image_n/nCD013631-CMP-008.11.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013631.pub2/media/CDSR/CD013631/image_t/tCD013631-CMP-008.11.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 8.11</div> <div class="figure-caption"> <p>Comparison 8: Probiotic versus placebo or no treatment, Outcome 11: GI function: faecal pH at 12 weeks </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013631.pub2/references#CD013631-fig-0076">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013631.pub2/media/CDSR/CD013631/image_n/nCD013631-CMP-008.11.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013631-fig-0077"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013631.pub2/media/CDSR/CD013631/urn:x-wiley:14651858:media:CD013631:CD013631-CMP-008.12" target="_blank"><b></b></a></p> </div><img alt="Comparison 8: Probiotic versus placebo or no treatment, Outcome 12: Adverse events: any adverse event (number of participants)" data-id="CD013631-fig-0077" src="/cdsr/doi/10.1002/14651858.CD013631.pub2/media/CDSR/CD013631/image_n/nCD013631-CMP-008.12.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013631.pub2/media/CDSR/CD013631/image_t/tCD013631-CMP-008.12.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 8.12</div> <div class="figure-caption"> <p>Comparison 8: Probiotic versus placebo or no treatment, Outcome 12: Adverse events: any adverse event (number of participants) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013631.pub2/references#CD013631-fig-0077">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013631.pub2/media/CDSR/CD013631/image_n/nCD013631-CMP-008.12.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013631-fig-0078"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013631.pub2/media/CDSR/CD013631/urn:x-wiley:14651858:media:CD013631:CD013631-CMP-008.13" target="_blank"><b></b></a></p> </div><img alt="Comparison 8: Probiotic versus placebo or no treatment, Outcome 13: Withdrawals due to adverse events" data-id="CD013631-fig-0078" src="/cdsr/doi/10.1002/14651858.CD013631.pub2/media/CDSR/CD013631/image_n/nCD013631-CMP-008.13.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013631.pub2/media/CDSR/CD013631/image_t/tCD013631-CMP-008.13.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 8.13</div> <div class="figure-caption"> <p>Comparison 8: Probiotic versus placebo or no treatment, Outcome 13: Withdrawals due to adverse events </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013631.pub2/references#CD013631-fig-0078">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013631.pub2/media/CDSR/CD013631/image_n/nCD013631-CMP-008.13.svg" target="_blank">Open in new tab</a></div> </div> </div> <div class="tables-list"> <div class="table"> <table class="summary-of-findings framed" data-id="CD013631-tbl-0001"> <div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Synbiotic versus another synbiotic for people with chronic kidney disease</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Synbiotic versus another synbiotic for people with chronic kidney disease</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Patient or population:</b> people with CKD<br/><b>Setting:</b> hospital or primary care<br/><b>Intervention:</b> synbiotic 2<br/><b>Comparison:</b> synbiotic 1 </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>No. of participants<br/>(RCTs)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with synbiotic 1</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with synbiotic 2</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>eGFR</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Albuminuria or proteinuria</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Indoxyl sulfate</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Change in any GI upset or intolerance</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Microbiota composition</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Graft function</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Graft infection</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% CI) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><br/><b>CI:</b> confidence interval; <b>CKD:</b> chronic kidney disease; <b>eGFR:</b> (estimated) glomerular filtration rate; <b>GI:</b> gastrointestinal; RCT: randomised controlled trial; <b>RR:</b> risk ratio. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="6"> <div class="table-footnote"> <p>No data were reported for these outcomes under this comparison.</p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Synbiotic versus another synbiotic for people with chronic kidney disease</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013631.pub2/full#CD013631-tbl-0001">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD013631-tbl-0002"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Synbiotic versus prebiotic for people with chronic kidney disease</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Synbiotic versus prebiotic for people with chronic kidney disease</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Patient or population:</b> people with CKD<br/><b>Setting:</b> hospital or primary care<br/><b>Intervention:</b> synbiotic<br/><b>Comparison:</b> prebiotic </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>No. of participants<br/>(RCTs)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with prebiotic</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with synbiotic</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>eGFR</b> </p> <p>(mL/min)</p> <p>Follow‐up: 4 weeks</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>CKD stage 3Ga (transplant)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>34 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/><b>very low<sup>1</sup> </b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>The mean eGFR was 3.8 mL/min lower (17.98 lower to 10.38 higher) with synbiotic compared prebiotic </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Albuminuria or proteinuria</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Indoxyl sulfate</b> </p> <p>(ng/mL)</p> <p>Follow‐up: 4 weeks</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>CKD stage G5D</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>42 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/><b>very low<sup>1</sup> </b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>The mean indoxyl sulfate was 128.3 ng/mL higher (242.77 lower to 499.37 higher) with synbiotic compared prebiotic </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Change in any GI upset (borborygmi)</b> </p> <p>Follow‐up: 4 weeks</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>CKD stage 3Ga (transplant)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 15.26<br/>(0.99 to 236.23) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>34 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/><b>very low<sup>1</sup> </b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0 per 1,000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0 per 1,000<br/>(0 to 0) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p><b>Change in any GI upset (GSRS total index)</b> </p> <p>Follow‐up: 12 months</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>CKD stage 3 to 4</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>56 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>⊕⊝⊝⊝<br/><b>very low<sup>1</sup> </b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p>The mean change in any GI upset was 0.00 (0.27 lower to 0.27 higher) with synbiotic compared prebiotic </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Microbiota composition</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Graft function</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Graft infection</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% CI) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><br/><b>CI:</b> confidence interval; <b>CKD:</b> chronic kidney disease; <b>eGFR:</b> estimated glomerular filtration rate; <b>GI:</b> gastrointestinal; <b>RR:</b> risk ratio; <b>RCT:</b> randomised controlled trial </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="6"> <div class="table-footnote"> <p><sup>1</sup> Downgraded twice for serious risk of bias, and once for sparse or small study data. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Synbiotic versus prebiotic for people with chronic kidney disease</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013631.pub2/full#CD013631-tbl-0002">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD013631-tbl-0003"> <div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">Prebiotic versus another prebiotic for people with chronic kidney disease</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Prebiotic versus another prebiotic for people with chronic kidney disease</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Patient or population:</b> people with CKD<br/><b>Setting:</b> hospital or primary care<br/><b>Intervention:</b> prebiotic 2<br/><b>Comparison:</b> prebiotic 1 </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>No. of participants<br/>(RCTs)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> </tr> <tr class="table-header separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with prebiotic 1</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with prebiotic 2</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>eGFR</b> </p> <p>(mL/min)</p> <p>Follow‐up: 12 weeks</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>CKD stage 3 to 5 (non‐dialysis)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>50 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/><b>very low<sup>1</sup> </b> </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>The mean eGFR was 0 mL/min lower (1.73 lower to 1.73 higher) with prebiotic 2 compared to prebiotic 1 </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Albuminuria or proteinuria</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Indoxyl sulfate</b> </p> <p>(μg/mL)</p> <p>Follow‐up: 6 weeks</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>CKD stage G5D with diabetes</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>64 (2)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/><b>very low<sup>1</sup> </b> </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>The mean indoxyl sulfate was 0.2 μg/mL lower (1.01 lower to 0.61 higher) with prebiotic 2 compared to prebiotic 1 </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Change in any GI upset or intolerance</b> </p> <p>Follow‐up: 4 weeks</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>CKD stage G5D with diabetes</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="8" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="8" valign="top"> <p>24 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="8" valign="top"> <p>⊕⊝⊝⊝<br/><b>very low<sup>1</sup> </b> </p> </td> </tr> <tr class="separated"> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Burping</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>The mean burping was 0.17 higher (0.5 lower to 0.84 higher) with prebiotic 2 compared to prebiotic 1 </p> </td> </tr> <tr class="separated"> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cramping</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>The mean cramping was 0.17 lower (0.5 lower to 0.16 higher) with prebiotic 2 compared to prebiotic 1 </p> </td> </tr> <tr class="separated"> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Distension</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>The mean distension was 0.33 higher (0.04 lower to 0.7 higher) with prebiotic 2 compared to prebiotic 1 </p> </td> </tr> <tr class="separated"> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Flatulence</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>The mean flatulence was 1 higher (0.25 higher to 1.75 higher) with prebiotic 2 compared to prebiotic 1 </p> </td> </tr> <tr class="separated"> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Nausea</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>The mean nausea was 0 (0 to 0 ) with prebiotic 2 compared to prebiotic 1</p> </td> </tr> <tr class="separated"> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Reflux</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>The mean reflux was 0 (0.5 lower to 0.5 higher) with prebiotic 2 compared to prebiotic 1 </p> </td> </tr> <tr class="separated"> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Rumblings</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>The mean rumblings was 0.5 higher (0.14 lower to 1.14 higher) with prebiotic 2 compared to prebiotic 1 </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Microbiota composition</b> </p> <p>Follow‐up: 4 weeks</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>CKD stage G5D with diabetes</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="14" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="14" valign="top"> <p>24 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="14" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><i>Actinobacteria</i> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>The mean <i>Actinobacteria</i> was 1.26 lower (4.46 lower to 1.94 higher) with prebiotic 2 compared to prebiotic 1 </p> </td> </tr> <tr class="separated"> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><i>Bacteriodetes</i> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>The mean <i>Bacteriodetes</i> was 3.23 higher (8.24 lower to 14.7 higher) with prebiotic 2 compared to prebiotic 1 </p> </td> </tr> <tr class="separated"> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><i>Proteobacteria</i> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>The mean <i>Proteobacteria</i> was 0.11 higher (1.61 lower to 1.83 higher) with prebiotic 2 compared to prebiotic 1 </p> </td> </tr> <tr class="separated"> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><i>Firmicutes</i> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>The mean <i>Firmicutes</i> was 2.44 lower (14.19 lower to 9.31 higher) with prebiotic 2 compared to prebiotic 1 </p> </td> </tr> <tr class="separated"> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><i>Synergistetes</i> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>The mean <i>Synergistetes</i> was MD 0.25 lower (0.89 lower to 0.39 higher) with prebiotic 2 compared to prebiotic 1 </p> </td> </tr> <tr class="separated"> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><i>Verrucomicrobia</i> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>The mean <i>Verrucomicrobia</i> was 0.96 higher (1.36 lower to 3.28 higher) with prebiotic 2 compared to prebiotic 1 </p> </td> </tr> <tr class="separated"> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Faecal acetate</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>The mean faecal acetate was 69.91 lower (203.95 lower to 64.13 higher) with prebiotic 2 compared to prebiotic 1 </p> </td> </tr> <tr class="separated"> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Faecal propionate</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>The mean faecal propionate was 19.35 lower (63.87 lower to 25.17 higher) with prebiotic 2 compared to prebiotic 1 </p> </td> </tr> <tr class="separated"> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Faecal butyrate</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>The mean faecal butyrate was 11.04 lower (39.57 lower to 17.49 higher) with prebiotic 2 compared to prebiotic 1 </p> </td> </tr> <tr class="separated"> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Faecal total short‐chain fatty acids</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>The mean faecal total short‐chain fatty acids were 104.71 lower (293.34 lower to 83.92 higher) with prebiotic 2 compared to prebiotic 1 </p> </td> </tr> <tr class="separated"> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Faecal total short‐chain fatty acids</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>The mean faecal total short‐chain fatty acids were 104.71 lower (293.34 lower to 83.92 higher) with prebiotic 2 compared to prebiotic 1 </p> </td> </tr> <tr class="separated"> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Faecal indoles</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>The mean faecal indoles were 2.71 higher (69.78 lower to 75.2 higher) with prebiotic 2 compared to prebiotic 1 </p> </td> </tr> <tr class="separated"> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Faecal P‐cresol</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>The mean faecal p‐cresol was 28.84 higher (105.07 lower to 162.75 higher) with prebiotic 2 compared to prebiotic 1 </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Graft function</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Graft infection</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% CI) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><br/><b>CKD:</b> chronic kidney disease; <b>CI:</b> confidence interval; <b>eGFR:</b> estimated glomerular filtration rate; <b>GI:</b> gastrointestinal; <b>RR:</b> risk ratio; <b>RCT:</b> randomised controlled trial </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="6"> <div class="table-footnote"> <p><sup>1</sup> Downgraded twice for serious risk of bias, and once for sparse or small study data. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">Prebiotic versus another prebiotic for people with chronic kidney disease</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013631.pub2/full#CD013631-tbl-0003">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD013631-tbl-0004"> <div class="table-heading"><span class="table-label">Summary of findings 4.</span> <span class="table-title">Prebiotic versus probiotic for people with chronic kidney disease</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>Prebiotic versus probiotic for people with chronic kidney disease</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>Patient or population:</b> people with CKD </p> <p><b>Settings:</b> hospital or primary care </p> <p><b>Intervention:</b> prebiotic </p> <p><b>Comparison:</b> probiotic </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>No. of participants<br/>(RCTs)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Quality of the evidence<br/>(GRADE)</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Assumed risk</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Corresponding risk</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with probiotic</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with prebiotic</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>eGFR</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Albuminuria or proteinuria</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Indoxyl sulfate</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Change in any GI upset or intolerance</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Microbiota composition</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Graft function</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Graft infection</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% CI) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). </p> <p><b>CKD:</b> chronic kidney disease; <b>CI:</b> confidence interval; <b>eGFR:</b> estimated glomerular filtration rate; <b>GI:</b> gastrointestinal; <b>RCT:</b> randomised controlled trial </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/><b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/><b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/><b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/><b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="6"> <div class="table-footnote"> <p>No data were reported for these outcomes under this comparison.</p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 4.</span> <span class="table-title">Prebiotic versus probiotic for people with chronic kidney disease</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013631.pub2/full#CD013631-tbl-0004">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD013631-tbl-0005"> <div class="table-heading"><span class="table-label">Summary of findings 5.</span> <span class="table-title">Probiotic versus another probiotic for people with chronic kidney disease</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Probiotic versus another probiotic for people with chronic kidney disease</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Patient or population:</b> people with CKD<br/><b>Setting:</b> hospital or primary care<br/><b>Intervention:</b> probiotic 2<br/><b>Comparison:</b> probiotic 1 </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>No. of participants<br/>(RCTs)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with probiotic 1</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with probiotic 2</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>eGFR</b> </p> <p>(mL/min)</p> <p>Follow‐up: 8 weeks</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>CKD stage G3 to G4</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>30 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/><b>very low<sup>1</sup> </b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>The mean eGFR was 0.64 mL/min lower (9.51 lower to 8.23 higher) with probiotic 2 than probiotic 1 </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Albuminuria or proteinuria</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Indoxyl sulfate</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Change in any GI upset or intolerance</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Microbiota composition</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Graft function</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Graft infection</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% CI) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><br/><b>CKD:</b> chronic kidney disease; <b>CI:</b> confidence interval; <b>eGFR:</b> estimated glomerular filtration rate; <b>GI:</b> gastrointestinal; <b>RR:</b> risk ratio; <b>RCT:</b> randomised controlled trial </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="6"> <div class="table-footnote"> <p><sup>1</sup> Downgraded twice for serious risk of bias, and once for sparse or small study data. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 5.</span> <span class="table-title">Probiotic versus another probiotic for people with chronic kidney disease</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013631.pub2/full#CD013631-tbl-0005">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD013631-tbl-0006"> <div class="table-heading"><span class="table-label">Summary of findings 6.</span> <span class="table-title">Synbiotic versus placebo or no treatment for people with chronic kidney disease</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Synbiotic versus placebo or no treatment for people with chronic kidney disease</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Patient or population:</b> people with CKD<br/><b>Setting:</b> hospital or primary care<br/><b>Intervention:</b> synbiotic<br/><b>Comparison:</b> placebo or no treatment </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>No. of participants<br/>(RCTs)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> </tr> <tr class="table-header separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with placebo or no treatment</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with synbiotic</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>eGFR</b> </p> <p>(mL/min)</p> <p>Follow‐up: 6 or 12 weeks</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>CKD stage G3b</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>98 (2)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/><b>very low<sup>1</sup> </b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>The mean eGFR was 1.42 mL/min higher (0.65 higher to 2.2 higher) with synbiotic than placebo or no treatment </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Albuminuria or proteinuria</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Indoxyl sulfate</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Change in any GI upset or intolerance</b> </p> <p>(GSRS)</p> <p>Follow‐up: 12 weeks</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>CKD stage 3b</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="5" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="5" valign="top"> <p>23 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="5" valign="top"> <p>⊕⊝⊝⊝<br/><b>very low<sup>1</sup> </b> </p> </td> </tr> <tr class="separated"> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Rumbling</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>The mean rumbling was 0.54 GSRS lower (0.77 lower to 0.31 lower) with synbiotic than placebo or no treatment </p> </td> </tr> <tr class="separated"> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Hard stools</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>The mean hard stools was 0.09 GSRS lower (0.35 lower to 0.17 higher) with synbiotic than placebo or no treatment </p> </td> </tr> <tr class="separated"> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Abdominal pain</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>The mean abdominal pain was 0.22 GSRS higher (0.02 lower to 0.46 higher) with synbiotic than placebo or no treatment </p> </td> </tr> <tr class="separated"> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Constipation syndrome</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>The mean constipation syndrome was 0.17 GSRS lower (0.72 lower to 0.38 higher) with synbiotic than placebo or no treatment </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Microbiota composition</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Graft function</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Graft infection</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% CI) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><br/><b>CKD:</b> chronic kidney disease; <b>CI:</b> confidence interval; <b>eGFR:</b> estimated glomerular filtration rate; <b>GI:</b> gastrointestinal; <b>RR:</b> risk ratio; <b>RCT:</b> randomised controlled trial </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="6"> <div class="table-footnote"> <p><sup>1</sup> Downgraded twice for serious risk of bias, and once for sparse or small study data. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 6.</span> <span class="table-title">Synbiotic versus placebo or no treatment for people with chronic kidney disease</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013631.pub2/full#CD013631-tbl-0006">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD013631-tbl-0007"> <div class="table-heading"><span class="table-label">Summary of findings 7.</span> <span class="table-title">Prebiotic versus placebo or no treatment for people with chronic kidney disease</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Prebiotic versus placebo or no treatment for people with chronic kidney disease</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Patient or population:</b> people with CKD<br/><b>Setting:</b> hospital or primary care<br/><b>Intervention:</b> prebiotic<br/><b>Comparison:</b> placebo or no treatment </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>No. of participants<br/>(RCTs)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> </tr> <tr class="table-header separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with placebo or no treatment</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with prebiotic</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>eGFR</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Albuminuria or proteinuria</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Indoxyl sulfate</b> </p> <p>(mg/L)</p> <p>Follow‐up: 8 weeks</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>CKD stage G5D</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>75 (2)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/><b>very low<sup>1</sup> </b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>The mean indoxyl sulfate was 0.14 mg/L lower (0.6 lower to 0.31 higher) with prebiotic than placebo or no treatment </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Any change in GI upset or intolerance</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Microbiota composition</b> </p> <p>Follow‐up: 8 weeks</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>CKD stage 5GD</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p>44 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p>⊕⊝⊝⊝<br/><b>very low<sup>1</sup> </b> </p> </td> </tr> <tr class="separated"> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><i>Faecalibacterium</i> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>The mean <i>Faecalibacterium</i> was 2.37 higher (0.23 higher to 4.51 higher) with prebiotic than placebo or no treatment </p> </td> </tr> <tr class="separated"> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><i>Parabacteroides</i> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>The mean <i>Parabacteroides</i> was 0.22 higher (0.06 higher to 0.38 higher) with prebiotic than placebo or no treatment </p> </td> </tr> <tr class="separated"> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><i>Bifidobacteria</i> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>The mean <i>Bifidobacteria</i> was 3.92 lower (9.83 lower to 1.99 higher) with prebiotic than placebo or no treatment </p> </td> </tr> <tr class="separated"> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><i>Ruminococcus</i> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>The mean <i>Ruminococcus</i> was 3.86 higher (0.32 lower to 8.04 higher) with prebiotic than placebo or no treatment </p> </td> </tr> <tr class="separated"> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><i>Prevotella</i> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>The mean <i>Prevotella</i> was 0.43 lower (1.45 lower to 0.59 higher) with prebiotic than placebo or no treatment </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Graft function</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Graft infection</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% CI) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><br/><b>CKD:</b> chronic kidney disease; <b>CI:</b> confidence interval; <b>eGFR:</b> estimated glomerular filtration rate; <b>GI:</b> gastrointestinal; <b>RR:</b> risk ratio; <b>RCT:</b> randomised controlled trial </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="6"> <div class="table-footnote"> <p><sup>1</sup> Downgraded twice for serious risk of bias, and once for sparse or small study data. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 7.</span> <span class="table-title">Prebiotic versus placebo or no treatment for people with chronic kidney disease</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013631.pub2/full#CD013631-tbl-0007">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD013631-tbl-0008"> <div class="table-heading"><span class="table-label">Summary of findings 8.</span> <span class="table-title">Probiotic versus placebo or no treatment for people with chronic kidney disease</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Probiotic versus placebo or no treatment for people with chronic kidney disease</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Patient or population:</b> people with CKD<br/><b>Setting:</b> hospital or primary care<br/><b>Intervention:</b> probiotic<br/><b>Comparison:</b> placebo or no treatment </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>No. of participants<br/>(RCTs)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> </tr> <tr class="table-header separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with placebo or no treatment</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with probiotic</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p><b>eGFR</b> </p> <p>(mL/min)</p> <p>Follow‐up: 8, 12 or 15 weeks</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>CKD stage 1 with type 2 diabetes mellitus</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>40 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p>⊕⊝⊝⊝<br/><b>very low<sup>1</sup> </b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>The mean eGFR was 12.1 mL/min higher (4.19 higher to 20.01 higher) with probiotic than placebo or no treatment </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>CKD stage 3A with diabetes and hypertension</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>28 (1)</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>The mean eGFR mL/min was 0.4 higher (4.15 lower to 4.95 higher) with probiotic than placebo or no treatment </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>CKD stage G5D with diabetes and hypertension</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>60 (1)</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>The mean eGFR was 0.02 mL/min higher (0.63 lower to 0.67 higher) with probiotic than placebo or no treatment </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Albuminuria</b> </p> <p>(g/dL)</p> <p>Follow‐up: 12 or 24 weeks</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>CKD stage G5D</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>33 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊕⊝⊝<br/><b>low<sup>2</sup> </b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>The mean albuminuria was 0 g/dL (0.19 lower to 0.19 higher) with probiotic than placebo or no treatment </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>CKD stage G5D with diabetes and hypertension</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>160 (3)</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>The mean albuminuria was 0.03 g/dL higher (0.1 lower to 0.16 higher) with probiotic than placebo or no treatment </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Proteinuria</b> </p> <p>(mg/dL)</p> <p>Follow‐up: 12 or 24 weeks</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>CKD stages 1 to 5 with diabetic nephropathy</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>60 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/><b>very low<sup>1</sup> </b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p>The mean albuminuria was 15.6 g/dL (34.3 lower to 3.1 higher) with probiotic than placebo or no treatment </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Indoxyl sulfate</b> </p> <p>(mg/dL)</p> <p>Follow‐up: 12 or 24 weeks</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>CKD stage G5D</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>33 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/><b>very low<sup>1</sup> </b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>The mean indoxyl sulfate was 6 mg/dL lower (15.02 lower to 3.02 higher) with probiotic than placebo or no treatment </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>CKD stage G5D with diabetes and hypertension</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>50 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>⊕⊝⊝⊝<br/><b>very low<sup>1</sup> </b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>The mean indoxyl sulfate was 3.14 mg/dL lower (10.26 lower to 3.98 higher) with probiotic than placebo or no treatment </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Change in any GI upset or intolerance (abdominal pain/diarrhoea)</b> </p> <p>Follow‐up: 12 weeks</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>CKD stage G5D</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 2.13<br/>(0.21 to 21.22) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>33 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/><b>very low<sup>1</sup> </b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>59 per 1,000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>125 per 1,000<br/>(12 to 1,000) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Change in any GI upset or intolerance (constipation)</b> </p> <p>Follow‐up: 12 weeks</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>CKD stage G5D</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 3.18<br/>(0.14 to 72.75) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>33 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/><b>very low<sup>1</sup> </b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0 per 1,000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0 per 1,000<br/>(0 to 0) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Microbiota composition</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Graft function</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Graft infection</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% CI) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><br/><b>CKD:</b> chronic kidney disease; <b>CI:</b> confidence interval; <b>eGFR:</b> estimated glomerular filtration rate; <b>GI:</b> gastrointestinal; <b>RR:</b> risk ratio; <b>RCT:</b> randomised controlled trial </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="6"> <div class="table-footnote"> <p><sup>1</sup> Downgraded twice for serious risk of bias, and once for sparse or small study data. </p> <p><sup>2</sup> Downgraded twice for serious risk of bias. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 8.</span> <span class="table-title">Probiotic versus placebo or no treatment for people with chronic kidney disease</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013631.pub2/full#CD013631-tbl-0008">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD013631-tbl-0009"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Synbiotic versus synbiotic</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.1 Patient‐reported outcomes: HRQoL at 12 weeks <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1.1 CKD stage G5D with diabetes and hypertension</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>46</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.98 [‐11.12, 15.08]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Synbiotic versus synbiotic</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013631.pub2/references#CD013631-tbl-0009">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD013631-tbl-0010"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Synbiotic versus prebiotic</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.1 Kidney function: eGFR at 4 weeks <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1.1 CKD stage 3Ga (transplant)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>34</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐3.80 [‐17.98, 10.38]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.2 Kidney function: serum creatinine at 8 weeks <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2.1 CKD stage G5D</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>42</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.20 [‐1.50, 1.10]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.3 Uraemic toxins: urea at 4 weeks <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.3.1 CKD stage G5D</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>42</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐2.10 [‐13.93, 9.73]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.4 Uraemic toxins: indoxyl sulfate at 4 weeks <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.4.1 CKD stage G5D</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>42</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>128.30 [‐242.77, 499.37]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.5 Uraemic toxins: p‐cresol sulfate at 4 weeks <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.5.1 CKD stage 3Ga (transplant)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>34</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐2.10 [‐3.92, ‐0.28]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.6 GI function: change in any GI upset or intolerance (prevalence of borborygmi) at 4 weeks <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.6.1 CKD stage 3Ga (transplant)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>34</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>15.26 [0.99, 236.23]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.7 GI function: change in any GI upset or intolerance (GSRS Total Index at 12 months) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.7.1 CKD Stage 3 to 4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>56</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.00 [‐0.27, 0.27]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.8 GI function: faecal pH at 7 weeks <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.8.1 CKD stage G5D</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>58</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.63 [‐1.13, ‐0.13]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.9 GI function: faecal characteristics (Bristol Stool Chart) at 4 weeks <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.9.1 CKD stage 3Ga (transplant)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>34</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.50 [‐1.15, 0.15]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.10 GI function: faecal characteristics (Bristol Stool Chart) at 12 months <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.10.1 CKD stage 3 to 4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>56</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.50 [‐0.18, 1.18]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.11 Patient‐reported outcomes: HRQoL at 24 weeks <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.11.1 CKD stage G5D with diabetes and hypertension</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>65</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>6.38 [‐4.88, 17.64]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.12 Adverse events: any adverse event <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.12.1 CKD stage G3a (transplant)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>64</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>15.26 [0.99, 236.23]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.12.2 CKD stage 3 to 4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>68</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.48 [0.65, 3.36]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.12.3 CKD stage 5GD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>147</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.10 [0.58, 2.09]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.13 Withdrawals due to adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.13.1 CKD stage 3Ga (transplant)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>64</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Not estimable</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.13.2 CKD stage G5D</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>147</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.78 [0.38, 1.62]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Synbiotic versus prebiotic</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013631.pub2/references#CD013631-tbl-0010">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD013631-tbl-0011"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">Prebiotic versus prebiotic</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.1 Kidney function: eGFR at 12 weeks <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1.1 CKD stage 3 to 5 (non‐dialysis)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>50</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.00 [‐1.73, 1.73]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.2 Uraemic toxins: indoxyl sulfate at 6 weeks <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.2.1 CKD stage G5D with diabetes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>64</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.20 [‐1.01, 0.61]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.3 Uraemic toxins: p‐cresol sulfate at 6 weeks <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.3.1 CKD stage G5D with diabetes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>64</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.04 [‐0.53, 0.45]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.4 GI function: change in any GI upset or intolerance (burping) at 4 weeks <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.4.1 CKD stage G5D with diabetes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>24</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.17 [‐0.50, 0.84]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.5 GI function: change in any GI upset or intolerance (cramping) at 4 weeks <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.5.1 CKD stage G5D with diabetes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>24</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.17 [‐0.50, 0.16]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.6 GI function: change in any GI upset or intolerance (distension) at 4 weeks <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.6.1 CKD stage G5D with diabetes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>24</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.33 [‐0.04, 0.70]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.7 GI function: change in any GI upset or intolerance (flatulence) at 4 weeks <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.7.1 CKD stage G5D with diabetes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>24</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.00 [0.25, 1.75]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.8 GI function: change in any GI upset or intolerance (nausea) at 4 weeks <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.8.1 CKD stage G5D with diabetes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>24</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.00 [‐0.00, 0.00]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.9 GI function: change in any GI upset or intolerance (reflux) at 4 weeks <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.9.1 CKD stage G5D with diabetes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>24</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.00 [‐0.50, 0.50]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.10 GI function: change in any GI upset or intolerance (rumblings) at 4 weeks <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.10.1 CKD stage G5D with diabetes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>24</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.50 [‐0.14, 1.14]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.11 GI function: microbiota composition (Actinobacteria) at 4 weeks <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.11.1 CKD stage G5D with diabetes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>24</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.26 [‐4.46, 1.94]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.12 GI function: microbiota composition (Bacteriodetes) at 4 weeks <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.12.1 CKD stage G5D with diabetes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>24</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.23 [‐8.24, 14.70]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.13 GI function: microbiota composition (Proteobacteria) at 4 weeks <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.13.1 CKD stage G5D with diabetes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>24</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.11 [‐1.61, 1.83]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.14 GI function: microbiota composition (Firmicutes) at 4 weeks <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.14.1 CKD stage G5D with diabetes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>24</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐2.44 [‐14.19, 9.31]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.15 GI function: microbiota composition (Synergistetes) at 4 weeks <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.15.1 CKD stage G5D with diabetes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>24</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.25 [‐0.89, 0.39]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.16 GI function: microbiota composition (Verrucomicrobia) at 4 weeks <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.16.1 CKD stage G5D with diabetes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>24</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.96 [‐1.36, 3.28]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.17 GI function: microbiota composition (faecal acetate) at 4 weeks <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.17.1 CKD stage G5D with diabetes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>24</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐69.91 [‐203.95, 64.13]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.18 GI function: microbiota composition (faecal propionate) at 4 weeks <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.18.1 CKD stage G5D with diabetes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>24</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐19.35 [‐63.87, 25.17]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.19 GI function: microbiota composition (faecal butyrate) at 4 weeks <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.19.1 CKD stage G5D with diabetes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>24</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐11.04 [‐39.57, 17.49]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.20 GI function: microbiota composition (faecal total short‐chain fatty acids) at 4 weeks <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.20.1 CKD stage G5D with diabetes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>24</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐104.71 [‐293.34, 83.92]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.21 GI function: microbiota composition (faecal indoles) at 4 weeks <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.21.1 CKD stage G5D with diabetes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>24</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.71 [‐69.78, 75.20]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.22 GI function: microbiota composition (faecal p‐cresol) at 4 weeks <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.22.1 CKD stage G5D with diabetes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>24</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>28.84 [‐105.07, 162.75]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.23 GI function: faecal characteristics (bowel movements) at 4 weeks <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.23.1 CKD stage G5D with diabetes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>24</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.27 [‐1.23, 0.69]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.24 GI function: faecal characteristics (ease of passage) at 4 weeks <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.24.1 CKD stage G5D with diabetes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>24</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.00 [‐0.90, 0.90]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.25 GI function: faecal characteristics (consistency) at 4 weeks <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.25.1 CKD stage G5D with diabetes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>24</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.19 [‐1.34, 0.96]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.26 Adverse events: number participants reporting an event <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.26.1 CKD stage G5D</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>79</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.92 [0.10, 88.03]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.27 Withdrawals due to adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.27.1 CKD stage G5D</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>39</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.70 [0.13, 3.75]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">Prebiotic versus prebiotic</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013631.pub2/references#CD013631-tbl-0011">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD013631-tbl-0012"> <div class="table-heading"><span class="table-label">Comparison 4.</span> <span class="table-title">Prebiotic versus probiotic</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4.1 Dialysis outcomes: peritonitis at 24 weeks <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.1.1 CKD stage G5D with diabetes and hypertension</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>47</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Not estimable</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 4.</span> <span class="table-title">Prebiotic versus probiotic</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013631.pub2/references#CD013631-tbl-0012">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD013631-tbl-0013"> <div class="table-heading"><span class="table-label">Comparison 5.</span> <span class="table-title">Low versus high dose probiotic</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5.1 Kidney function: GFR at 8 weeks <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.1.1 CKD stage G3 to G4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.64 [‐9.51, 8.23]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5.2 Kidney function: serum creatinine at 8 weeks <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.2.1 CKD stage G3 to G4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.13 [‐0.89, 0.63]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5.3 Uraemic toxins: urea at 8 weeks <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.3.1 CKD stage G3 to G4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>4.57 [‐9.52, 18.66]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 5.</span> <span class="table-title">Low versus high dose probiotic</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013631.pub2/references#CD013631-tbl-0013">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD013631-tbl-0014"> <div class="table-heading"><span class="table-label">Comparison 6.</span> <span class="table-title">Synbiotic versus placebo</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6.1 Kidney function: eGFR at 6 or 12 weeks <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.1.1 CKD stage G3b</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>98</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.42 [0.65, 2.20]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6.2 Kidney function: SrCr at 6 or 12 weeks <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>98</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.57 [‐1.08, ‐0.07]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.2.1 CKD stage G3b</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>98</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.57 [‐1.08, ‐0.07]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6.3 Uraemic toxins: urea at 6 or 12 weeks <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>117</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.34 [‐15.65, 22.32]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.3.1 CKD stage G3b</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>75</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐3.48 [‐14.50, 7.54]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.3.2 CKD stage G5D with diabetes and hypertension</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>42</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>17.10 [‐8.80, 43.00]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6.4 GI function: GSRS Item 6 (rumbling) at 12 weeks <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.4.1 CKD stage 3b</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>23</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.54 [‐0.77, ‐0.31]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6.5 GI function: GSRS Item 13 (hard stools) at 12 weeks <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.5.1 CKD stage 3b</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>23</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.09 [‐0.35, 0.17]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6.6 GI function: abdominal pain at 12 weeks <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.6.1 CKD stage 3b</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>23</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.22 [‐0.02, 0.46]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6.7 GI function: constipation syndrome at 12 weeks <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.7.1 CKD stage 3b</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>23</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.17 [‐0.72, 0.38]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 6.</span> <span class="table-title">Synbiotic versus placebo</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013631.pub2/references#CD013631-tbl-0014">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD013631-tbl-0015"> <div class="table-heading"><span class="table-label">Comparison 7.</span> <span class="table-title">Prebiotic versus placebo or no treatment</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7.1 Kidney function: serum creatinine at 8 or 12 weeks <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>145</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.52 [‐2.39, 3.44]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.1.1 CKD stage A2 with diabetic nephropathy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>70</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>4.70 [0.47, 8.93]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.1.2 CKD stage G5D</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>75</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.75 [‐3.16, 1.66]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7.2 Uraemic toxins: urea at 12 weeks <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.2.1 CKD stage A2 with diabetic nephropathy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>70</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.40 [‐0.86, 0.06]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7.3 Uraemic toxins: indoxyl sulfate at 8 weeks <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.3.1 CKD stage G5D</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>75</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.14 [‐0.60, 0.31]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7.4 Uraemic toxins: p‐cresyl sulfate at 8 weeks <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.4.1 CKD stage G5D</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>44</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.68 [‐14.30, 10.94]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7.5 GI function: microbiota composition (Facealibacterium) at 8 weeks <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.5.1 CKD stage 5GD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>44</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.37 [0.23, 4.51]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7.6 GI function: microbiota composition (Parabacteroides) at 8 weeks <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.6.1 CKD stage 5GD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>44</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.22 [0.06, 0.38]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7.7 GI function: microbiota composition (Bifidobacteria) at 8 weeks <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.7.1 CKD stage 5GD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>44</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐3.92 [‐9.83, 1.99]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7.8 GI function: microbiota composition (Ruminococcus) at 8 weeks <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.8.1 CKD stage 5GD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>44</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.86 [‐0.32, 8.04]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7.9 GI function: microbiota composition (Prevotella) at 8 weeks <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.9.1 CKD stage 5GD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>44</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.43 [‐1.45, 0.59]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7.10 Adverse events: any adverse event (number of participants) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.10.1 CKD stage G5D</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>50</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.50 [0.53, 11.70]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7.11 Withdrawals due to adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.11.1 CKD stage G5D</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>50</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.00 [0.13, 70.30]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 7.</span> <span class="table-title">Prebiotic versus placebo or no treatment</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013631.pub2/references#CD013631-tbl-0015">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD013631-tbl-0016"> <div class="table-heading"><span class="table-label">Comparison 8.</span> <span class="table-title">Probiotic versus placebo or no treatment</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8.1 Kidney function: GFR at 8, 12 or 15 weeks <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>128</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.73 [‐2.28, 7.75]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.1.1 CKD stage 1 and type 2 diabetes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>40</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>12.10 [4.19, 20.01]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.1.2 CKD stage 3A with diabetes and hypertension</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>28</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.40 [‐4.15, 4.95]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.1.3 CKD stage G5D with diabetes and hypertension</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>60</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.02 [‐0.63, 0.67]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8.2 Kidney function: serum creatinine at 8, 12 or 24 weeks <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>303</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.51 [‐1.06, 0.04]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.2.1 CKD stage G5D</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>33</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.70 [‐4.48, 3.08]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.2.2 Diabetic nephropathy all CKD stages</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>120</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.19 [‐2.96, 0.57]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.2.3 CKD stage G5D with diabetes and hypertension</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>110</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.08 [‐0.48, 0.64]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.2.4 CKD stage 1 and type 2 diabetes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>40</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.17 [‐0.26, ‐0.08]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8.3 Kidney function: albuminuria at 12 or 24 weeks <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>193</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.02 [‐0.08, 0.13]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.3.1 CKD stage G5D</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>33</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.00 [‐0.19, 0.19]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.3.2 CKD stage G5D with diabetes and hypertension</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>160</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.03 [‐0.10, 0.16]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8.4 Kidney function: proteinuria at 12 weeks <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.4.1 Diabetic nephropathy all CKD stages</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>60</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐15.60 [‐34.30, 3.10]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8.5 Uraemic toxins: urea at 12 or 24 weeks <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>263</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.11 [‐2.58, 0.35]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.5.1 CKD stage G5D</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>33</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.80 [‐9.59, 13.19]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.5.2 Diabetic nephropathy all CKD stages</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>120</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.90 [‐5.06, 1.26]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.5.3 CKD stage G5D with diabetes and hypertension</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>110</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.06 [‐5.61, 5.72]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8.6 Uraemic toxins: indoxyl sulfate at 12 or 24 weeks <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>83</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐4.24 [‐9.83, 1.35]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.6.1 CKD stage G5D</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>33</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐6.00 [‐15.02, 3.02]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.6.2 CKD stage G5D with diabetes and hypertension</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>50</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐3.14 [‐10.26, 3.98]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8.7 Uraemic toxins: p‐cresyl sulfate at 4, 12 or 24 weeks <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>125</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐2.12 [‐5.19, 0.95]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.7.1 CKD stage G5D</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>75</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.27 [‐2.31, ‐0.24]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.7.2 CKD stage G5D with diabetes and hypertension</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>50</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐6.21 [‐13.92, 1.50]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8.8 Uraemic toxins: indole‐3‐acetic acid acid at 12 weeks <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.8.1 CKD stage G5D</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>33</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐288.10 [‐464.41, ‐111.79]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8.9 GI function: any GI upset or intolerance (abdominal pain/diarrhoea) at 12 weeks <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.9.1 CKD stage G5D</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>33</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.12 [0.21, 21.22]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8.10 GI function: any GI upset or intolerance (constipation) at 12 weeks <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.10.1 CKD stage G5D</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>33</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.18 [0.14, 72.75]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8.11 GI function: faecal pH at 12 weeks <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.11.1 CKD stage G5D</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>20</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.30 [‐0.83, 0.23]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8.12 Adverse events: any adverse event (number of participants) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>205</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.96 [0.63, 6.12]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.12.1 CKD stage 1 and type 2 diabetes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>44</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.80 [0.25, 2.59]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.12.2 CKD stage G5D</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>105</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>4.95 [0.90, 27.12]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.12.3 CKD stage G5D with diabetes and hypertension</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>56</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>5.00 [0.25, 99.67]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8.13 Withdrawals due to adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>205</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>4.96 [1.13, 21.77]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.13.1 CKD stage G5D</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>105</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>4.95 [0.90, 27.12]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.13.2 CKD stage G5D with diabetes and hypertension</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>56</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>5.00 [0.25, 99.67]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.13.3 CKD stage 1 and type 2 diabetes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>44</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Not estimable</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 8.</span> <span class="table-title">Probiotic versus placebo or no treatment</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013631.pub2/references#CD013631-tbl-0016">Navigate to table in review</a></div> </div> </div> <noscript> <img height="1" src="/scolaris-auth/report/nonjs/fulltexthtmlreg?doi=10.1002%2F14651858.CD013631.pub2&amp;rf=&amp;articleType=CDSR" style="display:none" width="1"> </img></noscript> <section class="translation-notes-modal" data-modal-class="translation-notes" data-modal-title="Translation notes" data-ok-btn-selector=".ok-btn" style="display: none"> <div class="translation-notes"> <div class="section-language-toggles"> <nav class="section-languages"> <ul> <li class="section-languages-legend">Available in</li> <li class="section-language"> <a class="" href="es#CD013631-note-0024">Español</a> </li> <li class="section-language"> <a class="" href="fa#CD013631-note-0020">فارسی</a> </li> <li class="section-language"> <a class="" href="fr#CD013631-note-0022">Français</a> </li> <li class="section-language"> <a class="" href="hr#CD013631-note-0019">Hrvatski</a> </li> <li class="section-language"> <a class="" href="id#CD013631-note-0021">Bahasa Indonesia</a> </li> <li class="section-language"> <a class="" href="ja#CD013631-note-0018">日本語</a> </li> <li class="section-language"> <a class="" href="ko#CD013631-note-0015">한국어</a> </li> <li class="section-language"> <a class="" href="ms#CD013631-note-0017">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="pl#CD013631-note-0023">Polski</a> </li> <li class="section-language"> <a class="" href="th#CD013631-note-0016">ภาษาไทย</a> </li> <li class="section-language"> <a class="" href="zh_HANS#CD013631-note-0013">简体中文</a> </li> <li class="section-language"> <a class="" href="zh_HANT#CD013631-note-0014">繁體中文</a> </li> </ul> </nav> </div> <section class="translation-notes-content"> </section> <button class="btn primary ok-btn pull-right" type="button">Close</button> </div> </section></article> </div> <div class="citation-modal" style="display: none"> <div class="export-citation-header"> <p class="inset-message" data-load-error="Unable to load citation data" id="citeProcText"></p> </div> <div class="export-citation-body row-fluid"> <div class="span12"> <div class="addthis_toolbox addthis_default_style addthis_16x16_style"> <nav class="inline-nav-list is-bordered"> <li> <h4 class="heading">Save citation to:</h4> </li> <li><a class="citation-btn-refworks at300b btn btn-link" href="#" id="refWorksCitationBtn"><span class="citation-icon refworks"></span>RefWorks</a></li> <li><a class="citation-btn-sciwheel at300b btn btn-link disabled" href="#" id="sciWheelCitationBtn" target="_blank"><span class="citation-icon sciwheel"></span>SciWheel</a></li> </nav> </div> </div> </div> <div class="row-fluid"> <div class="span12"> <div class="citation-format"> <h4>Copy or download citation</h4> <a href="/en/help/exporting-search-results" rel="noopener noreferrer" target="_blank">Export help</a> </div> <nav class="inline-nav-list has-dividers"> <li class="citation-option" data-option="plain"><button class="btn btn-link" type="button">Plain text</button></li> <li class="citation-option" data-option="endnote"><button class="btn btn-link" type="button">EndNote</button></li> <li class="citation-option" data-option="refmanager"><button class="btn btn-link" type="button">Reference Manager</button></li> <li class="citation-option" data-option="procite"><button class="btn btn-link" type="button">ProCite</button></li> <li class="citation-option" data-option="bibtex"><button class="btn btn-link" type="button">BibteX</button></li> <li class="citation-option" data-option="csv"><button class="btn btn-link" type="button">CSV (Excel)</button></li> </nav> <div class="citation-content"> <pre data-load-error="Unable to load citation data" id="citationContent" tabindex="0"></pre> </div> <div class="clearfix"> <form class="download-citation-form" data-citation-citeproc-url="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=citation-citeproc&amp;p_p_cacheability=cacheLevelPage&amp;p_p_col_id=column-1&amp;p_p_col_count=1" method="GET" target="citation-download-iframe"> <input id="siteId" name="siteId" type="hidden" value=""> <input id="downloadType" name="downloadType" type="hidden" value=""> <input id="style" name="style" type="hidden" value=""> <input id="articleId" name="articleId" type="hidden" value=""> <input name="p_p_id" type="hidden" value="scolariscontentdisplay_WAR_scolariscontentdisplay"><input name="p_p_lifecycle" type="hidden" value="2"><input name="p_p_state" type="hidden" value="normal"><input name="p_p_mode" type="hidden" value="view"/><input name="p_p_resource_id" type="hidden" value="citation-download"/><input name="p_p_cacheability" type="hidden" value="cacheLevelPage"/><input name="p_p_col_id" type="hidden" value="column-1"/><input name="p_p_col_count" type="hidden" value="1"/> <button class="btn primary wide pull-right" type="submit">Download</button> <div class="inline-checkbox pull-right"> <label title=" for=" withabstract"=""> <input checked="" class="checkbox" name="withAbstract" type="checkbox"/> <span class="checkbox-label">Include abstract</span> </label> </div> </input></input></input></input></input></input></input></form> <iframe aria-hidden="true" name="citation-download-iframe" src="" style="display: none; visibility: hidden" title="Citation download frame"></iframe> </div> </div> </div> </div> <div class="print-modal" data-modal-title="Print this review" style="display: none;"> <div class="print-options-wrapper"> <p><strong>All sections are selected by default</strong>, please select the sections you do not wish to print or use the select or deselect all button to add or remove sections.</p> <div class="print-options-controls"> <input checked="checked" class="print-options-select-all" title="Select/deselect all" type="checkbox"/> <span class="checkbox-label">Select/deselect all</span> </div> <ul class="print-options checkbox-list"> </ul> <button class="btn primary print-article pull-right"><i aria-hidden="true" class="fa fa-print"></i> Print</button> </div> </div> <div class="download-stats-data-modal" data-modal-title="Download data package" style="display: none;"> <div> <p> The data available are protected by copyright and may only be used in accordance with the <a class="external" href="/about/data-download" target="_blank">Terms and Conditions.</a> </p> <div class="hide-for-zip"> <p> <a class="external" href="https://revman.cochrane.org/#/rm5Converter" target="_blank">RevMan 5 files</a> can be converted to a <a class="external" href="https://links.cochrane.org/review-datapack-userguide" target="_blank">data package.</a> </p> </div> <p> Files in the data package can be imported to <a class="external" href="https://revman.cochrane.org/info" target="_blank">Review Manager software</a> or opened in other tools that support CSV and RIS. </p> <form class="download-stats-data-form" method="GET" target="_blank"> <input name="content-disposition" type="hidden" value="attachment"/> <input name="mime-type" type="hidden" value="application/octet-stream"/> <p class="print-options-controls"> <input aria-label="I agree to these terms and conditions" class="download-stats-data-toc-check-box" type="checkbox"/> <span aria-hidden="true" class="checkbox-label">I agree to these terms and conditions</span> <button class="btn primary download-stats-data pull-right" disabled=""><i aria-hidden="true" class="fa fa-download"></i> Download data</button> </p> </form> </div> </div> <div class="share-modal" data-modal-title="Share this review" style="display:none;"> </div> <div class="viewer-thumbnail-pane-html" style="display:none;"> <div class="figure-viewer-options"> <nav class="inline-nav-list"> <li class="figure-options-btn-container"><button class="btn btn-link" id="figureOptionBtn" type="button">Figures</button></li> <li class="table-options-btn-container"><button class="btn btn-link" id="tableOptionBtn" type="button">Tables</button></li> </nav> </div> <div class="figure-viewer-thumbnails"> <div class="figure-thumbnails is-visible" id="figureThumbnails"></div> <div class="table-thumbnails" id="tableThumbnails"></div> </div> </div> <div class="utilities-html" style="display:none;"> <div class="figure-viewer-utilities"> <a class="figure-viewer-menu-toggle" href="#"> <i class="fa fa-chevron-left"></i><span class="toggle-label" data-figure-hide-text="Hide thumbnails" data-figure-show-text="Show thumbnails" data-table-hide-text="Hide table list" data-table-show-text="Show table list">Hide thumbnails</span> </a> <a class="figure-viewer-navigateback" href="#"> <i class="fa fa-chevron-left"></i> </a> <a class="figure-viewer-rotate" href="#"> <i class="fa fa-undo"></i> </a> <a class="figure-viewer-download" href="#"> <i class="fa fa-download"></i> </a> <a class="figure-viewer-share" href="#"> <i class="fa fa-share-alt"></i> </a> <a class="figure-viewer-zoomin" href="#"> <i class="fa fa-plus"></i><span>zoom in</span> </a> <a class="figure-viewer-zoomout" href="#"> <i class="fa fa-minus"></i><span>zoom out</span> </a> </div> </div> <div class="controls-html" style="display:none;"> <div class="figure-viewer-navigation"> <a class="figure-viewer-nav previous" href="#"> <i class="fa fa-chevron-left"></i><span>left</span> </a> <a class="figure-viewer-nav next" href="#"> <i class="fa fa-chevron-right"></i><span>right</span> </a> </div> </div> <div class="mobile-thumbnail-selector-html" style="display:none;"> <div class="figure-viewer-mobile-thumbnails"> <select class="figure-selection"> <option>Figures</option> </select> <select class="table-selection"> <option>Tables</option> </select> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div>
<div class="portlet-boundary portlet-boundary_1_WAR_kaleodesignerportlet_ portlet-static portlet-static-end kaleo-designer-portlet" id="p_p_id_1_WAR_kaleodesignerportlet_">
<span id="p_1_WAR_kaleodesignerportlet"></span>
</div>
<form action="#" id="hrefFm" method="post" name="hrefFm">
<span></span>
</form>
</div>
<footer class="footer">
<div class="main-footer">
<div class="main-footer-wrapper container">
<div class="brand">
<p class="brand-name">Cochrane</p>
<a href="http://www.cochrane.org/" title="Cochrane logo">
<img alt="Cochrane logo" class="footer-logo logo-part-1" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-1.png"> <img alt="" class="footer-logo logo-part-2" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-2.png"> </img></img></a> </div> </div> </div> <div class="aux-footer"> <div class="aux-footer-nav-container container"> <nav class="aux-footer-nav"> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse Publications</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse by Subject</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/advertisers">Advertisers &amp; Agents</a></li> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Contact Us</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Help &amp; Support</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/terms-and-conditions">Terms &amp; Conditions</a></li> </ul> </nav> </div> <div class="brand"> <div class="brand-container container"> <p class="copyright"> Copyright © 2000 - 2025 by <a class="" href="http://www.wiley.com">John Wiley &amp; Sons, Inc.</a> All Rights Reserved <br> Review our <a href="https://www.wiley.com/privacy"><strong>Privacy Policy</strong></a> <a href="https://www.wiley.com/cookies"><strong>Cookie Policy</strong></a> <a href="#" onclick="Osano.cm.showDrawer('osano-cm-dom-info-dialog-open')"><strong>Cookie Preferences</strong></a> </br></p> <a href="http://eu.wiley.com/"><img alt="Wiley logo" class="logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_wiley-footer-logo.png"/></a> </div> </div> <span class="wiley-semi-circle"></span> </div> <!--BEGIN QUALTRICS WEBSITE FEEDBACK SNIPPET--> <script type="text/javascript"> (function(){var g=function(e,h,f,g){ this.get=function(a){for(var a=a+"=",c=document.cookie.split(";"),b=0,e=c.length;b<e;b++){for(var d=c[b];" "==d.charAt(0);)d=d.substring(1,d.length);if(0==d.indexOf(a))return d.substring(a.length,d.length)}return null}; this.set=function(a,c){var b="",b=new Date;b.setTime(b.getTime()+6048E5);b="; expires="+b.toGMTString();document.cookie=a+"="+c+b+"; path=/; "}; this.check=function(){var a=this.get(f);if(a)a=a.split(":");else if(100!=e)"v"==h&&(e=Math.random()>=e/100?0:100),a=[h,e,0],this.set(f,a.join(":"));else return!0;var c=a[1];if(100==c)return!0;switch(a[0]){case "v":return!1;case "r":return c=a[2]%Math.floor(100/c),a[2]++,this.set(f,a.join(":")),!c}return!0}; this.go=function(){if(this.check()){var a=document.createElement("script");a.type="text/javascript";a.src=g;document.body&&document.body.appendChild(a)}}; this.start=function(){var t=this;"complete"!==document.readyState?window.addEventListener?window.addEventListener("load",function(){t.go()},!1):window.attachEvent&&window.attachEvent("onload",function(){t.go()}):t.go()};}; try{(new g(100,"r","QSI_S_ZN_cGCHHvWNpnJb1zf","https://zncgchhvwnpnjb1zf-wiley.siteintercept.qualtrics.com/SIE/?Q_ZID=ZN_cGCHHvWNpnJb1zf")).start()}catch(i){}})(); </script><div id="ZN_cGCHHvWNpnJb1zf"><!--DO NOT REMOVE-CONTENTS PLACED HERE--></div> <!--END WEBSITE FEEDBACK SNIPPET--> </footer> <div class="scolaris-modal-overlay"></div> <div class="scolaris-modal"> <div class="scolaris-modal-titlebar clearfix"> <p class="scolaris-modal-title"></p> <a class="scolaris-modal-close" href="#"><span>close</span><span class="icon fa fa-times"></span></a> <div class="scolaris-modal-ui"></div> </div> <!-- Static injection of addtoAny as dynamic injection not working properly--> <div class="scolaris-share-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"> <div class="a2a_kit a2a_kit_size_32 a2a_default_style"> <a class="a2a_button_facebook share-button">  Facebook</a> <a class="a2a_button_x share-button">  X(Twitter)</a> <a class="a2a_button_whatsapp share-button">  WhatsApp</a> <a class="a2a_dd share-button">  View more</a> </div> </div> </div> <div class="scolaris-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="english-only-modal-wrapper" data-modal-class="english-only-modal" data-modal-title="Feature in English only" style="display: none"> <div class="english-only-modal"> <p class="message"></p> <button class="btn primary ok-btn pull-right" type="button">OK</button> <button class="btn primary border-only cancel-btn pull-right" type="button">Cancel</button> </div> </div> <!--[if gte IE 9]><!--> <script src="/cochrane-theme/vendor/ie9.js?t=1738734064000" type="text/javascript"></script> <!--<![endif]--> <script src="https://www.cochranelibrary.com/cochrane-theme/js/theme.js?t=1738734064000" type="text/javascript"></script> <script src="https://content.readcube.com/cochrane/checkout.js"></script> <script src="https://content.readcube.com/cochrane/epdf_linker.js" type="text/javascript"></script> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js" type="text/javascript"></script> <script src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/hit-highlighting.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/topics-lookup.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/institution.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/api-manager.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/pico.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/reference-linking.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/rightsLink.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.submit.failed.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.comment.form.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/safety-alerts.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.translation-notes-modal.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/notifications-portlet/notifications/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772751000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-search/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772894000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-topics/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772894000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-language-portlet/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772746000" type="text/javascript"></script> <script type="text/javascript">Liferay.Util.addInputFocus();</script> <script type="text/javascript">Liferay.Portlet.register("scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_",portletId:"scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD013631\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD013631\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD013631\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD013631\x2epub2"});Liferay.Portlet.register("scolariscontentdisplay_WAR_scolariscontentdisplay");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_",portletId:"scolariscontentdisplay_WAR_scolariscontentdisplay",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentdisplay_WAR_scolariscontentdisplay\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dcolumn-1\x26p_p_col_pos\x3d0\x26p_p_col_count\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD013631\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD013631\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D"});Liferay.provide(Liferay.Util,"openKaleoDesignerPortlet",function(c){var b=AUI();var e=Liferay.PortletURL.createURL("https://www.cochranelibrary.com/en/content?p_p_id=2_WAR_kaleodesignerportlet&p_p_lifecycle=0");e.setParameter("mvcPath","/designer/edit_kaleo_draft_definition.jsp");e.setParameter("availableFields",c.availableFields);e.setParameter("availablePropertyModels",c.availablePropertyModels);e.setParameter("ddmStructureId",c.ddmStructureId);e.setParameter("draftVersion",c.draftVersion);e.setParameter("kaleoProcessId",c.kaleoProcessId);e.setParameter("name",c.name);e.setParameter("openerWindowName",c.openerWindowName);e.setParameter("portletResourceNamespace",c.portletResourceNamespace);e.setParameter("propertiesSaveCallback",c.propertiesSaveCallback);e.setParameter("refreshOpenerOnClose",c.refreshOpenerOnClose);e.setParameter("saveCallback",c.saveCallback);e.setParameter("version",c.version);e.setWindowState("pop_up");c.uri=e.toString();var d=c.dialog;if(!d){var f=b.one(Liferay.Util.getOpener()).get("region");d={destroyOnHide:true};c.dialog=d}if(!("align" in d)){d.align=Liferay.Util.Window.ALIGN_CENTER}var a=c.dialogIframe;if(!a){a={closeOnEscape:false};c.dialogIframe=a}Liferay.Util.openWindow(c)},["liferay-portlet-url"]);Liferay.Portlet.register("1_WAR_kaleodesignerportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_1_WAR_kaleodesignerportlet_",portletId:"1_WAR_kaleodesignerportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3d1_WAR_kaleodesignerportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD013631\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD013631\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD013631\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD013631\x2epub2"});Liferay.Portlet.register("scolarissearchportlet_WAR_scolarissearch");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarissearchportlet_WAR_scolarissearch_",portletId:"scolarissearchportlet_WAR_scolarissearch",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarissearchportlet_WAR_scolarissearch\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD013631\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD013631\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD013631\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD013631\x2epub2"});Liferay.Portlet.register("scolariscontentlanguagebanner_WAR_scolarislanguageportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_",portletId:"scolariscontentlanguagebanner_WAR_scolarislanguageportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentlanguagebanner_WAR_scolarislanguageportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD013631\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD013631\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD013631\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD013631\x2epub2"});AUI().use("aui-base","liferay-menu","liferay-notice","liferay-poller","liferay-session",function(a){(function(){Liferay.Util.addInputType();Liferay.Portlet.ready(function(b,c){Liferay.Util.addInputType(c)});if(a.UA.mobile){Liferay.Util.addInputCancel()}})();(function(){new Liferay.Menu();var b=Liferay.Data.notices;for(var c=1;c<b.length;c++){new Liferay.Notice(b[c])}})();(function(){Liferay.Session=new Liferay.SessionBase({autoExtend:true,sessionLength:1800,redirectOnExpire:false,redirectUrl:"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane",warningLength:0})})()});</script> <script src="https://www.cochranelibrary.com/cochrane-theme/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" type="text/javascript"></script> <script type="text/javascript"></script> <div class="mobile-righthand-nav"> <a class="rh-nav-close-btn" href="#"> <span>Close</span> <span class="fa fa-chevron-down"></span> </a> <div class="wrapper"> </div> <a class="rh-nav-open-btn" href="#"> <span>Review tools &amp; navigation</span> </a> </div> <iframe aria-hidden="true" id="printframe" name="printframe" style="position: absolute; left: -2000px; top: 0;" title="Print frame"></iframe> <iframe aria-hidden="true" id="citationExportFrame" name="citationExportFrame" style="position: absolute; left: -2000px; top: 0;" title="scolaris.citation.export.frame"></iframe> <nav> <div class="mobile-navigation"> <div class="close-container"> <a aria-label="Navigate back" class="main-nav-back-btn" href="#"><i class="fa fa-chevron-left"></i></a> <a class="main-nav-close-btn" href="#" title="Close menu">Close menu <i class="fa fa-times"></i></a> </div> <div class="mobile-search basic-search-container"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="ymag__null__null" src="/scolaris-search/icon.png"> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </img></span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=XHP2gG4h&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"> <input name="facetDisplayName" type="hidden" value=""> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</input></input></form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD013631.pub2&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD013631.pub2';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<a class="btn secondary" href="/en/browse-by-topic">Browse </a>
<a class="btn secondary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
<div class="menu-items parent">
<div>
<div class="nav-root-item parent">
<a class="language-selection-title-link" href="#" title="Select language">
<span class="mobile-nav-language-title">Select your preferred language </span></a> <span class="icon fa fa-caret-down"></span>
<div class="mob-child">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="fdkn__null__null" src="/scolaris-language-portlet/icon.png"> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </img></span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> English </a> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> English </a> </div> <div class="form-content language-selector-modal child"> <div class="row-fluid"> <h3><i class="fa fa-file-text"></i> Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> <div class="dropdown-trigger" id="active-content-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="content-language-selector" data-languagecode="de" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=de">Deutsch</a> <a class="content-language-selector is-active" data-languagecode="en" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=en">English</a> <a class="content-language-selector" data-languagecode="es" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=es">Español</a> <a class="content-language-selector" data-languagecode="fa" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fa">فارسی</a> <a class="content-language-selector" data-languagecode="fr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fr">Français</a> <a class="content-language-selector" data-languagecode="hi" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hi">हिन्दी</a> <a class="content-language-selector" data-languagecode="hr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hr">Hrvatski</a> <a class="content-language-selector" data-languagecode="id" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=id">Bahasa Indonesia</a> <a class="content-language-selector" data-languagecode="ja" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ja">日本語</a> <a class="content-language-selector" data-languagecode="ko" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ko">한국어</a> <a class="content-language-selector" data-languagecode="hu" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hu">Magyar</a> <a class="content-language-selector" data-languagecode="ms" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ms">Bahasa Malaysia</a> <a class="content-language-selector" data-languagecode="nl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=nl">Nederlands</a> <a class="content-language-selector" data-languagecode="pl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pl">Polski</a> <a class="content-language-selector" data-languagecode="pt" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pt">Português</a> <a class="content-language-selector" data-languagecode="ru" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ru">Русский</a> <a class="content-language-selector" data-languagecode="ro" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ro">Română</a> <a class="content-language-selector" data-languagecode="ta" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ta">தமிழ்</a> <a class="content-language-selector" data-languagecode="th" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=th">ภาษาไทย</a> <a class="content-language-selector" data-languagecode="zh_HANT" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANT">繁體中文</a> <a class="content-language-selector" data-languagecode="zh_HANS" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANS">简体中文</a> </div> </div> <div class="row-fluid"> <h3 class="portal-language-header"><i class="fa fa-globe"></i> Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> <div class="dropdown-trigger" id="active-portal-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="portal-language-selector is-active" data-portallanguage="en" href="/en/cdsr/doi/10.1002/14651858.CD013631.pub2/full/en">English</a> <a class="portal-language-selector" data-portallanguage="es" href="/es/cdsr/doi/10.1002/14651858.CD013631.pub2/full/es">Español</a> </div> </div> <a class="btn secondary ok-btn pull-right" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
<div class="parent">
<a class="mobile-link signin" data-redirect="false" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD013631.pub2%2Ffull" rel="nofollow">
                        Sign In
                    </a>
</div>
</div>
<div class="menu-items-footer">
<div class="utility-links">
<a class="cochrane-link" href="http://www.cochrane.org/" target="_blank">Visit Cochrane.org</a>
</div>
</div>
</div>
<div class="menu-items child"></div>
</div>
</nav><div class="basic-login-form-content" data-modal-title="Sign in" style="display: none;">
<div class="form-content">
<div class="row-fluid">
<div class="span12">
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_MODAL_">
<span id="p_58_INSTANCE_MODAL"></span>
<section class="portlet" id="portlet_58_INSTANCE_MODAL">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="dbam__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_MODAL" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_MODAL&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_MODAL_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_MODAL_fm" method="post" name="_58_INSTANCE_MODAL_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_MODAL_formDate" type="hidden" value="1740719086423"> <input class="field" id="_58_INSTANCE_MODAL_saveLastPath" name="_58_INSTANCE_MODAL_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_MODAL_redirect" name="_58_INSTANCE_MODAL_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD013631.pub2/full"> <input class="field" id="_58_INSTANCE_MODAL_doActionAfterLogin" name="_58_INSTANCE_MODAL_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_login"> Email Address </label> <input class="field clearable" id="_58_INSTANCE_MODAL_login" name="_58_INSTANCE_MODAL_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_password"> Password </label> <input class="field" id="_58_INSTANCE_MODAL_password" name="_58_INSTANCE_MODAL_password" type="password" value=""/> </div> <span id="_58_INSTANCE_MODAL_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="clearfix"> <div class="checkbox-list pull-left"> <div class="checkbox-list-item"> <div class="control-group form-inline input-checkbox-wrapper"> <label for="_58_INSTANCE_MODAL_rememberMeCheckbox"> <input id="_58_INSTANCE_MODAL_rememberMe" name="_58_INSTANCE_MODAL_rememberMe" type="hidden" value="true"/> <input checked="" class="field" id="_58_INSTANCE_MODAL_rememberMeCheckbox" name="_58_INSTANCE_MODAL_rememberMeCheckbox" onclick="Liferay.Util.updateCheckboxValue(this); " type="checkbox" value="true"/> Remember Me </label> </div> </div> </div> <div class="pull-right"> <a href="https://onlinelibrary.wiley.com/user/forgottenpassword" target="_blank">Forgotten password?</a> </div> </div> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> <a class="btn secondary" href="https://onlinelibrary.wiley.com/user-registration" target="_blank">Register</a> </div> <div class="pull-right"> <a class="institutional-login-form-button" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=0&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolariscontentdisplay_WAR_scolariscontentdisplay_action=institution-access">Institutional login</a> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div></div>
<div class="institution-login-form-content" data-modal-title="Institutional login" style="display: none;">
<div class="form-content">
<div class="row-fluid access-content-wrapper">
<div class="span12">
<div class="section">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="obft__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="access-content-section"> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/>
</div>
<button class="btn primary" name="button" type="submit">Go</button>
</div>
<div class="message error" id="institutionLookupErrorDiv" style="display:none">
                        '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access.
                    </div>
</div>
<input id="entityId" name="entityId" type="hidden" value=""/>
</form>
<h4>Previously accessed institutions</h4>
<ul class="plain" id="previousInstitutions">
<li>(none)</li>
</ul>
</div>
<div class="section-content">
<div class="open-athens-login">
                Login using <a href="/openathens">OpenAthens</a>
</div>
</div>
</div>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_4_">
<span id="p_58_INSTANCE_4"></span>
<section class="portlet" id="portlet_58_INSTANCE_4">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="joiu__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_4" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <p>If you have a <strong>Wiley Online Library</strong> institutional username and password, enter them here.</p> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_4&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_4_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_4_fm" method="post" name="_58_INSTANCE_4_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_4_formDate" type="hidden" value="1740719086427"> <input class="field" id="_58_INSTANCE_4_saveLastPath" name="_58_INSTANCE_4_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_4_redirect" name="_58_INSTANCE_4_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD013631.pub2/full"> <input class="field" id="_58_INSTANCE_4_doActionAfterLogin" name="_58_INSTANCE_4_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_login"> Username </label> <input class="field clearable" id="_58_INSTANCE_4_login" name="_58_INSTANCE_4_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_password"> Password </label> <input class="field" id="_58_INSTANCE_4_password" name="_58_INSTANCE_4_password" type="password" value=""> </input></div> <input class="field" id="_58_INSTANCE_4_institutionalLogin" name="_58_INSTANCE_4_institutionalLogin" type="hidden" value="true"/> <span id="_58_INSTANCE_4_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div></div>
<div class="get-access-form-content" data-modal-title="Unlock gold-standard Cochrane evidence" style="display: none;">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="wpdq__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="readcube-checkout-container-outer"> <div class="row-fluid access-content-wrapper"> <div class="span6 access-left-content"> <div class="section"> <div class="section-content"> <p>Improve your health decisions with access to trusted, independent evidence from the Cochrane Library. Unlock this review for uninterrupted access.</p> <p>Still deciding? <a href="https://m.info.wiley.com/webApp/cochranenewsletter"> Sign up to our newsletter to learn more </a> </p> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title">Institutional users</h3> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/> </div> <button class="btn primary" name="button" type="submit">Go</button> </div> <div class="message error" id="institutionLookupErrorDiv" style="display:none"> '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access. </div> </div> <input id="entityId" name="entityId" type="hidden" value=""/> </form> <h4>Previously accessed institutions</h4> <ul class="plain" id="previousInstitutions"> <li>(none)</li> </ul> </div> <div class="section-content"> <div class="open-athens-login"> Login using <a href="/openathens">OpenAthens</a> </div> </div> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title"> Other access options </h3> <div class="section-content"> <ul class="plain"> <li> <a class="get-access-individual-login-button" href="/c/portal/login"> Individual access - via Wiley Online Library </a> </li> </ul> </div> </div> </div> </div> <div class="span6 access-right-content readcube-checkout-container"> <div class="section"> </div> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/> <input id="openlabel" name="openlabel" type="hidden" value="Open access"/> </div> </section> </div> </div> <!-- Scolaris Version: --> <script type="text/javascript">if(window._satellite){_satellite.pageBottom()};</script> </div> <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'918de028b8411be4',t:'MTc0MDcxOTA4Ni4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script></body> </html> 